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Clinical Deterioration during Antituberculosis Treatment  
in a High HIV-1 Prevalence Setting 
 
Dominique Justin Pepper 
 
Background 
Tuberculosis and HIV-1 pose a number of clinical challenges, one of which is clinical 
deterioration during antituberculosis treatment. The foci of this thesis were two-fold. The first 
objective was to determine the incidence, causes, risk factors and outcomes of clinical 
deterioration in a high HIV-1 prevalence setting. The second was to describe the rare but 
potentially lethal condition of neurologic tuberculosis-associated immune reconstitution 
inflammatory syndrome (TB-IRIS). 
Methods 
Three studies were conducted; two at a referral hospital and one at a tuberculosis clinic in Cape 
Town, South Africa. The first study was conducted at GF Jooste Hospital over a 3-month 
period to determine the causes for clinical deterioration. We subsequently conducted a 9-month 
prospective study at Site B Khayelitsha tuberculosis clinic to determine the incidence, causes, 
risk factors and outcomes of clinical deterioration. Lastly, we retrospectively reviewed patients 
presenting with neurologic TB-IRIS to GF Jooste Hospital over a 29 month period.  
Significant Findings and Conclusions 
Our first study found that 17% of medical inpatient admissions at GF Jooste Hospital were due 
to clinical deterioration during antituberculosis treatment. Drug resistant Mycobacterium 
tuberculosis and bacterial infections were important reasons for clinical deterioration and death. 
Additional illnesses to tuberculosis accounted for most referrals, particularly new AIDS-
defining illnesses and bacterial infections. In the subsequent study at the tuberculosis clinic, we 
found that 40% of patients starting antituberculosis treatment experienced clinical deterioration. 
Frequent causes for clinical deterioration in this setting were co-morbid illnesses, tuberculosis-
related illnesses and AIDS- defining illnesses (in decreasing frequency). Significant risk factors 
for clinical deterioration were HIV-1 infection and profound immune suppression at 
tuberculosis diagnosis. The clinical outcomes after 24 weeks of antituberculosis treatment were 
concerning: 22% of patients were lost to follow-up and 8% of patients died. Lastly, we report 
the first case series of neurologic TB-IRIS. In a hospital setting, 10% of patients diagnosed 
with TB-IRIS had neurologic involvement. Outcome was fair; 13% of patients with neurologic 
TB-IRIS died and 87% required hospital admission (median of 12 days).  In summary, clinical 
deterioration during antituberculosis treatment is a formidable challenge in our high HIV-1 
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Tuberculosis and HIV-1 cause considerable morbidity and mortality. One-third of the world’s 
population is infected with Mycobacterium tuberculosis (M.tb). Almost nine million new cases 
of tuberculosis and approximately two million tuberculosis deaths occur annually (Corbett 
2003, WHO 2006a). In 2008, almost 33.4 million people were infected with HIV-1 and 2.0 
million people died of the Acquired Immune Deficiency Syndrome (AIDS) (UNAIDS 2009).  
 
Co-infection is an increasingly common problem.  In 2000, almost 11 million people were co-
infected with HIV-1 and tuberculosis (Corbett 2003), the majority of whom were in the 
developing world (Dye 1999). Sub-Saharan Africa epitomises the synergy of these two 
pandemics. More than half of tuberculosis patients tested are HIV-1 infected (WHO 2007) and 
many of the 22.5 million HIV-1 infected people are co-infected with M.tb (WHO 2005).  The 
annual incidence of tuberculosis doubles within the first year of HIV-1 infection (Sonnenberg 
2005) and may exceed 30% per annum in the profoundly immune-suppressed (Wood 2000). 
Likewise, tuberculosis disease accelerates the progression of HIV-1 infection to AIDS by 
inciting viral replication in immunologically activated CD4+ cells (Collins 2002, Lawn 2001, 
Toosi 2001).  
 
Often dual antituberculosis and antiretroviral treatment is necessary to save co-infected 
patients. Chapter 2 describes the challenges of treating these patients. Few studies in high HIV-
1 prevalence settings have prospectively investigated the entity of clinical deterioration during 












we prospectively investigated the causes and frequency of clinical deterioration over a 3-month 
period. 
 
Using experience gained from the first study, advice from senior colleagues and reports from 
the published literature, I formulated an algorithm to systematically determine the reasons for 
clinical deterioration (Figures 1.1 and 1.2). The accompanying poster was placed in the 
Accident and Emergency Unit, where it received favourable reviews from doctors in the 
departments of Internal Medicine and Emergency Medicine. Possible reasons for clinical 
deterioration include: i) poor adherence (Brudney 1992), ii) drug toxicities from antimicrobial 
treatment (Hoffman 2007, Kwara 2005, McIlleron 2007, Pepper 2007) iii) drug resistant M.tb 
(Small 1993, Gandhi 2006), iv) co-morbid illnesses (Ansari 2002, Greenberg 2005, Eza 2006, 
Martinson 2007), v) an alternate illness to tuberculosis, vi) tuberculosis associated-immune 
reconstitution inflammatory syndrome (TB-IRIS) (Narita 1998, Lawn 2005), vii) a paradoxical 
tuberculosis reaction (if not receiving ART), viii) incorrect antituberculosis treatment, and ix) 


























Figure 1.2a: Deterioration during TB treatment – History checklist  
Presenting complaint 
 List each presenting complaint and its duration 
 
History of this TB episode 
 Initial TB symptoms and likely site of disease ( e.g. pulmonary, pleural, meningeal) 
 TB diagnosis 
o Final smear, culture and sensitivity results sent at initial diagnosis 
o If smear and culture negative: reason for empiric diagnosis (e.g. USS, LP results) 
 Date started TB treatment 
 Current TB regimen 
 Response to TB treatment (if any): symptoms and weight 
 
HIV/ ART history 
 HIV status not known: offer VCT 
 If HIV infected 
o Date of HIV diagnosis 
o WHO Stage, Baseline CD4 and date 
o ART initiation date, regimen and doses 
o Results of latest CD4 and VL if > 6 months ART 
 If HIV uninfected 
o Date last test performed, if >6 months offer VCT 
o Is there another reason for immune suppression? 
 
Past medical history 
 Previous TB (details)  
 Other opportunistic infections (details) 
 Other medical illnesses 
 Recent hospital admission (<60 days) 
 
Medication 
 List all medication patient is receiving as well as the dosage 
 Traditional medication/ over the counter medication? Drug allergies? 
 
Assess adherence 
 HAART (how many doses missed during preceding 3 days?) 
 TB treatment (?DOTS, check clinic card) 
 
 Social history 















Bacterial pneumonia, PCP, Kaposi’s sarcoma, lymphoma, fungal infection 




Space occupying lesion   Toxoplasmosis, lymphoma, cryptococcoma, brain abscess  
Meningeal   Cryptococcal, lymphoma, syphilitic  
Spinal cord   CMV, lymphoma  
ABDOMEN/ 
WASTING SYNDROME  
Lymphoma, Kaposi’s sarcoma, MAC, enteric pathogens, CMV,  systemic fungal 
infection (cryptococcosis, histoplasmosis)  
Figure1.2b: Diagnostic Algorithm for Clinical Deterioration during Antituberculosis Treatment 
5. Additional/ alternate illness to TB  
(differential diagnoses according to CD4 count and site of disease) 
1. Assess adherence 
See green TB card and obtain collateral evidence from TB clinic and relatives 
DOTS (Nomphilo), Ensure correct TB dose for weight 
Exclude oesophageal candida and gastrointestinal intolerance due to drugs 
2. Drug side effect 
Can deterioration be explained by side-effect of drug/s that patient is taking 
E.g. cotrimoxazole, TB therapy, ART, other drugs?  
If yes, manage appropriately 
4. TB Drug Susceptibility 
Testing (DST) results 
Check baseline TB Drug Susceptibility Test (DST) results 
If resistance detected, initiate appropriate TB therapy and request 2nd line 
sensitivities 
If no resistance detected but TB symptoms persist, send additional specimen 
to laboratory for TB MCS 
3. Confirm TB diagnosis 
Follow up all specimens sent for TB MC+S, exclude MAC 
If specimens confirm TB diagnosis or if there was an initial improvement of 
symptoms then review TB DST and consider an additional diagnosis to TB / 
drug resistant TB 
If all specimens do not confirm TB and there is no initial improvement of TB 
symptoms then consider alternative diagnosis/ drug resistant TB 
6. Is this TB-IRIS? 
Initial improvement of TB symptoms prior to ART 
New, worsening or recurrent symptoms 2 – 4 weeks after ART initiation  
Inflammatory in nature e.g. nodes, pulmonary infiltrates, tuberculomata 
Risk factors: low CD4 nadir, disseminated TB, short interval (< 4 - 6/52) 
between TB therapy and ART 
 Consider steroids in severe cases and if drug resistant TB excluded 
7. Is this a paradoxical TB reaction? 
Diagnosis of exclusion: 
 Initial improvement of TB symptoms  
 New, worsening or recurrent symptoms TB symptoms  
 No ART prior to deterioration 
 Drug resistant TB and other causes for deterioration  excluded 


















Bacterial pneumonia, PCP, Kaposi’s sarcoma, lymphoma, sarcoid,  fungal (cryptococcosis, 
histoplasmosis), lung carcinoma,bronchiectasis, bacterial  infection, empyema, nocardiosis 
1. Sputum TB microscopy and culture if cough or infiltrate  
2. Induced sputum if non-productive cough 
3. Sputum MCS  
4. CXR (consider lateral decubitus CXR if suspect aspergilloma or to demonstrate pleural fluid run-off) 
5. Examine skin and oral mucosa for Kaposi’s sarcoma if reticulonodular infiltrate +/- nodes 
6. Oxygen saturation (finger probe), check for exertional desaturation if PCP suspected 
7. Arterial blood gas if respiratory rate >30 or sats <95% room air 
8. Bacterial blood culture prior to broad spectrum antibiotics 
9. Consider nosocomial sepsis if > 48hrs admission or admitted to hospital within preceding 60 days  






Space occupying lesion   Toxoplasmosis, lymphoma, cryptococcoma, brain abscess  
Meningeal   Cryptococcal, lymphoma, syphilitic, bacterial  
Spinal cord   CMV, lymphoma  
Encephalitis/ encephalopathy HIV, drugs such as INH and efavirenz 
1. Blood sugar and serum sodium for all confused/ fitting patients 
2. If no focal neurology/ papilloedema/ cerebellar signs: 
 10ml lumbar puncture ( opening pressure/ chemistry/ cells/ India-Ink/ CLAT/ cryptococcal culture/ TB 
MCS/ syphilis serology – RPR and FTA-Abs)  
3. If lumbar puncture contraindicated: 
 Serum CLAT 
 Toxoplasmosis  and syphilis serology – RPR and VDRL 
 Aseptic blood culture prior to Ceftriaxone 




Adverse drug reaction, lymphoma, Non-salmonella typhi, Kaposi’s sarcoma, MAC, UTI, 
enteric pathogens (esp. if diarrhea or vomiting), CMV,  systemic fungal infection 
(cryptococcosis, histoplasmosis), HIV wasting 
1. If abdominal pain: 
 ALT, ALP, lipase, lactate (if > 6months D4T/DDI) 
 If transaminitis (ALT > 160) stop all hepatotoxic drugs, check HepBsAg, INR, total bilirubin 
2. Urine:  
 Dipstix if jaundice/ dysuria/ haematuria, pregnancy test in all women 
 MCS if urinary symptoms 
3. Stool: 
 Coccidian parasites (Cryptosporidium, Microsporidium, Isospora belli) if chronic (> 2 weeks) 
 Stool MCS if inflammatory (pus, blood), also blood culture 
4. Consider abdominal USS  
5. Aseptic ascitic tap if ascites 
6. Appropriate antibiotics if clinically septic or acute inflammatory diarrhea 
7. MycoFlytic blood culture if MAC or fungal infection considered 












In order to determine the burden of clinical deterioration in our high HIV-1 prevalence setting, 
I used this algorithm during a prospective observational study at a tuberculosis clinic (Site B 
Khayelitsha, Figure 1.3). Chapters 4-5 describe the incidence, causes, risk factors and outcomes 
of clinical deterioration in this high HIV-1 prevalence setting. This work will be important in 
defining future priorities for tuberculosis and ART programmes in South Africa. 
 
TB-IRIS is a unique form of clinical deterioration that occurs in profoundly immune-
suppressed patients who receive both antituberculosis and antiretroviral treatment. Chapter 6 
describes the clinical manifestations and outcomes of neurologic TB-IRIS, which is the most 
severe manifestation of TB-IRIS. This is the first reported case series of neurologic TB-IRIS.  
 
Finally, chapter 7 discusses strategies that may alleviate the high burden of clinical 















Figure 1.3 Map of Cape Town Metropole (bordered yellow) showing  
the catchment population of GF Jooste Hospital (bordered orange) and  
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Tuberculosis is the commonest cause of morbidity and mortality in HIV-1 infected people in 
sub-Saharan Africa (Corbett 2003). The mortality associated with tuberculosis is considerably 












higher mortality are: i) the rapid progression of tuberculosis in HIV infected people (Corbett 
2004),  and ii) the delay in diagnosis due to the reduced sensitivity of sputum smear and the 
atypical manifestations of disease (Harries 2001, Mendelson 2007). Post-mortem studies of 
hospitalized HIV-1 infected patients report a myriad of diseases causing deterioration and 
death. Unfortunately, most diagnoses considered of clinical significance are not suspected ante-
mortem (Eza 2006, Borges 1997). A post-mortem study from Botswana reported that among 
HIV-1 infected patients, the most common pathologic findings were tuberculosis (40%), 
bacterial pneumonia (23%), Pneumocystis jirovecii pneumonia (11%), and Kaposi's sarcoma 
(11%); these conditions were the cause of death in 38%, 14%, 11%, and 6%, respectively 
(Ansari 2002). Similarly, Martinson et al from South Africa found that concomitant 
disseminated tuberculosis and severe bacterial infections, including salmonellosis, were the 
leading co-morbid illnesses in 47 patients who died with advanced HIV-1 disease.  
 
Timely antituberculosis, antiretroviral and other antimicrobial treatment should prevent these 
unnecessary deaths. Numerous factors are responsible for delays in the diagnosis and treatment 
of tuberculosis (Storla 2008), one of which is the delay of microbiologic confirmation of 
tuberculosis.  In the South African public sector, rapid tuberculosis diagnostics, such as the 
GenoType® MTBDRplus (Hain Lifescience), are not consistently used in all centres. Often, 
antituberculosis treatment is empirically commenced using WHO case definitions for smear 
negative pulmonary and extra-pulmonary tuberculosis (WHO 2006b). This likely facilitates 
earlier initiation of antituberculosis treatment and prevents deterioration due to progressive 
tuberculosis. Over the past few years, there was considerable debate regarding the optimal 
interval to initiate ART after tuberculosis diagnosis. Recently, a trial from KwaZulu Natal 












following paragraphs describe the antituberculosis and antiretroviral treatment regimens in 
South Africa during the course of my research. 
 
2.1 Rationale of ART & antituberculosis treatment in the South African public sector 
Antituberculosis treatment is a multi-drug regimen given over a long period of time. Single 
agent antituberculosis treatment rapidly gives rise to drug-resistant organisms (Mitchison 
2005). Possible explanations include: M.tb divides slowly, it is metabolically capable of 
becoming drug insensitive and/or bacilli may become sequestered (Connolly 2007). The advent 
of rifampin and pyrazinamide allowed highly effective ‘short course’ antituberculosis regimes. 
In South Africa (SATB 2004), the national tuberculosis programme manages new tuberculosis 
cases with 6 months of treatment (isoniazid, rifampin, pyrazinamide, and ethambutol [HRZE] 
for 2 months followed by HR for 4 months [2HRZE/4HR]). The retreatment regimen adds 
streptomycin (S) as follows 2HRZES/1HRZE/5HRE. New tuberculosis cases do not routinely 
have tuberculosis drug susceptibility testing (DST) performed. Retreatment cases and patients 
not responding to antituberculosis treatment may have DST performed. Multi-drug resistant 
(MDR) tuberculosis, defined as M.tb resistant to RH, is treated with less effective agents for up 
to 18 months after sputum conversion. Treatment is often individualised and regimes last up to 
24 months.  
 
ART is a life-long multi-drug regimen. In patients infected with HIV-1, millions of virions are 
produced daily, and the reverse transcriptase target mutates rapidly. Hence, initial therapies 
with single or dual nucleoside reverse transcriptase inhibitors (NRTI) such as zidovudine 
(AZT) and didanosine (ddI) were only partially effective and rapidly led to viral drug resistance 
(Erice 1993). Effective therapy only became possible when non-nucleoside reverse 












these three drug classes lead to prolonged suppression of HIV-1 replication and ultimately to a 
degree of immune recovery. Adherence to ART is crucial to successful viral suppression, 
which is very closely related to immune restoration and survival (Nachega 2007).  
 
In South Africa (SA ART 2006), first-line ART is stavudine (d4T), lamivudine (3TC) and 
either nevirapine or efavirenz (NVP, EFZ). EFZ is preferred in patients receiving rifampin-
based antituberculosis treatment. Patients with a CD4+ count less than 200cells/ µL and/or a 
history of a WHO stage 4 illness are eligible to commence ART (SA ART 2006). In patients 
diagnosed with tuberculosis, ART is deferred if there is no history of a WHO Stage 4 illness 
and the CD4+ count is greater than 200 cells/ µL. If there is a history of a WHO Stage 4 illness 
and/or the CD4+ count is less than 200 cells/ µL, ART is commenced 2 months after initiating 
antituberculosis treatment. If the CD4+ count is less than 50 cells/µL or a serious HIV-1 related 
illness exists, ART may be commenced two weeks after initiating antituberculosis treatment 
(SA ART 2006).  
 
Despite the availability of these antituberculosis and antiretroviral therapies, many people are 
still dying in South Africa. This occurs i) because the drugs are ineffective against resistant 
organisms, and ii) because substantial difficulties are encountered with combined concurrent 













2.2  Drug resistance  
Drug resistant tuberculosis 
Drug resistant M.tb is an important reason for deterioration during antituberculosis treatment. 
Exogenous re-infection with MDR- M.tb in patients with advanced HIV-1 infection was first 
reported in 1993 (Small 1993). Recently, extensively drug-resistant (XDR-) tuberculosis – 
defined as MDR plus resistance to at least a quinolone and a second line injectable drug (CDC 
2006a, CDC 2006b) – was found to be a cause of death in patients co-infected with tuberculosis 
and HIV-1 in a rural area of kwaZulu Natal (Gandhi 2006). Exogenous re-infection was 
implicated as two-thirds of patients were recently hospitalised before the onset of XDR-TB. 
Genotyping of the isolates showed that 85% of the patients had similar strains. The extent of 
transmission of drug resistant M.tb in Khayelitsha, Cape Town has only just been determined. 
A retrospective study from 2005 to 2007 uncovered a three-fold increase in the case-load of 
patients with MDR-TB and HIV-1 (Virginia de Azevedo, City of Tygerberg- personal 
communication). A similar concomitant increase among HIV-1 uninfected patients was not 
documented.   
 
The continued emergence of drug-resistant M.tb (Shah 2007) may be due to several factors: W-
Beijing strains of M.tb are associated with HIV-1 and have a greater propensity to become drug 
resistant (Rad 2003). Biologically these strains are postulated to interact in an immune 
subverting manner because they produce an immunosuppressive phenolic glycolipid (Reed 
2004). Tuberculosis/HIV-1 co-infection is also associated with significantly reduced rifampin 
drug levels, which may allow the selection of drug-resistant M.tb bacilli (Gurumurthy 2004, 
Sahai 1997). Patients receiving MDR-TB treatment may also be at risk of XDR- TB. Current 
MDR-TB treatment is prolonged, poorly tolerated and less effective than first-line 












documented (Gandhi 2006). In order to combat the expanding tuberculosis pandemic and 
prevent the spread of drug-resistant M.tb, the following are required: Rapid diagnostic methods 
to ascertain drug resistance (Rattan 1998), functional socio-political infrastructures, a 
substantial financial commitment by both first and third world countries, and new 
antituberculosis drugs.  
 
Drug-resistant bacteria  
Bacterial pneumonia is more common in patients with advanced HIV infection (Tumbarello, 
2001).  Exposure to beta lactam agents, multiple hospitalizations and low CD4+ cell counts are 
all risk factors for the acquisition of methicillin-resistant Staphylococcus aureus 
(MRSA)(Tumbarello 2002). Profound immune suppression is an important risk factor for 
community acquired pneumonia, while prolonged hospitalisation significantly increases the 
risk of nosocomial bacterial pneumonia (Hirschtick 1995). S. pneumonia and methicillin-
sensitive S. Aureus are frequently cultured from patients with community acquired bacterial 
pneumonia (Hirschtick 1995) while Pseudomonas aeruginosa and MRSA are cultured from 
those with nosocomial bacterial pneumonia (Franzetti 2006). The incidence of bacterial 
infections has declined among HIV infected patients in the developed world. 
Chemoprophylaxis with trimethoprim–sulfamethoxazole was associated with a 67% reduction 
in confirmed episodes of bacterial pneumonia(Hirschtick 1995). ART reduces the incidence of 
bacterial infections by restoring immune function (Deeks 1997) and reducing AIDS-defining 
illnesses (Mouton 1997). This indirectly reduces the length of hospitalisation and results in a 
















The prevalence of multi-drug-resistant HIV-1 is increasing (Turner 2006). This may be 
explained partly by the transmission of HIV-1 from ART-experienced to HIV-1 uninfected 
individuals (Wensing 2005).Whilst drug resistance (DR) is not associated with increased 
virulence (Brenner 2002), DR is the leading cause of treatment failure amongst patients 
infected with HIV-1 (Lorenzi 1999). Fortunately, this is not yet a significant problem in sub-
Saharan Africa. High adherence (>95%) to ART reduces viral replication, which limits the 
emergence of drug-resistance mutations (Burman 2005). Intermediate ART adherence (70–
90%), as well as ART mono-/ dual therapy, increases the incidence of DR (Nachega 2007). 
Recent data suggest that moderate adherence to NNRTIs leads to sustained viral suppression 
(Nachega 2007). Certain reverse transcriptase mutations conferring resistance to NRTI (K65R, 
M184V) are associated with reduced viral fitness (Turner 2004), whilst mutations conferring 
NNRTI resistance are usually neutral. Interestingly, NNRTI hypersusceptibility is more 
common amongst viruses from NRTI experienced/ NNRTI-naive patients compared with 
viruses from NRTI/ NNRTI-naive patients, suggesting that mutations in NRTI-resistant viruses 
confer structural conformational advantages for NNRTIs at the NNRTI-binding site (Whitcomb 
2002). Reduced viral fitness of DR HIV-1 strains allows their growth to be exceeded by wild-
type HIV-1 strains (Brenner 2004). The detection of DR HIV-1 in ART-naive patients may 
consequently be difficult, as standard population-based genotyping methods only detect viral 
populations that are greater than 20% of the total HIV-1 population (Brenner 2004); drug 
pressure allows the subsequent detection of DR strains (Turner 2006). In addition, DR is 
increased when a failing ART regimen is maintained (even though CD4+ counts are stable  and 
viral loads are preserved over time) and may limit future treatment options (Kantor 2004, 












imperative to prevent this possibility from occurring. South Africa can ill afford the dual 
epidemics of MDR-HIV-1 and MDR-TB.  
 
2.3 Difficulties associated with combining current antituberculosis and antiretroviral  
 treatments.  
Antituberculosis and antiretroviral treatment is complicated by shared drug toxicities, drug 
interactions, high pill burdens, and the immune reconstitution inflammatory syndrome. Co-
morbid illnesses and the treatment of latent tuberculosis infection provide additional 
challenges.  
 
Shared drug toxicities 
Concomitant therapy for HIV-1 and tuberculosis is associated with increased risks of adverse 
drug effects such as nausea, gastrointestinal tract disturbance, peripheral neuropathy, cutaneous 
reactions, renal toxicity and potentially fatal liver toxicity (Dean 2002). Certain drug 
combinations should be used with caution (Table 2.1). These toxicities may necessitate therapy 
discontinuation, which exacerbates immune suppression and predisposes to other opportunistic 
infections. Shared drug toxicities also compromise adherence to the treatment regimen, leading 
to suboptimal treatment, and increasing the possibility of drug resistance.  
 
Drug interactions 
Numerous concurrent diseases occur in profoundly immune-suppressed HIV-1 infected patients 
with tuberculosis. They include Pneumocystis jiroveci pneumonia, toxoplasmosis, Kaposi’s 
sarcoma, deep vein thrombosis, seizure disorders and sepsis (Ansari 2002). The potential for 
drug interactions increases when treatment for these illnesses is prescribed concomitantly with 












Side-effect Anti-retrovirals First-line TB drugs MDR-TB drugs Other drugs Other HIV disease 
Peripheral neuropathy d4T, ddI, ddC H, E (rare) Cy, Te, FQ, Et, Ka, Am, Lin  HIV itself 
Hearing loss  S Ka, Am, Cpr, Clr   
Vertigo  S Ka, Am, Clr   
Optic neuritis  E, H (rare) Et (rare), PAS (rare), Lin    
Seizures  H Cy, Te, Of, Ci [and other FQ – rare]   
Psychosis EFV H Cy, Te, Of, Ci,[other FQ] Et TMP-SMX, steroids HIV itself 
Depression EFV  Cy, Te, Of, Ci, Et TMP-SMX HIV itself 
Nausea & vomiting AZT, ddI, PI: 
IDV,amprena-vir 
(other PIs) 
Z, Rfm, H, E Et, Of, Ci,[other FQ, PAS, Clf, Lin TMP-SMX, 
Amphotericin B 
OI, IRIS 
Gastritis  E, Z Et    





Hepatic steatosis d4T    OI, IRIS 
Cholestasis  R Clr TMP-SMX AIDS cholangiopathy 
Nephrotoxicity TDF  
(Fanconi syndrome) 
S, 
R (interstitial nephritis & GN), Z+H 
also rarely cause interstitial nephritis 
Ka, Am, Cpr, 
FQ – rarely cause IN, PAS causes 
crystalluria 




Hypokalaemia TDF  Ka, Am, Cpr Amphotericin B  
Renal calculi IDV   TMP-SMX  
Arthralgias and gout  E, Z, H, R Of, Ci, [other FQ, PAS] Thiazide (gout) HIV itself 
SJS/ TEN NNRTIs R, H (both rarely) Thiacetazone, Clr, PAS, FQ TMP-SMX  
Skin rash NNRTIs, ABC, PI Z, R, H, S, E FQ, Clf, PAS, Clr, Cpr, Et, Cy, Te TMP-SMX Folliculitis & asteatosis 
Hypersensitivity ABC R, S  TMP-SMX  
Leucopenia, anaemia AZT, 3TC R, H, Z(sideroblastic anaemia), 
RHZE rarely cause thrombocytopenia 
FQ, strep, Cy (megaloblastic), PAS, 






Lactic acidosis d4T, ddI, ddC, AZT  Lin   
Pancreatitis ddI, d4T, ddC H Lin, Clr TMP-SMX, steroids  
Insulin resistance PI esp IDV     
Hyperlipidaemia PI (except ATV), d4T   steroids  
Lipoatrophy d4T     
Lipodystrophy PIs     
Hepatitis B flare if drug 
discontinued 
TDF, FTC, 3TC     
Teratogenic EFV S Et   
Osteoporosis  TDF     















 Antiretrovirals: D4T = stavudine, ddI = didanosine, ddC = zalcitabine, Efv = efavirenz, AZT = zidovudine, IDV =indinavir, PI = Protease inhibitor, NVP = 
nevirapine, TDF = tenofovir, NNRTI = Efv + NVP, ABC = abacavir, ATV = atazanavir  
 First-line TB drugs: Rfm = rifamycins, R = rifampin, H = isoniazid, E = ethambutol, Z = pyrazinamide, S = streptomycin 
 MDR-TB drugs: Cy = cycloserine, Te = Terizidone, Of = Ofloxacin, Ci = Ciprofloxacin, Et = Ethionamide[+prothionamide], Ka = Kanamycin, Am = 
Amikacin, FQ = fluoroquinolones, Lin = linezolid, Cpr = capreomycin, Clr = clarithromycin, Clf = clofazimine,  PAS = p-amino-salicylate 
 TMP-SMX = trimethoprim sulfamethoxazole, IRIS = immune reconstitution inflammatory syndrome, OI = opportunistic infections 
 Drugs highlighted in blue should not be used simultaneously because they potentiate the drug side-effect or are associated with significantly increased 
morbidity or mortality. 



























Figure 2.1: Potential contributors to drug-drug and drug-disease interactions: 
tuberculosis, HIV-1 and co-morbid diseases and therapy 
 
Co-morbid diseases 
Opportunistic infections, sepsis, thrombosis, 
malignancy, pain, seizure disorder,  




Site of disease,  
TB drug susceptibility profile 
  
HIV-1 disease 







Therapy for co-morbid diseases 
Antivirals, antibacterials, antifungals, 
anticoagulants, antineoplastic and 
immunomodulatory agents, analgesics, 
anticonvulsants, H2 antagonists,  oral 
hypoglycaemic agents, lipid lowering agents, 
















While ART partially restores immune function and prolongs life, HIV-1 infected patients are at 
increased risk of metabolic and vascular disorders; these disorders may occur as a direct result 
of HIV-1 infection (Kaplan 2008), as side-effects of ART (von Hentig 2008, Calza 2004, Feve 
2004), or because prolonged survival allows HIV-1 infected patients to develop diseases that 
would otherwise occur later in life. As the two epidemics of HIV-1 and metabolic syndrome 
unfold in Africa, simultaneous treatment for HIV-1, diabetes mellitus and diseases due to 
atherosclerosis will challenge many clinicians. Furthermore, a subgroup of patients will still 
have an increased risk of tuberculosis recurrence (Lawn 2006) and require additional treatment 
with rifamycins.  
 
Potential drug-interactions should always be considered in HIV-1 infected patients with 
tuberculosis, especially as many drugs utilized to treat HIV-1, tuberculosis and co-morbid 
diseases are either inducers, inhibitors or substrates of cytochrome p450 (CYP) – (tables 2.2, 
2.3, 2.4). Drugs that induce a particular CYP iso-enzyme increase the rate at which the CYP 
iso-enzyme metabolizes its substrate to metabolites. Conversely, inhibitors decrease the rate of 
metabolite production resulting in increased substrate. Rifampin is a potent inducer of CYP3A4 
whereas ritonavir is an inhibitor of CYP3A4. Suboptimal anticoagulation and contraceptive 
failure may occur when warfarin and oral contraceptives, respectively, are co-administered 
with CYP inducers. Similarly, rhabdomyolysis, symptomatic hypotension and excessive 
sedation may result when statins, calcium antagonists and benzodiazepines, respectively, are 















Table 2.2: Substrates, inhibitors and inducers of cytochrome p450 enzymes (CYP),  
                   and P-glycoprotein (PGP) 
 Substrates Inhibitors Inducers 
CYP1A2 Acetaminophen  
Caffeine   
Clozapine   








































































































Abbreviations: SMX-TMP, trimethoprim-sulfamethoxazole 












Table 2.3: Pharmacokinetics of antituberculosis drugs 
Drug Name 
 
CYP P-glycoprotein Drug metabolism 
(other than CYP) 
Percentage (%) protein 
binding, principal protein 
bound to 
Substrate Inducer Inhibitor Substrate Inducer Inhibitor 
1st line TB drugs 
Rifampin No 3A4, 
1A2, 
2C, 2D6 
  Yes  Metabolized by deacetylation 
induces UDPGT and 
sulphotransferase 
85% protein bound  
Rifapentine  3A4, 
2C8/9 
     97% protein bound  
Rifabutin 3A 3A, 2D      Least protein bound -70% 
Isoniazid No 2E1 2C9, 2C19    Metabolized by NAT2 and 2E1 
Inhibits  MAO 
 
Pyrazinamide No No     Metabolite inhibits uric acid 
secretion by renal tubules 
 
Ethambutol No No     15% metabolised to aldehyde and 
dicarboxylic metabolites 
 
Streptomycin No  No   No     No identified metabolites  
Second line drugs 
Kanamycin No No  No     No identified metabolites  
Amikacin No  No  No     No identified metabolites  
Ofloxacin    Yes     
Ciprofloxacin   1A2 Yes    20 – 40% 
Moxifloxacin    Yes    40 – 50% 
Ethionamide 3A        
Capreomycin         
Clarithromycin 3A  3A1    Hydroxylation and oxidative N-
demethylation 
 
PAS       >50% acetylated  
Augmentin         
Linezolid       Metabolised by non-enzymatic 
oxidation, reversible inhibitor of 
MAO A/ B 
31%, albumin 
Cycloserine         
Terizidone         
Abbreviations: TB = tuberculosis, CYP = cytochrome p450 iso-enzyme, PAS = para-aminosalicylic acid, UDPGT = uridine diphosphate glucuronyltransferase, MAO = 
monoamine oxidase, NAT2 = N-acetyltransferase 2 












Table 2.4: Pharmacokinetics of antiretroviral drugs 
Drug Name CYP P-glycoprotein Drug metabolism 
(other than CYP) 
Percentage (%) protein 
binding, principal protein 
bound to 
Substrate Inducer Inhibitor Substrate Inducer Inhibitor 
Nucleoside Reverse Transcriptase Inhibitors 
Zidovudine       Glucuronidation 34-38% 
Stavudine        5% 
Lamivudine       5 to 10% metabolised to inactive 
trans-sulphoxide metabolite 
< 36% 
Didanosine        5% 
Zalcitabine        5% 
Abacavir       alcohol dehydrogenase, 
glucuronosyltransferase 
50% 
Nucleotide Reverse Transcriptase Inhibitor 
Tenofovir         
Non-Nucleoside Reverse Transcriptase Inhibitors 
Efavirenz 3A4, 2B6 3A4 2C9/19, 
3A4 
Yes    >99%, albumin 
Nevirapine 3A4, 2B6 3A4, 2B6  Yes    60%, albumin 
Delavirdine 3A4, 2D6, 
2C9/19 
 3A4, 2C9, 
2C19, 2D6 
Yes    98%, albumin 
Protease Inhibitors 
Amprenavir 3A4, 2D6  3A4 Yes    90% α-acid glycoprotein 
Atazanavir[ 3A4  3A, GT Yes     89%, α-acid glycoprotein 
86%, albumin 
Darunavir 3A4  3A4 Yes   Hydroxylation, hydrolysis 95% α-acid glycoprotein 
Indinavir 3A4, GT  3A4 Yes    60%, α-acid glycoprotein 
Lopinavir 3A4 GT 3A4, 2D6 Yes    98-99% α-acid glycoprotein 
Nelfinavir 3A4, 2C9 , 
2C19, 2D6 
GT 3A4 Yes    >98%, α-acid glycoprotein 
Ritonavir 3A4, 2D6 GT, 1A2, 
3A, 2C9 
3A4, 2D6 Yes  Yes  98-99%, α-acid glycoprotein 
Saquinavir 3A4  3A4 Yes    98%, α-acid glycoprotein 
Tipranavir 3A4 3A4  Yes Yes  glucuronidation >99%, α-acid glycoprotein 
Fusion Inhibitor 
Enfuvirtide       NADPH hydrolysis 92%, albumin 
Abbreviations: CYP = cytochrome p450 iso-enzyme, GT = glucuronyl transferase, NADPH = Nicotinamide adenine dinucleotide phosphate 












Rifamycins form the backbone of regimens for drug-susceptible M.tb because they reduce the 
duration of therapy, are highly effective, and are less likely than other antituberculosis drugs to 
select out resistant strains in multi-drug regimens (Rattan 1998). However, through its 
activation of a master transcriptional regulator, the pregnane X receptor (PXR), rifampin 
induces the expression of a broad array of enzymes and drug-transporting molecules including 
cytochrome P450 (CYP) 3A and CYP2C iso-enzymes, CYP2D6, CYP2B6 and p-glycoprotein, 
amongst others (Rae 2001). Thus, repeated doses of rifampin result in clinically important 
reductions in the levels of many drugs, such as PIs, NNRTIs, trimethoprim and 
sulfamethoxazole (the latter two co-formulated in co-trimoxazole widely used for prophylaxis 
in patients with advanced HIV-1 infection) (CDC 2007, Ribera 2001). The co-localization of p-
glycoprotein and CYP enzymes in enterocytes, hepatocytes and renal tubular cells may enhance 
the effects of rifampin on common substrates, such as PIs, causing more extensive pre-systemic 
metabolism and accelerated drug elimination. The clinical consequences of rifampin-related 
decreases in serum concentrations of the anti-retroviral drugs have not been fully studied, but 
they potentially lead to loss of anti-viral efficacy and stepwise accumulation of resistance 
mutations (de Requena 2005, Marzolini 2001, Dumon 2000, Masquelier 2002). Whilst 
NNRTIs, besides delavirdine, can be given with rifampin (Borin 1997), dose increases may be 
necessary. With the exception of ritonavir-boosted PIs, all other PIs are contraindicated with 
rifampin (Burman 1999).  Certain ritonavir-boosted PIs can be used with rifampin, but 
increased doses of ritonavir or a higher dose of the companion PI are required. Rifapentine, a 
rifamycin with a longer half-life, allows intermittent administration that may simplify therapy. 
Rifapentine is also a less potent inducer of CYP than rifampin. However, rifapentine has not 
been widely introduced as it is associated with increased rates of TB drug resistance when used 
once weekly during the continuation phase of antituberculosis treatment (Vernon 1999). 












resistance in patients with advanced HIV-1 infection (Burman 2009). Rifabutin, the rifamycin 
which induces CYP enzymes the least, is safe to use with most NNRTIs and PIs, except 
delavirdine and saquinavir. However, it is also a substrate for CYP3A4 (Burman 2001). Thus, 
its serum concentration and toxicity are increased when co-administered with PIs and decreased 
when co-administered with efavirenz. Rifabutin dose adjustments are required in these settings 
(CDC 2007). Rifabutin and the anti-retroviral nevirapine can be given together at standard 
doses, but delavirdine is contraindicated with rifabutin (CDC 2007). Also, the cost of rifabutin 
precludes its use in the developing world. Although they are of lesser importance, other 
pharmacokinetic interactions may confound combined treatments. Isoniazid is an inhibitor of 
CYP2C19 and CYP3A, PIs inhibit CYP3A, CYP2D6 and p-glycoprotein, and efavirenz and 
nevirapine induce the expression of CYP3A4 and CYP2B6. Other commonly co-administered 
drugs also cause important changes in anti-retroviral concentrations through induction or 
inhibition of CYP iso-forms (e.g.  anticonvulsants like carbamazepine and phenytoin may 
decrease, and azole anti-fungals, macrolide antibiotics and H2 antagonists may substantially 
increase PI or NNRTI  concentrations). 
 
Pharmacodynamic interactions further complicate combined treatment of tuberculosis and 
HIV-1. Unanticipated hepatotoxicity has been reported in healthy volunteers receiving dose-
adjusted PIs in combination with rifampin (La Porte 2004, Grange 2005). Interestingly, 
repeated doses of rifamycins before the introduction of the PIs appear to be associated with a 
higher risk of hepatotoxicity than the introduction of rifampin after establishing regular doses 
of the PIs. Although not adequately studied, such high rates of hepatotoxicity have not been 
reported in patients receiving increased doses of PIs with rifampin-based antituberculosis 
regimens, indicating that disease-related modulation of hepatotoxicity can occur. The effect of 












also a concern. It appears that HIV-1 infected patients achieve not only somewhat lower 
concentrations of rifampin and ethambutol, but also lower concentrations of isoniazid and 
pyrazinamide (Gurumurthy 2004, McIlleron 2006, Sahai 1997, Zhu 2004). Patients with more 
advanced HIV-1 disease and those with diarrhoea appear to be at most risk. Although these 
drug-disease interactions do not appear to have a marked effect on treatment outcomes, their 
importance has not been fully evaluated.  
 
High pill burden 
Combined therapies for tuberculosis and HIV-1, together with the recommended co-
trimoxazole prophylaxis, lead to a very high pill burden – an average of 15 pills per day for 6–
22 months in South Africa (fixed dose combinations (FDC) for antituberculosis medication but 
not ART). Furthermore, in high burden countries standard treatment approaches are adopted 
and FDCs are often used to reduce the pill burden and to simplify drug supply, prescribing and 
administration. Pharmacokinetic interactions necessitating dose adjustment of individual drug 
components complicate treatment delivery, especially in the context of standardised approaches 
using FDCs. Thus, optimisation of therapy inevitably leads to a greater pill burden.  
 
Immune reconstitution inflammatory syndrome 
Immune reconstitution inflammatory syndrome (IRIS), which results from dysregulated 
immune recovery (French 2000), occurs in severely immune-suppressed HIV-1 patients 
typically one to four weeks after ART initiation (Breton 2004, Narita 1998). In tuberculosis-
related IRIS, an exuberant inflammatory reaction is directed towards mycobacterial antigens 
(Bourgarit 2006). This causes worsening pulmonary infiltrates, pleural effusions, lymphadenitis 
and potentially fatal neurologic tuberculomata (Breton 2004, Narita 1998). Risk factors for TB–












antituberculosis treatment to ART initiation, and disseminated tuberculosis (Breton 2004, 
Shelburne 2005). Determining the optimal time to initiate ART in severely immune-suppressed 
tuberculosis patients is difficult (Dean 2002, Burman 2001). Early initiation of ART may 
increase the risks of TB–IRIS, non-adherence, drug toxicities and drug interactions, but the 
risks of death, other opportunistic infections (OIs) and malignancies may be greater if ART 
initiation is delayed (Lawn 2007). Corticosteroid treatment for TB–IRIS is sometimes 
recommended, but such immunosuppressive therapy may be associated with reactivation of 
occult OIs and malignancies, such as CMV and Kaposi’s sarcoma. Recently, a randomised trial 
of corticosteroids vs. placebo for TB–IRIS demonstrated the benefit of corticosteroids in 
reducing hospital admissions and improving symptoms (Meintjes 2009, Conference of 
Retroviruses and Opportunistic Infections [CROI]). However, a substantial proportion of 
patients with TB-IRIS develop life-threatening infections. Furthermore, up to 10% of patients 
presenting with TB-IRIS may have drug resistant M.tb (Meintjes 2009, CID). The benefit of 
corticosteroids always needs to be weighed against the risks of exascerbating occult infections.  
 
Co-morbid illnesses 
HIV-1 induced immunosuppression, predisposing to OIs and malignancies, coupled with 
antituberculosis/ antiretroviral drug side effects and TB–IRIS can give rise to multiple 
pathologies in certain organs, especially the liver (Table 2.2). When faced with significant 
biochemical or clinical evidence of hepatitis, it is a dilemma whether to withdraw all drugs or 
the most likely offending candidates. Evidence certainly suggests withdrawal of rifampin, 
isoniazid, pyrazinamide and NNRTI medications, the latter under the cover of a two NRTI 
‘tail’ to reduce the risk of NNRTI resistance. Substituting ‘liver friendlier’ alternatives such as 
streptomycin and quinolones to continue the treatment of tuberculosis is of uncertain efficacy. 












endoscopic retrograde cholangio-pancreatography or biopsy, poses major challenges to 
clinicians in resource-limited settings. A further problem on resolution of the hepatitis is when 
and how drugs should be re-introduced. Consensus is that no attempt be made to re-introduce 
nevirapine therapy after significant drug-induced toxicity, but it is common experience that all 
anti-tuberculosis drugs may be re-introduced. This is usually done sequentially with monitoring 
of clinical signs and hepatic enzymes. But this is a prolonged empirical exercise that maintains 
the patient in expensive hospital care and at risk of nosocomial infection. Well-conducted 
clinicopathologic studies with adequate numbers of patients are required to address these issues 




Table 2.2: Causes of liver disease in patients with tuberculosis and HIV-1 
 
 Drugs Infections Malignancies 
Transaminitis (ALT > 3 times normal) 








Canalicular Pattern (ALP > 3 times normal) 









  - Cholangiopathy 







- Enzyme induction Macrolides   
 
Protease inhibitors can cause unconjugated hyperbilirubinaemia 
Sepsis causes transaminitis with conjugated hyperbilirubinaemia 
If non-specific hepatitis (ALT < 3x normal), then consider malnutrition, NRTIs, ethanol, herbal medication 












 Treatment of HIV-1-associated latent tuberculosis infection  
ART reduces the incidence of tuberculosis, though it remains to be seen whether this benefit 
may be offset by increased survival and an overall increase in lifetime risk. Treatment of latent 
tuberculosis infection (LTBI) also reduces the risk of subsequent tuberculosis in HIV-1 infected 
people, though the duration of protection is relatively short (Woldehanna 2004). It therefore 
appears logical to potentially combine therapies to prevent tuberculosis. However, the risk-
benefit profile of preventive antituberculosis treatment in these circumstances is unknown: 
There are significant overlapping hepatic and neurological toxicities (as outlined above). In 
addition, the most effective preventive therapy is isoniazid monotherapy, but this may be 
associated with an increased risk of isoniazid resistance if inadvertently given to patients with 
active disease (de Jong 2004). Therefore, whilst the prescribing of either isoniazid or ART has 
significant benefits in HIV-1 infected persons, a randomised controlled trial is still needed to 
determine the efficacy and risks of combination isoniazid and ART. The combination regimen 
of rifampin and pyrazinamide for two months was associated with liver toxicity, even among 
HIV-1 uninfected persons, and is no longer recommended (American Thoracic Society 2000). 
There is very little evidence to guide prescription of preventive therapies in persons exposed to 
MDR-M.tb (Jasper 2002). 
 
2.4  Conclusion 
Substantial challenges exist during antituberculosis treatment in profoundly immune-
suppressed patients. These challenges relate to multi-drug therapy, high pill burdens, drug 
resistant pathogens, complex drug interactions and IRIS. Despite the incessant collision of 
tuberculosis and HIV, the entity of clinical deterioration during antituberculosis treatment is 
poorly characterised in sub-Saharan Africa. In the following chapters, I relate my previous 3 

















Clinical Deterioration during Antituberculosis Treatment 
at a District Hospital in South Africa: The importance of 














Contributions: The study was conceived and designed by the candidate, Chelsea Morroni, 
Robert J. Wilkinson and Graeme Meintjes. Data was obtained by the candidate, Kevin Rebe, 
Robert J. Wilkinson and Graeme Meintjes. The data was analysed by the candidate and Chelsea 
Morroni. The candidate compiled the initial draft which was critically revised by Kevin Rebe, 
Chelsea Morroni, Robert J. Wilkinson and Graeme Meintjes. 
Publications: Pepper DJ, Rebe K, Morroni C, Wilkinson RJ, Meintjes G. Clinical 
deterioration during antituberculosis treatment at a district hospital in South Africa: the 
importance of drug resistance and AIDS defining illnesses. PloSONE  2009; 4(2):e4520 
 
This study determined the causes and frequency of clinical deterioration during antituberculosis 




A prospective observational study conducted from 9 January to 8 April 2007 at GF Jooste 
Hospital. This is an urban 200-bed adult (>15 years age) referral hospital in Cape Town, South 
Africa that serves 1.3 million people and receives 8,000 referrals per month (Burch 2006) from 
30 primary care clinics. The national HIV-1 and Tuberculosis Programmes were described in 
Chapter 2. By April 2007, over 10,000 people had initiated ART within the hospital’s 




Eligibility. We assessed adult patients (>15 years) who received >14 days of antituberculosis 












Department or Infectious Diseases Unit. Prior to referral, patients were diagnosed with 
tuberculosis at any of the 12 tuberculosis clinics within the hospital’s catchment area. Patients 
commenced antituberculosis treatment at their tuberculosis clinic and if they deteriorated or did 
not stabilise on treatment they were referred to our hospital for assessment. Patients were 
considered eligible if clinical worsening or failure to stabilise on therapy was confirmed on 
clinical assessment by a medical doctor at the hospital. During the study, doctors and nurses at 
the clinics were not notified that the study was occurring. Patients were referred and managed 
according to current provincial practice, as recorded in the following paragraphs. 
 
Tuberculosis diagnosis and referral. Microbiological confirmation of tuberculosis disease was 
defined as a specimen, obtained from a patient with symptoms and signs of tuberculosis, which 
cultured M.tb and/or was smear positive for acid-fast bacilli (SATB guidelines 2004). An 
empiric diagnosis of tuberculosis was defined as: Antituberculosis treatment initiated when the 
tuberculosis specimen was smear negative for acid fast bacilli and culture negative (or pending) 
for M.tb but the South African National Tuberculosis Control Programme’s case definitions for 
smear-negative and extra-pulmonary tuberculosis were fulfilled (SATB guidelines 2004).  
 
Data collection. Clinical data regarding tuberculosis diagnosis, antituberculosis treatment, 
HIV-1 status and ART were recorded. Reasons for clinical deterioration were determined by 
clinical assessment and laboratory investigations performed by medical doctors working at the 
hospital. All eligible patients were assessed at admission to hospital by attending physicians in 
Internal Medicine and reviewed weekly during inpatient stay by attending physicians in 
Infectious Diseases. We performed investigations according to clinical presentation. 
Investigations included C-reactive protein, full blood count (also called complete blood cell 












renewed/ repeated diagnostic procedures to either confirm tuberculosis disease (if previously 
microbiologically unconfirmed) or to exclude drug-resistant M.tb. Specimens for tuberculosis 
microscopy, culture and sensitivity included sputum, pleural fluid, lymph node aspirates, ascitic 
fluid or cerebrospinal fluid (CSF). Chest radiography and computerised tomographic scanning 
were performed as indicated. Investigations also included sputum direct immuno-fluorescent 
antigen tests (DFAT) for Pneumocystis jiroveci pneumonia, CSF bacterial and fungal cultures, 
stool microscopy for coccidian parasites, and culture for bacteria. All patients who developed 
drug-induced hepatitis were initially managed as inpatients according to a standardised 
protocol, as follows. The tuberculosis diagnosis was evaluated by reviewing results of all 
tuberculosis specimens. After clinical stabilisation and return to baseline of liver function tests, 
patients with non-life threatening hepatitis and microbiologically proven tuberculosis were 
monitored and antituberculosis drugs were sequentially re-introduced. In severe cases 
(coagulopathy or encephalopathy), rechallenge with antituberculosis treatment causing the 
hepatitis was not attempted. Instead, patients were treated with an alternative antituberculosis 
regimen.  
 
Tuberculosis diagnostics. The South African National Health Laboratory Services performed 
tuberculosis diagnostics. Ziehl-Nielsen staining was performed within 24 hours on all 
tuberculosis specimens, while auramine staining was performed on broth culture isolates. M.tb 
liquid culture, solid media susceptibility testing for isoniazid and rifampin, and quality 
assurance were performed, as described by Barnard et al 2008. According to provincial 
protocol ethambutol (7.5 mcg/mL), ethionamide (20 mcg/mL), amikacin (30 mcg/mL), 
kanamycin (6 mcg/mL) and ofloxacin (2 mcg/mL) susceptibility testings were only performed 












the remaining three second line drugs—terizidone, capreomycin, para-aminosalicylic acid— 
were not performed.  
 
Definitions.  
Positive cultures for M.tb were categorised on the basis of drug susceptibility as: (i) susceptible 
to both isoniazid and rifampin; (ii) mono-resistant to rifampin; (iii) resistant to at least isoniazid 
and rifampin (MDR- M.tb); (iv) resistant to isoniazid, rifampin and either resistant to an 
injectable agent (amikacin or kanamycin) or ofloxacin (pre-XDR M.tb); and 
(v) resistant to isoniazid, rifampin, ofloxacin, and an injectable agent (XDR M.tb). ‘Rifampin 
resistance’ was defined as any resistance to rifampin and included rifampin monoresistant-, 
MDR- , pre-XDR- and XDR- M.tb (WHO 2007). 
 
Extended-spectrum beta lactamase (ESBL) producing bacteria were defined as bacteria having 
clavulanate-inhibited transferable enzymes able to hydrolyse third and fourth generation 
cephalosporins while methicillin-resistant Staphylococcus aureus (MRSA) had an oxacillin 
minimum inhibitory concentration (MIC) >4 mg/l.  
 
TB-IRIS was defined according to a clinical case definition (Meintjes 2008). Adherence to 
antituberculosis treatment was assessed by patient report, tuberculosis clinic cards (upon which 
daily doses taken are recorded) and/or collateral information from the health care worker at the 
tuberculosis clinic. No specific criteria were utilised but if no subsequent cause for 
deterioration was found and the patient had <80% adherence, the patient was assessed as 
having poor adherence. An additional illness to tuberculosis was defined as a second illness in 
patients where the initial tuberculosis diagnosis was microbiologically confirmed or initial 












additional illness to tuberculosis excluded poor adherence to antituberculosis treatment, 
rifampin resistant M.tb, TB-IRIS or a paradoxical tuberculosis reaction. The use of concomitant 
ART distinguished IRIS from a paradoxical tuberculous reaction; IRIS occurred in patients 
receiving ART while paradoxical TB reactions occurred in the absence of ART. An alternate 
illness to tuberculosis was diagnosed when a clinical illness initially diagnosed as tuberculosis 
was not confirmed by smear or culture, there was no clinical response to antituberculosis 
treatment and we found evidence of an alternate illness to explain the clinical presentation and 
course. 
 
Outcomes. The primary outcome of the study was reasons for clinical deterioration during 
antituberculosis treatment. The secondary outcome was the proportion of patients who started 
antituberculosis treatment and required referral to hospital for clinical deterioration 
 
Analysis. Data analysis was conducted using STATA-10 (Stata Corporation, College Station, 
Texas). Descriptive statistics were employed for basic characterization of variables. Wilcoxon 
rank-sum tests to compare medians, and Fisher’s exact test of probability to compare 
proportions were used, as appropriate, to identify associations. The Research Ethics Committee 














Characterization of cohort 
Three hundred and fifty-two patients met inclusion criteria during the 3-month period. At initial 
tuberculosis diagnosis, 163 (46%) had pulmonary tuberculosis, 67 (19%) had extra-pulmonary 
tuberculosis and 122 (35%) had pulmonary and extra-pulmonary tuberculosis. The median 
duration from initiation of antituberculosis treatment to clinical presentation was 93 days 
(interquartile range, IQR 43–149). Eighty-four percent of tuberculosis patients (n=296) 
required hospital admission for a median duration of 9.5 days (IQR 4–18). Patients admitted for 
deterioration during antituberculosis treatment accounted for 17% of medical admissions 
(296/1,755) during the three-month study period.  
 
Eighty-three percent of tuberculosis patients (n=291) were HIV-1 infected and 9% (n= 33) 
were HIV-1 uninfected (Figure 3.1). HIV-1 testing was not performed in 28 patients prior to 
referral or during investigation at our hospital; reasons included: not offered voluntary 
counselling and testing (VCT), VCT declined or patient too sick to obtain informed consent. 
Baseline features of tuberculosis patients stratified by HIV-1 status are shown in Table 3.1. 
HIV-1 infected tuberculosis patients were more likely to be female, and less likely to have a 
past history of tuberculosis or microbiological confirmation of tuberculosis (p=0.01). The 
median CD4+ count among HIV-1 infected tuberculosis patients was 89 cells/µL (n= 270). Of 
255 patients who met the South African Department of Health criteria to receive ART (SATB 




An additional illness to tuberculosis was found in 72% of tuberculosis patients whose HIV-1 























Rifampin resistant  M.tb 30 (10%)  Rifampin resistant  M.tb 11 (33%)  
Poor adherence 20   (7%)  Poor adherence 4 (12%)              
TB-IRIS 51 (18%)  TB-IRIS - 
Paradoxical tuberculosis reaction 10   (3%)         Paradoxical tuberculosis reaction - 
Alternate illness to tuberculosis 12   (4%)         Alternate illness to tuberculosis 3   (9%)        
Additional illness to tuberculosis 208 (72%)   Additional illness to tuberculosis 24 (73%)     
Additional illness to tuberculosis*   Additional illness to tuberculosis*  
New AIDS defining illness 
    20 Pneumocystis pneumonia 
    18 Cryptococcal meningitis 
    14 HIV-1 encephalopathy 
      6 Toxoplasmosis 
      6 Oesophageal candida 
      5 Non-Hodgkin’s lymphoma 
      4 Kaposi’s sarcoma  
      7 Other  
 
80   Complication of tuberculosis  
     5 Pneumothorax 
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8 Bacterial infection 








Drug toxicity  
    11 Drug induced hepatitis 





Deep vein thrombosis 
 







352 patients with clinical deterioration on 
antituberculosis treatment 
(9 January – 8 April 2007) 
324 had known 
HIV-1 status 
28 had unknown 






Figure 3.1: Final diagnoses in 352 patients with clinical deterioration on antituberculosis treatment: * Many patients had 
> 1 cause for clinical deterioration, particularly additional illnesses, HIV-1 = human immunodeficiency virus, M.tb = 
Mycobacterium tuberculosis, TB-IRIS = tuberculosis associated-immune reconstitution inflammatory syndrome, Paradoxical 
tuberculosis reaction = initial clinical improvement with subsequent recurrence of tuberculosis clinical features but no evidence 
of drug resistant tuberculosis/ or any other illness and patient not receiving antiretroviral therapy, MRSA = methicillin resistant 













Table 3.1: Characteristics of patients deteriorating on antituberculosis treatment (N=324) 















































Demographics    
Male – n (%) 138 (47) 24  (73) 0.006 
Median age – years (range) 34 (16-86) 37 (19-68) NS1 
    
Basis of tuberculosis diagnosis     
Smear +ve – n (%)  106 (36) 22 (67) 0.001 
Smear -ve / Culture +ve – n (%) 28   (10) 1   (3) NS 
Empiric diagnosis – n (%)2 157 (54) 10 (30) 0.01 
    
Previous tuberculosis      
– n (%) 101 (35) 19 (58) 0.01 
    
Admitted                              
– n (%) 238 (82) 31 (94) NS 
Median  duration  – days (IQR3) 10 (4 – 18) 11 (5 – 22) NS 
    
Outcome    
Died as inpatient – n (%) 43 (15) 5 (15) NS 
    
Illness contributory to death    
Bacterial illness  
Enteric illness  
Pneumocystis jiroveci pneumonia  
Venous thromboembolism  
Drug side effects  
Rifampin resistant-tuberculosis4  
Kaposi sarcoma  
Cryptococcal meningitis  
Neurologic TB-IRIS 
Chronic renal failure 
























1 NS: not significant, p-value significant at p≤0.05 
2 i.e. No microbiological proof at commencement of tuberculosis treatment 
3 Interquartile range 
4 Rifampin resistant-tuberculosis = Mycobacterium tuberculosis, with resistance to 
at least rifampin, cultured from a patient with clinical deterioration of symptoms 












 IRIS (n= 51) and other drug resistant bacterial infections (n =12). Twenty-four tuberculosis 
patients had poor adherence to antituberculosis treatment and fifteen patients had an alternate 
illnesses to tuberculosis.  
 
Additional illness to tuberculosis. Additional illnesses to tuberculosis differed according to 
HIV-1 status (Figure 3.1). In the HIV-1 infected group, new AIDS-defining illnesses (n= 80), 
bacterial infections (n= 53), gastroenteritis (n= 37) and drug toxicities due to ART/ 
antituberculosis/ antibiotic/ antineoplastic medications (n= 35) were most frequent. In the HIV-
1 uninfected group, complications of tuberculosis, or its therapy (n= 7), and bacterial infections 
(n =6) were most common.  
 
Antituberculosis drug resistance. Rifampin-resistant M.tb was found in 41 tuberculosis patients 
(Figure 3.2). Eight had rifampin mono-resistant M.tb, 24 had MDR- M.tb, four had pre-XDR- 
M.tb and five had XDR- M.tb. Extended sensitivity testing was performed in only 15 (37%) of 
the 41 rifampin-resistant tuberculosis cases; one third (5/ 15) of these patients had XDR- M.tb, 
while a further 27% (4/15) had pre-XDR- M.tb. Figure 2 shows M.tb culture results at initial 
TB diagnosis (left figure) and at subsequent deterioration (right figure). At initial tuberculosis 
diagnosis specimens were sent for tuberculosis culture in 237/352 (67%) patients, with 131 TB 
patients having a positive culture (Figure 3.2). Of 131 patients that cultured M.tb from 
specimens at initial tuberculosis diagnosis, 46 (35%) did not have drug susceptibility testing 
performed. Of the 85 TB patients who did have tuberculosis drug sensitivity analysis at 
diagnosis, 12 (14%) cultured rifampin-resistant M.tb and 73 patients (86%) cultured rifampin-
sensitive M.tb. At clinical deterioration, specimens were sent for tuberculosis culture in 
234/352 (66%) patients, with 69 patients culturing M.tb. Of these 69 patients, 4 (6%) did not 














Figure 3.2: Comparison of TB cultures sent (i) at TB diagnosis and (ii) when deteriorated on antituberculosis treatment (9 January – 8 April 2007): 
TB= Tuberculosis, M.tb = M. tuberculosis, RS= rifampin sensitive, RR= rifampin resistant 
6 of 12 patients who had rifampin resistant M. tuberculosis at initial tuberculosis diagnosis, re-cultured rifampin resistant M. tuberculosis at clinical deterioration  
i.e. 29 new cases of rifampin resistant M. tuberculosis were diagnosed at clinical deterioration, 8 of 73 patients who had rifampin sensitive M. tuberculosis at initial tuberculosis 
diagnosis cultured rifampin resistant M. tuberculosis at clinical deterioration 
 
2 Rifampin monoresistant M.tb 
9 MDR- M.tb 
1 XDR- M.tb 
7   Rifampin mono-resistant M.tb 
19 MDR- M.tb 
4   pre-XDR- M.tb 
5   XDR- M.tb 
352 patients  
234 patients had TB culture(s) 
69 patients cultured  M.tb 
30 patients cultured RS- M.tb 
35 patients cultured RR- M.tb 
352 patients  
237 patients had TB culture(s) 
131 patients cultured  M.tb 
73 patients cultured RS- M.tb 
12 patients cultured RR- M.tb 












Of 65 patients who had antituberculosis drug sensitivity testing at clinical deterioration, 35 
patients (54%) cultured rifampin-resistant M.tb and 30 patients (46%) cultured rifampin-
sensitive M.tb. Thus, at clinical deterioration, 29 new cases of rifampin-resistant tuberculosis 
were diagnosed. These 29 cases had the following tuberculosis results at initial diagnosis: 6 
M.tb sensitive to rifampin and isoniazid, 4 M.tb no sensitivities requested, and 3 no 
mycobacteria cultured. Sixteen of these 29 new cases of rifampin-resistant tuberculosis had no 
tuberculosis culture sent at initial tuberculosis diagnosis. Of 73 patients who had rifampin-
sensitive M.tb at initial tuberculosis diagnosis, eight (11%) cultured rifampin-resistant M.tb at 
clinical deterioration. Of these eight, 2 patients cultured rifampin-mono-resistant M.tb, 5 MDR- 
M.tb and 1 XDR- M.tb, 12 to 419 days following the start of antituberculosis treatment. Thirty-
seven percent of patients with rifampin-resistant M.tb (15/41) are known to have died within 
six months of initial assessment at the hospital. The median duration from assessment to death 
was 28 days (IQR 11–72). Forty-one patients who at initial tuberculosis diagnosis were culture 
negative (n= 11) or no culture was sent (n= 30), subsequently cultured M.tb at deterioration. In 
11% (39/352) of cases, no tuberculosis cultures were sent at initial tuberculosis diagnosis and at 
clinical deterioration. 
 
Extended spectrum beta lactamase producing organisms/ methicillin-resistant S. aureus.  
At clinical deterioration, 214/352 (61%) tuberculosis patients had specimens sent for bacterial 
culture (blood cultures performed in 128 patients). Of 214 tuberculosis patients who had >1 
specimen/s sent for bacterial culture, 35 (16%) cultured clinically significant organisms. 
Cultured organisms and specimen sites are detailed in table 3.2. Of 53 HIV-1 infected 
tuberculosis patients treated empirically for bacterial infections (Figure 3.1), 32 had 



















Table 3.2. Organisms cultured and  sites from which they were obtained* 





































*44 organisms were cultured from 38 sites from 35 patients: 
  3 patients cultured MRSA from >2 sites, 












(Table 3.3).  The CD4+ count of these 12 tuberculosis patients was 57 cells/mm3 (median, IQR 
21–80). Of nine tuberculosis patients culturing ESBL organisms, five had intermediate or high 
level resistance to amikacin while seven had high level resistance to ciprofloxacin. All were 
sensitive to imipenem, meropenem or piperacillin-tazobactam. Four tuberculosis patients had a 
septic illness due to MRSA, all were sensitive to vancomycin. One tuberculosis patient cultured 
both ESBL and MRSA organisms.   
 
Antibiotics administered to these 12 tuberculosis patients are shown in Table 3.3. Of these 13 
drug-resistant isolates, nine (69%) were drug-resistant bacteria cultured >48 hours after 
admission at GFJH (range 2–21days) while four (31%) were cultured on the day of admission. 
Six of the twelve (50%) tuberculosis patients were admitted to hospital in the month preceding 
the enrolment admission – for a median duration of 10 days (IQR 8–26). Nine tuberculosis 
patients (75%) with ESBL/MRSA infections died within 10.5 days of obtaining the specimen 
(median, IQR 6.3–14.5). 
 
TB-IRIS. We diagnosed fifty one (18%) of 291 HIV-1 infected tuberculosis patients with TB-
IRIS. The median CD4+ count nadir was 65 cells/µL (IQR 33–113). The interval from 
initiation of antituberculosis treatment to initiation of ART was 69 days (median, IQR 35–94), 
and the interval from ART initiation to onset of TB-IRIS symptoms was 14 days (median, IQR 
7-24).  
 
Alternate illness to tuberculosis. We found an alternate illness to tuberculosis in 9% of patients 
(16/181) who started empiric antituberculosis treatment. In the HIV-1 infected group (n =12), 




















































(days) A C V 
1 Klebsiella 
spp.(ESBL) 
Blood R R - Ceftriaxone + 
ciprofloxacin 
4 Yes Died 5 Yes No - 
2 Klebsiella 
spp.(ESBL) 
Blood I R - - 89 No Died 22 Yes Yes 5 
3 Klebsiella 
spp.(ESBL) 












MRSA Pus swab x2 - - S 13 No 
4 E. coli (ESBL) Blood I R - Amikacin 20 Yes Died 61 Yes Yes 11 
5 E. coli (ESBL) Blood S R - Amikacin 51 No Died 6 Yes Yes 9 
6 E. coli (ESBL) Blood S R - Amikacin 76 No Discharged alive - Yes No - 
7 E. coli (ESBL) Midstream urine S R - Amikacin unknown Yes Discharged alive - Yes No - 
8 E. coli (ESBL) Blood R S - - 167 Yes Died 10 No Yes 30 
9 E. coli (ESBL) Blood S S - Amikacin 21 No Died 11 No No - 
10 MRSA Pus swab x2 - - S Cloxacillin 38 No Died 10 Yes No - 
11 MRSA Blood - - S Vancomycin 166 No Died 8 Yes No - 
12 MRSA Pus swab x2 - - S Clindamycin 62 Yes Discharged alive - No Yes 7 
Median (IQR)      57 (21-80)   10 (8 – 14)    
Percentage       50% Died 75%  Yes, 69% Yes, 54%  
Klebsiella spp. (ESBL)=Klebsiella spp. demonstrating extended spectrum beta-lactamase activity, sensitive to Imipenem, Meropenem or Piperacillin-tazobactam, E.coli (ESBL)= 
Escherichia coli demonstrating extended spectrum beta-lactamase activity, sensitive to Imipenem, Meropenem or Piperacillin-tazobactam, MRSA = methicillin-resistant Staph. aureus, 











Kaposi’s sarcoma (n= 2), Pneumocystis jiroveci pneumonia (n =2) and non-Hodgkin’s 
lymphoma (n =2). 
 
Inpatient mortality 
Inpatient mortality did not differ significantly according to HIV-1 status (p= 0.566, Table 3.1). 
Inpatient deaths of HIV-1 infected patients (n = 43) were mainly due to bacterial infections (n= 
12), new AIDS-defining illnesses (n =10), enteric illnesses (n= 8), and pulmonary embolism 
(n= 5).  
 
Incidence of clinical deterioration 
An estimated 3500 patients start antituberculosis treatment every three months at public sector 
primary care tuberculosis clinics within our catchment area (Judy Caldwell, Western Cape 
Tuberculosis Control Programme- personal communication). Private sector antituberculosis 
treatment is not provided within our catchment area. During the 3-month study period, 352 
patients (10%, 95% confidence interval: 9–11%) deteriorated during antituberculosis treatment 













We undertook this study to investigate which reasons for clinical deterioration during 
antituberculosis treatment were most important in a setting with a high prevalence of 
tuberculosis and HIV-1. Focusing on this particular patient group may inform strategies 
seeking to improve the performance of tuberculosis and HIV-1 programmes, as well as 
optimise the rational use of limited resources. We found that at least 10% of patients starting 
antituberculosis treatment at the tuberculosis clinics experienced clinical deterioration and 
require referral to hospital. We also found that drug resistant M.tb and drug resistant bacterial 
infections were important reasons for clinical deterioration and death. Additional illnesses to 
tuberculosis accounted for most referrals, particularly new AIDS-defining illnesses and 
bacterial infections. 
 
Our findings are best explained in the context of rigorous admission criteria due to bed 
pressures at our 200-bed referral hospital; only 7.5% of adult patients referred to the emergency 
department are admitted to the medical wards. Admission is prioritised for life-threatening 
illnesses that require intravenous fluids or intravenous antibiotics (such as antibacterial or 
antifungal agents), drug resistant M.tb requiring daily inpatient intramuscular amikacin or 
kanamycin injections (while awaiting a bed at the nearby MDR-TB hospital) or patients 
requiring monitored supervision of antituberculosis treatment because of severe disease. It is 
inevitable that a larger group of patients with clinical deterioration not meeting such strict 
admission criteria was not referred to hospital for assessment. Chapter 4 reports our subsequent 
prospective study. We found that this larger group existed and that the causes for clinical 













Nearly one-sixth of our patients cultured either drug resistant M.tb or other drug resistant 
bacterial infections. This has two important implications. Firstly we have identified a clinical 
subgroup of patients, namely patients deteriorating during antituberculosis treatment, in whom 
the incidence of rifampin resistant tuberculosis (8.2%, 95% confidence interval: 5–11%) is high 
compared to the reported percentage of 2.5% for tuberculosis cases in South Africa (Weyer 
2007). Secondly, tuberculosis and HIV-1 co-infected patients in a hospital setting appear prone 
to acquire ESBL and MRSA organisms. Studies need to be conducted at other hospitals to 
confirm our findings.  
 
Nosocomial acquisition of XDR- M.tb among HIV-1 infected patients with a very poor 
outcome has recently been described in South Africa (Gandhi 2006); the contribution to death 
by co-morbid HIV-1 associated illnesses, however, was not discussed in that report. Our study 
suggests co-morbid HIV-1 associated illnesses may play a role in the death of such patients 
(Figure 3.1). The evolution from isoniazid and rifampin sensitive M.tb to rifampin mono-
resistant-, MDR-, preXDR- and XDR- M.tb in eight patients may be due to initial mixed M.tb 
strain infection (Niemann 2000), exogenous re-infection with rifampin resistant M.tb (Small 
1993) or the rapid development of M.tb drug resistance mutations despite a multidrug-regimen 
i.e. amplified drug resistance. Nosocomial re-infection of HIV-1 infected patients with MDR- 
and XDR M. tb has been documented in both resource rich and resource-constrained settings 
(Small 1993, Gandhi 2006). The possibility that drug resistance evolved rapidly in drug 
susceptible cases receiving optimal treatment appears less likely – based on clinical history and 
collateral information regarding adherence obtained from tuberculosis clinics and relatives. The 
decline in proportion of patients culturing M.tb at initial tuberculosis diagnosis and subsequent 
clinical deterioration may indicate efficacious antituberculosis treatment, inability of the patient 













Nosocomial acquisition of drug resistant bacteria is also suggested by the temporal association 
between i) the timing of specimens that cultured ESBL and MRSA organisms and ii) the 
duration of current and previous hospital admissions. The unavailability of appropriate 
antimicrobial agents likely contributed to the high mortality rate in these 12 HIV-1 infected 
tuberculosis patients. At the time of the study, the standard regimen for suspected nosocomial 
sepsis was amikacin and ceftriaxone in the absence of renal impairment, and ciprofloxacin and 
ceftriaxone if present. Vancomycin was available to treat MRSA. Because of our study 
findings, ertapenem is now available.  
 
The incidence of additional illnesses such as new AIDS-defining illnesses, bacterial infections 
and gastroenteritis is indicative of the profound immune suppression in the HIV-1 infected 
group. Multiple opportunistic infections occur simultaneously in AIDS patients. A necropsy 
study of HIV-1 infected patients from Brazil reported more than one post-mortem diagnosis in 
52% of the patients. In 48% of post-mortems, at least one AIDS-related disease not clinically 
suspected (Borges 1997). These researchers recommended aggressive investigation for 
infections and cancers in sick patients with AIDS, particularly in those not responding to initial 
antimicrobial therapy (Borges 1997). Bacterial infections and enteric illnesses were found in 
26% and 18% of HIV-1 infected patients, respectively, in our study. Current provincial 
government protocols recommend starting co-trimoxazole prophylaxis in all HIV-1 positive 
patients one month after initiating antituberculosis treatment in order to differentiate between 
side effects from antituberculosis treatment and co-trimoxazole (SATB guidelines 2004, 
TB/HIV Policy 2004). This would likely reduce bacterial infections. Adherence to this 












(chapter 4). Although only 48% of patients eligible for ART were receiving ART at 
deterioration, it is likely that some patients subsequently initiated ART.  
 
TB-IRIS was a final diagnosis in 18% (51/291) of HIV-1 infected patients. This probably 
reflects the high incidence of disseminated tuberculosis and the relatively late initiation of ART 
in profoundly immune suppressed HIV-1 patients. TB-IRIS is more likely to occur in patients 
with a low baseline CD4+ count, disseminated tuberculosis, and a short interval from initiation 
of antituberculosis treatment to ART (Breton 2004, Shelburne 2006, Dhasmana 2008).  
 
Fifteen cases of venous thrombo-embolic disease (12 deep vein thrombosis and 3 pulmonary 
embolus) were observed among this cohort. HIV-1 and rifampin are postulated risk factors for 
venous thrombo-embolic disease (White 1989, Matta 2008). 
 
Both HIV-1 uninfected and infected patients had prolonged admissions (9.5 days) compared to 
the typical duration of admission at GFJH (4 days) (Burch 2006). Longer inpatient admissions 
increase the risk of acquisition of nosocomial drug resistant pathogens, particularly in immune-
compromised patients.  
 
Our study’s limitations fundamentally relate to its design within routine care in an 
exceptionally busy setting. Firstly, studies based in hospitals suffer referral bias. Therefore, the 
extent of the problem of clinical deterioration during antituberculosis treatment cannot be 
precisely determined. This problem is clearly very significant, and is likely to impact adversely 
on overall national tuberculosis programme success. Secondly, the initial tuberculosis diagnosis 
was often defined by clinical algorithm rather than mycobacterial culture and, even at clinical 












deterioration, 182 (52%) did not culture M.tb at both tuberculosis diagnosis and at 
deterioration. Thirdly, final diagnosis relied on available diagnostic modalities, better than in 
many parts of Africa but not state-of-the-art. Resistance to second line antituberculosis agents 
was not always assayed: thus our estimates of pre-XDR and XDR- M.tb may be falsely low. 
Genotyping of drug resistance M.tb and other bacterial strains would have allowed us to better 
assess the likelihood of nosocomial transmission. 8% of patients were not tested for HIV-1 
infection. All these factors were considered in a follow-up clinic-based study of this problem 
reported in chapter 4.  
 
As a result of these findings, basic infection control measures have been strengthened; 
extraction fans have been installed at high congestion areas and natural ventilation is 
encouraged to reduce M.tb transmission. N95 respirator masks are readily available to patients, 
relatives and health care workers to reduce aerosol transmission and infection of tuberculosis. 
In September 2009, 3 isolation beds were installed into the female medical ward. Currently, the 
male ward is undergoing similar architectural modifications to further improve ventilation and 



























Chapter 4  
Clinical Deterioration during Antituberculosis Treatment 
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Our preliminary study informed us that clinical deterioration was a significant problem at our 
referral hospital, accounting for 17% of inpatient medical admissions. Moreover, drug resistant 
bacteria and AIDS-defining illnesses were important causes for deterioration and death. 
However, we still did not know the incidence or risk factors for clinical deterioration. Also, we 
did not know if the causes for clinical deterioration differed between the referral hospital and 
tuberculosis clinic.  
 
In this subsequent study, we assessed patients at initiation of antituberculosis treatment and 












clinical deterioration. We also discuss initiatives to reduce the high burden of clinical 
deterioration in resource-limited settings. 
 
4.1 Methods 
We conducted a prospective cohort study at Khayelitsha Site B tuberculosis clinic (Cape Town, 
South Africa) from 1 June 2008 through 15 February 2009. We assessed adult (>18 years age) 
patients diagnosed with tuberculosis at Khayelitsha Site B tuberculosis clinic from 1 June 2008 
through 31 August 2008 (3-month assessment period). Patients were followed for 24 weeks 
from initiation of antituberculosis treatment. Our study was nested within a tuberculosis drug 
susceptibility testing (DST) survey in which first-line DST (for isoniazid and rifampin) was 
routinely performed, regardless of HIV-1 status or previous tuberculosis. The Research Ethics 
Committee of the University of Cape Town approved this study (REC 178/2008). 
 
Study site and setting. Khayelitsha Site B tuberculosis clinic is a primary-level outpatient 
health care facility, which serves 100,000 indigent people within its catchment area. 
Approximately 1,200 adult (>18 years age) cases of tuberculosis are diagnosed per annum at 
Site B tuberculosis clinic. HIV-1 voluntary counselling and testing is offered to all patients 
diagnosed with tuberculosis at Site B Khayelitsha. In 2006, the antenatal HIV- 1 
seroprevalence in this community was 33% (95%:  29.1 – 36.9%) (Provincial Administration of 
the Western Cape [PAWC] 2007). As of March 2009, >5,000 people had initiated ART at 
Khayelitsha Site B HIV-1 clinic. The national protocols for treating tuberculosis and HIV-
AIDS were described in Chapter 2.  
 
Definitions. “Tuberculosis patients” refers to patients diagnosed with tuberculosis and initiated 












Mycobacterium tuberculosis cultured or acid-fast bacilli visualised in a biological specimen. 
Biological specimens included sputum, pleural fluid, urine, nodal aspirates, pericardial 
aspirates and cerebrospinal fluid. We defined microbiologically-unconfirmed tuberculosis 
according to the WHO case definitions for smear-negative and extra-pulmonary tuberculosis 
(WHO 2007). Biological specimens were obtained at tuberculosis diagnosis, at 8 and 20 weeks’ 
follow-up and at clinical deterioration. First-line DST using the GenoType MTBDRplus assay 
(Hain Lifescience 2009) was performed on biological specimens that were smear-positive for 
acid-fast bacilli and/ or culture positive for M.tb. We defined multidrug-resistant (MDR) 
tuberculosis as M.tb with resistance to isoniazid and rifampin. 
 
We defined clinical deterioration as symptomatic worsening or failure to stabilise within 24 
weeks following initiation of antituberculosis treatment. We subdivided the causes of clinical 
deterioration into HIV-1 related illnesses and HIV-1 unrelated illnesses. HIV-1 related causes 
included AIDS-defining illnesses (according to WHO criteria), and non AIDS-defining 
illnesses i.e. Non AIDS-defining HIV-1 related infections. HIV-1 unrelated illnesses included 
tuberculosis-related illnesses, and non tuberculosis-related illnesses i.e. co-morbid illnesses. 
Tuberculosis-related illnesses included MDR-TB, deterioration due to poor adherence, 
paradoxical tuberculosis-associated immune reconstitution inflammatory syndrome (TB-IRIS) 
and paradoxical reactions. Co-morbid illnesses were acute illnesses that occurred after 
tuberculosis diagnosis and were considered not to be directly attributable to HIV-1 or 
tuberculosis. Pre-existing conditions were not included in co-morbid illnesses. 
 
We defined TB-IRIS according to the consensus clinical case definition for resource-limited 












consensus clinical case definition of paradoxical TB-IRIS (Meintjes 2008). Three criteria were 
required for a diagnosis of paradoxical reaction: 
1. Diagnosis of tuberculosis (microbiologic confirmation or according to WHO criteria [WHO 
2007]) with initial response to antituberculosis treatment, 
2. The recurrence/ new onset of tuberculosis disease manifestations within 24 weeks of 
antituberculosis treatment, and 
3. Exclusion of alternative explanations for clinical deterioration (such as antituberculosis 
drug resistance, poor adherence, drug toxicity or reaction, or an additional infection). 
Paradoxical reactions were diagnosed in both HIV-1 infected and uninfected patients. HIV-1 
infected patients receiving ART at clinical deterioration were diagnosed with TB-IRIS rather 
than a paradoxical reaction, according to our definitions.   
 
We defined a patient as being lost to follow-up if we were unable to trace a patient 24 weeks 
after initiation of antituberculosis treatment. We used clinic and hospital medical notes, as well 
as the National Health Laboratories Service database to trace specimens and the Provincial 
Government of the Western Cape’s electronic tuberculosis register to trace patients. 
 
Assessment of patients with clinical deterioration. The study was discussed with physicians 
and nurses at the tuberculosis clinic prior to commencement of the study. Adult patients with 
clinical deterioration within 24 weeks of initiation of antituberculosis treatment were 
prospectively evaluated (regardless of severity of illness, eventual diagnosis, or inpatient or 
outpatient management) to determine the reason for clinical deterioration. Stable patients were 
assessed at Khayelitsha Site B tuberculosis clinic; patients requiring hospital admission or 
invasive outpatient procedures were assessed at GF Jooste Hospital (the clinic’s referral 












drug-resistant M. tuberculosis. Specimens were also cultured for bacterial organisms. Deaths 
were recorded using the Provincial Government of the Western Cape’s electronic tuberculosis 
register and Clinicom Systems, and included both inpatient deaths and death outside the 
hospital. Various spellings and combinations of a patient’s first and last name were utilised, 
with the date of birth, to follow-up patients. Where patients were alive or lost to follow-up at 24 
weeks, the electronic database was checked on three successive occasions, each 2 weeks apart. 
 
Data collection and analysis. Data collected included demographic information, tuberculosis 
specimen results, HIV-1 status, ART, CD4+ cell count at tuberculosis diagnosis, diagnosis at 
clinical deterioration and outcome 24 weeks after initiation of antituberculosis treatment. 
Statistical analyses were performed using Stata 10.0 (Texas, USA). Wilcoxon rank-sum and 
Kruskall-Wallis tests were used for group comparisons, and Fisher’s exact tests to compare 
proportions. Variables with the outcome of interest were entered into Cox proportional hazards 
models to assess independent effects of covariates. Significant variables were removed from 
the model to assess whether these effects remained. The assumptions of the Cox model were 
verified; non-informative censoring was performed and the test for the proportional hazards 
assumption was not significant. We censored patients at clinical deterioration when performing 
Cox-proportional hazards model analysis and relative risk calculations. We censored patients at 
loss to follow-up when determining the incidence rate of clinical deterioration (illnesses 















During the 3-month assessment period (figure 4.1), 305 adults (> 18 years age) initiated 
antituberculosis treatment, 7 of whom had untraceable clinical records and 6 of whom declined 
HIV-1 testing. We restricted our data analysis to the 292 (96%) patients whose HIV-1 status 
and clinic records were available. In 209 HIV-1 infected and 83 HIV-1 uninfected patients, loss 
to follow-up (46 [22%] of 209 vs. 29 [35%] of 83, p-value= 0.026) and mortality (16 [8%] of 
209 vs. 1 [1%] of 83, p-value= 0.048) differed significantly at 24 weeks of follow-up. 
 
At initial tuberculosis diagnosis (table 4.1), HIV-1 infected patients were more likely than HIV-
1 uninfected patients to be female, be of younger age, have extra-pulmonary tuberculosis and 
be diagnosed with tuberculosis at the referral hospital. HIV-1 uninfected patients were more 
likely than HIV-1 infected patients to have microbiologic confirmation of tuberculosis at initial 
tuberculosis diagnosis and during the 24 weeks of follow-up.  
 
Prior to tuberculosis diagnosis, 34 (23%) of 145 HIV-1 infected patients qualifying for ART 
under the national guidelines were receiving ART. Six months later, 109 (75%) of 145 patients 
had received ART.   
 
Causes of Clinical Deterioration and Hospital Admission 
During the 24 weeks of follow-up, 117 (40%, 95% CI: 35 –46%) of 292 tuberculosis patients 
experienced clinical deterioration, of whom 101 were HIV-1 infected and 16 were HIV-1 
uninfected. Causes of clinical deterioration (table 4.2) included: co-morbid illnesses (70 
patients), tuberculosis-related illnesses (47 patients), non AIDS-defining HIV-1 related 
































Figure 4.1: Flow-diagram of 305 adult patients who started antituberculosis treatment 
during 3-month assessment period (1 June – 31 August 2008) 
1 Subsequent data analysis for 292 patients with known HIV-1 status 
2 CD4+ counts not performed in 3 of 209 HIV-1 infected patients 
 
305 Adults (> 18 years) started TB chemotherapy from 1 June through 31 August 2008 
7 records untraceable  
6 declined HIV testing 
292 HIV-1 status known1 
209 HIV-1 infected2 83 HIV-1 uninfected 
1 died 
29 lost to follow-up 
16 died 
46 lost to follow-up 
147 completed 24 
weeks of follow-up 
53 completed 24 












Table 4.1: Baseline characteristics and microbiologic confirmation of tuberculosis in 209 HIV-1 infected 
and 83 HIV-1 uninfected patients receiving antituberculosis treatment
 HIV-1 infected (n=209) HIV-1 uninfected (n=83) p-value 
Female, n (%) 112 (54) 25 (30) <0.001 
Age  in years, median (IQR) 35 (30-41) 38 (29-49) 0.035 
CD4+ count at TB diagnosis, n (%):    
>350 cells/mm3 36 (17) -  
200 – 350 cells/mm3 37 (18) -  
< 200 cells/mm3 133 (64) -  
Not performed 3 (1) -  
Previous TB, n (%) 71 (34) 19 (23) 0.070 
TB diagnosed at referral hospital, n (%): 79 (38) 13 (16) <0.001 
Microbiologic confirmation at TB diagnosis1, n (%) 123 (59) 68 (82) <0.001 
Drug susceptibilities known at TB diagnosis1, n (%) 67 (32) 49 (59) <0.001 
Culture sent at TB diagnosis, n (%) 169 (81) 68 (82) 1.000 
Extra-pulmonary TB, n (%): 82 (39) 14 (17) <0.001 
Weight at TB diagnosis in kg, median (IQR) 54 (49–62) 54 (49–64) 0.644 
Microbiologic confirmation at TB diagnosis and during 24 
weeks of follow-up2, n (%) 
153 (73) 70 (84) 0.048 
Drug susceptibilities known at TB diagnosis and during 24 
weeks of follow-up2, n (%) 
117 (56) 57 (69) 0.296 
Culture sent at TB diagnosis and/ or during 24 weeks of 
follow-up, n (%) 
190 (91) 76 (92) 1.000 
1 within 14 days of TB diagnosis. No TB specimens sent in 12 HIV-1 infected patients and 3 HIV-1 uninfected patients at TB diagnosis.  
2 no TB specimens sent in 2 HIV-1 infected patients. 












Table 4.2: Illnesses (n=199) in 101 HIV-1 infected and 16 HIV-1 uninfected patients                                                            






number of illnesses = n, (total number of patients = pnts) 180 (101) 19 (16) 
1. Tuberculosis-related illnesses, n (pnts) 49 (43) 5 (5) 
TB-IRIS 22 - 
Paradoxical reaction 17 4 
MDR-TB1 4 1 
Deterioration due to poor adherence 5 - 
Low rifampin concentration in comparison to the recommended 
range 
1 - 
2. AIDS-defining illnesses, n (pnts) 29 (21) - 
Oesophageal candida  11 - 
Pneumocystis jiroveci pneumonia2  5 - 
Cryptococcal meningitis 4 - 
Cytomegalovirus retinitis 3 - 
Other3 6 - 
3. Non-AIDS defining HIV-1 related infections, n (pnts) 27 (25) - 
Superficial herpes infection4 9 - 
Bacterial infection5 9 - 
Fungal (oral/ vaginal/superficial) infection 9 - 
4. Co-morbid illnesses, n (pnts) 76 (59)6 14 (11)7 
Key:  
TB = tuberculosis; TB-IRIS = TB-associated immune reconstitution inflammatory syndrome 
1 MDR-TB: Mycobacterium tuberculosis resistant to rifampin and isoniazid 
2 All patients diagnosed with Pneumocystis jirovecii pneumonia had a history of good compliance with 
trimethoprim sulfamethoxazole chemoprophylaxis(160/800mg daily). 
3 Other = HIV-1 associated nephropathy (2), HIV-1 associated encephalopathy (2), Disseminated Kaposi’s 
sarcoma (2) 
4 5 patients diagnosed with herpes simplex, 4 patients diagnosed with herpes zoster (all < 1 month duration) 
5 Urinary tract infection (3) – E.coli, Klebsiella sp., enterococcus; Pelvic inflammatory disease (3); H.influenza 
pneumonia (1); otitis media(1); carbuncle(1) 
6 76 illnesses diagnosed in 59 patients: 
CD4+ > 350 cells/ mm3 = 7 illnesses diagnosed in 7 patients: deep venous thrombosis (2); sacroiliitis (1); 
acute asthmatic attack (1); cardiomyopathy (1); severe epistaxis (1); supra-condylar fracture (1), 
CD4+ 200 – 350 cells/ mm3 = 12 illnesses diagnosed in 7 patients: enteric illness with no pathogen isolated 
(4); hyperglycaemic emergency (2); seizures, cause not determined (2); acute asthmatic attack (1); efavirenz 
side-effect (1); deep venous thrombosis (1); haemorrhoids/ fistula-in-ano (1), 
CD4+ < 200 cells/mm3 = 56 illnesses in 44 patients: peripheral neuropathy (12); enteric illness with no 
pathogen isolated (8); deep venous thrombosis (7); dermatitis (4); cerebrovascular accident (3); scabies (3); 
minor traumatic injury (3); pneumothorax (2); pancreatitis (1); cardiomyopathy (1); miscarriage (1); 
cryptococcal IRIS (immune reconstitution inflammatory syndrome) adenitis (1); drug induced hepatitis (1); 
cause not determined but patient subsequently improved (9). 
7 14 illnesses diagnosed in 11 patients: Drug side effect (3) – hydrochlorothiazide (1), pyrazinamide (1), 
kanamycin (1); hyperglycaemic emergency (2); post-TB bronchiectasis (1); peripheral neuropathy (1); 













enteric illness and deep venous thrombosis were frequent reasons for co-morbid illnesses. TB-
IRIS and paradoxical reactions were frequent reasons for tuberculosis-related illnesses. 
Oesophageal candida, Pneumocystis jirovecii pneumonia and cryptococcal meningitis were 
frequent reasons for AIDS-defining illnesses. Of 117 patients who experienced deterioration, 
30 (26%) required hospital admission [27 (27%) of 101 HIV-1 infected and 3 (19%) of 16 
HIV-1 uninfected patients (p-value= 0.756)]. Causes of inpatient hospital admission were 
paradoxical reaction or TB-IRIS (9 patients), new AIDS-defining illness (8 patients), deep 
venous thrombosis (6 patients), MDR-TB (2 patients), cardiomyopathy (1 patient), 
pneumothorax (1 patient), symptomatic deterioration due to poor adherence with 
antituberculosis treatment (1 patient), hyperglycaemic emergency (1 patient) and seizure 
disorder (1 patient). 
 
Risk Factors for Clinical Deterioration 
In the 292 tuberculosis patients (Table 4.3a), 4 factors were significantly associated with 
clinical deterioration in univariate analysis: HIV-1 infection, diagnosis of tuberculosis at the 
referral hospital, evidence of extra-pulmonary tuberculosis, and absence of a DST result at 
tuberculosis diagnosis. Only HIV-1 infection (figure 4.2a) remained significant in multivariate 
analysis (hazard ratio [HR]= 2.0, 95% CI=1.1–3.6). 
 
In subsequent analysis (figures not shown), we assessed whether the probability of clinical 
deterioration from non HIV-1 related causes was associated with HIV-1 infection. In univariate 
analysis, we found a significant association with HIV-1 infection and non HIV-1 related causes 
for deterioration (RR = 1.3, 95% CI: 1.07 – 1.50). However, in the Cox proportional hazards 












analysis suggests that HIV-1 infection is a significant variable for clinical deterioration because 
of HIV-1 related illnesses (either AIDS- or non AIDS-defining illnesses). 
 
In the 209 HIV-1 infected tuberculosis patients (Table 4.3b), 3 factors were significantly 
associated with clinical deterioration in univariate analysis: a lower CD4+ count, diagnosis of 
tuberculosis at the referral hospital, and ART received during antituberculosis treatment. Only a 
lower CD4+ stratum at tuberculosis diagnosis (figure 4.2b) remained significant in multivariate 
analysis (HR = 1.5, 95% CI=1.1–2.2). 
 
In subsequent analysis (figures not shown), we assessed whether the probability of clinical 
deterioration from non HIV-1 related causes was associated with decreasing CD4+ counts. We 
found no significant association with decreasing CD4+ counts and non HIV-1 related causes in 
both univariate analysis (P=0.189) and the Cox proportional hazards model (HR=1.3, 95%CI: 
0.88 – 1.97). This analysis suggests that decreasing CD4+ counts are a significant variable for 














Table 4.3a: Univariate risk factor analysis for clinical deterioration in 292 patients                                                                             





p-value RR 95% CI 
Female, n (%) 62 (53) 75 (43) 0.095 1.3 0.96 - 1.69 
Age  in years, median (IQR) 36 (31-45) 35 (29- 43) 0.327   
Previous TB, n (%) 35 (30) 55 (31) 0.798 1.0 0.70 - 1.30 
HIV-1 infected, n (%) 101 (86) 106 (61) <0.001 2.6 1.63 - 4.12 
Weight at TB diagnosis in kg, median (IQR) 54 (49–61) 54 (49–64) 0.599   
TB diagnosed at hospital, n (%): 52 (44) 40 (23) <0.001 1.7 1.33 - 2.28 
Extra-pulmonary TB, n (%): 50 (43) 46 (26) 0.005 1.5 1.16 – 2.00 
Microbiologic confirmation at TB diagnosis1, n (%) 69 (59) 122 (70) 0.061 0.8 0.58 – 1.00 
Microbiologic confirmation with drug susceptibilities known 
at TB diagnosis1, n (%) 
37 (32) 79 (45) 0.028 0.7 0.51 – 0.96 
Table 4.3b: Univariate risk factor analysis for clinical deterioration in 209 HIV-1 infected patients                                                      





p-value RR 95% CI 
Female, n (%) 55 (54) 57 (53) 0.890 1.0 0.78 – 1.37 
Age  in years, median (IQR) 36 (29 – 43) 35 (30 – 41) 0.517   
Previous TB, n (%) 31 (31) 40 (37) 0.381 0.9 0.63 – 1.18 
Median CD4 count (cells/mm3), n (IQR) 79 (33 - 199) 184 (80 - 350) <0.001   
Weight at TB diagnosis in kg, median (IQR) 55 (49 – 62) 53 (49 – 62) 0.885   
TB diagnosed at hospital, n (%) 50 (50) 28 (26) <0.001 1.6 1.26 – 2.16 
Extra-pulmonary TB, n (%) 46 (46) 36 (33) 0.089 1.3 0.98 – 1.71 
Microbiologic confirmation at TB diagnosis1, n (%) 57 (56) 66 (61) 0.574 0.9 0.68 – 1.20 
Microbiologic confirmation with drug susceptibilities known 
at TB diagnosis1, n (%) 
29 (29) 38 (35) 0.374 0.9 0.62 – 1.17 
TMP-SMX2 chemoprophylaxis, n (%) 91 (90) 90 (83) 0.162 1.4 0.84 – 2.36 
Antiretroviral treatment3 during TB treatment, n (%) 62 (61) 47 (44) 0.013 1.5 1.09 – 1.96 
1 Within 14 days of TB diagnosis. No TB specimens sent in 12 HIV-1 infected patients and 3 HIV-1 uninfected patients at TB 
diagnosis. 
2 TMP-SMX = trimethoprim sulfamethoxazole 160/800mg daily 
3 Antiretroviral treatment regimens were as follows: D4T/3TC/EFV (89 patients), D4T/3TC/NVP (3 patients), AZT/3TC/EFV 
(13 patients), AZT/3TC/NVP (2 patients), TDF/3TC/EFV (2 patients); D4T= stavudine 30mg twice daily, 3TC = lamivudine 
150mg twice daily, EFV = efavirenz 600mg nocte, AZT = zidovudine 300mg twice daily,  NVP = nevirapine 200mg twice 
daily, TDF = tenofovir 300mg daily 
















Adjusted Hazard Ratio (95% CI) 
0.9 (0.64 – 1.40) 
1.0 (0.68 – 1.54) 
1.1 (0.72 – 1.70) 
2.0 (1.13 – 3.63) 
0.8 (0.50 – 1.20) 
1.3 (0.86 – 2.08) 
1.4 (0.82 – 2.20) 
1.1 (0.67 – 1.68) 
1.0 (0.64 – 1.52) 
0.9 (0.57 – 1.42) 
1.5 (1.05 – 2.17) 
0.8 (0.50 – 1.27) 
1.6 (0.97 – 2.47) 
1.1 (0.68 – 1.72) 
1.3 (0.76 – 2.06) 
0.9 (0.42 – 1.71) 
0.8 (0.48 – 1.24) 
1.0 (0.62 – 1.59) 
Adjusted Hazard Ratio (95% CI) 
*CD4 count not performed in 3 of 209 HIV-1 infected patients 
(1) Microbiologic confirmation with drug susceptibilities known at tuberculosis diagnosis 
(2) CD4 strata used: Stratum 1 = CD4+ > 350 cells/ µL, stratum 2 = CD4+ from 200 – 350 cells/ µL, stratum 3 = CD4+ < 200 cells/ µL;  
(3) TMP-SMX chemoprophylaxis = Trimethoprim sulfamethoxazole 160/800mg daily 
(4) Antiretroviral treatment regimens as follows: D4T/3TC/EFV (89), D4T/3TC/NVP (3), AZT/3TC/EFV (13), AZT/3TC/NVP (2), TDF/3TC EFV (2); D4T= 
stavudine 30mg twice daily, 3TC = lamivudine 150mg twice daily, EFV = efavirenz 600mg nocte, AZT = zidovudine 300mg twice daily,  NVP = nevirapine 
200mg twice daily, TDF = tenofovir 300mg daily  
TB = tuberculosis, DST = drug susceptibility testing, ART = antiretroviral treatment, 95% CI = 95% confidence interval 
 
 
Figure 4.2a: Hazard ratios (95% CI) of risk factors 
for clinical deterioration during 24 weeks of 
antituberculosis (TB) treatment in 292 patients 
(Cox proportional hazards model) 
Figure 4.2b: Hazard ratios (95% CI) of risk 
factors for clinical deterioration during 24 weeks 
of TB treatment in 206 HIV-1 infected patients 












Relative Risk and Incidence Rate of Clinical Deterioration 
HIV-1 infection and a low CD4+ count were the only significant risk factors for clinical 
deterioration in multivariate analysis. We therefore used HIV-1 status and CD4+ stratum to 
determine the relative risk and incidence rate of clinical deterioration during the 24 weeks of 
follow-up. Using HIV-1 uninfected patients as referent group, the relative risk (RR) of clinical 
deterioration increased as the CD4+ counts in HIV-1 infected patients decreased (CD4+ >350 
cells/L: RR = 1.4, 95% CI = 0.7–2.9; CD4+ 200–350 cells/L: RR = 2.0, 95% CI = 1.1–3.6; 
CD4+ <200 cells/L: RR = 3.0, 95% CI = 1.9–4.7). The incidence rate (IR) of clinical 
deterioration (illnesses diagnosed per 100 months of follow-up) also increased as the CD4+ 
counts decreased. Incidence rates differed significantly between HIV-1 uninfected patients (IR 
= 5.1, 95% CI = 3.1–7.5) and HIV-1 infected patients with a CD4+ count of 200-350 cells/L 
(IR = 12.3, 95% CI = 8.2–17.0). Similarly, incidence rates differed significantly between HIV-
1 infected patients with a CD4+ count of 200-350 cells/L and HIV-1 infected patients with a 
CD4+ count < 200 cells/L (IR = 20.7, 95% CI 17.8–23.9). 
 
Figure 4.3 is a Lowess plot showing the proportion of patients who experienced clinical 
deterioration during the 24 weeks of antituberculosis treatment. The initial peak at 6 weeks in 
HIV-1 uninfected patients corresponds with tuberculosis-related illnesses (mostly paradoxical 
reactions) and the baseline fluctuations represent co-morbid illnesses. The curve for HIV-1 
infected patients with a CD4+ count > 350 cells/L is similar to that of HIV-1 uninfected 
patients, despite an earlier peak for paradoxical reactions. The proportion of HIV-1 infected 
patients with a CD4+ count of 200-350 cells/L who experienced clinical deterioration 
substantially increased after 10 weeks of follow-up. Furthermore, a substantially higher 
proportion of HIV-1 infected patients with a CD4+ count <200cells/L experienced clinical 














Fifteen of 17 deaths occurred in HIV-1 infected patients with a CD4+ count < 200cells/L. The 
median interval from antituberculosis treatment to death was 98 days (IQR= 59 -128). Eight of 
17 deaths occurred between 10 and 20 weeks of follow-up. Diagnoses at time of death 
included: AIDS-defining illnesses (5), poor adherence with antituberculosis treatment (4), 
paradoxical neurologic TB-IRIS (3), enteric illness (2), MDR-TB (1), pulmonary embolus (1) 























Week  1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 
Number in follow-up                          
HIV-1 uninfected  79 76 76 74 74 72 72 71 69 68 66 65 64 63 62 60 59 59 57 57 56 55 54 53 
HIV-1 infected, CD4+ > 350  36 35 35 35 33 33 33 31 31 31 31 30 30 30 29 28 28 28 28 26 24 24 24 24 
HIV-1 infected, CD4+ = 200-350  37 37 37 37 37 37 37 36 36 36 36 36 36 36 35 34 32 32 32 32 32 32 32 31 
HIV-1 infected, CD4+ < 200  132 129 126 126 124 125 125 125 122 116 116 114 112 111 109 107 106 103 100 99 96 94 93 92 
                         
Number with deterioration                          
HIV-1 uninfected  1 0 1 2 1 3 2 2 1 0 0 0 0 0 0 1 0 0 2 0 0 0 1 1 
HIV-1 infected, CD4+ > 350  0 1 0 3 1 2 0 0 1 0 0 0 1 0 0 0 0 0 0 1 0 0 1 0 
HIV-1 infected, CD4+ = 200-350  1 0 1 1 0 3 0 1 0 0 1 2 2 0 1 3 1 1 0 1 0 0 1 1 
HIV-1 infected, CD4+ < 200  6 12 10 3 4 3 10 7 6 6 7 6 6 6 4 2 3 4 6 4 1 2 1 1 
                         
Percentage with deterioration                          
HIV-1 uninfected  1.3 0.0 1.3 2.7 1.4 4.2 2.8 2.8 1.4 0.0 0.0 0.0 0.0 0.0 0.0 1.7 0.0 0.0 3.5 0.0 0.0 0.0 1.9 1.9 
HIV-1 infected, CD4+ > 350  0.0 2.9 0.0 8.6 3.0 6.1 0.0 0.0 3.2 0.0 0.0 0.0 3.3 0.0 0.0 0.0 0.0 0.0 0.0 3.8 0.0 0.0 4.2 0.0 
HIV-1 infected, CD4+ = 200-350  2.7 0.0 2.7 2.7 0.0 8.1 0.0 2.8 0.0 0.0 2.8 5.6 5.6 0.0 2.9 8.8 3.1 3.1 0.0 3.1 0.0 0.0 3.1 3.2 
HIV-1 infected, CD4+ < 200  4.5 9.3 7.9 2.4 3.2 2.4 8.0 5.6 4.9 5.2 6.0 5.3 5.4 5.4 3.7 1.9 2.8 3.9 6.0 4.0 1.0 2.1 1.1 1.1 
                         
Number of deaths                          
HIV-1 uninfected  0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
HIV-1 infected, CD4+ > 350  0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
HIV-1 infected, CD4+ = 200-350  0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 













During 24 weeks of follow up, 40% of patients experienced clinical deterioration.  In 
multivariate analyses, significant risk factors for clinical deterioration were HIV-1 infection 
and a low CD4+ count at tuberculosis diagnosis. The relative risk of clinical deterioration in 
HIV-1 infected patients did not differ significantly in two of three CD4+ strata (CD4+ count of 
200 - 350 cells/L and < 200cells/ L). However, the incidence rate of clinical deterioration 
was significantly higher in those with a CD4+ count < 200 cells/ L. This difference can be 
attributed to multiple illnesses occurring in profoundly immune suppressed patients.  
 
A distinct pattern of clinical deterioration emerged during the 24 weeks of follow-up (Figure 
3). After 10 weeks of follow-up, we observed a rise in the proportion of patients with a CD4+ 
count of 200 -350 cells/ L who experienced clinical deterioration. Few of these patients had 
initiated ART (according to national protocol [SATB guidelines 2004]). Further studies are 
needed to determine whether ART initiated soon after tuberculosis diagnosis in this subgroup 
could reduce the incidence of clinical deterioration. A triple wave of illnesses occurred in 
profoundly immune-suppressed HIV-1 infected patients (CD4+ count < 200cells/L). The first 
wave (0–4 weeks) comprised co-morbid illnesses and AIDS-defining illnesses (data not 
presented). This highlights the profound immune-suppression at tuberculosis diagnosis and the 
rapid occurrence of AIDS-defining illnesses soon thereafter. The second wave represented co-
morbid illnesses, tuberculosis-related illnesses and non AIDS-defining HIV-1 related 
infections, while the third wave included tuberculosis-related and co-morbid illnesses. This 
demonstrates that immune restoration during antituberculosis treatment and ART is not without 
complications (Meintjes 2008). The substantial occurrence of co-morbid illnesses throughout 
the 24 weeks of follow-up was unexpected. Hepatic, renal and cardiovascular related morbidity 












illnesses causing death in HIV-1 uninfected tuberculosis patients have also been reported 
(Sterling 2006). However, the magnitude of co-morbid illnesses in HIV-1 infected patients 
receiving antituberculosis treatment has not previously been reported. The plethora of illnesses 
and the 15 deaths (related to AIDS-defining illnesses, poor adherence, and neurologic TB-IRIS) 
suggest that the management of tuberculosis in profoundly immune-suppressed HIV-1 infected 
patients is complicated. 
 
Due to the observational nature of our study, we were unable to compare the incidence of 
clinical deterioration after ART initiation in two groups of tuberculosis patients: those with a 
CD4+ count of 200-350 cells/L and those with a CD4+ count < 200cells/ L. Only patients in 
the latter group were eligible for ART according to South African guidelines (SATB guidelines 
2004). Further interventional research is needed to determine whether initiation of ART after 
tuberculosis diagnosis reduces the incidence of clinical deterioration in patients with a CD4+ 
count of 200 -350 cells/ L. 
  
Fewer deaths than anticipated occurred during the first 8 weeks [5]; many deaths (8 of 17) 
occurred from weeks 10 to 20 of follow-up. It is possible that patients with severe tuberculosis 
may have died in the referral hospital, precluding enrolment in our study. Patients requiring 
hospital admission for fatal AIDS-defining illnesses at tuberculosis diagnosis would similarly 
have not been enrolled. Ninety-two (32%) of 292 patients were diagnosed with tuberculosis at 
hospital, suggesting that tuberculosis disease at tuberculosis diagnosis was severe. 
 
Bacterial pneumonia is an important cause of hospitalisation and death in HIV-1 infected 
patients with (Corbett 2002), or without (Martinson 2007) a diagnosis of tuberculosis. In our 












influenzae). We attribute this finding to the combined antibacterial properties of rifampin and 
trimethoprim-sulfamethoxazole (TMP-SMX) (Dirienzo 2002). Most HIV-1 infected patients 
(86%) in our study received TMP-SMX chemoprophylaxis (160/ 800mg daily).  
 
We diagnosed symptomatic drug-induced hepatitis in one patient. Drug-induced hepatitis, 
defined as a 5-fold rise in liver enzymes (AST or ALT), is reported in 2-28% of patients 
receiving antituberculosis treatment (Tostmann 2008) and 6% of HIV-1 infected patients 
receiving both antituberculosis and antiretroviral treatment (Dean 2002). In our study, liver 
function tests were not performed in asymptomatic patients receiving antituberculosis treatment 
or efavirenz-based ART, according to routine practice. Liver function tests were performed 
when patients experienced clinical deterioration.  
 
During the course of our study, DST was performed at tuberculosis diagnosis, at 8 and 20 
weeks of follow-up and at clinical deterioration. This differs from routine practice in South 
Africa where only certain patients (such as those receiving retreatment for tuberculosis and 
those who do not respond to antituberculosis treatment – SATB guidelines 2004) receive DST 
due to resource constraints. The ability to perform DST in all patients in our study, regardless 
of previous tuberculosis, likely expedited diagnosis and appropriate management of MDR-TB, 
especially where the differential diagnoses included MDR-TB and TB-IRIS.  
 
Our study has some limitations. Our definition of clinical deterioration (symptomatic 
worsening or failure to stabilise within 24 weeks after initiation of antituberculosis treatment) 
did not include episodes of clinical deterioration that occurred after 24 weeks of follow-up. 
Twenty-four weeks of follow-up is a short period of observation. It is possible that the causes 












patients diagnosed with MDR-TB during follow-up (n=5) may underestimate the incidence of 
MDR-TB presenting after 24 weeks. It is noteworthy that 6 patients were diagnosed with 
MDR-TB during the 24 weeks of follow-up without fulfilling our definition of clinical 
deterioration. We have previously described the phenomenon of initial clinical improvement 
with rifampin-resistant M. tuberculosis despite receiving standard antituberculosis treatment 
(Meintjes 2009). At diagnosis of MDR-TB in these 6 patients, we appropriately intensified 
their antituberculosis treatment and no subsequent clinical deterioration occurred. We also 
excluded isolated radiological worsening from our case definition of clinical deterioration. 
Thus, our finding of clinical deterioration in 40% of patients may be an underestimate. A 
substantial proportion of patients were lost to follow-up. The median CD4+ count among HIV-
1 infected patients who were lost to follow-up was 150 cells/µL (IQR= 67-338). Chapter 5 
describes risk factors for loss to follow-up. Also, there were some patients in whom the cause 
of deterioration could not be identified. Our study did not evaluate the proportion of patients 
with known HIV-1 status prior to tuberculosis diagnosis. Patients who we initially assessed at 
the tuberculosis clinic, who subsequently presented to the hospital, and then deteriorated and 
died during their first hospital admission, were included in the analysis. It is possible that some 
patients within the tuberculosis clinic’s catchment area were not included in the study. These 
patients might have died prior to assessment at the tuberculosis clinic. Lastly, this study was 
conducted at a tuberculosis clinic and a referral hospital that serve a large population with a 
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In chapter 4, we found that clinical deterioration during antituberculosis treatment was 
significantly associated with profound immune-suppression in HIV-1 infected patients. Here, at 
24 weeks follow-up, we determined the clinical outcomes of the same cohort of adult HIV-1 
infected patients who received antituberculosis treatment. We also determined factors 
associated with death, loss to follow-up and not receiving ART. 
5.1 Methods 
We have previously described our cohort of patients, the study site, the study setting and the 
study definitions in chapter 4. In this analysis, we determined the clinical outcomes of 209 
HIV-1 infected patients. The Research Ethics Committee of the University of Cape Town 
approved this study (REC 178/2008). 
 
Assessment of outcomes. We followed 209 HIV-1 infected patients for 24 weeks after 
initiation of antituberculosis treatment. The primary objectives were: 
1. The clinical outcome at 24 weeks, and  













We classified clinical outcomes as: i) alive and in follow-up, ii) dead, and iii) lost to follow-up. 
We defined a patient as ‘lost to follow-up’ if we were unable to trace a patient 24 weeks after 
initiation of antituberculosis treatment. We used clinic and hospital medical notes, as well as 
the Provincial Government of the Western Cape’s electronic tuberculosis register to trace 
patients and record clinical outcomes. We performed statistical analyses using Stata 10.0 
(Texas, USA). Wilcoxon rank-sum and Kruskall-Wallis tests were used for group comparisons, 
and Fisher’s exact tests to compare proportions. 
 
The secondary objective was to determine risk factors related to death, loss to follow-up and 
not receiving ART. We used multivariate logistic regression models to determine significant 
(p<0.05) risk factors. Variables considered in the analysis were: demographic information (age, 
sex,), tuberculosis information (previous tuberculosis, microbiologic confirmation with drug 
susceptibility testing, diagnosis at a tuberculosis clinic, presence of only pulmonary 
tuberculosis, weight at tuberculosis diagnosis), HIV-1 information (CD4+ count at tuberculosis 
diagnosis, TMP-SMX chemoprophylaxis, ART), and operational information (assessed by a 
tuberculosis doctor, referred to an ART clinic, experienced an episode of clinical deterioration, 
admitted to hospital). Variables with the outcome of interest were entered into logistic 
regression models to assess independent effects of covariates. Variables having a significant 
association with the outcome of interest were removed from the model to ensure no other 













Descriptive analyses of outcomes 
ART initiation. Of 209 patients, 34 (16%) patients received ART prior to tuberculosis 
diagnosis, 75 (36%) initiated ART during the 24 weeks of follow-up and 100 (48%) did not 
receive ART during follow-up (figure 5.1). In patients who received ART prior to tuberculosis 
diagnosis, the interval from ART initiation to antituberculosis treatment was 359 days (median, 
IQR=164-872) and the CD4+ count at tuberculosis diagnosis was 242 cells/ L (median, IQR: 
151-395). In patients who initiated ART during the 24 weeks of follow-up, the interval from 
antituberculosis treatment to ART initiation was 60 days (median, IQR=37-90) and the CD4+ 
count at tuberculosis diagnosis was 66 cells/ L (median, IQR: 30-110). 
 
Eligibility for ART. Of 175 patients not receiving ART at tuberculosis diagnosis, 121 (69%) 
were eligible for ART according to South African ART guidelines. Of 121 eligible patients, 71 
(59%) initiated ART during 24 weeks of follow-up, while 50 (31%) did not. 
 
Loss to follow-up. Forty-six (22%) patients were lost to follow-up. The interval from 
antituberculosis treatment to loss to follow-up was 80 days (median, IQR=37-126). The median 
CD4+ count among HIV-1 infected patients who were lost to follow-up was 150 cells/µL 
(IQR= 67-338). 
 
Death. Sixteen (8%) patients died during follow-up. Diagnoses at death were AIDS-defining 
illnesses (5), poor compliance with antituberculosis treatment (3), paradoxical neurological TB-
IRIS (3), enteric illness (2), MDR-TB (1), pulmonary embolus (1) and tension pneumothorax 





























Figure 5.1: Flow diagram showing the 24 week clinical outcomes of 209 HIV-1 infected 











4 lost to follow-up 
65 completed 24 
weeks of follow-up 
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8 died 
39 lost to follow-up 
53 completed 24 
weeks of follow-up 
100 did not receive ART during 
24 weeks of TB treatment 













Univariate and logistic regression analyses of outcomes 
Death. In univariate analysis (table 5.1), three factors were significantly associated with death: 
a lower CD4+ count at tuberculosis diagnosis, occurrence of clinical deterioration, and 
admission to hospital during follow-up. In multivariate analysis (table 5.3), only a lower CD4+ 
count at tuberculosis diagnosis remained significant (RR = 4.0, 95% CI=1.06–14.67). 
 
Loss to follow-up. In univariate analysis (table 5.1), five factors were significantly associated 
with loss to follow-up:  younger age, lower weight at tuberculosis diagnosis, failure to be 
referred to the HIV clinic, ART not received, and absence of clinical deterioration. In 
multivariate analysis (table 5.3), which did not include the collinear variable ‘failure to be 
referred to the HIV clinic’, only ‘ART not received’ remained significant (RR = 7.0, 95% 
CI=2.60–19.01). 
 
ART not received during the 24 weeks of follow-up. In univariate analysis, 9 factors were 
significantly associated with the failure to initiate ART during 24 weeks of follow-up:  a higher 
CD4+ count, microbiological confirmation of tuberculosis (with DST) at tuberculosis 
diagnosis, diagnosis of tuberculosis at the tuberculosis clinic, absence of extra-pulmonary 
tuberculosis, not receiving TMP-SMX chemoprophylaxis, failure to be assessed by a 
tuberculosis doctor, failure to be referred to the HIV-1 clinic, absence of clinical deterioration 
and loss to follow-up. In multivariate analysis (table 5.3), only a CD4+ count greater than 200 
cells/L remained significant (RR = 5.5 [95% CI=1.77–16.91]). Figure 5.2 depicts Kaplan-
Meier plots, which show i) the proportion of patients lost to follow-up, according to whether 













Table 5.1: Univariate risk factor analysis for 24 week outcomes in 209 HIV-1 infected patients who received antituberculosis treatment 
 Alive  Lost to follow-up4  Died5  
  (n=147)  (n=46) p-value RR 95% CI (n=16) p-value RR 95% CI 
Female, n (%) 80 (54) 26 (57) 0.866 1.1 0.64 – 1.78 6 (38) 0.292 0.5 0.20 – 1.41 
Age in years, median (IQR) 36 (30 -43) 32 (30 - 38) 0.041   33 (29 - 36) 0.158   
Previous TB, n (%) 51 (35) 15 (33) 0.860 0.9 0.54 – 1.60 5 (31) 1.000 0.9 0.32 – 2.38 
CD4 count in cells/L, median (IQR) 144 (66 - 272) 150 (67 - 347) 0.362   34 (26 - 89) 0.003   
Weight at TB diagnosis in kg, median (IQR) 55 (49 - 66) 52 (48 - 59) 0.035   52 (45 - 56) 0.063   
TB diagnosed at hospital, n (%) 55 (37) 16 (35) 0.861 0.9 0.54 – 1.56 8 (50) 0.419 1.6 0.63 – 4.01 
Extra-pulmonary TB, n (%) 62 (42) 13 (28) 0.119 0.6 0.35 – 1.10 7 (44) 1.000 1.1 0.41 – 2.71 
Microbiologic confirmation at TB diagnosis1, n (%) 84 (57) 28 (61) 0.733 1.1 0.67 – 1.89 11 (69) 0.433 1.6 0.57 – 4.32 
Microbiologic confirmation with drug susceptibilities 
known at TB diagnosis1, n (%) 
40 (27) 21 (46) 0.028 1.8 1.11 – 2.98 6 (38) 0.391 1.5 0.59 – 3.96 
TMP-SMX2 chemoprophylaxis, n (%) 128 (87) 40 (87) 1.000 1.0 0.47 – 2.10 13 (81) 0.456 0.7 0.21 – 2.18 
Referred to HIV Clinic 114 (78) 23 (50) < 0.001 0.4 0.25 – 0.67 9 (56) 0.071 0.4 0.17 – 1.05 
ART3 during TB chemotherapy, n (%) 93 (63) 8 (17) 0.018 0.2 0.09 – 0.39 8 (50) 0.416 0.6 0.24 – 1.55 
Experienced clinical deterioration, n (%) 74 (50) 13 (28) 0.011 0.5 0.27 – 0.85 16 (100) < 0.001 > 2  
Hospital admission during 24 weeks of TB 
chemotherapy, n (%) 
49 (33) 15 (33) 1.000 1.0 0.57 – 1.67 16 (100) < 0.001 > 2  
Microbiologic confirmation at 24 weeks, n (%) 104 (71) 35 (76) 0.574 1.2 0.68 – 2.25 14 (88) 0.239 2.7 0.63 – 11.28 
Microbiologic confirmation with drug susceptibilities 
known at 24 weeks, n (%) 
77 (52) 29 (63) 0.237 1.4 0.83 – 2.37 11 (69) 0.292 1.9 0.68 – 5.15 
1 No TB specimens sent in 12 HIV-1 infected patients and 3 HIV-1 uninfected patients at TB diagnosis;  
2 TMP-SMX = trimethoprim sulfamethoxazole 160/800mg daily;  
3 Antiretroviral treatment regimens were as follows: D4T/3TC/EFV (89 patients), D4T/3TC/NVP (3 patients), AZT/3TC/EFV (13 patients), AZT/3TC/NVP (2 patients), 
TDF/3TC/EFV (2 patients); D4T= stavudine 30mg twice daily, 3TC = lamivudine 150mg twice daily, EFV = efavirenz 600mg nocte, AZT = zidovudine 300mg twice 
daily,  NVP = nevirapine 200mg twice daily, TDF = tenofovir 300mg daily; TB = Tuberculosis, RR = relative risk, 95% CI = 95% confidence interval    
4 Risk factor analysis compared patients who were lost to follow-up against patients who were alive at 24 weeks 5 Risk factor analysis  compared patients who died against 

















Table 5.3: Logistic regression analysis in 209 HIV-1 infected tuberculosis patients 
showing significant risk factors in multivariate analysis for loss to follow-up, death and 
not receiving ART during 24 weeks of follow-up 
 
 p-value RR 95% CI 
Loss to follow-up    
Antiretroviral treatment not received during 24 weeks of follow-up1 < 0.001 7.0 2.60 – 19.01 
Death    
Lower CD4+ stratum (relative to stratum 1)2 0.040 4.0 1.06 – 14.67 
ART not received during follow-up    
CD4+ count > 200 cells/L at this tuberculosis episode 0.003 5.5 1.77 – 16.91 
1 Antiretroviral treatment regimens were as follows: D4T/3TC/EFV (89 patients), D4T/3TC/NVP (3 
patients), AZT/3TC/EFV (13 patients), AZT/3TC/NVP (2 patients), TDF/3TC/EFV (2 patients); D4T= 
stavudine 30mg twice daily, 3TC = lamivudine 150mg twice daily, EFV = efavirenz 600mg nocte, 
AZT = zidovudine 300mg twice daily,  NVP = nevirapine 200mg twice daily, TDF = tenofovir 300mg 
daily;  
2 CD4+ strata used (CD4+ counts not performed in 3 of 209 HIV-1 infected patients):  
   Stratum 1 = CD4+ > 350 cells/ µL (36 patients)  
   Stratum 2 =  CD4+ from 200 – 350 cells/ µL (37 patients)  
   Stratum 3 = CD4+ < 200 cells/ µL (133 patients)  













Figure 5.2a: Kaplan Meier plot showing the proportion of HIV-1 infected TB patients lost to
follow-up, according to whether antiretroviral treatment was received or not
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Figure 5.2b: Kaplan Meier plot showing the proportion of HIV-1 infected































We conducted a prospective, clinic-based study in an urban setting in sub-Saharan Africa, in 
which we followed 209 HIV-1 infected patients for 24 weeks after initiation of antituberculosis 
treatment. We found that 70% of patients completed follow-up, 22% of patients were lost to 
follow-up and 8% of patients died. We found a significant association between not receiving 
ART and being lost to follow-up. We also showed that patients were less likely to initiate ART 
if they were not profoundly immune-suppressed (CD4+ count greater than 200 cells/ µL at 
tuberculosis diagnosis), in keeping with national guidelines (SATB guidelines 2004). Lastly, 
we confirmed that profound immune-suppression increases the risk of death. 
 
Our study adds to previous observational data detailing the benefits of ART during 
antituberculosis treatment. Our study’s strengths include its prospective design, its nesting 
within a drug susceptibility testing survey and the use of multivariate analysis, which 
incorporated a number of demographic, HIV-1, tuberculosis and operational factors. Although 
not novel, our study resonates with previous studies, which describe the effect of profound 
immune-suppression on clinical outcome. 
 
Eight percent of our HIV-1 infected patients with tuberculosis died during the 24 weeks of 
follow-up. In sub-Saharan Africa, up to 30% of HIV-1 infected patients die during 
antituberculosis treatment (Harries 2001). In South-East Asia, 7 – 30% of HIV-1 infected 
patients die during antituberculosis treatment (Akksilp 2007, Cain 2007, Quy 2006, Thuy 
2007). We attribute our low mortality to early ART initiation. Amongst the 75 patients who 
initiated  ART during antituberculosis treatment, the CD4+ count at tuberculosis diagnosis was 
very low (median of 66 cells/ L, IQR: 30-110), but the interval from antituberculosis 












benefits of ART in restoring pathogen-specific immunity and preventing further immune 
suppression are well described (Akksilp 2007, Karim 2009), the optimal timing of ART during 
antituberculosis treatment has yet to be determined. It is concerning that in our study, 31% of 
patients who were eligible for ART at tuberculosis diagnosis did not initiate ART within 24 
weeks. Reasons for not initiating ART in eligible patients require investigation in future 
studies. Alternative explanations for our low mortality rate do exist: Our study was clinic-based 
so patients with fatal tuberculosis may not have been enrolled if they required immediate 
referral to hospital at initial presentation; also, a substantial proportion of patients (22%) was 
lost to follow-up and may have died. We consider the latter less likely as written and electronic 
charts – recording deaths from the referral hospitals, tuberculosis clinic and ART clinic – were 
assessed on 3 separate occasions following conclusion of the study.  
 
In multivariate analysis, we found death to be associated with profound immune-suppression 
i.e. a CD4+ count of less than 200 cells/µL. We found that deaths were predominantly due to 
AIDS-defining illnesses, poor compliance with antituberculosis treatment and neurologic TB-
IRIS. Neurologic TB-IRIS is regarded as one of the more severe manifestations of paradoxical 
TB-IRIS (Pepper 2009). Other studies have shown that ART reduces deaths due to tuberculosis 
and HIV-1 related illnesses (Manosuthi 2006). 
 
The high proportion of patients lost to follow-up (22%) was unexpected and concerning. 
International literature reports that 7-9% of HIV-1 infected patients are lost to follow-up during 
antituberculosis treatment (Varma 2009, Makombe 2007). This likely represents publication 
bias. Risk factors for loss to follow-up are difficult to ascertain.  In multivariate analysis, we 
found that loss to follow-up was positively associated with not receiving ART. It is not known 












failure to start ART in these patients resulted in loss to follow-up. The latter is certainly 
plausible: the occurrence of profound immune-suppression with life-threatening illnesses 
necessitates ART initiation. This likely improves follow-up as ART programmes offer a safety 
net of counselling and medical support. Studies have shown the benefit of dual therapy: ART 
with antituberculosis treatment is associated with increased retention during follow-up when 
compared to ART alone (Akksilp 2007). In our study, the positive association of receiving 
ART and retaining patients merits further research. If confirmed in other similar settings, the 
reasons for this association need to be determined.  
 
Our study shows that the only significant barrier to initiating ART is the current national 
protocol, which offers ART at CD4+ counts of less than 200 cells/L (SA TB guidelines 2004). 
This barrier exists despite knowledge that ART improves the survival of HIV-1 infected 
patients with CD4+ counts up to 350 cells/L. In December 2009, the South African 
government announced its intention to provide ART to all pregnant mothers and those with 
tuberculosis provided the CD4+ count is less than 350 cells/L. This intention is yet to be 
implemented. 
 
We acknowledge certain limitation in this study. Referral bias is inevitable; in a clinic-based 
study, patients with fatal tuberculosis who required hospital admission may not have been 
enrolled. In addition, we were unable to assess the reasons for loss to follow-up. In our setting, 
the following obstacles preclude investigation of reasons for loss to follow-up: 1) Most patients 
reside in informal housing (‘shacks’) and the addresses of informal houses are vulnerable to 
change with inclement weather and the building of formal settlements. 2) Cellular/ mobile 
telephones are the preferred method of contacting patients in informal housing, but these 












dynamic flux of patients between Cape Town and the Eastern Cape Province (located 1000km 
eastward of Cape Town). Patients may have returned to the Eastern Cape Province and 
received health care or died there. Future studies are needed to determine the reasons for loss to 
follow-up. 
 
In conclusion, we demonstrate the importance of ART initiation in HIV-1 infected patients with 
tuberculosis. We also show that loss to follow-up is a significant problem and that ART is 
underutilised. ART and tuberculosis programmes need to be strengthened in South Africa. In 
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In chapters 3 and 4, we found that tuberculosis-associated immune reconstitution inflammatory 
syndrome (TB-IRIS) occurred in 18 – 22% of HIV-1 infected patients who experienced clinical 
deterioration during antituberculosis treatment. Our frequent interaction with TB-IRIS, its 
manifestations and its clinical course suggests that TB-IRIS is not the benign condition 
reported in the literature. In our prospective cohort study, neurologic TB-IRIS was responsible 
for three of seventeen deaths. In this chapter, we share our experiences of this clinical entity. 
 
6.1 Introduction 
Paradoxical and unmasking TB-IRIS (Meintjes 2008) are emerging complications of ART in 
countries with high rates of tuberculosis, especially in Africa (Meintjes 2009). The temporal 












antituberculosis treatment precedes ART in paradoxical TB-IRIS, whereas ART precedes 
tuberculosis diagnosis in unmasking TB-IRIS (Meintjes 2008). Currently, there is no 
confirmatory diagnostic test for paradoxical TB-IRIS. Differential diagnoses include: failure of 
antituberculosis treatment due to antimicrobial resistance or suboptimal antituberculosis drug 
concentrations, drug reactions, and alternative opportunistic conditions (McIlleron 2006, 
Pepper 2007). Published case definitions require the exclusion of these differential diagnoses, if 
possible, before diagnosis of paradoxical TB-IRIS (Meintjes 2008, Colebunders 2006, 
Shelburne 2006). Severe and life-threatening manifestations of paradoxical TB-IRIS include 
respiratory failure (Fishman 2000, Buckingham 2004) and neurologic involvement (Burman 
2007, Lee 2007, Dautremer 2007, Sumner 2003, and Vidal 2003). Several case reports of 
paradoxical neurologic TB-IRIS have been published (Burman 2007, Lee 2007, Dautremer 
2007, Sumner 2003, and Vidal 2003); this is the first case series.  
 
In paradoxical neurologic TB-IRIS, inflammation in the central nervous system (CNS) may 
result in death or permanent neurologic disability. Adjunctive corticosteroid therapy is often 
used to treat neurologic TB-IRIS, despite a dearth of evidence indicating benefit. Determining 
the cause of neurologic deterioration in patients with tuberculosis who are receiving ART is 
important; inappropriate adjunctive corticosteroid therapy for profoundly immune-suppressed 
patients with sub-optimally treated tuberculosis or other untreated opportunistic infections may 
be fatal. However, if treatment with corticosteroids is effective, then failure to administer them 
may have severe consequences. Unfortunately, access to expensive tests, such as neuroimaging 














In this study, we evaluated patients with suspected TB-IRIS who were referred to our hospital 
for investigation of neurologic deterioration. We used a published consensus clinical 
case definition of paradoxical TB-IRIS for resource-limited settings (Meintjes 2008) to identify 
paradoxical neurologic TB-IRIS. Here, we describe the clinical presentation, management, and 
outcomes of paradoxical neurologic TB-IRIS. We also discuss the challenges of diagnosis and 













 6.2 Methods 
Study site and setting. We conducted a prospective study at GF Jooste Hospital (Cape Town, 
South Africa) from 1 June 2005 through 31 October 2007. The study site, the study setting, and 
the national protocols for treating HIV and tuberculosis were described in chapters 2 and 3. The 
Research Ethics Committee of the University of Cape Town approved this study (REC 
337/2004). 
 
Definitions. Patients with suspected TB-IRIS were defined as patients with HIV-1 infection 
who received antituberculosis treatment, then commenced ART, and subsequently deteriorated 
within 3 months, with symptoms or signs of tuberculosis disease. Patients with suspected 
neurologic TB-IRIS were defined as having at least one new/ recurrent neurologic symptom 
and/or sign, which included: headache, focal neurologic deficit, nuchal rigidity, confusion, 
seizures, cerebellar signs, cognitive impairment, and/or psychiatric manifestations.  
 
We adapted the consensus clinical case definition of paradoxical TB-IRIS for resource-limited 
settings (Meintjes 2008). We expanded the major neurologic criterion of this case definition 
(i.e., new or worsening CNS tuberculosis, including meningitis or focal neurologic deficit [e.g., 
caused by tuberculoma]) to include the following 3 neurologic disease categories:  
(1) new or worsening tuberculous meningitis;  
(2) new or worsening intracerebral space-occupying lesion (probable tuberculoma); and  
(3) new or worsening radiculomyelopathy.  
 
The consensus clinical case definition requires exclusion of alternative explanations for clinical 












alternative explanations for clinical deterioration, but our clinical diagnosis was likely 
paradoxical neurologic TB-IRIS. We therefore included patients:  
(1) who died despite treatment interventions,  
(2) who, in addition to TB-IRIS treatment, received therapeutic trimethoprim-sulfamethoxazole 
(320 mg/1600 mg twice daily) to treat possible cerebral toxoplasmosis (the principal 
differential diagnosis in cases of tuberculoma IRIS), and/or  
(3) in whom antituberculosis treatment was intensified from 2 drugs (isoniazid and rifampin) to 
4 drugs (isoniazid, rifampin, pyrazinamide, and ethambutol) or from 4 drugs (isoniazid,  
rifampin, pyrazinamide, and ethambutol) to 7 drugs (isoniazid, rifampin, pyrazinamide, and 
ethambutol plus amikacin, ofloxacin, and ethionamide) (in the latter case, to cover for the 
possibility of drug-resistant tuberculosis).  
We regarded all cases of paradoxical neurologic TB-IRIS as ‘probable’, because a confirmatory 
test for TB-IRIS is not yet available.  
 
We defined the following:  
1. Microbiologically confirmed tuberculosis as Mycobacterium tuberculosis (M.tb) 
cultured or acid-fast bacilli seen in a sputum, nodal aspirate, or CNS specimen. The 
CNS specimens included cerebrospinal fluid and brain or paraspinal biopsy specimens.  
2. Microbiologically unconfirmed tuberculosis according to World Health Organization 
case definitions for smear-negative and extra pulmonary tuberculosis (WHO 2007).  
3. Multidrug-resistant (MDR) tuberculosis as M.tb with resistance to isoniazid and 
rifampin.  
4. Disseminated tuberculosis as tuberculosis disease at >2 non-contiguous sites or a 












5. HIV-1 encephalopathy as chronic cognitive impairment (with or without cerebral 
atrophy on computed tomography), with exclusion of opportunistic infections as the 
cause for neurologic deterioration. Delirium was considered if patients presented with a 
systemic illness and acute cognitive deterioration. We diagnosed delirium when we 
observed a return to baseline cognitive function on resolution of systemic illness.  
6. Clinical improvement as symptom improvement (e.g., improvement of headache) or 
improvement assessed by neurologic examination (e.g., focal weakness or Glasgow 
Coma Scale score improvement from admission). Patients assessed as having initial 
clinical improvement did not need to have complete resolution of symptoms and/or 
signs.  
7. A residual deficit as persistence of any neurologic symptom or sign.  
8. A complete physical and mental recovery as a return to baseline functioning, as 
assessed by the physician who discharged the patient from the hospital, and lastly 
9. A patient as ‘lost to follow-up’ if we were unable to trace a patient 6 months after initial 
assessment for neurologic deterioration. We used hospital records, as well as the 
National Health Laboratories Service and the Provincial Government of the Western 
Cape’s electronic databases, to trace patients.  
 
Assessment of patients with suspected TB-IRIS and data collection. We assessed patients with 
suspected TB-IRIS from June 2005 through October 2007, during recruitment to a randomized 
controlled trial of prednisone versus placebo for mild and moderate paradoxical TB-IRIS. 
Before the trial, clinical case definitions for TB-IRIS were prepared, circulated, and discussed 
with participating primary care physicians. Patients with suspected TB-IRIS who were referred 
to GF Jooste Hospital were prospectively assessed (regardless of severity of illness, eventual 












example, we excluded bacterial and cryptococcal meningitis in patients with features that were 
suggestive of meningitis. We also requested mycobacterial culture and drug susceptibility 
testing on specimens, such as sputum, cerebrospinal fluid, and nodal aspirates, to exclude drug-
resistant M. tuberculosis. Patients with severe paradoxical TB-IRIS manifestations, such as 
respiratory failure, altered level of consciousness, or new focal neurologic signs, were excluded 
from the randomized controlled trial and often received prednisone. For patients with suspected 
neurologic TB-IRIS, we collected the following data: tuberculosis diagnosis, ART, CD4+ cell 
count before and after initiation of ART, details of neurologic deterioration, eventual diagnosis, 














During the 29-month study period, we assessed 279 patients with suspected TB-IRIS (figure 
6.1). Two hundred twenty-five (81%) of 279 patients with suspected TB-IRIS had suspected 
non-neurologic TB-IRIS, and 54 (19%) had suspected neurologic TB-IRIS on the basis of >1 
neurologic symptom and/or sign. TB-IRIS was diagnosed more often among patients with 
suspected non-neurologic TB-IRIS than it was among those with suspected neurologic TB-IRIS 
(166 [74%] of 225 vs. 23 [43%] of 54; P <0.001, by X2 test). In the 54 patients with suspected 
neurologic TB-IRIS, we diagnosed paradoxical neurologic TB-IRIS in 23 patients and other 
illnesses in 31 patients. Therefore, of 190 patients with a diagnosis of paradoxical TB-IRIS, 23 
(12%; 95% confidence interval, 7%–17%) had neurologic TB-IRIS: 8 had meningitis, 7 had 
tuberculoma, 5 had both tuberculoma and meningitis, and 3 had radiculomyelopathy. Among 
the 31 patients with illnesses other than paradoxical neurologic TB-IRIS, the most frequent 
diagnoses were HIV-1 encephalopathy with delirium (7 patients), cryptococcal meningitis (5 
patients), and MDR tuberculosis (4 patients). 
 
 
Table 6.1 gives the baseline characteristics and neurologic symptoms and signs for patients 
with a diagnosis of paradoxical neurologic TB-IRIS. The median CD4+ cell count was 61 cells/ 
µL (IQR: 29–97 cells/ µL) before ART and 293 cells/ µL (IQR, 128–482 cells/ µL) a median of 
183 days (IQR, 161–223 days) after ART initiation. The median duration from antituberculosis 
treatment to initiation of ART was 65 days (IQR, 41–87 days), and median duration from ART 
initiation to new or recurrent neurologic symptoms was 14 days (IQR, 5–29 days). The most 
frequent neurologic symptoms and signs were headache (16 patients; 70%), nuchal rigidity (9 
patients; 39%), and seizure(s) (7 patients; 30%). The median duration from onset of neurologic 





































Figure 6.1: Diagnoses of 279 TB-IRIS suspects (1 June 2005 – 31 October 2007) 
TB = tuberculosis, TB-IRIS = tuberculosis-associated immune reconstitution inflammatory syndrome, MDR-TB = multidrug resistant M.tb 
resistant to rifampin and isoniazid, NTM = Non-tuberculous mycobacteria, CMV = cytomegalovirus, Other *= headache cause undetermined (3), 
motor axonopathy cause undetermined (2), cerebrovascular accident (1), nosocomial pneumonia and hypoxic ischaemic brain insult (1), cauda 
equine lesion cause undetermined (1), sub-therapeutic drug level (1)
TB-IRIS suspects (n=279) 
 
Neurologic TB-IRIS suspects (n=54) 
Other Illnesses (n=31) 
 7 HIV-1 encephalopathy with delirium  
 5 Cryptococcal meningitis 
 4 MDR-TB  
(3 MDR-TB meningitis, 1 pulmonary MDR-TB) 
 2 CMV retinitis with encephalitis/ radiculitis  
 2 Seizure disorder 
 2 Progressive TB due to poor compliance 
 9 Other*   
Non-neurologic TB-IRIS suspects (n=225) 
Other Illnesses (n=59) 
 12 MDR-TB 
 8 Bacterial illness 
 5 Poor adherence 
 4 Gastroenteritis 
 3 Pneumocystis jiroveci pneumonia 
 3 Symptomatic anaemia 
 3 Drug side effect 
 2 Renal failure 
 2 NTM 




Paradoxical neurologic TB-IRIS (n=23)  
Neurologic disease categories: 
Space-occupying lesion (n=7) 















Table 6.2 summarizes details of the 23 patients with neurologic TB-IRIS. Cerebrospinal fluid 
analysis for the 13 patients diagnosed with meningitis revealed the following: median 
lymphocyte count, 30 cells/ µL (IQR, 14–65 cells/µL); median polymorph count, 0 cells/µL 
(IQR, 0–5 polymorphs/µL); median protein level, 1.6 g/L (IQR, 1.0–2.3 g/L); and median 
glucose level, 2.1 mmol/L (IQR, 1.7–2.5 mmol/L).  
 
For 21 of 23 patients, we performed computed tomography or magnetic resonance imaging of 
the brain or spinal cord. Space-occupying lesions were found in 13 of 21 patients who 
underwent CNS imaging. Immunoglobulin G (IgG) serologic analysis for Toxoplasma species 
was performed for 11 of these 13 patients, 7 of whom had positive results; however, all 7 had 
radiologic features of tuberculosis outside of the nervous system. We treated 7 patients with 
therapeutic trimethoprim-sulfamethoxazole (320 mg/1600 mg twice daily) to cover possible 
cerebral toxoplasmosis; 4 of these 7 patients had IgG test results positive for Toxoplasma 
species.  
 
Six patients (patients 7, 8, 10, 11, 18, and 21) had evidence of neurologic tuberculosis before 
ART initiation. The remaining patients did not have clinical features of neurologic tuberculosis 
before ART initiation. At neurologic deterioration, we sent 17 patients’ CNS specimens for 
mycobacterial culture; 16 had negative results, and 1 patient’s culture grew M.tb (patient 20).  
 
Twenty (87%) of 23 patients required hospital admission (median duration, 12 days; IQR, 6–24 
days), 21 (91%) received corticosteroids (median duration of therapy, 58 days; IQR, 29– 86 
days), and 7 (30%) received intensified antituberculosis treatment. Initial clinical improvement 
occurred in 19 (83%) of the 23 patients; 18 of 19 patients with initial improvement received 












improvement was 10 days (IQR, 4–22 days). Three (13%) of 23 patients died within 6 months 
after initial assessment for neurologic deterioration. Four (17%) of 23 patients were lost to 
follow-up 6 months after the initial assessment for neurologic deterioration. In these 4 patients, 
duration from initial assessment to loss to follow-up (presumed dead) ranged from 121 to 278 
days. Known survival was thus 70% at 6 months after neurologic TB-IRIS diagnosis. We 
documented full physical and mental recovery in 10 (63%) of 16 patients who were alive and 
under our care at 6 months. Six (37%) of 16 patients had residual neurologic deficits at 6 
months after initial presentation.  
 
Below, we describe case reports of tuberculoma IRIS, tuberculous meningitis IRIS, and TB-
IRIS spondylitis with radiculopathy, which occurred in patients 12, 14, and 23, respectively, 

































Site of TB prior to 






1 M 43 No Nodal AFB visualised, (node + sputum) 7 
2 F 34 Yes Pleural No microbiological confirmation 8 
3 M 44 No Disseminated M. tuberculosis cultured, (node) 4 
4 M 35 Yes Pleural M. tuberculosis cultured, (sputum) 12 
5 F 24 No Disseminated  M. tuberculosis cultured, (node) 4 
6 F 39 No Pulmonary No microbiological confirmation 11 
7 F 28 Yes Disseminated M. tuberculosis cultured, (sputum) 19 
8 F 23 Yes Disseminated M. tuberculosis cultured,( CSF) 9 
9 F 37 No Disseminated No microbiological confirmation 5 
10 F 43 No Meningitis, SOL AFB visualised, (CSF) 35 
11 F 30 No Meningitis No microbiological confirmation 13 
12 F 36 No Disseminated AFB visualised, (sputum) 19 
13 F 30 Yes Abdominal nodes No microbiological confirmation 5 
14 M 34 No Disseminated No microbiological confirmation 2 
15 F 33 No Disseminated No microbiological confirmation 10 
16 F 28 No Disseminated M. tuberculosis cultured, (sputum) 13 
17 M 37 Yes Disseminated AFB visualised, (sputum) 7 
18 M 30 No Meningitis No microbiological confirmation 12 
19 M 27 Yes Disseminated AFB visualised, (sputum) 2 
20 M 31 No Pulmonary AFB visualised (sputum) 7 
21 F 41 No Meningitis No microbiological confirmation 10 
22 F 26 Yes Disseminated M. tuberculosis cultured, (sputum) 6 
23 F 31 No Disseminated M. tuberculosis cultured, (sputum) 34 
Percentage (%) M: 35  No: 65    
Median  33    9 
IQR  28-37    6-13 
Key: TB = tuberculosis, TB-IRIS =TB immune reconstitution inflammatory syndrome, ART = combination antiretroviral  
All patients received  D4T/3TC/EFV antiretroviral treatment except cases 16, 17 and 21 who received AZT/3TC/EFV and   





























Neurological symptoms and signs 
14 89 260 178 Headache, cognitive impairment, left arm weakness 
9 25 - - Confusion, fever 
19 134 502 224 Headache and focal seizures of right arm 
11 139 423 151 Seizures and left hemiparesis  
3 12 6 23 Generalized tonic clonic seizures and post-ictal confusion 
28 79 326 306 Sudden onset right arm and leg weakness with sensory loss 
2 33 - - Seizures and confusion 
49 254 1043 214 Headache and generalized tonic clonic seizures 
33 17 - - Headache, left arm and leg seizures, confusion 
21 3 - - Headache, neck stiffness, confusion and fever 
4 95 423 187 Headache, fever, neck stiffness, generalized tonic clonic seizures 
16 50 - - Headache, neck stiffness, vomiting and hysteria  
5 19 104 157 Headache, confusion, neck stiffness, photophobia and vomiting 
1 77 207 173 Headache, fever, vomiting 
1 61 539 359 Headache, nausea, vomiting and night sweats 
8 37 118 110 Headache, fever and neck stiffness 
1 8 111 221 Neck stiffness, confusion, generalized tonic clonic seizures 
30 158 - - Headache, fever, vomiting and neck stiffness 
38 48 - - Headache, neck stiffness, fever  
14 52 159 301 Headache, neck stiffness 
30 80 - - Headache and worsening lower limb weakness 
7 137 - - Headache and lower limb weakness, incontinence of urine + faeces 
61 99 703 173 Right leg weakness, lower back and right hip pain  
     
14 61 293 183  
5-29 29-97 128-482 161-223  
therapy, AFB = acid fast  bacilli, SOL = space-occupying lesion,  CSF = cerebrospinal fluid,  IQR = interquartile range, 
case 10 who received D4T/3TC/NVP, D4T= stavudine 30mg twice daily, 3TC = lamivudine 150mg twice daily,  












Table 6.2: Neurological disease category, investigations, management and outcome 
 
Case Neurological   
TB-IRIS category 







L P Pr Glc 
1 SOL - - - - CT brain: 1 SOL AFB visualised, (node) HRZE 
2 SOL 0 0 1.6 3.1 CT brain: 1 SOL Culture negative (CSF) HRZE 
3 SOL 0 0 0.3 3 CT brain: multiple SOL No culture (CSF) HR 
4 SOL - - - - CT brain: SOL No specimen obtained HRE 
5 SOL 0 0 0.4 3.1 CT brain: 4 SOL Culture negative (CSF) HRZE 
6 SOL - - - - CT brain: 1 SOL Culture negative (sputum) HR 
7 SOL 3 0 0.9 2.1 MRI brain: 1 SOL Culture negative (CSF) HR 
8 SOL + Meningitis 8 3 0.8 NP CT brain: 3 SOL No culture (CSF) HRZE 
9 SOL + Meningitis 29 0 1.3 4.1 CT brain: 3 SOL Culture negative (CSF) HRZE 
10 SOL + Meningitis 2 0 2.3 2 CT brain: 3 SOL No culture (CSF) HR 
11 SOL + Meningitis 72 0 1.8 2 CT brain: 1 SOL Culture negative (CSF) HR 
12 SOL + Meningitis 16 0 2.3 0.7 CT brain: 1 SOL Culture negative (CSF) HR 
13 Meningitis 45 0 1.1 1.5 CT brain: atrophy Culture negative (CSF) HRZES 
14 Meningitis 35 8 1.4 2.6 NP Culture negative (CSF) HRZE 
15 Meningitis 
28 74 0.7 1.6 CT brain: basal ganglia 
infarct 




31 5.1 2 CT brain: multiple SOL Culture negative (CSF) HRZE 




0 0.9 2.7 CT brain: no SOL Culture negative (CSF) HR 
19 Meningitis 
5 2 1.6 0.4 CT brain: Meningeal 
enhancement,  
1 infarct 
Culture negative (CSF) HRZES 
20 Meningitis 30 0 2.3 2.2 CT brain: no SOL M.tb cultured (CSF) HR 
21 Radiculomyelitis - - 23 2.9 NP Culture negative (CSF) HRZE 
22 Radiculomyelitis 
86 0 72 2.3 MRI spine: 
radiculomyelitis 




- - - - MRI spine: spondylitis Culture negative (aspirate) HR 
Key: TB = tuberculosis, TB-IRIS =TB immune reconstitution inflammatory syndrome, ART = combination antiretroviral therapy, 
cell/L, polymorphonuclear cells (< 1 cell/L), protein (0.15 – 0.45g/L), glucose (2.2 – 3.9mmol/L), CT = computerised 
 Isoniazid, P = Pyrazinamide, E = Ethambutol, S = Streptomycin, TMP-SMX = trimethoprim sulfamethoxazole, SOL =space- 










































No Yes, 10* No Yes Pos No Pos (blood) Alive, # 
Yes Yes, 5 Yes Yes Neg Yes NP Died 
Yes Yes, 49* Yes Yes Neg Yes Neg (blood) Alive 
No Yes, 13* No Yes Neg Yes Neg (blood) Alive 
No Yes, 17* No Yes Pos Yes NP Alive, # 
No No* No NA Pos Yes Neg (blood) Alive, # 
Yes Yes, 4* No Yes Pos Yes Neg (blood) LTF 
No Yes, 11* No Yes Pos No Neg (blood) Alive, # 
No Yes, 4* No NA Neg No Neg (CSF) Alive 
Yes Yes, 1 Yes Yes Pos Yes Neg (CSF) Died 
Yes Yes, 1* No NA NP No NP Alive, # 
Yes Yes, 8* No Yes Pos No Neg (CSF) Alive 
No Yes, 1* No Yes NP No Neg (blood) Alive 
No Yes, 2* No Yes NP No Neg (blood) Alive, # 
No 











No Yes, 1* No Yes NP No Neg (blood) Alive, # 




LTF,   # 





Yes Yes, 11* No Yes NP No Neg (CSF) Alive, # 
No No No NA NP No Neg (blood) LTF 










L = lymphocytes, P = polymorphonuclear cells, Pr = protein, Glc = glucose,  Normal cerebrospinal fluid values: lymphocytes < 5 
tomography, MRI = magnetic resonance imaging, M.tb = Mycobacterium tuberculosis, TB regimens: R = Rifampin, H = 
occupying lesion, NA = not ascertained, NP = not performed, Neg = negative, Pos = positive, CSF = cerebrospinal fluid, 6-month 












Patient 12: paradoxical brain tuberculoma and meningitis IRIS. A 36-year-old woman with 
HIV-1 infection received a diagnosis of disseminated tuberculosis. Acid-fast bacilli were seen 
in her sputum sample, a chest radiograph showed a miliary pattern, and abdominal ultrasound 
visualized splenic hypo-densities, ascites, and a pericardial effusion. She commenced 
antituberculosis treatment with isoniazid, rifampin, pyrazinamide, and ethambutol. She gained 
weight, her cough and sweating improved, and her fever resolved. Her CD4+ cell count nadir 
was 50 cells/ µL, and 19 weeks after starting antituberculosis treatment, she initiated ART 
(stavudine 30 mg twice daily, lamivudine 150 mg twice daily, efavirenz 600 mg nightly). She 
received trimethoprim-sulfamethoxazole chemoprophylaxis (160 mg/800 mg twice daily). 
Sixteen days after initiation of ART, she developed headache, neck stiffness, and vomiting. 
Computed tomography of her brain showed a 10-mm partly solid, partly cystic, 
inhomogenously enhancing lesion in the left temporo-parietal area (figure 6.2), with 
surrounding oedema. Lumbar puncture showed an aseptic lymphocytic meningitis (table 6.2). 
Results of bacterial and fungal cultures, as well serological tests for syphilis performed on 
cerebrospinal fluid samples, were negative. Although serological test results were positive for 
toxoplasmosis, the patient did not receive therapeutic trimethoprim-sulfamethoxazole (320 mg/ 
1600 mg twice daily). We intensified antituberculosis treatment from isoniazid and rifampin to 
isoniazid, rifampin, pyrazinamide, and ethambutol, and we prescribed prednisone (60 mg daily; 
1.5 mg/kg/day) for 4 weeks, followed by a 4-week taper. The patient’s headache and neck 















               
 
Figure 6.2: Paradoxical brain tuberculoma (arrowed) and meningitis IRIS 
Computed tomography showing a 10-mm partly solid, partly cystic, non-homogenously 














Patient 14: paradoxical TB-IRIS meningitis. A 33-year old man with HIV-1 infection 
received a diagnosis of miliary tuberculosis on the basis of chest radiograph findings. We were 
unable to obtain microbiological confirmation of tuberculosis, because sputum induction was 
unsuccessful. The patient had no history of tuberculosis and started treatment with isoniazid, 
rifampin, pyrazinamide, and ethambutol. He experienced improvement while receiving 
antituberculosis treatment; cough, shortness of breath, and generalized weakness resolved. 
Sixteen days after starting antituberculosis treatment, he initiated ART (stavudine, lamivudine, 
and efavirenz), because his CD4+ cell count nadir was 41 cells/ µL. One day after initiation of 
ART, the patient developed headache, fever, and vomiting. On physical examination, he was 
febrile and tachycardic (heart rate, 128 beats per min) but had no nuchal rigidity. We performed 
a lumbar puncture, which revealed an aseptic lymphocytic meningitis (table 2). The patient 
continued to receive antituberculosis treatment with isoniazid and rifampin and received 
prednisone (40 mg twice daily) for 16 days. His headache, fever, and vomiting resolved, and he 
experienced no subsequent deterioration. 
 
Patient 23: Paradoxical TB-IRIS spondylitis complicated by radiculopathy. A 31-year old 
HIV-1 infected woman was diagnosed with disseminated tuberculosis; she had constitutional 
symptoms, abdominal ultrasound showed ascites and adenopathy and we cultured 
Mycobacterium tuberculosis sensitive to isoniazid and rifampin from her sputum.  She had no 
previous history of tuberculosis and commenced isoniazid, rifampin, pyrazinamide, and 
ethambutol. She stopped coughing, she gained weight and her malaise and night sweats 
resolved. Her CD4+ count nadir was 99 cells/L, and 24 weeks after starting antitubercular 
treatment she initiated ART – (stavudine, lamivudine, and efavirenz). Ten days after ART 
initiation, her symptoms of night sweats and anorexia recurred and chest radiograph showed a 












her right leg. On examination, we found weakness of hip flexion and knee extension, loss of the 
right knee reflex but no sensory deficit; her clinical features were in keeping with a right L3/4 
radiculopathy. Magnetic resonance imaging of her spine confirmed tuberculous spondylitis 
with an epidural component impinging the right aspect of the thecal sac (arrowed black). We 
diagnosed a neurological manifestation of paradoxical TB-IRIS and she started prednisone 
60mg daily (1.5mg/kg/day). Despite prednisone, her pain persisted. We performed a CT guided 
paraspinal fine needle aspirate (arrowed white), which on microscopy showed 1+ neutrophils, 
and was culture negative for pyogenic bacteria, mycobacteria and fungi. She received a total of 
152 days of corticosteroids, which we tapered on cessation. Her back pain improved with 
opiate and non-steroidal anti-inflammatory drugs, but she had residual weakness and sensory 
loss affecting the lateral aspect of her right thigh. 173 days after ART initiation, her CD4+ 

































Figure 6.3: Paradoxical TB-IRIS spondylitis complicated by radiculopathy.  
Magnetic resonance imaging of the spine showing tuberculous spondylitis (arrowed black) with 
an epidural component impinging the right aspect of the thecal sac, as well as a paravertebral 












 6.4 Discussion 
Our study is, to our knowledge, the first case series of neurologic TB-IRIS. We found that 
neurologic TB-IRIS accounts for 10% of paradoxical TB-IRIS cases in a hospital setting. We 
found a mortality rate of 13% (3 deaths among 23 patients) for neurologic TB-IRIS, but the 
mortality rate may have been 30% (7 deaths among 23 patients) if all 4 patients who were lost 
to follow-up died. Published data suggest that, in developing countries, many patients in 
antiretroviral programs who are lost to follow-up actually die (Braitstein 2006). In a 
Vietnamese report that described 44 patients with HIV-1 infection who received 
dexamethasone for tuberculous meningitis, 27 (61%) of 44 patients died (Thwaites 2004). 
Reasons for differences in mortality rates include non-availability of ART in the Vietnamese 
study and the fact that the Vietnamese study assessed outcome at 9 months, not 6 months. In 
addition, in our study, by analyzing data for patients who were referred with TB-IRIS, we may 
have selected for a group of patients with neurologic tuberculosis who had a more favourable 
prognosis. Patients with more-severe and more-extensive neurologic tuberculosis may have 
died before receiving ART. Also, patients who developed neurologic TB-IRIS may have died 
before referral to our hospital. The published literature reports only 1 death due to neurologic 
TB-IRIS (Burman 2007); however, this is almost certainly because of a paucity of published 
case reports (Lee 2007, Dautremer 2007, Sumner 2003, and Vidal 2003).  
 
In our study, initial improvement of symptoms and/or signs occurred in 19 of 23 patients; 18 of 
these 19 patients with initial improvement received corticosteroids. Full physical and mental 
improvement occurred in 10 of 16 patients who were alive and in care at 6 months. A 
substantial number of patients (6 of 16 patients) had residual neurologic disability at 6 months 
that was likely to be permanent. A recent meta-analysis of published literature does not support 












HIV-1 infection who have tuberculous meningitis (Prasad 2008). Corticosteroids are proposed 
as a treatment for TB-IRIS, although available evidence is anecdotal (Lawn 2007, Lesho 2006). 
To date, only one clinical trial supports the use of corticosteroids in treating non-life-
threatening TB-IRIS (Meintjes 2009). Corticosteroids reduced duration of hospital admission 
and improved symptoms. We are unable to conclude from our observational study whether 
corticosteroids reduce mortality or disability in neurologic TB-IRIS. 
 
To diagnose TB-IRIS, differential diagnoses need to be excluded or resolution should occur 
without treatment for other opportunistic infections (Meintjes 2009). This is difficult in cases 
involving space-occupying lesions because of limited access to brain biopsy. Differential 
diagnoses for TB-IRIS include cryptococcoma, progressive multifocal leukoencephalopathy 
IRIS (Torok 2008), bacterial abscess, lymphoma, neurocysticerci, and syphilitic gumma. We 
were unable to definitively exclude all other differential diagnoses by means of brain biopsy; 
however, 10 of 12 patients with space-occupying lesions did not experience deterioration 
despite receiving no treatment for these other aforementioned illnesses. 
 
The major differential diagnosis for tuberculoma IRIS, however, is cerebral toxoplasmosis. A 
subgroup of patients (7 of 12 patients) received simultaneous treatment for toxoplasmosis and 
tuberculosis in our study. In certain parts of South Africa, Toxoplasma gondii is isolated more 
commonly than M.tb from biopsy specimens and aspirates of  intracranial mass lesions 
(Bhigjee 1999), whereas in other parts of South Africa, M.tb is isolated more commonly (Modi 
2004). We anticipate a higher proportion of tuberculosis cases in South Africa, because the 
tuberculosis case notification rate in Cape Town is one of the highest in the world (Harrison 
2007). In addition, key features that suggest tuberculosis, rather than other infectious causes, 












and (2) basal meningeal enhancement (Modi 2004). All of the patients in our study whose 
tuberculosis diagnosis was microbiologically unconfirmed had radiologic features of non-
neurologic tuberculosis. In addition, of 7 patients who were treated for possible cerebral 
toxoplasmosis, 3 had serologic test results that were negative for toxoplasmosis, and all 7 had 
radiologic evidence of non-neurologic tuberculosis. Although we had strong clinical suspicion 
of paradoxical neurologic TB-IRIS in these 7 patients, we opted to also treat for possible 
cerebral toxoplasmosis, because the clinical condition of these patients was severe, and a 
confirmatory diagnostic test for TB-IRIS is not yet available. Trimethoprim-sulfamethoxazole, 
used in our setting, and pyrimethamine-sulfadiazine, used elsewhere, have no significant 
difference with respect to clinical efficacy during short-term therapy for toxoplasmic 
encephalitis (Torre 1998). 
 
 Patients without apparent neurologic tuberculosis before ART may present with neurologic 
TB-IRIS after ART initiation. This occurred in 17 of 23 patients in our case series. Presumably, 
this is attributable to subclinical seeding of M. tuberculosis into neurologic tissue that provokes 
an inflammatory response at the time of IRIS. Although mycobacterial culture results are 
usually negative at TB-IRIS diagnosis, M. tuberculosis may be cultured, particularly if IRIS 
occurs early during antituberculosis treatment (Meintjes 2008). This occurred in 1 patient.  
 
Incident MDR tuberculosis may occur in ≈10% of HIV-1 infected patients with tuberculous 
meningitis (Torre 1998). Patients with MDR tuberculous meningitis have significantly poorer 
outcomes (Thwaites 2005). Previously, we diagnosed rifampin-resistant tuberculosis in >10% 
of patients with suspected TB-IRIS (Meintjes 2009). In this study, we diagnosed MDR 
tuberculosis in ≈10% of patients with suspected neurologic TB-IRIS. We empirically 












awaiting mycobacterial culture and drug susceptibility results; however, none of these patients 
cultured MDR tuberculosis. We are unable to ascertain the extent that intensified 
antituberculosis treatment improved clinical outcome. It is possible that the 7 patients who 
received a diagnosis of HIV-1 encephalopathy and delirium (figure 1) may have experienced 
cognitive deterioration as a result of cerebral inflammation (cerebritis) due to TB-IRIS. 
However, in these patients, we did not diagnose neurologic TB-IRIS, because either (1) the 
patient did not have a space-occupying lesion and thus did not fulfil our case definition, or (2) 
the imaging modality that we used (computed tomography rather than magnetic resonance 
imaging in most cases) was not sensitive enough to detect all space-occupying lesions (Wasay 
2003, Morgado 2005). This may be a limitation of our case definition and warrants further 
investigation.  
 
We report a median duration of 14 days from ART initiation to the onset of TB-IRIS symptoms 
in both this study and our previous study of paradoxical TB-IRIS (Meintjes 2009). Other 
studies report a median duration from ART initiation to the onset of TB-IRIS symptoms of 12 
days (IQR, 5–17 days, Narita 1998), 34 days (IQR, 8–97 days, Burman 2007), and 47 days 
(IQR, 36–81 days, Kumarasamy 2004). Variability in baseline CD4+ cell counts and duration 
of antituberculosis treatment before ART initiation may account for the discrepancy among 
studies, because these are risk factors for TB-IRIS (Michailidis 2005, Shelburne 2005). The 
median duration of hospitalization in patients with TB-IRIS is usually 1 week (Burman 2007), 
which is similar to our findings. In HIV-1–infected patients with tuberculous meningitis, the 
median symptom duration before assessment varies from 11 to 18 days (Katrak 2000, Thwaites 
2005, Torok 2008). Our shorter median symptom duration of 6 days before assessment for 
neurologic TB-IRIS may indicate increased inflammation from IRIS. Differing referral patterns 













In a hospital setting, patients with suspected non-neurologic TB-IRIS are more likely than 
patients with suspected neurologic TB-IRIS to receive an eventual diagnosis of TB-IRIS. We 
attribute this finding to screening of patients by physicians at primary care clinics. It is likely 
that patients with suspected non-neurologic TB-IRIS with alternative illnesses to TB-IRIS were 
not assessed at our hospital, because they improved with appropriate treatment prescribed by 
primary care physicians. Intuitively, patients with suspected TB-IRIS with neurologic 
deterioration require rapid referral to the hospital for inpatient admission and investigation, thus 
increasing the likelihood of diagnosis of other illnesses.  
 
Although paradoxical neurologic TB-IRIS is a potentially life threatening manifestation of 
paradoxical TB-IRIS, there is most likely a spectrum of disease severity in neurologic TB-IRIS. 
The milder forms of neurologic TB-IRIS with spontaneous recovery, and the extremely severe 
neurologic TB-IRIS with rapid progression to death before referral, may not have been 
included in our case series. We did not microbiologically confirm tuberculosis in 9 (39%) of 23 
patients; however, tuberculosis is difficult to confirm microbiologically in neurological disease. 
M.tb was cultured from only 31% of patients with tuberculous meningitis in a Vietnamese 
study (Thwaites 2004). All 3 patients who died with a diagnosis of paradoxical neurologic TB-
IRIS did not have cultures positive for M. tuberculosis; thus, drug susceptibility testing to 
exclude MDR tuberculosis could not be performed. We obtained cerebrospinal fluid for 
analysis from 18 of 23 patients but could have improved diagnostic accuracy by performing 
autopsies and brain biopsies. Brain biopsies carry the risk of postoperative haemorrhage 
(Nicolato 1997) and are difficult to access in our setting. Standardized tools were not used to 
assess neurocognitive function or neurologic outcomes. Rather, we relied on the bedside 












records from clinic follow-up. Lastly, this study was conducted at a referral hospital that served 
a large population with a high incidence of HIV-1–associated tuberculosis. Our findings may 
not be generalizable to primary care settings or settings where HIV-1–associated tuberculosis is 
less common.  
 
In conclusion, in a hospital setting, neurologic TB-IRIS is a not-infrequent manifestation of 
TB-IRIS and causes considerable short-term morbidity but is associated with reasonable long-
term outcomes. Future prospective studies may better (1) determine the incidence of neurologic 
TB-IRIS among patients with initial neurologic and non-neurologic tuberculosis disease; (2) 
determine optimal management strategies to reduce death, neurologic deficits, and disabilities; 










































Contributions: The candidate prepared the initial draft, which was critically revised by Robert 
J. Wilkinson, Helen McIlleron, Feriyl Bhaijee and Graeme Meintjes. 
Publications: Section 7.2 of this chapter is obtained from the following publication: 
Pepper DJ, Meintjes G, McIlleron H, Wilkinson RJ. Combined therapy for tuberculosis 
and HIV-1: the challenge for drug discovery. Drug Discovery Today. 2007; 12 (21-
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7.1 Key findings and future work 
This thesis focused on various issues relating to clinical deterioration during antituberculosis 
treatment in a high HIV-1 prevalence setting. We report the following findings: 
Firstly, clinical deterioration is frequently encountered in our setting. At the tuberculosis clinic 
(Khayelitsha Site B), up to 40% of patients experienced clinical deterioration within 24 weeks 
of commencing antituberculosis treatment. At the referral hospital (GF Jooste Hospital), 
clinical deterioration accounted for 17% of medical inpatient admissions.  The most significant 
risk factor for clinical deterioration was profound immune-suppression due to HIV-1 infection.  
Secondly, the causes for clinical deterioration in HIV-1 infected patients at the referral hospital 
and at the tuberculosis clinic are similar (table 7.1); the baseline characteristics and the 
proportion of patients who died are also similar. The median interval from commencing 
antituberculosis to clinical deterioration differed: this is likely related to study design. The 
clinic-based study followed patients for the first 24 weeks from initiation of antituberculosis 
treatment, whereas the hospital-based study enrolled patients presenting over a 3-month period, 
regardless of duration of antituberculosis treatment. A higher proportion of patients in the 












ascertainment of venous thrombosis in the clinic based study, but does not explain why this 
difference only occurred with the diagnosis of venous thrombosis. Thirdly, drug resistance is an 
important but infrequent cause of clinical deterioration. Drug resistant M.tb occurred in 4-10% 
of HIV-1 infected patients with clinical deterioration; 37% of these patients died within 6 
months of clinical deterioration.  
 
Table 7.1: Comparison of HIV-1 infected patients who experienced clinical deterioration in the 
hospital based (n=291) and clinic based (n=101) studies 





Female, n (%) 153 (53) 45 (54) 0.168 
Age  in years, median (IQR) 34 (28 – 41) 36 (29 – 43) 0.051 
Previous TB, n (%) 101 (35) 31 (31) 0.394 
Median CD4 count (cells/mm3), n (IQR) 82 (38 – 157) 79 (33 - 199) 0.579 
Extra-pulmonary TB, n (%) 141 (48) 46 (46) 0.645 
Microbiologic confirmation at TB diagnosis1, n (%) 134 (46) 57 (56) 0.083 
Microbiologic confirmation with drug 
susceptibilities known at TB diagnosis1, n (%) 
85 (29) 29 (29) 0.621 
TMP-SMX2 chemoprophylaxis, n (%) - 91 (90) - 
Interval from TB treatment to clinical 
deterioration, n (IQR) 
93 (44 - 155) 50 (20 - 88) <0.001 
Receiving ART at clinical deterioration, n (%) 122 (48) 31 (30) 0.058 
Diagnoses at clinical deterioration, n (%)    
MDR-TB 30 (10) 4 (4) 0.063 
TB-IRIS 51 (18) 22 (22) 0.344 
Paradoxical reaction 31 (11) 17 (17) 0.114 
AIDS 80 (27) 21 (21) 0.234 
Bacterial infection 32 (11) 9 (9) 0.706 
Gastroenteritis 37 (13) 8 (8) 0.211 
Drug side-effects 35 (12) 14 (14) 0.605 
Deep vein thrombosis 12 (4) 10 (10) 0.042 
Death 43 (15) 15 (15) 1.000 
Key 
TB: tuberculosis, TMP-SMX: trimethoprim sulfamethoxazole (160/800mg), ART: antiretroviral treatment, 
MDR-TB: Mycobacterium tuberculosis resistant to rifampin and isoniazid,  
TB-IRIS: tuberculosis-associated immune reconstitution inflammatory syndrome 
AIDS: Acquired Immune Deficiency Syndrome 












Drug resistant bacterial infections, caused by organisms such as ESBL and MRSA, only 
occurred in the first hospital study; 75% (9/12) of these patients died within 11 days of 
obtaining the specimen. We attribute the absence of ESBL and MRSA organisms in the second 
study to improved infection control measures and antibiotic policies as cultures were requested 
on all specimens obtained during hospitalisation in the clinic-based study. Also, ESBL and 
MRSA organisms appear less common in the community setting, strengthening the conclusion 
that these were hospital acquired bacterial infections.  
 Fourthly, the poor outcome of HIV-1 infected patients at 24 weeks is very concerning: 22% of 
patients were lost to follow-up, 8% of patients died, and 31% of patients eligible for ART at 
tuberculosis diagnosis did not receive ART within 24 weeks. The reasons for loss to follow-up 
need to be determined in future prospective studies. While a major breakthrough has been 
achieved in now being able to offer ART to tuberculosis patients with CD4+ counts < 350 
cells/ µL, this breakthrough is not without its own challenges. The benefits of ART initiation at 
higher CD4+ counts requires major changes in current medical infrastructure: a major 
paradigm shift in the South African public health care sector is still needed. The current 
reactionary approach needs to be replaced with a pro-active, investigatory approach, 
encouraging continuity of care and patient follow-up. Medical information systems require 
further development and improvements to allow consistent access to patients’ health 
information across districts and provinces.  
Fifthly, TB-IRIS is a rising phenomenon in our setting. TB-IRIS accounts for approximately 
20% of the reasons for clinical deterioration during antituberculosis treatment, both in the clinic 
and hospital setting. In the hospital setting, neurologic TB-IRIS is a not infrequent 
manifestation of TB-IRIS and causes considerable short-term morbidity. Numerous potential 












pathophysiology of TB-IRIS. The temporal sequence of events in paradoxical TB-IRIS may 
prove crucial. Focusing on the intervals between tuberculosis diagnosis, ART initiation and 
TB-IRIS occurrence may better define the pathophysiology of TB-IRIS. Figure 7.1 describes 
the temporal sequence of events leading to TB-IRIS. Furthermore, cerebrospinal cytokine 
analysis, proteomics and metabolomics may offer invaluable insights regarding TB-IRIS 
meningitis. Magnetic resonance imaging, single photon emission computed tomography 
(SPECT) scanning and brain biopsies may prove invaluable in understanding TB-IRIS 
tuberculomata. These studies are already underway in Cape Town. We have also observed an 
interesting relationship between TB-IRIS and paradoxical reactions; figure 7.2 reports a patient 
who developed both conditions in succession. We are also investigating whether particular 
lineages of M.tb are associated with TB-IRIS. Lastly, we are investigating whether sub-
therapeutic rifampin drug levels are an important cause of clinical deterioration in patients 















Figure 7.1: Paradoxical pulmonary and pleural TB-IRIS treated with prednisone 
A 43 year-old HIV-infected woman was diagnosed with disseminated tuberculosis. An aspirate from 
a cervical node cultured Mycobacterium tuberculosis (susceptible to rifampicin and isoniazid) and 
her chest radiograph showed a bilateral reticulonodular infiltrate with large hilar adenopathy (A). She 
commenced antitubercular treatment – isoniazid (H), rifampicin (R), pyrazinamide (Z) and 
ethambutol (E). Her cough resolved, and her night sweats and appetite improved. Chest radiography 
also improved (B). Her CD4 count nadir was 20 cells/ μL. Ten weeks after starting antitubercular 
treatment she initiated combination antiretroviral treatment (ART) - stavudine (D4T) 30mg twice 
daily, lamivudine (3TC) 150mg twice daily, efavirenz (EFV) 600mg nocte. Eight days later, she 
developed shortness of breath, and recurrence of her cough. Her CD4 count had increased to 64 cells/ 
μL. Chest radiography at TB-IRIS showed a new right pleural effusion and recurrence of pulmonary 
infiltrate (C). We drained 750ml of straw-coloured pleural fluid, which did not culture mycobacteria. 
We continued HRZE and ART and prescribed prednisone 70mg daily (1.5mg/kg/day) for 4 weeks. 
Her cough and night sweats resolved. Chest radiography showed dramatic improvement (D). She, 
however, developed cytomegalovirus retinitis of her left eye. Prednisone was stopped and she was 
treated with intravitreal ganciclovir with improvement in vision. Six months after ART initiation, her 


















Figure 7.2: Paradoxical reaction and paradoxical TB-IRIS 
A 26-year-old HIV-infected man was diagnosed with recurrent pulmonary tuberculosis. His sputum cultured 
Mycobacterium tuberculosis (sensitive to rifampin and isoniazid) and his chest radiograph showed a left apical 
infiltrate (A). He commenced antituberculosis treatment – isoniazid (H), rifampin (R), pyrazinamide, ethambutol 
(E) and streptomycin. His cough, fever, nausea and appetite improved. Ten days after starting antituberculosis 
treatment, he developed shortness of breath on exertion (50 metres), as well as orthopnea. He had features in 
keeping with a pericardial effusion; his jugular venous pressure was raised at 10cm H20, cardiac sounds were 
muffled, and pulsus paradoxus was present (> 10mmHg). Chest radiography showed cardiomegaly (B). His 
cardiac ultrasound (C) confirmed a 61mm pericardial effusion with stranding and debris. 1200ml of straw-
coloured pericardial fluid was aspirated. He had dramatic improvement immediately after aspiration; he could 
walk 500 metres, orthopnea resolved and chest radiography improved (D). He also received prednisone for 4 
weeks (1.5mg/kg/day for 2 weeks, and 0.75mg/kg/day for 2 weeks). Chest radiography improved further (E). His 
CD4+ count nadir was 5 cells/ μL. Ten weeks after starting antituberculosis treatment, he initiated combination 
antiretroviral treatment (ART) - stavudine (D4T) 30mg twice daily, lamivudine (3TC) 150mg twice daily, 
efavirenz (EFV) 600mg nocte. Ten weeks later, he developed shortness of breath, and recurrence of his cough and 
fever. His CD4+ count had increased to 97 cells/ μL. Chest radiography at TB-IRIS showed a large left pleural 
effusion and worsening right pulmonary infiltrates (F). We percutaneously drained 850ml of straw-coloured 
pleural fluid (G), which did not culture mycobacteria. We continued antituberculosis treatment (HRE) but did not 
re-initiate prednisone. His cough, fever and shortness of breath resolved. Chest radiography showed improvement 
(H) although the pulmonary infiltrates persisted. The left pleural effusion did not recur. Six months after ART 












7.2 Drugs on the horizon 
In chapter 2, we described the difficulties associated with combining current antituberculosis 
and antiretroviral treatments. In order to meet the challenges of tuberculosis and HIV-1 co-
infection, new antituberculosis and antiretroviral drugs are urgently needed. These new 
antituberculosis drugs should i) shorten the duration of antituberculosis treatment or 
significantly reduce the number of doses under DOTS, ii) cure both drug-susceptible and drug-
resistant tuberculosis, iii) effectively treat  LTBI, iv) limit cross-resistance by utilizing a new 
site of drug activity, and v) not be metabolised by CYP or induce or inhibit CYP. These factors 
should limit shared toxicities between antituberculosis and antiretroviral treatment. 
Furthermore, new antiretroviral drugs are needed in the event that drug-resistant HIV-1 
emerges in South Africa. We have already seen that HIV-1 associated immune-suppression is a 
strong risk factor for clinical deterioration during antituberculosis treatment. If drug resistant 
HIV-1 were to emerge, serious setbacks would occur in the management of HIV-1 associated 
tuberculosis. 
 
Since 2000, several novel antituberculosis and antiretroviral drug candidates have been 
identified (Tables 7.2 – 7.4, Global Alliance 2007, Reeves 2005). Many of these antiretroviral 
drugs are now licensed by the United States Food and Drug Administration (FDA), but still 


















Novel chemical entities 
ATP synthase inhibitor: 
 DiarylquinolineTMC 207 
 FAS20013 
Cell wall inhibitors: 
 Nitroimidazole PA-824 
               Nitroimidazole OPC-67683 
               Dipiperidine SQ-609 
               Translocase I inhibitor 
               InhA inhibitors 
               Isocitrate lyase inhibitors 
Protein synthesis inhibitor 
 Pyrrole LL- 3858 
Other: Pleuromutilins 
 
Based on existing chemical entities 
Fluoroquinolones 
 Moxifloxacin 
              Gatifloxacin 
New quinolones 




              Thiolactomycin analogues 
              Nitrofuranylamines 
Rifamycin derivatives:  
              Rifalazil 
Oxazolidinones: 
              Linezolid 
Attachment inhibitors 
             Dextran sulphate 
             Heparin 
             Cyanovirin-N 
             Cyclotriazadisulfonamide analogues 
             PRO 2000 
             TNX 355 
             PRO 542 
             BMS 806 
Co-receptor binding inhibitors 
CCR5:  SCH-D 
             Maraviroc 
  Aplaviroc 
             TAK 779 
CXCR4: AMD 070 
               Plerixafor 
Fusion inhibitors 
              Tifuvirtide 
Non-nucleoside reverse transcriptase inhibitors 
               Etravirine 
Integrase inhibitors 
                L 731988 
                L 870810 
                L 870812 
Maturation inhibitors 
               PA 457 
Protease inhibitors  













Table 7.3: Potential benefits, toxicities and metabolism of new antituberculosis in development 
 
TB drugs in development 






effect on CYP 
Potential toxicities Other 
PA-8241 Bacterio-cidal and -static,  
No cross resistance,  
Treats MDR-TB 
Yes Yes/ No 
(Nuermberger 
2006) 
No CYP metabolism  Requires activation 
by mTB F420 factor 
(Rv3547 enzyme) 
OPC-676832 No cross resistance,   
High MTB specificity,  
Treats MDR-TB 




TMC 2073 Novel target limiting cross-resistance, 
Bacterio-cidal and -static,  
Treats MDR-TB 
 Yes Yes,  
CYP3A4 
 Synergistic with 
other TB meds esp. 
PZA 
Moxifloxacin4 Treats MDR-TB Yes Yes Ciprofloxacin 
inhibits hepatic 







Gatifloxacin5 Treats MDR-TB (weak data)  Yes Ciprofloxacin 
inhibits hepatic 





SQ-1096 May treat Ethambutol-resistant strains   CYP2D6 
CYP2C19 
  
1 Ginsberg 2009a, Ginsberg 2009b,  Global Alliance 2007, Nuermberger 2005, Nuermberger 2006 
2 Ginsberg 2007,  Global Alliance 2007, Matsumoto 2006 
3 Andries 2005, Cole 2005,  Diancon 2009,  Global Alliance 2007, Rustomjee 2008 
4 Ginsberg 2007, Global Alliance 2007, Hu 2003, Park-Wyllie 2006 
5 Burman 2006,  Dorman 2009, Global Alliance 2007,  Hu 2003, Nuermberger 2005, Rustomjee 2008 


















Antiretroviral drugs in development 
Drug Name Potential benefits CYP metabolism / effect Potential toxicities Other 
Etravirine1 Inhibits replication of wild-type & drug resistant 
HIV-1 
 No safety concerns in phase II 
trials 
 
Darunavir2 Retains efficacy against multi-PI-resistant 
viruses, higher genetic barrier to resistance 
Metabolised by CYP   
Maraviroc3 Active against diverse HIV-1 isolates from 
different clades, Does not compete with 
chemokine binding, 
Yes, substrate for CYP3A4 Mild/ moderate Headache, 
dizziness, asthenia, flatulence, 
rhinitis 
Immune modulation, escape 
mutants, altered viral tropism, 
Vicriviroc4 Beneficial in salvage therapy   Poor virological outcomes in 
naïve patients 
 
Raltegravir5 Virological benefit in salvage therapy No (metabolised by 
glucuronidation) 
Similar to placebo Potential interaction with 
antibiotics 
Elvitegravir5 Efficacy against MDR HIV-1 Metabolised by CYP and 
glucuronidation, induces CYP3A 
Similar to placebo Potential interaction with 
antibiotics 
1 Boone 2006 
2 de Bethune 2006, Towner 2010 
3 The Pinksheet 2007, Reeves 2005 
4 Reeves 2005, Suleiman 2010 












7.2.1 TB drugs in development 
PA-824 
PA-824 is a nitroimidazo-oxazine. It requires activation by M. tuberculosis F420 factor and 
inhibits synthesis of cell wall lipids as well as protein synthesis. Phase 1 clinical trials of PA-
824 by the Global TB Alliance showed good safety, tolerability, and pharmacokinetics. Of 
concern are reports that PA-824 causes creatinine levels to rise, possibly by inhibition of renal 
tubular creatinine secretion. Preliminary studies suggest that PA-824 will be active against 
MDR-TB and has no cross-resistance with other anti-tubercular drugs. Importantly, it is not 
metabolised by CYP and does not induce or inhibit CYP. It had similar bacteriostatic efficacy 
to rifampin and was more efficient than isoniazid or moxifloxacin but less efficient than 
rifampin and isoniazid in continuation phase therapy in the mouse model (Nuermberger 2005, 
Nuermberger 2006, Global Alliance 2007, Ginsberg 2009a, Ginsberg 2009b). 
 
OPC-67683 
OPC-67683 is a nitroimidazo-oxazole that is similar in structure to PA-824. It inhibits cell wall 
biosynthesis. Otsuka Pharmaceuticals (Japan) are currently conducting phase 2 clinical trials 
(Ginsberg 2007). Preclinical studies in rodents and dogs suggest that OPC-67683 could be used 
in HIV-1/AIDS as it has no effect on CYP. It may also shorten treatment, as a result of 
synergistic in vitro activity with rifampin and pyrazinamide. OPC-67683 is effective against 
MDR-TB in vitro and displayed no cross-resistance to first-line antituberculosis treatment. It 

















TMC207 is a diarylquinoline and is also known as Compound J and R207910. It inhibits ATP 
synthase (AtpE) leading to ATP depletion and pH imbalance (Andries 2005, Cole 2005). It was 
initially identified by Johnson & Johnson and subsequently developed by the subsidiary 
Tibotec Pharmaceuticals Limited. It has recently undergone phase 2a clinical trials in drug-
sensitive tuberculosis, as the first novel anti-TB compound to be studied in patients in nearly 4 
decades (Rustomjee 2008). While TMC207 demonstrated a delayed onset in bactericidal 
activity, it was well tolerated, and no serious adverse events occurred (Rustomjee 2008). For 
multidrug-resistant tuberculosis, the addition of TMC207 to standard therapy reduced the time 
to conversion to a negative sputum culture (Diancon 2009). TMC207 displays no cross-
resistance to other antituberculosis drugs, as it has a novel site of action. It also has the 
potential to shorten the duration of antituberculosis treatment. It is, however, metabolized by 
CYP, which will necessitate dose-adjustment if administered simultaneously with rifampin 
(Global Alliance 2007, Andries 2005, Cole 2005). This will be very difficult to manage due to 
the long half-life of TMC207. 
 
Gatifloxacin 
Gatifloxacin is a fluoroquinolone that inhibits DNA gyrase, thus inhibiting M.tb DNA 
replication and transcription. The OFLOTUB Consortium, the European Commission, WHO 
TDR and Lupin Ltd are among its sponsors and co-ordinators. Gatifloxacin is currently 
undergoing phase 3 clinical trials (Ginsberg 2007). Gatifloxacin is a front-runner as the first 
antituberculosis agent to reduce pulmonary antituberculosis treatment to 4 months’ duration. 
There are weak data to support its efficacy against MDR-TB (Global Alliance 2007, Hu 2003). 














Moxifloxacin is also a fluoroquinolone and has a similar mechanism of action to gatifloxacin. It 
is undergoing phase 2 and 3 clinical trials by CDC TBTC, Johns Hopkins University and UK 
MRC. The TB Alliance and Bayer are jointly pursuing clinical development for 
antituberculosis drugs. Moxifloxacin kills rifampin-tolerant persisters in vitro, and it may help 
treat MDR-TB if co-administered with ethionamide. Data from the mouse model support the 
possibility that moxifloxacin, when substituted for isoniazid or ethambutol in standard, first-
line antituberculosis treatment, will increase the 2-month sputum conversion rate and 
potentially shorten overall time to stable cure. It may thus shorten duration of antituberculosis 
treatment (Global Alliance 2007, Nuermberger 2005, Hu 2003, Burman 2006). In a phase 2 
trial, moxifloxacin was associated with a bi-exponential fall in colony counts during the early 
phase of antituberculosis treatment; this was superior to gatifloxacin, ofloxacin and ethambutol 
(Rustomjee 2008). Recently, in a phase 3 trial, moxifloxacin showed significant increases in 
week-8 culture negativity, compared to ethambutol. When substituted for isoniazid, 
moxifloxacin had a small but statistically non-significant increase in week-8 culture negativity 
(Dorman 2009).  
 
SQ-109  
SQ-109 is an ethylenediamine and is derived from ethambutol. It is postulated to inhibit cell 
wall biosynthesis; its intracellular targets have yet to be elucidated. Sequella Inc. (in 
collaboration with the National Institutes for Health) is currently conducting phase 1B clinical 
trials (Ginsberg 2007). Current data suggest that SQ-109 is effective against drug-resistant 
strains (including ethambutol- resistant strains). SQ-109 appears to be synergistic with 














Limited data are available regarding pyrrole LL3858. It is currently undergoing phase 1 clinical 
trials by Lupin Limited (India) (Global Alliance 2007). Available data suggest that LL3858 has 















7.2.2 Antiretroviral treatment in development 
Second generation agents 
 
Etravirine (TMC125) 
Etravirine, also known as TMC-125, is a next-generation NNRTI. It is a highly flexible, di-
aryl-pyrimidine (DAPY) compound that enables favourable binding interactions with mutant 
HIV-1 strains as well as with wild-type virus (Boone 2006). Developed by Tibotec (Johnson & 
Johnson), Etravirine has completed phase 3 clinical trials and is licenced by the FDA (Towner 
2010). When combined with a background regimen, such as darunavir/ritonavir and/or 
raltegravir, etravirine provided an effective treatment option in treatment-experienced patients 
with HIV-1 (Boone 2006).  
 
Darunavir (TMC 114) 
Darunavir is a second generation PI that is administered with low-dose ritonavir. It is relatively 
resistant to mutations that confer PI resistance (de Bethune 2006). In phase 3 trials of ART-
experienced patients, darunavir was an effective treatment option (Towner 2010). It is now also 












New class agents 
CCR5 inhibitors 
Maraviroc 
Maraviroc, also known as UK-427 and 857, is a CCR5 antagonist. It blocks the CCR5 co-
receptor on CD4+ cells, thus preventing CCR5-tropic HIV-1 from entering CD4+ cells. 
Manufactured by Pfizer, it was approved for use by the FDA on 24 April 2007. Furthermore, it 
was granted accelerated approval on 6 August 2007 for combination ART of adults infected 
only with detectable CCR5-tropic HIV-1, who have evidence of viral replication and have 
HIV-1 strains resistant to multiple anti-retroviral agents (The Pinksheet 2007). Maraviroc is a 
substrate for CYP3A4, so it may interact with  rifampin, NNRTIs and PIs; levels of maraviroc 
are increased in patients taking atazanavir, ritonavir-boosted lopinavir (Kaletra) and ritonavir-
boosted saquinavir (Invirase) (Reeves 2005). 
  
Vicriviroc (SCH-D)  
Vicriviroc is also a CCR5 antagonist and has a similar mechanism of action to maraviroc. It is 
being developed by Schering-Plough. In phase 2 clinical trials conducted in treatment-
experienced patients, vicriviroc administered with a protease inhibitor and ritonavir-containing 
regimen showed potent antiretroviral and immunologic activity sustained over 48 weeks 
(Suleiman 2010). Vicriviroc was discontinued in treatment-naive patients because of poor 
virological outcomes. In one study, five patients in the vicriviroc arm developed malignancies, 
but the Drug and Safety Monitoring Board could not determine a causal link so the study 













Integrase inhibitors: raltegravir and elvitegravir 
Raltegravir, also known as MK-0518, is an integrase inhibitor and inhibits HIV-1 DNA 
integration into host DNA. Developed by Merck, it underwent phase 3 clinical trials and 
showed comparable efficacy to enfuvirtide (de Castro 2009). Raltegravir’s safety profile is 
comparable to placebo, and it has demonstrated virological benefit in salvage ART (Cooper 
2007) and first-line ART. It is metabolised by glucuronidation (UGT1A1) and has no 
significant effect on CYP3A4 (Reeves 2005, Cooper 2007, Pommier 2005). Elvitegravir, 
known as Gilead-9137, is also an integrase inhibitor and has a similar mechanism of action to 
raltegravir. Elvitegravir demonstrates efficacy against multi-drug-resistant HIV-1 and has a 
side effect profile similar to placebo. It is metabolised by glucuronidation and CYP, so it has 
important drug interactions. It is also an inducer of CYP3A4. In clinical studies, it is used with 
ritonavir boosting to increase its half-life from three to nine hours, increase its AUC and 
prevent auto-induction of its metabolism (Reeves 2005, Pommier 2005, Mathias 2006). The 
FDA has also licensed raltegravir and elvitegravir. 
 
Maturation inhibitor: PA-457 
PA-457, also known as DSB, is a maturation inhibitor and blocks HIV-1 maturation by 
disrupting cleavage of the capsid precursor. Panacos Pharmaceuticals has recently completed 
phase 2 clinical trials (Smith 2007). Single oral doses of PA-457 were well tolerated, and there 
was a dose-dependent reduction in viral load. Encouragingly, no PA-457 resistance mutations 













7.2.3 Future areas of research  
Insight into how M. tb persists may illuminate novel ways to reduce the prolonged duration of 
antituberculosis treatment and the emergence of drug resistance. In particular, a recent advance 
has occurred in understanding M.tb’s adaptation to hypoxia, which is theoretically important in 
latent lesions (Voskuil 2003). It is also increasingly clear that metabolic adaptation to 
persistence involves a switch to fatty acid metabolism as a source of carbon; deletion of both 
genes encoding isocitrate lyases 1 and 2 impairs the persistence of M.tb (Munoz-Elias 2005). 
The absence of these gene products in humans may facilitate the development of glyoxylate 
cycle inhibitors as new drugs for the treatment of tuberculosis (Munoz-Elias 2005).  
 
In summary, many novel and efficacious antituberculosis and antiretroviral drugs are swelling 
the drug development pipeline. Reassuringly, these drugs promise to alleviate the 













7.3 Concluding remarks 
In this thesis, I related my experiences of clinical deterioration during antituberculosis 
treatment. Two important issues emerged:  the association of clinical deterioration with HIV-1, 
and the difficulties encountered in the diagnosis and management of these profoundly ill 
patients.  Reducing the extraordinary burden of clinical deterioration during antituberculosis 
treatment is clearly an urgent priority for South Africa. 
 
Numerous efforts have already been made, which merit acknowledgement. South African-
based research centres are empowering and training local and international clinician scientists. 
Strong local and international funding supports MDR-TB and TB-IRIS research.  Recently, the 
South African government announced it would consider increasing the entry CD4+ count to 
<350cells/ µL in patients with tuberculosis and pregnancy. Furthermore, philanthropic 
organisations, pharmaceutical companies and the TB alliance have re-invigorated the 
tuberculosis and HIV drug development pipeline. Novel drugs promise to improve combined 
antituberculosis and antiretroviral treatment with the mitigation of shared drug toxicities, drug 
resistance and the long duration of antituberculosis treatment. It is my hope that these research 
ventures will impact those most affected by HIV-1 and tuberculosis. All current efforts will be 
in vain without improving the infrastructure of DOTS and ART programmes, as well as 
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Combining drug therapies for dual infection by Mycobacterium tuberculosis and HIV-1 is made complex
by high pill burdens, shared drug toxicities, drug–drug and drug–disease interactions, immune
reconstitution inflammatory syndrome, co-morbid diseases and drug resistance in both bacillus and
virus. Recently, novel anti-tubercular and anti-retroviral drugs have bolstered the tuberculosis–HIV drug
pipelines and may help ameliorate these difficulties. This review article discusses the reasons for current
problems of therapy for dual infection. It also identifies promising agents, which may significantly
improve co-therapy and thus diminish the great morbidity and mortality of these two pandemics.






ficiency virus-1 (HIV) cause considerable morbidity and mortal-
ity. One-third of the world’s population is infected with
Mycobacterium tuberculosis (TB), and almost nine million new
cases of TB and approximately two million TB deaths occur
annually [1,2]. Worldwide, almost 40 million people were
infected with HIV and 2.9 million people died with AIDS in
2006 [3]. In 2000, almost 11 million people were co-infected with
HIV and TB [1], the majority of who were in the developing world
[4]. These two pandemics fuel each other. TB hastens HIV pro-
gression to AIDS by accelerating viral replication [5], whilst HIV
increases the risk of TB disease (up to 30% annual risk of TB disease
in profoundly immune-suppressed patients in endemic areas) [6].
TB–HIV drug therapy is complicated by high pill burdens, shared
drug toxicities, drug–drug and drug–disease interactions and the
immune reconstitution inflammatory syndrome. Co-morbid dis-
eases, drug resistance and the treatment of latent TB infection
provide additional challenges. This review article describes cur-
rent therapy for TB and HIV, discusses the problems with current
Un
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Current therapy for tuberculosis and HIV
TB therapy is a multi-drug regimen given over a long period of
time. Single agent TB therapy rapidly gives rise to drug-resistant
organisms [7]. Multi-drug treatment needs to be prolonged; pos-
sible explanations include: M. tuberculosis divides slowly, it is
metabolically capable of becoming drug insensitive and/or bacilli
may become sequestered [8]. The advent of rifampicin and pyr-
azinamide allowed highly effective ‘short course’ TB Regimes—
usually a two-month intensive phase with rifampicin (R), isoniazid
(H), pyrazinamide (Z) and ethambutol (E), followed by a four-
month continuation phase with RH (2RHZE/4RH) [9]. Multi-drug-
resistant (MDR)-TB, defined as TB resistant to RH, is treated with
less effective agents for up to 18 months after sputum conversion.
Treatment is often individualised and regimes may be as long as 24
months. Patient adherence is a major problem with such pro-
longed treatment regimens. There is an urgent need for shorter,
effective TB drug regimens.
Highly active anti-retroviral therapy (HAART or ART) for HIV is
a life-long multi-drug regimen. In patients infected with HIV,ee front matter  2007 Elsevier Ltd. All rights reserved. doi:10.1016/j.drudis.2007.08.001


















millions of virions are produced daily, and the reverse transcrip-
tase target mutates rapidly. Hence, initial therapies with single or
dual nucleoside reverse transcriptase inhibitors (NRTI) such as
zidovudine (AZT) and didanosine (ddI) were only partially effec-
tive and rapidly led to viral drug resistance [10]. Effective therapy
only became possible when non-nucleoside reverse transcriptase
(NNRTI) and viral protease inhibitor (PI) drugs were developed.
Combinations of these three drug classes lead to prolonged sup-
pression of HIV replication and ultimately to a degree of immune
recovery. Adherence to ART is crucial to successful viral suppres-
sion, which is very closely related to immune restoration and
survival [11].
Difficulties associated with combining current TB–HIV
therapies
Shared drug toxicities
Concomitant therapy for HIV and TB is associated with increased
risks of adverse drug effects such as nausea, gastrointestinal tract
disturbance, peripheral neuropathy, cutaneous reactions, renal
toxicity and potentially fatal liver toxicity [12]. Certain drug
combinations are contraindicated (Table 1). These toxicities
may necessitate therapy discontinuation, which exacerbates
immune suppression and predisposes to other opportunistic infec-
tions. Shared drug toxicities also compromise adherence to the
treatment regimen leading to suboptimal TB and HIV treatment
and increasing the possibility of drug resistance.
Drug interactions
Clinically significant pharmacokinetic drug interactions are com-
mon in TB–HIV therapy. Many TB–HIV drugs are substrates of
metabolising enzymes and drug transporters that are induced or
inhibited by key components of anti-TB and ART regimens.
Rifamycins form the backbone of regimens for drug-susceptible
TB because they are highly effective, reduce the duration of therapy
and are less likely thanotherTBdrugs toselectout resistant strains in
multi-drug regimens [13]. However, through its activation of a
master transcriptional regulator, the pregnane X receptor (PXR),
rifampicin induces the expression of a broad array of enzymes and
drug-transporting molecules including cytochrome P450 (CYP) 3A
and CYP2C isoenzymes, CYP2D6, CYP2B6 and p-glycoprotein,
amongst others [14]. Thus, repeated doses of rifampicin result in
clinically important reductions in the levelsofmanydrugs, amongst
themPIs, NNRTIs, trimethoprimand sulfamethoxazole (the last two
co-formulated in co-trimoxazole widely used for prophylaxis in
patients with advanced HIV-1 infection) [15,16]. The co-localiza-
tion of p-glycoprotein and CYP enzymes in enterocytes, hepatocytes
and renal tubular cells may enhance the effects of rifampicin on
common substrates, such as PIs, causing more extensive pre-sys-
temic metabolism and accelerated drug elimination. The clinical
consequences of rifampicin-related decreases in serum concentra-
tions of the anti-retroviral drugs have not been fully studied, but
they potentially lead to loss of anti-viral efficacy and stepwise
accumulation of resistance mutations [17–20]. Whilst NNRTIs,
besides delavirdine, can be given with rifampicin [21], dose increase
may be necessary. All PIs, except ritonavir-boosted PIs, are contra-
indicated with rifampicin [22]. Certain ritonavir-boosted PIs can be
used with rifampicin, but increased doses of ritonavir or a higher




ty The rifamycin rifapentine has a longer half-life suitable to
intermittent administration that might simplify therapy. Whilst
rifapentine is also a marginally less potent inducer of CYP than
rifampicin it has not been widely introduced as it is associated with
increased rates of TB drug resistance when used once weekly
during the continuation phase of TB therapy [23]. Intermittent
rifampicin therapy in the continuation phase is also associated
with rifampicin resistance in patients with advanced HIV infection
[24]. Rifabutin, the rifamycin causing least induction of CYP
enzymes, is safe to use with most NNRTIs and PIs, except dela-
virdine and saquinavir. However, it is also a substrate for CYP3A4
[25]. Thus, its serum concentration and toxicity are increased
when co-administered with PIs and decreased when co-adminis-
tered with efavirenz and RFB dose adjustments are required in
these settings [15]. Rifabutin and the anti-retroviral nevirapine can
be given together at standard doses, but delavirdine is contra-
indicated with rifabutin [15]. Also, the cost of rifabutin precludes
its use in the developing world.
Although they are of lesser importance, other pharmacokinetic
interactions may confound combined treatments. Isoniazid is an
inhibitor of CYP2C19 and CYP3A, PIs inhibit CYP3A, CYP2D6 and
p-glycoprotein, and efavirenz and nevirapine induce the expres-
sion of CYP3A4 and CYP2B6. Other commonly co-administered
drugs also cause important changes in anti-retroviral concentra-
tions through induction or inhibition of CYP isoforms (e.g. anti-
convulsants like carbamazepine and phenytoin may decrease, and
azole anti-fungals, macrolide antibiotics and H2 antagonists may
substantially increase PI or NNRTI concentrations).
Pharmacodynamic interactions further complicate combined
treatment of TB and HIV. Unanticipated hepatotoxicity has been
reported in healthy volunteers receiving adjusted dose PIs in
combination with rifampicin [26,27]. Interestingly, repeated doses
of RIF before the introduction of the PIs appear to be associated
with a higher risk of hepatotoxicity than the introduction of
rifampicin after establishing regular doses of the PIs. Although
not adequately studied, such high rates of hepatotoxicity have not
been reported in patients receiving increased doses of PIs with
rifampicin-based TB regimens, indicating that disease-related
modulation of hepatotoxicity can occur.
The effect of HIV infection on the concentrations of orally
administered first-line anti-tubercular drugs is also a concern.
Whilst currently available studies are not entirely consistent, it
appears that HIV-infected patients achieve not only somewhat
lower concentrations of rifampicin and ethambutol in particular
but also isoniazid and pyrazinamide [28–31]. Patients with more
advanced HIV disease and those with diarrhoea appear to be at
most risk. Although these concentration reductions do not appear
to have a marked effect on treatment outcomes their importance
has not been fully evaluated.
High pill burden
Combined therapies for TB and HIV together with the recom-
mended co-trimoxazole prophylaxis lead to a very high pill bur-
den—average of 15 pills daily in South Africa for 6–22 months
(fixed dose combinations (FDC) for TB medication but not ART).
Furthermore, in high burden countries standard treatment
approaches are adopted and FDCs are often used to reduce the














































Shared drug toxicities in HIV/TB patients
Side-effect Anti-retrovirals First-line TB drugs MDR-TB drugs Oth drugs commonly
used in HIV
Other HIV disease
Peripheral neuropathy d4T, ddI H, E (rare) Cy, Te, FQ, Et, Ka, Am, Lin HIV itself
Hearing loss S Ka, Am, Cpr, Clr
Vertigo S Ka, Am, Clr
Optic neuritis E, H (rare) Et (rare), PAS (rare), Lin
Seizures H Cy, Te, Of, Ci [and other FQ – rare]
Psychosis EFV H Cy, Te, Of, Ci, [other FQ] Et TMP MX, steroids HIV itself
Depression EFV Cy, Te, Of, Ci, Et TMP MX HIV itself
Nausea &
vomiting
AZT, ddI, PI: IDV,amprena-vir
(other PIs)
Z, Rfm, H, E Et, Of, Ci, [other FQ], PAS, Clf, Lin TMP MX, Amphotericin B OI, IRIS
Gastritis E, Z Et
Transaminitis NVP, PI, EFZ Z, R, H Of, Ci [other FQ], Et, Cy, Te, PAS, Clr TMP MX, Azoles OI
Hepatic steatosis d4T OI, IRIS
Cholestasis R Clr TMP MX AIDS cholangiopathy
Nephrotoxicity TDF (including Fanconi
syndrome)
S, R (interstitial nephritis & GN),
Z+H also rarely cause interstitial nephritis
Ka, Am, Cpr, FQ – rarely cause IN,
PAS causes crystalluria
Am otericin B, TMP-SMX
(inte titial nephritis)
HIVAN
Hypokalaemia TDF Ka, Am, Cpr Amp otericin B
Renal calculi IDV TMP MX
Arthralgias and gout E, Z, H, R Of, Ci, [other FQ, PAS] Thia ide (gout) HIV itself
SJS/TEN NNRTIs R, H (both rarely) Thiacetazone, Clr, PAS, FQ TMP MX
Skin rash NNRTIs, ABC, PI Z, R, H, S, E FQ, Clf, PAS, Clr, Cpr, Et, Cy, Te TMP MX Folliculitis & asteatosis
Hypersensitivity ABC R, S TMP MX
Leucopenia, anaemia AZT, 3TC R, H, Z (sideroblastic anaemia),
RHZE rarely cause thrombocytopenia
FQ, strep, Cy (megaloblastic), PAS,




Lactic acidosis d4T, ddI, AZT Lin
Pancreatitis ddI, d4T H Lin, Clr TMP MX
Insulin resistance PI esp IDV stero s
Hyperlipidaemia PI (except ATV), d4T stero s
Lipoatrophy d4T
Lipodystrophy PIs
Hep B flare if drug
discontinued
TDF, FTC, 3TC
Teratogenic EFV S Et stero s
Osteoporosis TDF stero s
Antiretrovirals D4T = stavudine, ddI = didanosine, Efv = efavirenz, AZT = zidovudine, IDV = indinavir, PI = Protease inhibitor, NVP = nevirapine, TDF = tenofovir, NNRTI = Efv + NVP, A C = abacavir APV. First-line TB drugs Rfm = rifamycins,
R = rifampicin, H = isoniazid, E = ethambutol, Z = pyrazinamide, S = streptomycin. MDR-TB drugs Cy = cycloserine, Te = Terizidone, Of = Ofloxacin, Ci = Ciprofloxacin, Et = Ethiona ide[+prothionamide], Ka = Kanamycin, Am = Amikacin,
FQ = fluoroquinolones, Lin = linezolid, Cpr = capreomycin, Clr = clarithromycin, Clf = clofazimine, PAS = p-amino-salicylate. TMP-SMX = trimethoprim sulfamethoxazole, IRIS = immu e reconstitution inflammatory syndrome,








































































istration. Pharmacokinetic interactions necessitating dose adjust-
ment of individual drug components complicate treatment deliv-
ery in the setting of programmes reliant on standardised
approaches using FDCs. Thus, optimisation of therapy inevitably
leads to a greater pill burden.
Immune reconstitution inflammatory syndrome
Immune reconstitution inflammatory syndrome (IRIS), which is
due to dysregulated immune recovery [32], occurs in severely
immune-suppressed HIV patients typically one to four weeks after
ART initiation [33,34]. In tuberculosis-related IRIS an exuberant
inflammatory reaction is directed towards mycobacterial antigens
[35], resulting in worsening pulmonary infiltrates, pleural effu-
sions, lymphadenitis and potentially fatal neurological tubercu-
lomata [33,34]. Risk factors for TB–IRIS include low baseline CD4
count, high baseline viral load, short duration between TB and
ART initiation and disseminated tuberculosis [33,36]. Determin-
ing the optimal time to initiate ART in severely immune-sup-
pressed TB patients is difficult [12,25]. Whilst early initiation of
ART may increase the risk of TB–IRIS, non-adherence, drug toxi-
cities and drug interactions, the risk of death, other opportunistic
infections (OIs) and malignancies may be greater if ART initiation
is delayed [37]. Corticosteroid treatment of TB–IRIS is sometimes
recommended, but such immunosuppressive therapy may be
associated with reactivation of occult OIs and malignancies, such
as CMV and Kaposi’s sarcoma. A randomised trial of corticoster-
oids against placebo for TB–IRIS would help resolve this issue.
Co-morbid diseases
HIV-induced immunosuppression, predisposing to OIs and malig-
nancies, coupled with TB–HIV drug side effects and TB–IRIS can
give rise to multiple pathologies in certain organs, especially the
liver (Table 2). When faced with significant biochemical or clinical
evidence of hepatitis it is a dilemma whether to withdraw all drugs
or the most likely offending candidates. Evidence certainly sug-
gests withdrawal of rifampicin, isoniazid, pyrazinamide and




Causes of liver disease in TB–HIV patients
Drugs Infectio
Transaminitis (ALT >3 times normal)
TB drugs: Rif, INH, Z Viral He
ART: NNRTI, PI CMV
Azoles EBV
TMP-SMX
Canalicular pattern (ALP >3 times normal)








 Certain protease inhibitors (atazanavir and indinavir) can cause unconjugated h
 Sepsis causes transaminitis with conjugated hyperbilirubinaemia
 If non-specific hepatitis (ALT <3 times normal) then consider malnutrition, NRT
Un
ivto reduce the risk of NNRTI resistance. Substituting ‘liver friendly’
alternatives such as streptomycin and quinolones to continue the
treatment of TB is of uncertain efficacy. Investigating these differ-
ential diagnoses without the use of invasive techniques such as
endoscopic retrograde cholangio-pancreatography or biopsy poses
major challenges to clinicians in resource-limited settings. A
further problem on resolution of the hepatitis is when and how
drugs should be re-introduced. No attempt to re-introduce nevir-
apine therapy should be made after significant drug-induced
toxicity, but it is common experience that anti-TB drugs may
all be re-introduced. This is usually done sequentially with mon-
itoring of clinical signs and hepatic enzymes but is a prolonged
empirical exercise that maintains the patient in expensive hospital
care and at risk of nosocomial infection. Well-conducted clinico-
pathological studies of adequate numbers of patients are required
to address these issues and inform practice.
Drug-resistant HIV
The prevalence of multi-drug-resistant HIV is increasing [38]. This
may be accounted for, partly, by the transmission of HIV-1 from
drug-experienced to uninfected individuals [39]. Whilst drug
resistance (DR) is not associated with increased virulence [40],
DR is the leading cause of treatment failure amongst patients
infected with HIV [41]. High adherence (>95%) to ART reduces
viral replication, which limits the emergence of drug-resistance
mutations [42]. Intermediate ART adherence (70–90%) and ART
monotherapy or dual therapy increase the incidence of DR [11].
Recent data suggest that moderate adherence to NNRTIs leads to
sustained viral suppression [11]. Certain reverse transcriptase
mutations conferring resistance to NRTI (K65R, M184V) are asso-
ciated with reduced viral fitness [43], whilst mutations conferring
NNRTI resistance are usually neutral. Interestingly, NNRTI hyper-
susceptibility is more common amongst viruses from NRTI experi-
enced/NNRTI-naı̈ve patients compared with viruses from NRTI/
NNRTI-naı̈ve patients, suggesting that mutations in NRTI-resistant
viruses confer structural conformational advantages for NNRTIs at







patitis A, B, C
matous hepatitis Kaposi’s sarcoma
Lymphomaobacterium avium-intracellulare/TB–IRIS
ella, Campylobacter, Isospora belli, Microsporidium,
poridium
yperbilirubinaemia
Is, ethanol, herbal medication and viral hepatitis serology
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TABLE 3
TB–HIV drugs in development
TB HIV
Novel chemical entities Attachment inhibitors
ATP synthase inhibitor: Dextran sulfate
R 207910/diarylquinolineTMC 207 Heparin
FAS20013 Cyanovirin-N
Cell wall inhibitors: Cyclotriazadisulfonamide analogues
Nitroimidazo-oxazine PA-824 PRO 2000
Nitroimidazo-oxazole OPC-67683 TNX 355
Dipiperidine SQ-609 PRO 542
Translocase I inhibitor BMS 806
InhA inhibitors Co-receptor binding inhibitors
Isocitrate lyase inhibitors CCR5: SCH-D
Protein synthesis inhibitor Maraviroc
Pyrrole LL-3858 Aplaviroc
Other: Pleuoromutilins TAK 779
Ancriviroc
CXCR4: AMD 070










Thiolactomycin analogues L 870810
Nitrofuranylamines L 870812



















strains allows their growth to be exceeded by wild-type HIV strains
[45]. The detection of DR HIV-1 in ART-naı̈ve patients may con-
sequently be difficult, as standard population-based genotyping
methods only detect viral populations that are greater than 20% of
the total HIV-1 population [45]; drug pressure allows the subse-
quent detection of DR strains [38]. In addition, DR is increased
when a failing ART regimen is maintained (even though stable
levels of CD4 and VL are preserved over time) and may limit future
treatment options [46,47]. New HIV drugs are thus required to
overcome cross-resistance and offer alternative therapy in treat-
ment failure.
Drug-resistant tuberculosis
The continued emergence of drug-resistant TB [48] may be due to
several factors: poor directly observed treatment short course
(DOTS) implementation, the possible greater biological propensity
of some strains of TB to become drug resistant (e.g. W-Beijing [49])
and HIV co-infection that is likely to be associated with greater
bacterial burdens. W-Beijing strains of TB have been associated
with HIV and a greater propensity to become drug resistant.
Biologically these strains are postulated to interact in an immune
subverting manner because they produce an immunosuppressive
phenolic glycolipid [50]. National DOTS programmes require sub-
stantial infrastructure and political commitment, which are often
suboptimal in the developing world. TB–HIV co-infection is also
associated with significantly reduced RIF drug levels, which may
allow the selection of drug-resistant TB bacilli [28,30]. Patients
receiving MDR-TB treatment may also be at risk of extensively
drug-resistant (XDR) TB (defined as MDR plus resistant to at least a
quinolone and a second line injectable drug [51,52]) as current
MDR-TB therapy is prolonged, poorly tolerated and less effective
than first-line TB therapy. Worryingly, the nosocomial acquisition
of XDR-TB has recently been documented [53]. Rapid diagnostic
methods to ascertain drug resistance and correct infrastructure
augmented by a substantial financial commitment by both first
and third world countries will be required to combat the expand-
ing TB pandemic and prevent the spread of drug-resistant TB [13].
Treatment of HIV-1-associated latent tuberculosis infection
ART reduces the incidence of TB, though it remains to be seen
whether this benefit may be offset by increased survival and an
overall increase in lifetime risk. Treatment of latent TB infection
(LTBI) also reduces the risk of subsequent TB disease even in HIV-
infected people, though the duration of protection is relatively
short [54]. It therefore appears logical to potentially combine
therapies to prevent TB. However, the risk benefit of preventive
TB therapy in these circumstances is unknown: There are signifi-
cant overlapping hepatic and neurological toxicities as outlined
above. In addition, the most effective preventive therapy is iso-
niazid monotherapy, but this may be associated with an increased
risk of isoniazid resistance if inadvertently given to patients with
active disease [55]. Therefore, whilst the prescribing of either
isoniazid or ART has significant benefits in HIV-infected persons,
a randomised controlled trial is still needed to determine the
efficacy and risks of combination isoniazid/ART therapy. The
combination regimen of rifampicin and pyrazinamide for two
months was associated with liver toxicity especially in HIV-unin-
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persons exposed to MDR-TB [57].
Drugs on the horizon
In order to meet the challenges of TB–HIV co-infection, new TB
and HIV drugs are urgently needed. These new TB drugs should
shorten the duration of TB therapy or significantly reduce the
number of doses under DOTS, have efficacy against both drug-
susceptible and MDR-TB, be effective in treating LTBI, have a new
site of drug action thus limiting cross-resistance and not be meta-
bolised by CYP or induce or inhibit CYP, thus limiting shared
toxicities between HIV and TB therapy. Since 2000, several novel
TB and HIV drug candidates have been identified (Tables 3 and 4
[58,59]).
TB drugs in development
PA-824
PA-824 is a nitroimidazo-oxazine. It requires activation by
M. tuberculosis F420 factor and inhibits synthesis of cell wall lipids
as well as protein synthesis. The TB alliance is currently conduct-
ing phase 1 clinical trials of PA-824 [60]. Preliminary studies
suggest that PA-824 will be active against MDR-TB and has no
cross-resistance with other anti-tubercular drugs. Importantly, it is
not metabolised by CYP and does not induce or inhibit CYP. It had
similar bacteriostatic efficacy to rifampicin and was more efficient






















and isoniazid in continuation phase therapy in the mouse model
[58,61,62].
OPC-67683
OPC-67683 is a nitroimidazo-oxazole that is similar in structure to
PA-824. It inhibits cell wall biosynthesis. Otsuka Pharmaceuticals
(Japan) are currently conducting phase 2 clinical trials [60]. Pre-
clinical studies in rodents and dogs suggest that OPC-67683 could
be used in HIV/AIDS as it has no effect on CYP. It may have
treatment-shortening potential as it synergises in vitro with rifam-
picin and pyrazinamide. OPC-67683 is effective against MDR-TB in
vitro and displayed no cross-resistance to first line TB therapy. It
also has potential to treat LTBI [58,63].
R207910
R207910 is a diarylquinoline and is also known as Compound J and
TMC207. It inhibits ATP synthase (AtpE) leading to ATP depletion
and pH imbalance [64,65]. It was initially identified by Johnson &
Johnson and subsequently developed by the subsidiary Tibotec
Pharmaceuticals Limited, where it is undergoing phase 2a clinical
trials inboth drug sensitive and resistant disease [60]. Murine studies
suggest that R207910 has a good safety and tolerability profile and
potent early bactericidal activity, matching isoniazid. It had a
synergistic effect with pyrazinamide for MDR-TB; R207910/H/Z
or R207910/R/Z combinations were more effective than amika-
cin/Z/moxifloxacin/ethionamide regimens. R207910 displayed no
cross-resistance to other TB drugs as it has a novel site of action. It
also has the potential to shorten duration of TB therapy. Its draw-
back is its metabolism by CYP, which will necessitate dose-adjust-
ment if administered simultaneously with rifampicin [58,64,65].
Gatifloxacin
Gatifloxacin is a fluoroquinolone that inhibits DNA gyrase, thus
inhibiting TB DNA replication and transcription. Its sponsors and
co-ordinators include the OFLOTUB Consortium, the European
Commission, WHO TDR and Lupin Ltd. Gatifloxacin is currently
undergoing phase 3 clinical trials [60]. Gatifloxacin holds the
potential to be the first TB agent to reduce pulmonary TB therapy
to four-month duration. There are weak data to support its efficacy
against MDR-TB [58,66]. However, there have been concerns about
dysglycaemia with gatifloxacin [67].
Moxifloxacin
Moxifloxacin is also a fluoroquinolone andhas a similarmechanism
of action to gatifloxacin. It is undergoing phase 2 and 3 clinical trials
by CDC TBTC, Johns Hopkins University and UK MRC. The TB
alliance and Bayer are jointly pursuing clinical development for
tuberculosis. Moxifloxacin kills rifampicin-tolerant persisters in
vitro, and it may help treat MDRTB if co-administerd with ethiona-
mide. Data from the mouse model support the possibility that
moxifloxacin when substituted for isoniazid or ethambutol in
standard, first-line TB treatment will increase the two-month spu-
tum conversion rate and potentially shorten overall time to stable
cure. It may thus shorten duration of TB therapy [58,62,66,68].
SQ-109
SQ-109 is an ethylenediamine and is derived from ethambutol. It is






targets, which have not yet been elucidated. Sequella Inc. (in
collaboration with the National Institutes for Health) is currently
conducting phase 1 clinical trials [60]. Current data suggest that
SQ-109 is effective against drug-resistant strains (including etham-
butol-resistant strains). SQ-109 appears to be synergistic with
isoniazid and rifampicin [58,69].
Pyrrole LL3858
Limited data are available regarding pyrrole LL3858. It is currently
undergoing phase 1 clinical trials by Lupin Limited (India) [58].
Available data suggest that LL3858 has potency against standard
and drug-sensitive TB strains in vitro [58,70].
HIV drugs in development
Second generation agents
Etravirine (TMC125)
Etravirine, also known as TMC-125, is a next-generation NNRTI. It
is a highly flexible, di-aryl-pyrimidine (DAPY) compound that
enables favourable binding interactions with mutant HIV strains
as well as wild-type virus [71]. It is being developed by Tibotec
(Johnson & Johnson) and is currently in phase 3 clinical trials and
may become the first NNRTI suitable for use in NNRTI-experienced
patients [71,72].
Darunavir (TMC 114)
Darunavir is a second generation PI that is administered with low
dose ritonavir. It is relatively resistant to mutations that confer PI





Maraviroc, also known as UK-427 and 857, is a CCR5 antagonist. It
blocks the CCR5 co-receptor on CD4 cells preventing HIV that
uses this receptor from entering CD4 cells. It is manufactured by
Pfizer and was approved for use by FDA on 24 April 2007. Further-
more, it was granted accelerated approval on 6 August 2007 for
combination anti-retroviral treatment of adults infected only
with detectable CCR5-tropic HIV-1, who have evidence of viral
replication and who have HIV-1 strains resistant to multiple anti-
retroviral agents [74]. Maraviroc is a substrate for CYP3A4 so has
potential interactions with rifampicin, NNRTIs and PIs; levels of
maraviroc are increased in patients also taking atazanavir, rito-
navir-boosted lopinavir (Kaletra) and ritonavir-boosted saquina-
vir (Invirase) [59].
Vicriviroc (SCH-D) and aplaviroc (GSK-873140)
Vicriviroc is also a CCR5 antagonist and has a similar mechanism
of action to maraviroc. It is being developed by Schering-Plough
and is currently undergoing phase 2 clinical trials in treatment-
experienced patients. Vicriviroc was discontinued in treatment-
naı̈ve patients because of poor virological outcomes. In one study,
five patients in the vicriviroc arm developed malignancies, but the
Drug and Safety Monitoring Board could not determine a causal
link so the study was continued [59]. Phase 3 trials of GlaxoS-
mithKline’s CCR5 antagonist, aplaviroc, were stopped in October
















































Potential benefits, toxicities and metabolism of new TB–HIV drugs in development







B drugs in development
PA-824 Bacterio-cidal and bacterio-static, novel
target reducing potential cross-resistance
with existing drugs, treats MDR-TB
Yes Unknown No CYP metabolism Requires activation
by mTB F420 factor
(Rv3547 enzyme)
OPC-67683 Novel target reducing potential cross-resistance
with existing drugs, high MTB specificity,
Treats MDR-TB
Yes Yes No CYP metabolism Intracellular activity.
Requires activation
by Rv3547 enzyme
TMC 207/R207910 Novel target reducing potential cross-resistance
with existing drugs, Bacterio-cidal and
bacterio-static, Treats MDR-TB
Yes Yes Yes, CYP3A4 Synergistic with other
TB meds esp. PZA








Gatifloxacin Treats MDR-TB (weak data) Yes Ciprofloxacin inhibits hepatic
microsomal enzymes
As above, dysglycaemia Cross-resistance
amongst quinolones
SQ-109 May treat ethambutol-resistant strains CYP2D6
CYP2C19
Drug name Potential benefits CYP metabolism/effect Potential toxicities Other
HIV drugs in development
Etravirine Inhibits replication of wild-type and
drug-resistant HIV
No safety concerns in
phase 2 trials
Darunavir Retains efficacy against multi-PI-resistant
viruses, higher genetic barrier to resistance
Metabolised by CYP
Maraviroc Active against diverse HIV-1 isolates from
different clades, Does not compete
with chemokine binding





Aplaviroc Trials discontinued Yes, substrate for CYP3A4 Liver toxicity




Raltegravir Virological benefit in salvage therapy No (metabolised by
glucuronidation)
Similar to placebo Potential interaction with
antibiotics
Elvitegravir Efficacy against MDR-HIV Metabolised by CYP and
glucuronidation, induces CYP3A

















































Integrase inhibitors: raltegravir and elvitegravir
Raltegravir, also known as MK-0518, is an integrase inhibitor and
inhibits HIV–DNA integration into host DNA. It is being developed
by Merck and is undergoing phase 3 clinical trials. Raltegravir’s
safety profile is comparable to placebo, and it has demonstrated
virological benefit in salvage ART [76]. It is metabolised by glucur-
onidation (UGT1A1) and has no significant effect on CYP3A4
[59,76,77]. Elvitegravir, known as Gilead-9137, is also an integrase
inhibitor and has a similar mechanism of action to raltegravir.
Elvitegravir demonstrates efficacy against multi-drug-resistant
HIV and has a side effect profile similar to placebo. It is metabo-
lised by glucuronidation and CYP, so it has important drug inter-
actions. It is also an inducer of CYP3A4. In clinical studies it is
being used with ritonavir boosting to increase its half-life from
three to nine hours, increase its AUC and prevent auto-induction
of its metabolism [59,77,78].
Maturation inhibitor: PA-457
PA-457, also known as DSB, is a maturation inhibitor and blocks
HIV maturation by disrupting cleavage of the capsid precursor.
Panacos Pharmaceuticals is currently conducting phase 2 clinical
trials. Data on the metabolism and potential toxicity of PA-457 are
limited [59,79].
Future areas of research
Insight into how M. tuberculosis persists may illuminate novel ways
to reduce the prolonged duration of TB therapy and emergence of
drug resistance. In particular, there has been a recent advance in
determining the bacillary determinants involved in adaptation to
hypoxia: A state thought to be important in latent lesions [80]. It is
also increasingly clear that metabolic adaptation to persistence
involves a switch in metabolism to the use of fatty acids as a source
of carbon. Deletion of both genes encoding isocitrate lyases 1 and
2 impairs the persistence of TB [81]. The absence of these gene
products in humans may facilitate the development of glyoxylate
cycle inhibitors as new drugs for the treatment of tuberculosis [81].ers
ity
 oivGiven that novel anti-tuberculosis and anti-retroviral agents
will be used concurrently in the future, structure–activity and
structure–toxicity analyses combined with medicinal chemistry
may address drug interactions at the design phase. In vitro screen-
ing systems for drug interactions with CYP enzymes and drug
transporters are in use [82,83]. In silico prediction of adverse effects
triggered by drugs metabolised by cytochrome P450 3A4 (meta-
bolic transformations, drug–drug interactions) has been reported
and may become more widespread at the discovery phase [84]. The
clinical relevance of drug–drug interactions is best assessed in
relevant patient populations. Population-based methods can be
used during phases 2 and 3 of clinical drug development and in
post-marketing evaluation to quantify known pharmacokinetic
interactions and detect unanticipated interactions [85].
Conclusions
With the aid of philanthropic organisations, pharmaceutical com-
panies and the TB alliance, numerous TB and HIV drugs with novel
sites of action are currently in the drug development pipeline.
Whilst phase 3 clinical trials still have to be conducted, these novel
drugs hold the promise of improving combined TB–HIV therapy
with the reduction of shared drug toxicities, drug resistance and
long duration of TB therapy. It is our hope that these research
ventures will impact those most afflicted by HIV and TB. All
current labours will be in vain without the combined efforts of
garnering political and societal commitment, significantly
improving the infrastructure and adherence of DOTS and ART
and making these new drugs financially available to the develop-
ing world.
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Background. Tuberculosis (TB) immune reconstitution inflammatory syndrome (IRIS) is emerging as an
important early complication of combination antiretroviral therapy in patients with TB in developing countries.
The differential diagnosis of TB IRIS includes deterioration caused by other human immunodeficiency virus–
related morbidities and drug-resistant TB.
Methods. We prospectively evaluated consecutive patients with suspected TB IRIS from February 2005 through
July 2006 at a community-based secondary hospital in Cape Town, South Africa, by means of clinical case definitions
for TB IRIS. Specimens were sent for TB culture and susceptibility testing, and a rapid test (FASTplaque-Response)
was performed to expedite determination of rifampin susceptibility.
Results. One hundred patients with suspected TB IRIS were evaluated, 26 of whom were being retreated for
TB. IRIS symptoms developed a median of 14 days (interquartile range, 7–25 days) after the initiation of com-
bination antiretroviral therapy. In 7 patients, an alternative opportunistic disease was diagnosed. Rifampin-resistant
TB was present in 13 patients, 9 of whom received a diagnosis after study entry (7 of 9 had multidrug-resistant
TB). Undiagnosed rifampin-resistant TB was thus present in 10.1% of patients (95% confidence interval, 3.9%–
16.4%) who presented with TB IRIS, once those with alternative diagnoses and TB with known rifampin resistance
were excluded. In the remaining 80 patients, TB IRIS without rifampin resistance was the final diagnosis.
Conclusions. TB IRIS that is clinically indistinguishable from TB IRIS that occurs in the context of drug-
susceptible disease may occur in patients with undiagnosed multidrug-resistant TB. Antitubercular drug resistance
should be excluded in all cases of suspected TB IRIS, and corticosteroids should be used with caution for patients
with presumed TB IRIS until the result of drug-susceptibility testing is known.
The scale-up of combination antiretroviral therapy
(cART) in the developing world is progressing rapidly,
improving survival among HIV-infected persons [1, 2].
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An emerging complication of cART in countries with
high rates of tuberculosis (TB) is TB immune recon-
stitution inflammatory syndrome (IRIS). “Paradoxical”
TB IRIS manifests with new, worsening, or recurrent
symptoms, signs, and/or radiological manifestations of
TB after cART is initiated in patients receiving treat-
ment for TB [3]. It occurs in 8%–43% of patients who
initiate cART while receiving TB treatment [4–11] and
is associated with exuberant antimycobacterial immune
responses [12]. There is no diagnostic test for TB IRIS,
and the differential diagnosis is wide, including failure
of TB treatment attributable to antimicrobial resistance,
or suboptimal antitubercular drug concentrations [13],
drug reactions, or an alternative opportunistic condi-
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Table 1. Case definitions for tuberculosis (TB) immune reconstitution inflammatory syndrome (IRIS).
Criteria that must be met for the diagnosis of TB IRIS before the initiation of cART
Microbiologic, histologic, or very strong clinical evidence of TB
Initial improvement of 1 of the following during multidrug TB treatment: symptoms, Karnofsky
score, weight, fever, clinical signs, or radiographic findings
The infecting strain of Mycobacterium tuberculosis is susceptible to rifampin (if this result is available)
The patient was receiving antitubercular therapy when cART was initiated
Criteria that must be met for the diagnosis of TB IRIS within 3 months after the initiation of cART
New or recurrent TB-related symptoms and/or
New or worsening TB manifestations, such as 1 of the following:
New or expanding lymph nodes
New or expanding tuberculous cold abscesses
New or expanding intracranial tuberculomas
New or expanding pulmonary infiltrates (radiographically confirmed)
New or recurrent tuberculous meningitis (after exclusion of bacteria and fungi)
New or enlarging serous effusions (pericardial, pleural, or ascitic; radiographically confirmed)
New or worsening granulomatous hepatitis
New or worsening granulomatous infiltration of bone marrow
Other new or worsening tuberculous lesions
No other opportunistic disease to explain the new or recurrent symptoms and/or new or worsening
TB manifestations
excluded before a diagnosis of TB IRIS is made [14, 15]. TB
IRIS can be severe and life-threatening, and there are anecdotal
reports that suggest the use of adjunctive corticosteroid therapy
[16, 17].
Concurrent with the increase in the prevalence of TB IRIS,
the emergence of multidrug-resistant (MDR) and extensively
drug resistant TB in settings in Southern Africa where HIV
infection is prevalent has recently been highlighted [18, 19].
Determining the cause of deterioration in patients with TB
during cART in resource-limited settings is important, because
adjunctive corticosteroid therapy may worsen an already im-
munosuppressed patient’s condition if used in the presence of
incompletely efficacious TB treatment or other opportunistic
infections. This study prospectively evaluated clinical case def-
initions of TB IRIS among 100 patients who were considered
to have likely cases of TB IRIS. We found a high prevalence of
unsuspected drug-resistant TB in this cohort, which has im-
portant implications for the diagnosis and management of this
condition, as well as wider policy implications.
PATIENTS AND METHODS
Study site and participants. A prospective observational
study was conducted under program conditions that involved
100 consecutive patients who were referred to GF Jooste Hos-
pital (Cape Town, South Africa) with likely cases of TB IRIS.
The TB incidence rate in the Western Cape province in 2006
was 1031 cases per 100,000 population [20], and the prevalence
of antenatal HIV infection was as high as 33% [21]. More than
10,000 people have initiated cART within the catchment area
of GF Jooste Hospital (M. Osler, Provincial Government of the
Western Cape, personal communication). The national TB pro-
gram treats new TB cases with 6 months of therapy (rifampin,
isoniazid, pyrazinamide, and ethambutol for 2 months, fol-
lowed by rifampin and isoniazid for 4 months). The retreatment
regimen includes the addition of streptomycin, as follows: 2
months of rifampin, isoniazid, pyrazinamide, ethambutol, and
streptomycin; 1 month of rifampin, isoniazid, pyrazinamide,
and ethambutol; and 5 months of rifampin, isoniazid, and
ethambutol. Routine TB drug susceptibility testing (DST) is
not performed for new TB cases. Patients receiving retreatment
and patients not responding to TB treatment may have DST
performed. DST was only performed for rifampin, isoniazid,
and ethambutol during the study, in accordance with national
guidelines.
First-line cART in South Africa is stavudine, lamivudine, and
either nevirapine or efavirenz. Efavirenz is preferred for patients
receiving rifampin-based TB treatment. Patients with a CD4
cell count !200 cells/mL and/or World Health Organization
stage 4 disease are eligible to commence cART.
Clinical case definitions of TB IRIS (table 1) were prepared,
circulated, and discussed with participating primary care phy-
sicians. The definitions were in accordance with other published
case definitions for IRIS [14, 15], in that they excluded patients
with drug-resistant TB. Our case definitions, however, specif-
ically used known resistance to rifampin as an exclusion cri-
terion. We obtained information regarding initial TB diagnosis
from the referral letter and by search of records from the re-
gional laboratory, which processes all TB microbiologic spec-
imens in our referral area. All patients aged 13 years who
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Figure 1. Final diagnosis for 100 patients with suspected cases of
tuberculosis (TB) immune reconstitution inflammatory syndrome (IRIS).
MDR, multidrug resistant; NTM, nontuberculous mycobacteria.
cluded. TB treatment adherence was assessed by self-report and
on the basis of the patient’s TB clinic card, on which each daily
dose taken was documented with a tick. Patients who had !80%
adherence to TB treatment reported were not included as pa-
tients with suspected TB IRIS. The Research Ethics Committee
of the University of Cape Town approved this study (REC 337/
2004).
Clinical assessment sought to exclude differential diagnoses
based on clinical presentation. For example, for patients with
respiratory symptoms, bacterial and pneumocystis pneumonia
were investigated. Clinical specimens were sent for TB micro-
scopic examination, culture, and DST at the time of presen-
tation with suspected TB IRIS. DST for rifampin and isoniazid
was performed at 2 nationally accredited laboratories. Both
laboratories used the indirect proportion method: one labo-
ratory used liquid media with the MGIT system, and the other
used solid culture medium (Middlebrook 7H11 agar). For 36
patients, a rapid rifampin resistance assay was performed
(FASTplaque-Response; Biotec Laboratories) [22]. The result
of this assay was confirmed by culture-based DST, and the latter
result is reported unless stated otherwise. A purified protein
derivative enzyme-linked immunospot assay was performed, as
described elsewhere [23]. Patients were classified as having TB
IRIS if 2 clinicians agreed that, at initial assessment and during
the follow-up period, the patient fulfilled at least 1 of the case
definitions.
Statistical methods. Fisher’s exact test was used to compare
proportions, and the Mann Whitney U test was used to analyze
differences between medians. The unpaired Student’s t test with
Welch’s correction was used to compare enzyme-linked im-
munospot assay results.
RESULTS
One hundred patients (66 female and 34 male patients) with
suspected TB IRIS were evaluated from February 2005 through
July 2006. The median age was 31 years (interquartile range
[IQR], 26–35 years), and the median baseline CD4 cell count
was 50 cells/mL (IQR, 26–94 cells/mL). Twenty-six patients had
received 1 course of prior TB treatment. Patients developed
symptoms prompting referral with suspected TB IRIS a median
of 14 days (IQR, 7–25 days) after starting cART. These patients
were assessed during screening for a randomized placebo-con-
trolled trial of prednisone for mild and moderate TB IRIS
(ISRCTN 21322548). Thirty-eight patients were enrolled in that
study, and 25 received corticosteroid treatment for TB IRIS
outside that study, usually for severe TB IRIS. Final diagnoses
are shown in figure 1.
Follow-up CD4 cell counts during the first year of cART
were available for 77 patients. In 73 patients (95%), the follow-
up CD4 cell count increased (median increase, 139 cells/mL;
IQR, 64–241 cells/mL) from the pre-cART value. In 4 patients,
the CD4 cell count decreased by 1–50 cells/mL during the first
year of cART. Follow-up viral loads, usually measured after 6
months of cART, were available for 74 patients. The viral load
was !400 copies/mL in 65 patients, 400–1000 copies/mL in 5,
and 11000 copies/mL in 4. In all 4 of these patients, the CD4
cell count increased by 77–365 cells/mL during cART.
Among the whole cohort, the initial TB diagnosis was made
on the basis of culture of Mycobacterium tuberculosis in a clinical
specimen for 41 patients and positive smear microscopy results
for 31 patients. For 25 patients, a diagnosis of smear-negative
or extrapulmonary TB was made on the basis of clinico-ra-
diological data [24–26]. Although the other 3 patients were
receiving TB treatment at presentation, the initial diagnosis of
TB was incorrect, and they had nontuberculous mycobacterial
infection.
Seven of the 25 patients with a clinico-radiological diagnosis
had microbiological confirmation when they presented with
suspected TB IRIS (4 were smear positive, and 3 were culture
positive). For the other 18 patients, the diagnosis of TB was
not microbiologically proven. These patients had TB symptoms
and lymphadenopathy on abdominal ultrasound (5 patients),
on chest radiograph (2), or peripherally (1); miliary infiltrates
on chest radiograph (4); other radiographic pulmonary infil-
trates (2); pericardial effusion (2); or pleural effusion (2). One
of the patients who received a diagnosis on the basis of symp-
toms and abdominal nodes on ultrasound was subsequently
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Seven patients with suspected TB IRIS had clear evidence of
an alternative opportunistic condition (figure 1). In 3 patients,
this was a nontuberculous mycobacterial infection. These pa-
tients had experienced some symptomatic improvement while
receiving TB treatment before initiation of cART and were then
referred with suspected TB IRIS after commencing cART. Re-
view of the initial sputum culture results revealed nontuber-
culous mycobacterial infection. In 2 of the 3 patients, nontu-
berculous mycobacteria were also cultured from blood samples
at the time of assessment for suspected TB IRIS.
Twenty-five patients had DST performed at initial TB di-
agnosis. For 19 of these patients, the isolate was susceptible to
rifampin and isoniazid; 2 had isolates monoresistant to iso-
niazid, 1 had an isolate monoresistant to rifampin, and 3 had
MDR TB. In an additional patient (patient 3), DST of the isolate
at TB diagnosis was performed retrospectively after presenta-
tion with suspected TB IRIS, and the isolate demonstrated mo-
noresistance to rifampin (table 2). For this patient, the culture
result at the time of presentation with TB IRIS was negative.
All 4 patients who presented with suspected TB IRIS with
known rifampin resistance were receiving appropriate therapy
for MDR TB and reported at least partial clinical improvement
before initiation of cART. These patients then presented with
clinical deterioration 7–45 days after starting cART. Their clin-
ical manifestations included fever or night sweats (2 patients),
marked weight loss (2), new peripheral nodes (1), new pul-
monary infiltrates on chest radiograph (2), and other recurrent
TB symptoms. Although these features are typical of TB IRIS,
the case definitions that we used excluded this diagnosis.
Eighty-five patients had at least 1 culture for M. tuberculosis
performed during assessment for TB IRIS. Cultures for M.
tuberculosis were performed on sputum (for 55% of patients),
lymph node or abscess aspirate (18%), pleural fluid (8%), CSF
(8%), or other clinical specimens (11%). Culture yielded M.
tuberculosis for 17 patients (20%; 8 had MDR TB, 1 had iso-
niazid-monoresistant TB, and 7 had TB that was susceptible
to rifampin and isoniazid). Drug susceptibility was undeter-
mined for 1 patient (patient 6) (table 2), because the culture
of the patient’s sample yielded both nontuberculous mycobac-
teria and M. tuberculosis. This patient had a FASTplaque assay
indicative of rifampin resistance. Including the patient whose
initial isolate was rifampin resistant (patient 3) (table 2) and
the patient with a FASTplaque result indicating rifampin re-
sistance (patient 6) (table 2), 10 patients were found to have
rifampin-resistant TB at the time of TB IRIS presentation. One
of these patients was previously known to have MDR TB; thus,
9 (10.1%; 95% CI, 3.9%–16.4%) of 89 patients with suspected
TB IRIS had rifampin-resistant TB that was previously unsus-
pected (table 2). All 9 of these patients reported symptomatic
improvement after commencing standard TB treatment. For 1
of these patients (patient 8) (table 2), culture and DST at initial
TB diagnosis revealed susceptibility to rifampin and isoniazid,
but repeat DST performed for suspected TB IRIS revealed MDR
TB.
Table 3 compares the baseline characteristics of the 4 diag-
nostic groups. No statistically significant differences existed in
univariate analysis, with the exception of shorter duration from
initiation of TB treatment to initiation of cART in the group
of patients who received diagnoses of TB IRIS with no rifampin
resistance, compared with those who were known to have rif-
ampin-resistant disease when they presented with suspected TB
IRIS (median, 68 days vs. 199 days; ).P p .02
Table 4 shows clinical, radiological, and laboratory features
of the TB IRIS episode for the 80 patients who received a final
diagnosis of TB IRIS without rifampin resistance. The TB IRIS
case definitions that were fulfilled are also shown. Many patients
fulfilled 11 case definition, and frequently, TB IRIS involved
11 organ system. The most frequent TB IRIS symptoms among
these 80 patients were constitutional (68 patients; 85%), in-
cluding night sweats, malaise, anorexia, and weight loss; re-
spiratory (48; 60%); and abdominal (47; 59%), including ab-
dominal pain, nausea, vomiting, and diarrhea. The symptoms,
signs, and radiological findings for the 9 patients with rifampin-
resistant TB diagnosed after presentation with suspected TB
IRIS did not differ significantly from those of the patients who
had TB IRIS without rifampin-resistant TB, with the exception
of more frequent presence of lymphadenopathy on chest ra-
diograph (7 of 9 patients vs. 30 of 80 patients; ). BloodP p .03
investigations were also similar between the 2 groups, although
for the 9 patients with rifampin-resistant TB, the median C-
reactive protein level was higher (179 mg/L [IQR, 100–212 mg/
L] vs. 96 mg/L [IQR, 70–152 mg/L]; ). Purified proteinP p .05
derivative enzyme-linked immunospot assay demonstrated evi-
dence of immune activation in both groups, although the de-
gree was less in the patients with rifampin-resistant TB (fig-
ure 2).
DISCUSSION
In Cape Town, the triple coincidence of very high TB case
notification rates, an expanding epidemic of HIV infection, and
the large-scale roll-out of cART has led to a large increase in
the number of cases of TB IRIS (to date, there are hundreds
of cases) presenting at our health care service. We prospectively
evaluated clinical case definitions for TB IRIS for 100 cases;
this was, to our knowledge, the largest TB IRIS case series
reported to date. Once patients with alternative conditions (7
patients) and known rifampin-resistant TB (4 patients) were
excluded, 9 (10%) of the remaining 89 patients were found to
have rifampin-resistant TB only after presenting with suspected
TB IRIS. This has important implications for the diagnosis and
treatment of HIV-infected patients with TB whose conditions










Table 2. Cases of rifampin-resistant tuberculosis (TB) diagnosed after presentation with suspected TB immune reconsti-






cells/mL Previous TB Initial TB diagnosis Course of events TB IRIS manifestations






Rif, INH, Pza, and Eth;
started cART 8 weeks
later; suspected TB IRIS
onset 14 days later;
sputum culture negative
for TB twice at IRIS on-
set; sputum and pleural
aspirate samples from
8–10 weeks after IRIS












2 29 F 16 No Disseminated (pulmonary




Started on Rif, INH, Pza,
and Eth; symptoms im-
proved; started cART 13
weeks later; suspected
TB IRIS onset 39 days
later; bronchoscopy per-
formed 8 weeks later
(bronchial brushings
grew MDR TB); thereaf-
ter, ongoing IRIS mani-
festations despite MDR
TB treatment
High fevers, weight loss,
and abdominal and con-
stitutional symptoms;
right hilar node enlarge-
ment on CXR with bron-
chial compression (on
bronchoscopy); new
right middle lobe infil-
trate on CXR; enlarging
cervical nodes






berculosis; DST not re-
quested at the time
Started Rif, INH, Pza, Eth,
and Stm; reported 2-kg
weight gain, and CRP
level decreased (202 to
69 mg/L); started cART
1 month later; 5 days
later, developed sus-
pected TB IRIS; DST re-









bilical cold abscess, per-
itonism, and marked
tachycardia
4 51 F 35 No Pulmonary; sputum sam-
ple cultured for M. tu-
berculosis; DST not per-
formed at the time
Symptomatic improve-
ment while receiving




started cART 2 months
later; 7 days later, devel-
oped suspected TB
IRIS; lymph node aspi-










5 31 F 3 No Disseminated (CXR re-
vealed pulmonary infil-
trates and cervical ade-
nitis); lymph node
aspirate smear positive
and sputum culture pos-
itive for M. tuberculosis;
no DST performed at
the time
Initially improved while re-
ceiving Rif, INH, Pza,
and Eth (night sweats
resolved and general
condition improved);
then had chronic diar-
rhea followed by recur-
rent TB symptoms prior
to cART; started cART 4
months after TB treat-




























cells/mL Previous TB Initial TB diagnosis Course of events TB IRIS manifestations







positive for M. tubercu-
losis; no DST was per-
formed at the time
Reported symptomatic im-
provement while receiv-
ing Rif, INH, Pza, and
Eth; started cART 6
months after TB treat-




and NTM; thus, formal








7 28 F 187 Yesa Pulmonary (smear
positive)
Started receiving Rif, INH,




cART 5 months later; 7
days after starting cART,
developed suspected
TB IRIS; sputum culture










for M. tuberculosis; sus-
ceptible to Rif and INH
Symptomatically improved
while receiving Rif, INH,
Pza, and Eth, with re-
ported weight gain; 6
weeks after TB treat-
ment, started cART; de-
veloped suspected TB






toms; weight loss, fe-
ver, and tachycardia;
peritonism on examina-





9 31 M 12 Yesa Disseminated; CXR re-
vealed pulmonary infil-
trates and CSF smear
positive for acid-fast ba-
cilli; patient also re-
ceived a diagnosis of
cryptococcal meningitis
before initiation of cART
Symptomatically improved
while receiving treat-
ment for TB and crypto-
coccal meningitis prior














could have been due to
TB or cryptococcal IRIS
NOTE. cART, combined antiretroviral therapy; CRP, C-reactive protein; CXR, chest radiograph; DST, drug susceptibility testing; Eth, ethambutol;
INH, isoniazid; MDR, multidrug resistant; NTM, nontuberculous mycobacteria; Pza, pyrazinamide; Rif, rifampin; Stm, streptomycin.
a Previously defaulted TB treatment.
In the 9 patients with rifampin-resistant TB, presentation
was suggestive of TB IRIS, with improvement while receiving
TB treatment before initiation of cART and then deterioration
during the weeks after the initiation of cART. The obvious
question is whether the condition of the patients with drug-
resistant TB deteriorated because of suboptimally treated TB,
TB IRIS, or both? Our case definitions, which are similar to
those used by other researchers [14, 15], classified known rif-
ampin resistance as excluding TB IRIS. However, in light of
our observations, we propose that antitubercular drug resis-
tance and TB IRIS are not mutually exclusive and may overlap
in the same person. First, given that TB IRIS immunopathology
is attributable to restored antigen-specific immunity to M. tu-
berculosis antigens [12], it is reasonable to conclude that TB
IRIS may occur in response to drug-susceptible or drug-resis-
tant strains, whether the latter are treated or untreated. The
antigen stimulus for TB IRIS is unlikely to differ in these
scenarios.
Second, in the 4 patients with known rifampin-resistant TB,
all improved while receiving treatment for MDR TB, and then
their conditions deteriorated after cART initiation. The dete-
rioration of their conditions was most likely attributable to TB
IRIS, given the timing. These patients may be at higher risk of
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TB IRIS and then









TB IRIS and then
received a diagnosis of
an alternative OD
(n p 7)
Female sex 52 (65) 7 (78) 1 (25) 6 (86)
Age, years 31 (27–36) 29 (26–31) 31 (28–35) 30 (24–34)
Previous TB 18 (23) 3 (33) 2/3 (67) 3 (43)
Prior cARTa 4 (5) 1 (11) 1 (25) 0 (0)
WHO clinical stageb
3 28 (35) 2 (22) 0 (0) 2 (29)
4 52 (65) 7 (78) 4 (100) 5 (71)
cART regimen at assessment
d4T, 3TC, and EFV 64 (80) 8 (89) 4 (100) 6 (86)
Other 16 (20) 1 (11) 0(0) 1 (14)
TB disease formc
Pulmonary 36 (45) 3 (33) 2 (50) 3 (43)
Extrapulmonary 44 (55) 6 (67) 2 (50) 4 (57)
Time from start of TB treatment to start of cART, days 68 (35–93) 84 (47–115) 199 (121–447) 69 (21–125)
Time from start of cART to TB IRIS onset, days 14 (8–23) 13 (7–29) 35 (17–45) 35 (7–52)
Baseline CD4 cell count, cells/mL 50(26–94) d 44(16–94) 84 (55–184) 72 (13–85)
Baseline viral load measured 61 (76) 5 (56) 0 (0) 5 (71)
Baseline viral load, value  105 copies/mL 2.1 (9.8– 5.0) 1.7 (1.4–5.6) … 2.5 (1.1–5.0)
NOTE. Data are no. (%) of patients or median value (interquartile range). cART, combination antiretroviral therapy; d4T, stavudine; EFV, efavirenz; IRIS, immune
reconstitution inflammatory syndrome; OD, opportunistic disease; Rif, rifampin; TB, tuberculosis; 3TC, lamivudine; WHO, World Health Organization.
a Excludes patients who received single-dose nevirapine for prevention of mother-to-child transmission.
b WHO staging includes current TB diagnosis.
c The pulmonary TB category includes patients who had pulmonary TB only, and the extrapulmonary TB category includes patients with extrapulmonary TB
only and those with both pulmonary TB and extrapulmonary TB.
d Seventy-nine of these 80 patients had a baseline CD4 cell count available.
culosis bacillary load has been suggested as a risk factor for the
condition [7], and even those patients who are effectively
treated for MDR TB are likely to have slow bacillary clearance.
This may partially account for our observation that these 4
patients developed TB IRIS despite a long interval between
initiation of TB therapy and initiation of cART (table 3).
Third, 9 patients had undiagnosed rifampin-resistant TB
when they presented with suspected TB IRIS. These patients
all reported at least partial symptomatic response to standard
TB treatment before the initiation of cART. It is possible for
patients with MDR TB to initially respond to first-line TB
treatment [27–29], either because the organism is sensitive to
ethambutol and pyrazinamide or because the patient is dually
infected with MDR TB and a susceptible strain [30]. In ad-
dition, patients may improve while receiving treatment for
drug-susceptible TB and then be reinfected with drug-resistant
TB, or the infecting organism may develop rifampin resistance
during treatment. Either of these scenarios could have occurred
for patient 8 (table 2). For these 9 patients who received a
diagnosis of rifampin-resistant TB after presenting with sus-
pected TB IRIS, symptomatic deterioration occurred 3–48 days
after the initiation of cART—the characteristic timing of TB
IRIS. The clinical and radiological features of these patients
when they presented with suspected TB IRIS, with the exception
of more frequent presence of lymphadenopathy on chest ra-
diograph, were not significantly different from those of patients
with TB IRIS with no drug resistance. We propose that TB IRIS
exacerbated undiagnosed drug-resistant TB. Support for the
idea that TB IRIS was present in this group comes from the
enzyme-linked immunospot assay data, which showed expan-
sions of purified protein derivative–specific IFN-g–producing
T cells (which are a reported characteristic of TB IRIS [12]),
irrespective of drug susceptibility. The overlap of IRIS and drug
resistance with respect to cryptococcal infection has been high-
lighted elsewhere [31].
Seven patients with suspected TB IRIS had alternative op-
portunistic diseases that explained their clinical deterioration.
Patients with advanced immunosuppression may have multiple
opportunistic conditions. A thorough examination for alter-
native infections and malignancies before diagnosis of TB IRIS
is essential. Three patients receiving TB treatment at their local
clinic actually had nontuberculous mycobacterial infection
when the result of the original culture was followed up; this
underscored the importance of reviewing the original TB di-
agnosis during the assessment of these patients. The perfor-










Table 4. Clinical, radiographic, and laboratory features of tuberculosis (TB) immune reconstitution
inflammatory syndrome (IRIS) in 80 patients who received a diagnosis of TB IRIS without rifampin
resistance.
Variable Patients
TB IRIS case definitions fulfilled
New, recurrent, or worsening symptoms 80 (100)
New or worsening TB manifestations 59 (74)a
New or expanding lymph nodes 35 (44)
New or expanding cold abscesses 3 (4)
New or expanding intracranial tuberculomas 1 (1)
New or expanding pulmonary infiltrates 22 (28)
New or recurrent TB meningitisb 6 (8)
New or enlarging serous effusions 13 (16)
New or worsening granulomatous hepatitis 2 (3)
New or worsening granulomatous bone marrow infiltrate 5 (6)
Other new or worsening TB lesionc 3 (4)
Other physical signs




New neurological signs 7 (9)
Radiographic features
On chest radiograph
Pulmonary infiltrates 52/80 (65)
Hilar/mediastinal nodes 30/80 (38)
Pleural effusion 17/80 (21)
On ultrasound
Abdominal nodes 27/35 (77)
Ascites 10/35 (29)
Pericardial effusion 10/35 (29)
Focal splenic lesions 7/35 (20)
On CT: head lesions 3/8 (38)d
Laboratory features
Total bilirubin level, mmol/L (n p 13)e 54 (16–103) [0–21]
Alkaline phosphatase level, IU/L (n p 56) 181 (103–326) [40–120]
Alanine aminotransferase level, IU/L (n p 62) 41.5 (28–59.8) [5–40]
g-Glutamyl transferase level, IU/L (n p 15) 217 (152–482) [0–35]
Hemoglobin level, g/dL (n p 73) 9.1 (7.8–10) [M: 13.0–17.0; F: 12.0–15.0]
WBC count, value  109 cells/L (n p 71) 5.4 (3.7–8.7) [4.0–10.0]
Platelet count, value  109 cells/L (n p 65) 362 (268–462) [178–400]
C-reactive protein level, mg/L (n p 72) 96 (70–152) [0–10]
C-reactive protein level 110 mg/L (n p 72) 71 (99)
NOTE. Data are no. (%) of patients or median value (interquartile range) [reference range].
a The other 21 patients fulfilled only the case definition relating to new, worsening, or recurrent symptoms.
b TB IRIS meningitis was defined as 5 lymphocytes and/or polymorphs in a CSF sample from a patient with new or
recurrent meningism or other new neurological symptoms after exclusion of bacterial and fungal meningitis.
c The other manifestations were arthritis (in 2 patients) and bursitis (in 1 patient).
d Eight patients had CT performed: tuberculomas were shown for 1 patient and a new infarct ( in 1 patient) and hydrocephalus
(in 1 patient) were shown for the others.
e Bilirubin level measurement was performed mainly for those patients in whom jaundice was clinically apparent. Nine of
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Figure 2. Comparison of purified protein derivative enzyme-linked im-
munospot assay results for 33 patients with tuberculosis (TB) immune
reconstitution inflammatory syndrome (IRIS) with no rifampin (RIF) resis-
tance (median, 1047 spot-forming cells [SFC]  106 PBMCs; interquartile
range, 417–1700 SFC  106 PBMCs) with those for 5 patients who
received a diagnosis of RIF-resistant TB after presenting with TB IRIS
(median, 529 SFC  106 PBMCs; interquartile range, 89–680 SFC  106
PBMCs; ).P p .04
with lower TB incidence rates, where patients might more fre-
quently present with other reasons for deterioration.
Frequently, patients had signs, symptoms, and radiological
manifestations suggestive of multiple organ system involvement
with TB IRIS. This may be explained by profound immuno-
suppression (median nadir CD4 cell count, 50 cells/mL), pre-
disposing to disseminated TB. The most frequent organ systems
involved were the respiratory system (respiratory symptoms
and chest radiograph infiltrates) and, hitherto little appreciated,
the abdominal organs. Of the 80 patients with TB IRIS with
no rifampin resistance, 59% had abdominal symptoms; 56%
had hepatomegaly, 9% had splenomegaly, and 5% had peri-
tonism. Abdominal nodes were present in 77% of those who
underwent ultrasonography. Liver function derangement, par-
ticularly a cholestatic pattern, was common. These findings
suggest that, if patients develop abdominal symptoms or liver
function derangement after commencing cART, TB IRIS should
be considered in the differential diagnosis in addition to drug-
related adverse effects, such as pancreatitis, lactic acidosis, and
drug-induced hepatitis.
There were several limitations to our study. For most pa-
tients, the initial TB diagnosis had been made in primary care
according to program guidelines, and only 41% of the cases
were confirmed by culture. Most patients also initiated cART
at the same facilities; thus, examination and radiographic data
were incomplete. All patients had a chest radiograph performed
to investigate TB IRIS, but few were performed at the time of
cART initiation. In addition, patients who are smear positive
do not routinely undergo chest radiography at TB diagnosis.
Therefore, for many patients with symptoms of TB IRIS who
had radiographic pulmonary infiltrates (65% had infiltrates),
it was impossible to determine whether these were new or
expanding, which potentially underestimated the number of
cases fulfilling the pulmonary infiltrate case definition and, sim-
ilarly, the serous effusion case definition. Many patients had
hepatomegaly (56% of patients) with cholestatic liver derange-
ment, which suggested granulomatous hepatitis [32], but this
was only confirmed in 2 patients, because severity otherwise
was insufficient to warrant a biopsy. The number of cases ful-
filling the granulomatous hepatitis case definition might, for
this reason, also be underestimated. It is for these reasons that
the diagnosis of TB IRIS was made exclusively on the basis of
a clear history of symptom improvement before the initiation
of cART, followed by new, worsening, or recurrent TB symp-
toms after the initiation of cART in many patients (26% of
patients). Follow-up CD4 cell count and HIV viral load mea-
surements during cART were unavailable for one-quarter of
the patients. These tests are performed every 6 months during
cART under program conditions; however, many patients were
transferred to other facilities, and some were lost to follow-up
or died by 6 months. Determination of viral load or CD4 cell
count at the time of TB IRIS diagnosis did not, however, form
part of our case definitions. For patient 6 (table 2), the FASTp-
laque assay demonstrated rifampin resistance. This could not
be confirmed by culture-based DST. The presence of nontu-
berculous mycobacterial coinfection in the patient’s specimen
may have affected the FASTplaque result, but it is worth noting
that the specimen was culture positive for M. tuberculosis after
7 months of TB treatment; this supported a diagnosis of rif-
ampin-resistant TB.
Corticosteroids have been proposed as a treatment for TB
IRIS, although the only evidence currently available is anecdotal
[17]. There are potential risks of corticosteroid treatment for
HIV-infected patients with TB, including herpes virus reacti-
vation and Kaposi sarcoma [33, 34]. There is no present clinical
trials evidence supporting the use of corticosteroids for the
treatment of TB IRIS, other than for TB meningitis and, per-
haps, pericardial disease (neither with evidence in the context
of cART [35, 36]). Assessment of suspected TB IRIS should
trigger re-evaluation of the TB diagnosis and the adequacy of
antimicrobial therapy. Such assessment should occur before the
instigation of corticosteroid therapy; otherwise, there is a risk
that patients who remain deeply immunosuppressed (despite
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bial coverage. Our study highlights the pressing need to develop
and implement rapid techniques to diagnose drug resistance
that are appropriate to resource-limited conditions. The use of
the FASTplaque assay in the present study was an attempt to
overcome this problem, and there are encouraging data emerg-
ing from other studies of rapid tests [37]. Overall, our data
also support the use of routine DST for HIV-infected patients
with TB.
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HIV–TB Drug Interactions1)
Tolu Oni, Dominique J. Pepper, and Robert J. Wilkinson
6.1
Important Concepts and Definitions [1, 2]
. Combination antiretroviral therapy Antiretroviral therapy where typically three or
four drugs, in most cases from different drug classes, are given in combination.
. CytochromeP450 (CYP)Membrane-associated hemoproteins, located either in the
innermembrane of themitochondrion or in the endoplasmic reticulumof the cells
CYPs metabolize endogenous and exogenous compounds, such as hormones
(estrogen and testosterone) and xenobiotics.
. P-glycoproteinAn energy-dependent efflux pump that exports substrates out of the
cell, and is expressed in the epithelial cells of the gastrointestinal tract, the liver, the
kidneys, the blood–brain barrier, and in CD4þ lymphocytes.
. Drug interaction Said to occur when the disposition of one drug is altered by
another.
. Pharmacokinetic drug interaction Involves alteration in absorption, transport,
distribution, metabolism or excretion of a drug, the results of which can be a
decreased or an increased exposure, leading to reduced efficacy or increased
toxicity, respectively.
. Pharmacodynamic drug interaction Pharmacological response to the drug is
directly altered, leading to potentiation of effect (including toxicity) in either an
additive or synergistic manner, or antagonism.
1) The authors receive financial support from the
Wellcome Trust, MRC (UK), European Union
and from the Presidents Emergency Plan for
AIDS relief. None of these agencies were party
to the publication of this chapter and the views
expressed herein are those of the authors, not
the funding agencies. No author has a financial
or other conflict of interest in the publication of
this chapter.
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As of December 2007, two billion people globally are infected with Mycobacterium
tuberculosis-mediated tuberculosis (TB) [4], and 33.2 million with human immuno-
deficiency virus (HIV) [5]. Where these pandemics intersect, they are the most
common cause of death among young adults inmany countries. In 2007, 2.1million
AIDS-related deaths occurred worldwide [5], while in 2006 1.7 million deaths were
attributed to TB [6]. The developing world accounts for the majority of the 11million
people coinfected with HIV and TB (HIV-TB) [4]. In 2006, there were an estimated
709 000 newHIV-infected TB cases, 85% of which occurred in Africa [6]. TB andHIV
are inexorably entwined; the annual incidence of TB disease doubles within the first
year of HIV infection [7], andmay reach 30% per annum in the profoundly immune-
suppressed [8]. Likewise, TB disease synergistically accelerates the progression of
HIV infection to acquired immune deficiency syndrome (AIDS), by promoting viral
replication in immunologically activated CD4 cells [9–11]. Soon after the commence-
ment of TB therapy, combination antiretroviral therapy (cART) is often required
to ameliorate the profound immune suppression of AIDS. In addition, simultaneous
treatment(s) for associated AIDS-defining illnesses and complications is/are often
necessary. While dual HIV-TB therapy appears associated with improved survival
compared to delayed antiretroviral therapy [12], several substantial challenges
exist, namely drug–drug and drug–disease interactions, shared drug toxicities,
immune reconstitution inflammatory syndrome (IRIS), and high pill burdens [3].
In particular, the possibility for drug–drug interactions that have clinically important
consequences increases in HIV-infected patients receiving cART if three or more
comorbid illnesses occur simultaneously, or three or more antiretroviral agents
are taken concurrently [13]. In this chapter we describe the current therapy for HIV-
TB, and discuss the clinically relevant drug–drug and drug–disease interactions
that may occur in HIV-infected patients receiving dual HIV-TB therapy. A prediction
is also made of the potential drug interactions that are likely to occur in the
developed world.
6.3
Current Therapy for Tuberculosis and HIV
Tuberculosis therapy is a multidrug regimen prescribed for a minimum of six
months. Multidrug treatment needs to be prolonged as single-agent TB therapy
rapidly gives rise to drug-resistant organisms [14]. The advent of rifampin and
pyrazinamide allowed the development of highly effective short-course TB regi-
mens – usually a two-month intensive phase with rifampin (R), isoniazid (H),
pyrazinamide (Z) and ethambutol (E) – followed by a four-month continuation
phase with RH (2RHZE/4RH) [15]. Multi-drug resistant (MDR) TB, which is defined
as TB resistant to RH, is treated with less-effective agents for up to 18 months after
sputum conversion. Treatment is often initially empiric whilst awaiting drug
































































susceptibility results, and later individualized when such results are known. Regi-
mens may last for up to 24 months and include (according to susceptibility profile):
pyrazinamide, ethambutol, terizidone, ethionamide, an oral fluoroquinolone (oflox-
acin/ciprofloxacin/gatifloxacin/moxifloxacin), and an injectable agent (kanamycin/
amikacin/capreomycin). Extensively drug-resistant (XDR) TB, defined as MDR TB
with resistance to both an oral fluoroquinolone and an injectable agent [16], also
requires individualized treatment regimens [17, 18]. In addition, drugs to whichM.
tuberculosis remains susceptible, such as capreomycin, para-aminosalicylic acid
(PAS), co-amoxyclav and linezolid, may be added.
Combination antiretroviral therapy (cART) is a lifelong, multidrug regimen. In
patients infected with HIV, millions of virions are produced daily, and the reverse
transcriptase target rapidly mutates. Hence, initial therapies with single or dual
nucleoside reverse transcriptase inhibitors (NRTIs), such as zidovudine (AZT) and
didanosine (ddI), were only partially effective and rapidly led to viral drug resis-
tance [19]. Effective therapy only became possible when non-nucleoside reverse
transcriptase inhibitor (NNRTI) and viral protease inhibitor (PI) drugs were devel-
oped. Combinations of these three drug classes may lead to a prolonged suppression
of HIV replication, and ultimately to a degree of immune recovery. Adherence to
cART is crucial for successful viral suppression, which is very closely related to
immune restoration and survival [20].
6.4
Potential Drug–Drug and Drug–Disease Interactions
Numerous concurrent diseases occur in profoundly immune-suppressed HIV-TB
patients, including Pneumocystis jiroveci pneumonia, toxoplasmosis, Kaposis sarco-
ma, deep-vein thrombosis, seizure disorders, and sepsis [21]. The potential for
drug–drug and drug–disease interactions increases when treatment for these ill-
nesses is prescribed concomitantly with HIV and TB therapy (Figure 6.1). While
cARTpartially restores immune function and prolongs life, HIV-infected patients are
at increased risk of metabolic and vascular disorders; these disorders may occur as a
direct result of HIV infection [22], as side effects of HIV therapy [23–25], or because
prolonged survival allows HIV-infected patients to develop diseases that would
otherwise have occurred later in life. Simultaneous treatment for HIV, diabetes
mellitus and diseases due to atherosclerosis, will challenge many clinicians, espe-
cially as a subgroup of patients will still have an increased risk of TB disease [26] and
require treatment with rifamycins.
Potential drug–drug and drug–disease interactions should always be considered in
patients infected with HIV-TB, especially as many of the drugs used to treat HIV-TB
and comorbid diseases are either inducers, inhibitors, or substrates of cytochrome
p450 (CYP). Drugs that induce a particular CYP isoenzyme increase the rate at which
the CYP isoenzyme metabolizes its substrate to metabolites. Conversely, inhibitors
decrease the rate of metabolite production, resulting in increased substrate. Rifam-
pin is a potent inducer of CYP3A4, whereas ritonavir is an inhibitor of CYP3A4.
































































When warfarin and oral contraceptives are coadministered with CYP inducers,
suboptimal anticoagulation and contraceptive failure, respectively, may occur. Sim-
ilarly, when statins, calcium antagonists and benzodiazepines are coadministered
with CYP inhibitors, rhabdomyolysis, symptomatic hypotension and excessive
sedation, respectively, may result.
6.5
Treatment of Tuberculosis
Combination TB therapy with PAS and streptomycin was first reported in 1950 [27],
it having been recognized at an early stage that monotherapy rapidly gave rise to
bacterial resistance. With the later advent of rifampin, isoniazid, and pyrazinamide,
large studies demonstrated that the best chance of curing M. tuberculosis would be
provided by the combined use of rifampin and isoniazid for six months, with
pyrazinamide and ethambutol added for the first two months. Rifampin results in a
faster sputum conversion [28] and a shorter treatment duration [29]. The use of
Figure 6.1 Potential contributors to HIV-TB drug–drug and
drug–disease interactions: TB, HIV and comorbid diseases and
therapy.
































































rifampin in a multidrug regimen reduces the emergence of drug-resistant strains.
In order to optimize pharmacotherapy, factors affecting the absorption, distribu-
tion, metabolism and elimination of anti-tuberculosis drugs should be considered,




As rifampin interacts with a wide range of drugs, it is useful to understand its
pharmacokinetics in order to predict possible drug interactions. An important
mechanism of drug interactions with rifampin is the induction of drug-metabo-
lizing enzymes such as CYP 3A4 [30] in the small intestine and liver. Rifampin also
induces the CYP 2C isoenzymes, and therefore has the potential for interaction with
CYP 2C substrates, including sulfonylureas such as gliclazide [31]. However, other
possible mechanisms have been sought, as not all drug interactions can be
explained by an induction of the cytochrome P450 system (see Table 6.1). In
particular, the ATP-binding cassette (ABC) efflux transporter P-glycoprotein, located
in the apical membrane of enterocytes, has been found to have a role in the
elimination and bioavailability of certain drugs [32, 33]. Rifampin has been shown
to be an inducer of P-glycoprotein, and this represents another mechanism through
which drug–drug interactions can occur; indeed, this is thought to be the mech-
anism for rifampin–digoxin drug interaction [34]. Such induction is thought to be
tissue-specific, as renal P-glycoproteins do not appear to be induced by rifampin [34],
possibly because only enterocytes are locally exposed to high concentrations of orally
administered drug, and not the kidneys or liver. In addition, it was found that
human MRP2 (part of the multidrug-resistant protein family, a member of the ABC
transporters, and expressed also in small intestine enterocytes) is induced by
rifampin, thus alluding to another possible mechanism for drug interaction of
rifampin with other drugs [35].
Rifampinmay also activate the human glucocorticoid receptor by acting as a ligand
and binding to the receptor, and is therefore a potential immunosuppressive [36];
however, this point has attracted controversy [37]. Rifampin may reduce the con-
centration of drugs metabolized by uridine diphosphate glucuronosyl transferase
(UDPGT) and sulfotransferase (e.g., moxifloxacin) [38].
Trimethoprim-sulfamethoxazole is commonly used in HIV-infected patients as
prophylaxis against Pneumocystis jiroveci pneumonia (PJP) and toxoplasmosis. In
one clinical study it was suggested that rifampin could reduce the efficacy of co-
trimoxazole as prescribed for toxoplasmosis prophylaxis [39]. A pharmacokinetic
study conducted subsequent to this study showed reduced concentrations of both
trimethoprim and sulfamethoxazole in the presence of rifampin, with the suggested
mechanisms being rifampins induction of either the CYP450 system, the induction
of UDPGT, or by the induction of hepatic acetylation of sulfamethoxazole [40]. The
effect on clinical outcome of this reduction in plasma concentration, however, is not
known. Data are also available suggesting that rifampin levels increase after the


































































































































































































































































































































































































































































































































































































































































































































































































































































































administration of co-trimoxazole [41] but, again, the clinical significance of this is
unknown.
Dapsone is another drug used in the prophylaxis of PJP. It has been suggested that
rifampin decreases the serum concentration of dapsone through the induction of
CYP3A4 and, indeed, one study has shown dapsone clearance to be increased by
between 69% and 122% [42]. It was not clear whether this reduction in concentration
would result in a decreased efficacy in clinical practice [43], though some experts
believed this to be the case [44]. Rifampin is itselfmetabolized by deacetylation, and is
therefore unaffected by the CYP450 system; it is known to be capable of inducing its
own metabolism, however [45].
6.5.2
Rifapentine
Rifapentine is a long-acting cyclopentyl-derivative of rifampin, and is an inducer of
CYP3A4 andCYP2C8/9 of the sameorder ofmagnitude as rifampin [46]. Rifapentine
does not possess autoinductive properties [47] after repeated administration, how-
ever. In the plasma, rifapentine has been shown to be highly protein-bound
(97–99%), primarily to albumin, in healthy volunteers [48]. Such protein binding
may be important for the drugs pharmacodynamics when compared to rifabutin,
which is the least protein-bound rifamycin and shows little reduction in efficacy with
dose reduction [49].
The few drug interaction studies performed with rifapentine have shown themost
significant interaction to be with indinavir; coadministration of the two drugs led to a
reduction of 55% in the maximum plasma concentration, and of 70% in the area
under the concentration–time curve (AUC) [50].
6.5.3
Rifabutin
Rifabutin not only induces but is also metabolized by CYP 3A4; this results in
complex interactions with inhibitors of CYP450, such as protease inhibitors, anti-
fungal agents, andmacrolide antibiotics. Rifabutin is also a potent autoinducer. Some
data are available suggesting that microsomal cholinesterase is also involved in the
metabolism of rifabutin [51].
6.5.4
Isoniazid
Isoniazid inhibits CYP isoenzyme systems andmonoamine oxidase (MAO), and so is
associated with some drug interactions [52]. Isoniazid is mainly metabolized by
hepatic N-acetyltransferase 2 (NAT2) and CYP450 2E1. Unlike the rifamycins, it is
mostly excreted via the urine. It is believed that isoniazid kills the largest population
of M. tuberculosis in the rapidly growing phase. Several studies have shown that the
acetylator status of individuals may play a role in determining clinical outcome, with
































































slow acetylators showing a reduced enzyme activity. Despite this, it has been shown
that when isoniazid is given at least twice-weekly, the clinical outcome is independent
of acetylator status, although slow acetylators are more prone to hepatotoxicity [53].
These results have led some to suggest that NAT2 genotyping might be used to
ascertain acetylator status in the monitoring of TB treatment [54]. Acetylator status
appears relevant in isoniazids interaction with paracetamol (acetaminophen), with
some data showing rapid acetylators to have an increase in the levels of paracetamol
metabolites. It is thought that the induction of the CYP450 system leads to an
increase in hepatocellular injury due to an increased formation of toxicmetabolites of
paracetamol [55]. A study conducted in mice showed that aspirin antagonized
isoniazid treatment, with possible implications for the coadministration of salicy-
late-based anti-inflammatories and isoniazid.
6.5.5
Pyrazinamide and Ethambutol
Pyrazinamide and ethambutol each have a limited drug interaction profile [56].
The main metabolite of pyrazinamide, pyrazinoic acid, inhibits the renal tubular
secretion of uric acid and hencemay induce hyperuricemia. There is a scarcity of data
regarding possible drug interactions of pyrazinamide; hepatotoxicity following its
administration has also been demonstrated, although themechanism involved is not
clear [57]. An allopurinol–pyrazinamide interaction has been reported that causes a
build-up of pyrazinoic acid and reduces the renal secretion of uric acid [58].
Ethambutol, as an antituberculosis drug is predominantly bacteriostatic, and is
administered during the intensive phase of TB in an attempt to prevent further drug
resistance (see Table 6.1 for further information on metabolism). Various data have
suggested an interaction with aluminum-magnesium antacids, leading to a reduc-
tion in plasma ethambutol concentrations [59].
6.5.6
Ethionamide
Ethionamide is thought to be metabolized by the cytochrome P450 enzymes, and
maypotentially have interactionswith inducers or inhibitors of this system.However,
there is a paucity of data on the pharmacokinetics of this drug.
6.5.7
Fluoroquinolones
Ciprofloxacin, ofloxacin, gatifloxacin, and moxifloxacin, as fluoroquinolones, are
used to treat TB via their inhibitory effect on DNA gyrase. As a class, the fluor-
oquinolones are not significantly affected by coadministration with food [60]. One
known adverse effect of fluoroquinolones treatment is that of dysglycemia; this is
especially the case when gatifloxacin is administered to patients receiving concom-
itant treatment for diabetes, to elderly patients, and to those who are renally
































































impaired [61]. The most common drug interactions with fluoroquinolones in TB
therapy include malabsorption interactions associated with multivalent cations, and
cytochrome P450 interactions with ciprofloxacin [62, 63]. The combination of
pyrazinamide and ofloxacin appears to cause increased rates of asymptomatic
hepatitis and gastrointestinal intolerance [64, 65], while combined ofloxacin and
cycloserine may lead to an increased incidence of central nervous system (CNS) -
mediated effects, possibly due to altered g-aminobutyric acid (GABA) binding [66].
Modest, but potentially important, drug–drug interactions affecting the concentra-
tions of gatifloxacin and rifampin have been reported [67]. Importantly, the Rv2686c-
Rv2687c-Rv2688c genes ofM. tuberculosis encode an ABC transporter responsible for
fluoroquinolone efflux [68]; this efflux was shown to lead to a reduced accumulation
of fluoroquinolone by its active removal, thereby potentially contributing to fluoro-
quinolone resistance in M. tuberculosis.
6.5.8
Streptomycin/Amikacin/Kanamycin/Capreomycin
The aminoglycoside antibiotics consist of sugar and amino moieties. Among
these, streptomycin is used to treat drug-sensitive TB, while amikacin and
kanamycin are used for MDR TB. As the cytochrome P450 system neither induces
nor inhibits aminoglycoside activity, interactions with potent CYP inducers
(rifampin) and inhibitors (protease inhibitors) do not occur. Aminoglycosides
must be administered parenterally as they are poorly absorbed via the intestine.
They are also not metabolized and are excreted unchanged, predominantly in the
urine. The side effects of aminoglycoside are dose-dependent, and include
nephrotoxicity (potentially reversible), ototoxicity (usually irreversible), and neu-
romuscular blockade. Thus, the concomitant administration of aminoglycosides
with diuretics, radiographic contrast, angiotensin-converting enzyme (ACE) in-
hibitors, nonsteroidal anti-inflammatory drugs, amphotericin, and cisplatin is
usually avoided [69–71]. Capreomycin is a peptide antibiotic that is used extensively
to treat drug-resistant TB. However, as its adverse effects include nephrotoxicity




Terizidone is a combination of two molecules of cycloserine. A comparison of
cycloserine and terizidone showed the blood levels of terizidone to be higher at all
time points than those of cycloserine, although the difference was not proportional
to two molecules of cycloserine being contained in one molecule of terizidone [72].
The high concentration of terizidone in urine suggests that it may be of benefit in
genitourinary TB [72]. Evidence from South Africa has indicated that terizidone
causes fewer adverse effects (incidence ca. 1%) than cycloserine (ca. 11%) [73].
Terizidone is a valuable companion drug to prevent resistance to other second-line
































































drugs, as it does not share any cross-resistance with other active TB drugs.
Pyridoxine may decrease CNS-related effects, and a dose of 150mg should be
prescribed to all patients receiving terizidone or cycloserine. Terizidone should be




Linezolid does not induce cytochrome P450, and is not metabolized by this
process. This is important given the possibility of its use in patients concurrently
taking antiretrovirals [74, 75]. Linezolid is associated with mitochondrial toxicity,
and as a result causes side effects such as peripheral neuropathy and lactic
acidosis [76]. It is also known to cause reversible myelosuppression, thrombocy-
topenia and anemia in some patients [77]. The oral absorption (by AUC) of
linezolid is unaffected by the presence of food in the intestine [78]. Drug
interactions based on MAO inhibition are limited to increases in blood pressure




The early bactericidal activity of amoxicillin/clavulanate is comparable to that
reported for antituberculous agents other than isoniazid [80]. However, it has been
report unlikely that the combination of amoxicillin/clavulanic acid would have an
important role in the treatment of tuberculosis, with the exception of those patients
with MDR TB who otherwise are therapeutically destitute [81].
6.5.12
PAS
Para-aminosalicylic acid is metabolized to acetyl-PAS [82], and both compounds are
excreted renally; consequently, PAS should be avoided in renal failure. The gastro-
intestinal toxicity of PAS also limits its use, especially as other anti-TB drugs are less
likely to cause gastrointestinal side effects. Currently, PAS is formulated as granules
and taken with food [83].
6.5.13
Clarithromycin
Clarithromycin is a macrolide antibiotic. Potent inhibitors of CYP3A may alter the
metabolism of clarithromycin and its metabolites, while clarithromycin itself can
increase the steady-state concentrations of drugs that depend primarily upon CYP3A
metabolism [84].

































































Treatment of HIV Infection
6.6.1
Fusion Inhibitors
Enfuvirtide is a recently registered antiretroviral that inhibits HIV fusion to CD4
cells. It is not a substrate for CYP isoenzymes and neither inhibits nor induces
CYP3A; thus, no significant interactions with rifamycins exist [100–102].
6.6.2
Nucleotide/Nucleoside Reverse Transcriptase Inhibitors (NRTIs)
The NRTIs are predominantly excreted via the renal system (tubular secretion), and
interactions based upon CYP are infrequent [17]. However, drugs influencing renal
clearance or intracellular phosphorylation may interact with the NRTI. Significant
pharmacokinetic interactions have been demonstrated when zidovudine is pre-
scribed with probenecid, naproxen, and fluconazole [103].
Tenofovir is not a substrate, inducer or inhibitor of human cytochrome P450
enzymes (see Table 6.2). Tenofovir and rifampin may be used without dosage
adjustment for the treatment of TB inHIV-infected patients [104]. However, patients
with renal impairment (especially if receiving streptomycin) should be closely
monitored. Tenofovir has no clinically significant drug interactions, with the excep-
tion of didanosine and atazanavir, which will require dosage modifications to be
made [105]. HIV patients coinfected with hepatitis B virus/hepatitis C virus (HBV/
HCV) are likely to be treated with tenofovir and lamivudine or emtricitabine.
6.6.3
Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) and Protease Inhibitors (PIs)
The NNRTIs and PIs are extensively metabolized by the cytochrome P450 and
P-glycoprotein systems (summarized in Table 6.2). When drugs metabolized by the
same pathways are administered concomitantly, pharmacokinetic drug interactions
commonly result. Furthermore, ritonavir is both an inhibitor and substrate of the
drug transporter P-glycoprotein [2], thus increasing the potential for drug
interactions.
6.6.3.1 Oral Bioavailability of Delavirdine and PIs
The absorption of delavirdine and some PIs is affected by gastric pH and/or
simultaneous food intake; typically, a reduction in gastric acidity (pH >3) decreases
the absorption of delavirdine. Indinavir is extensively (80%) absorbed from an empty
stomach, and its bioavailability is decreased when administered with a fatty
meal [106]. The addition of ritonavir to indinavir increases bioavailability, regardless
of the stomach content [107]. The absorption of atazanavir (another PI) is dependent
on gastrointestinal pH [94]. The concomitant administration of didanosine 200mg































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































with atazanavir 400mg on an empty stomach reduces atazanavir absorption by 90%
(the didanosine absorption remains unchanged) [108]. The systemic absorption of
darunavir is increased by 30%when takenwith ameal, but acid-reducing agents have
no adverse effect on bioavailability [109].
6.6.3.2 CYP Interactions in PIs
In the plasma, darunavir is approximately 95% bound to proteins (especially a1-acid
glycoprotein), and is extensively and almost exclusivelymetabolized by CYP3A4. The
coadministration of darunavir with small doses of ritonavir results in an increase in
the bioavailability of the former, from 37% to 82% [95].
Tipranavir induces both CYP and P-glycoprotein (see Table 6.2), and although
ritonavir is a P-glycoprotein inhibitor, in vivo data suggest that the net effect of
tipranavir/ritonavir 500mg/200mg is P-glycoprotein induction [110]. Tipranavir
may therefore potentially decrease the absorption of concomitantly administered
drugs which are substrates for P-glycoprotein [97]. The potent CYP3A4 inhibitory
effects of ritonavir appear to outweigh the inducing effects of tipranavir.
6.7
Treatment Issues in Coinfection
6.7.1
Shared Toxicities
Shared drug toxicities, although clinically relevant, are beyond the scope of this
chapter. Rather, the reader should consult recent reviews on this subject [3, 111].
6.7.2
TB/Antiretroviral Drug Interactions
The most significant drug–drug interaction is between rifamycins and antiretrovir-
als. These interactions are important, as rifamycins form the backbone of current
antitubercular treatment in susceptible M. tuberculosis infection. An understanding
of these interactions is critical to appropriate management.
6.7.2.1 Rifamycins
The rifamycins induce the cytochrome P450 enzyme system in the liver and
intestinal wall, leading to a decrease in the serum half-life and in the concentrations
of drugsmetabolized by that system. The rifamycins vary in their ability to induce the
CYP450 3A4 enzymes, with rifampin being the most potent and rifabutin the least
active. In the developed world, rifabutin is the preferred rifamycin when coadminis-
tered with antiretroviral therapy; however, its high cost has hitherto precluded its use
in resource-limited settings where the burden of tuberculosis and HIV is highest.
As a result, the most important drug–drug interactions in the developing world
are between rifampin and antiretrovirals, especially the NNRTIs and the PIs.
































































The autoinduction of rifampins metabolism after repeated doses also merits
attention; a pharmacokinetic study of hospitalized TB patients showed a high
prevalence of low rifampin levels which could, in part, be due to autoinduction,
although this might also be related to other factors such as alcohol use, gender, and
drug formulation [112]. Some of these results are explained in Table 6.3, which
summarizes the details of cytochrome P450 substrates and inducers.
6.7.2.1.1 Rifampin þ NRTI Although there is some evidence to show that reduced
levels of NRTIs such as zidovudine are observedwhen coadministeredwith rifampin
as a result of rifampin inducing the glucuronidation of zidovudine [113], there is no
evidence of a decrease in the intracellular concentration of the active form of the
drug [114]. This implies that the efficacy of the drug is likely to be unaffected and can
be safely coadministered.
6.7.2.1.2 Rifampin þ NNRTI
Efavirenz There is often conflicting or lack of evidence over whether dose
increments are required when this drug is given concomitantly with rifampin,
although it is generally considered to be an adequate choice of antiretroviral. As
rifampin is a potent inducer of the cytochromeP450 system, it leads to a decrease
in the plasma levels of NNRTIs. Pharmacokinetic studies have indeed reported
that rifampin decreases plasma levels. In one study, efavirenz levels were
decreased by 13–25%; this was a modest decrease when compared to a 40%
reduction of nevirapine and 90% with delavaridine [115], and so efavirenz is
preferred for coadministration with rifampin. As a result of these pharmacoki-
netic studies, the CDC guidelines recommend that rifampin and delavirdine
should not be used together [116]. In another study, increasing the efavirenz dose
from 600mg to 800mg increased the plasma levels close to those observed in
patients receiving 600mg daily, without rifampin [117]. As a result of these
studies, some advise that the efavirenz dose should be increased from 600mg to
800mg when coadministered with rifampin [118]. However, further evidence
shows that trough levels are not associated with a poor clinical outcome. Several
studies, using either 600mg or 800mg, showed no association between trough
levels of efavirenz and clinical outcome, which indicated that a standard dose of
600mg might be sufficient [119]. Furthermore, an increased dose may increase
the side effects, especially in patientsweighing<55 kg, and also in someblack and
Asianpatientswhohave greatergenetic predisposition tohigher plasma levels and
adverse effects. This is related to a polymorphism in CYP 2B6 enzyme in these
patients, which is associated with elevated efavirenz concentrations [120, 121].
Nevirapine This is the most widely used NNRTI in resource-poor settings, as it
is cheaper than efavirenz and can be used in women of childbearing age as it is
not known to be teratogenic. However, it does interact with the CYP450 system,
both as a substrate and inducer. Studies have shown a greater reduction
in plasma levels when combined with rifampin compared to efavirenz [122].
The standard dose is an initial lead-in dose of 200mg daily for two weeks to
































































Table 6.3 Substrates, inhibitors and inducers of cytochrome p450
enzymes (CYP), and P-glycoprotein (PGP).
Substrate Inhibitor Inducer
Acetaminophen Erythromycin Cigarette smoke









CYP2C19 Benzodiazepine Cimetidine Rifampin




































































































allow for autoinduction of the CYP450 system by nevirapine, followed by
200mg every 12 h. In one study, this reduced bioavailability could be overcome
by increasing the dose to 300mg every 12 h, with no short-term increase in
adverse events [123]. Nevirapine has a higher risk, compared to efavirenz, of
hepatotoxicity. Despite these findings, several studies from a variety of settings
including Spain, Thailand and South Africa, have shown that nevirapine can be
used safely and effectively with rifampin, with no difference in virological and
immunological outcomes despite the plasma levels of nevirapine being reduced
by up to 42% in patients coadministered rifampin [122, 123]. A small study in
Thailand showed comparable short-term outcomes in both groups of nevira-
pine and nevirapine þ rifampin. In this study, the nevirapine levels were
reduced by 17% with rifampin coadministration, although the majority of the
trough plasma nevirapine levels were higher than the recommended trough
nevirapine level. In addition, there was no increase in adverse side effects of
skin rash and hepatotoxicity when nevirapine was coadministered with rifam-
pin [123]. The largest of these studies, conducted in South Africa, showed good
virological outcomes with 80% of patients in the nevirapine þ rifampin group
being virologically suppressed at 18 months [122]. However, the study also
showed there to be a higher probability of virological failure in the first two years
of therapy in this group compared to patients receiving an efavirenz-based
regimen. A possible reason for these contradictory findings was suggested as
being due to a drug interaction between rifampin and the lead-in dosing phase
of nevirapine which could, in theory, lead to a further induction by nevirapine of
a system already induced by rifampin. In general, these studies have demon-
strated good clinical outcomes despite a reduced bioavailability of nevirapine by
rifampin coadministration; this suggests that it may be unnecessary to increase
the standard nevirapine dose.
6.7.2.1.3 Rifampin þ Protease Inhibitors The induction of the CYP450 system by
rifampin results in markedly decreased levels of fos-amprenavir, atazanavir, indin-
avir, nelfinavir, saquinavir and lopinavir, ranging from 82% to 95% [43, 116] (see
Table 6.3). As a result it is not recommended that rifampin is used with any of these
drugs. Ritonavir, on the other hand, can be given with rifampin, either alone or in











































































CYP450 system it counteracts the effect of rifampin; this is of utility when the drug is
combined with lopinavir or saquinavir [124].
6.7.2.1.4 Rifabutin þ NNRTI In a study of healthy volunteers, rifabutin 300mg
daily appeared to have little or no effect on efavirenz concentrations, but the rifabutin
concentrations were reduced by efavirenz. As a result, the guidelines suggest
increasing the rifabutin dose to 450mg or 600mg to compensate for this interaction,
with the efavirenz dose unchanged [125]. There does not appear to be any significant
interaction between rifabutin and nevirapine, and the available data suggest that the
two drugs can be safely coadministered, without any need to change the dose of either
drug [126].
6.7.2.1.5 Rifabutin þ NRTI There does not appear to be any significant interaction
between NRTI and rifabutin.
6.7.2.1.6 Rifabutin þ Protease Inhibitors The coadministration of rifabutin and
PIs can lead to a reduction in PI exposure, aswell as a significantly increased rifabutin
concentration with an associated risk of uveitis due to toxicity [127]. Current guide-
lines therefore advise a reduction in the rifabutin dose by up to 75% when
coadministered with a PI [128]
6.8
Drug–Disease Interactions
There is conflicting evidence regarding the effect of HIV infection on the absorption
of antitubercular drugs, due to the virus itself, toHIVenteropathy, or to opportunistic
infections affecting the gastrointestinal tract. A study conducted in South Africa
showed 39% and 27% reductions in rifampin and ethambutol, respectively, in
patients with HIV infection, none of whom had diarrhea [112]. However, another
study showedno evidence that infectionwithHIVreduces the plasma concentrations
of antituberculosis drugs [129]. Results from a study in Nairobi showed that HIV
infection and diarrhea did not affect the pharmacokinetics of TB drugs [130]. Data
from a study in India showed an association betweenmalabsorption of TB drugs and
patients with advanced AIDS with and without diarrhea, with a low CD4 count and
gastrointestinal disturbance increasing the likelihood of malabsorption [131]. Data
are available which suggest that rifabutin is less frequently malabsorbed when
compared to rifampin [132]. Fluoroquinolones such as ciprofloxacin appear to be
well absorbed in the presence of HIV, regardless of the CD4 cell count [133].
6.8.1
TB Drugs in Development, and Potential Interactions
Moxifloxacin is unique among fluoroquinolones in that its bioavailability is not
affected by the concurrent administration of ranitidine (a histamine H2-receptor
































































antagonist), it hasminimal renal elimination, and it is almost entirely removed in the
feces (as sulfate and glucuronide conjugates) [134]. However, the absorption of
moxifloxacin is similar to that of other fluoroquinolones, which is impaired by
concomitant administration of aluminum- and magnesium-containing antacids.
The administration of these agents should be staggered by an interval of 2 h before or
4 h after taking the antacid [135].
6.8.2
HIV Drugs in Development, and Potential Interactions
Maraviroc, a CCR5 receptor antagonist, is metabolized by the CYP3A4 isoenzymes.
The coadministration of maraviroc with rifampin has been shown to result in a
reduction in the plasma concentration of maraviroc by as much as 70% [136]. As a
result, the current CDC guidelines recommend an increase in the dose of this
antiretroviral to 600mg twice daily when administered with rifampin. Maraviroc
could also potentially interact with PIs and NNRTIs [43]. Indeed, in one study it was
shown that the PI caused a significant increase in the plasma level of maraviroc,
whereas efavirenz was shown to reduce maraviroc exposure by up to 50% [136].
Raltegravir is neither a potent inhibitor nor inducer of CYP 3A4 [137], and is
predominantly metabolized by glucuronidation, specifically by the enzyme UDPGT
1A1[138].
6.8.3
Other Interactions of Note
A discussion of all potential drug–drug and drug–disease interactions in HIV-
infected patients receiving treatment for TB, HIV and comorbid illnesses is beyond
the scope of this chapter. However, some common comorbid diseases requiring
therapy will be described at this point; these therapies include oral hypoglycemic
agents, anticonvulsants, and anticoagulants. For example, beta-lactams can cause
changes to the gastrointestinal flora, leading to an alteration of those drugs that are
dependent on enterohepatic recirculation. An alteration in the gut flora that syn-
thesize vitaminK, thus reducing endogenous vitaminKproduction, can augment the
effect of warfarin-mediated elevations of the concentrations of statins (e.g., lovastatin
and simvastatin), and the development of rhabdomyolysis secondary to CYP3A4
inhibition has also occurred. Fluoroquinolones have also been associated with
fatalities secondary to hypoglycemia in patients receiving medication to manage
diabetesmellitus [139], in addition to drug- and dose-dependent prolongations of the
QTc interval.
6.8.3.1 Antituberculosis Drugs and Oral Hypoglycemic Agents
There is increasing evidence to suggest that diabetes mellitus (DM) significantly
increases the risk of TB. A recent meta-analysis of studies assessing the association
of TB and DM showed an increase of at least threefold in the risk of active TB
in people with DM [140]. Typically, after two months, the results of sputum
































































microscopic examinations were more often positive in diabetic patients (18.1%
versus 10.0%); after six months, 22.2% of cultured sputum specimens from diabetic
patients were positive for M. tuberculosis (adjusted odds ratio, 7.65; p¼ 0.004). The
maximum plasma concentration of rifampin was above the target concentration of
8mg l1 [33] in 6% of patients with TB who had DM, compared to 47% of patients
without DM. These pharmacokinetic differences might lead to an easier acquisition
of drug resistance, and might help to explain the inferior bacteriological response in
diabetic patients with TB [141]. Thus, it is important not only to understand any
possible interactions between drugs for these two conditions, but also to tease out
any interactions that are clinically significant, especially as the prevalence of DM in
TB-endemic areas in rising [142]. As the oral hypoglycemic agent gliclazide is
metabolized by the CYP450 2C9 isoenzymes – which are induced by rifampin –
there is a clear potential for an interaction between the two drugs. A recent case
study suggested such clinical significance, with a report of an increased gliclazide
requirement with rifampin coadministration in a patient with type 2 DM [143]. A
subsequent pharmacokinetic study in healthy volunteers showed a statistically
significant reduction in the blood glucose-lowering effect of gliclazide with rifampin
coadministration, that was thought to be clinically significant [144]. The results of
these studies suggested that a close monitoring of blood glucose levels, with a
possible adjustment of the gliclazide dose, might be required. Reports also exist of
interactions between the older sulfonylureas, chlorpropramide [145] and tolbuta-
mide, and rifampin [146, 147]. There is also evidence that rifampin significantly
reduces the blood glucose-lowering effect of glibenclamide [148], repaglinide [149],
and glipizide [150]. However, rifampin has not been shown to have any significant
effect on the blood glucose-lowering properties of a newer sulfonylurea drug,
glimepiride [31].
6.8.3.2 Antituberculosis Agents and Prednisolone
There is some evidence favoring the use of adjunctive corticosteroids in some forms
of extrapulmonary TB. A recent Cochrane review concluded that steroids should be
used routinely in the management of TB meningitis in HIV-negative patients.
However, whilst there is some evidence of benefit in HIV-infected patients, the
results are inconclusive [151]. Some data are available supporting the use of
adjunctive prednisolone in TB pericarditis [152]; notably, these results highlight the
need to understand the interaction of prednisolone with antituberculosis drugs. The
data have shown that the bioavailability of total and free prednisolone is reduced
when coadministered with rifampin [153, 154], which suggests a need for dose
adjustment when the two drugs are coadministered. One study conducted in India
showed that the coadministration of isoniazid with prednisolone resulted in an
increased renal clearance of isoniazid, regardless of the patients acetylator status.
Yet, the same study identified an increase in the acetylation rate of isoniazid in slow
acetylators, which led to a decrease in isoniazid plasma concentrations. In spite of
these findings, there was no difference in clinical outcome between those patients
receiving prednisolone and thosenot, thus raising doubt over the clinical significance
of these findings [155].


































































DualHIV-TB therapy is associated with numerous challenges, particularly drug–drug
and drug–disease interactions, shared drug toxicities, IRIS, and high pill burdens.
Comorbid conditions due to HIV immune suppression often necessitate additional
therapy,whichfurtherexacerbates thesechallenges.Atpresent,anumberofdrugsused
to treat HIV-TB either induce, inhibit, and/or are metabolized by CYP. In particular,
rifampin (a CYP inducer) and ritonavir (a CYP inhibitor) are implicated in significant
drug–drug interactions.There is a paucity ofdata relating toCYPmetabolismanddrug
interactions for other drugs used to treat TB, HIV and comorbid conditions. The
emergenceofmetabolicsyndromeanddrug-resistantTBwill challenge the therapeutic
strategies of clinicians, particularly in Africa, China, and India. Clearly, the limitations
of our current knowledge of these drug interactions require further investigation.
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Abstract
Background: Clinical deterioration on drug therapy for tuberculosis is a common cause of hospital admission in Africa.
Potential causes for clinical deterioration in settings of high HIV-1 prevalence include drug resistant Mycobacterium
tuberculosis (M.tb), co-morbid illnesses, poor adherence to therapy, tuberculosis associated-immune reconstitution
inflammatory syndrome (TB-IRIS) and subtherapeutic antitubercular drug levels. It is important to derive a rapid diagnostic
work-up to determine the cause of clinical deterioration as well as specific management to prevent further clinical
deterioration and death. We undertook this study among tuberculosis (TB) patients referred to an adult district level hospital
situated in a high HIV-1 prevalence setting to determine the frequency, reasons and outcome for such clinical deterioration.
Method: A prospective observational study conducted during the first quarter of 2007. We defined clinical deterioration as
clinical worsening or failure to stabilise after 14 or more days of antitubercular treatment, resulting in hospital referral. We
collected data on tuberculosis diagnosis and treatment, HIV-1 status and antiretroviral treatment, and investigated reasons
for clinical deterioration as well as outcome.
Results: During this period, 352 TB patients met inclusion criteria; 296 were admitted to hospital accounting for 17% of total
medical admissions (n = 1755). Eighty three percent of TB patients (291/352) were known to be HIV-1 co-infected with a
median CD4 count of 89cells/mm3 (IQR 38–157). Mortality among TB patients admitted to hospital was 16% (n = 48). The
median duration of hospital admission was 9.5 days (IQR 4–18), longer than routine in this setting (4 days). Among patients
in whom HIV-1 status was known (n = 324), 72% of TB patients (n = 232) had an additional illness to tuberculosis; new AIDS
defining illnesses (n = 80) were the most frequent additional illnesses (n = 208) in HIV-1 co-infected patients (n = 291).
Rifampin-resistant M.tb (n = 41), TB-IRIS (n = 51) and drug resistant bacterial infections (n = 12) were found in 12%, 14% and
3.4% of the 352 cases, respectively.
Interpretation: In our setting, new AIDS defining illnesses, drug resistant M.tb and other drug resistant bacteria are
important reasons for clinical deterioration in HIV-1 co-infected patients receiving antitubercular treatment. HIV-1 co-
infected patients may be at increased risk of acquiring nosocomial drug resistant pathogens because profound immune
suppression results in co-morbid illnesses that require prolonged inpatient admissions. Routine infection control is essential
and needs to be strengthened in our setting.
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Introduction
In 2007, of an estimated total population of 47.9 million people
in South Africa, an estimated 5.7 million were infected with HIV-1
and 0.35 million died from AIDS-related illnesses [1]. In 2006, the
annual tuberculosis incidence rate was estimated to be 628 cases
per 100,000 of the population per annum [2]. The two pandemics
of tuberculosis and HIV-1 fuel each other. The annual incidence
of tuberculosis disease doubles within the first year of HIV-1
infection[3] and may reach 30% per annum in the profoundly









immune-suppressed [4]. Likewise, tuberculosis disease synergisti-
cally accelerates the progression of HIV-1 infection to Acquired
Immune Deficiency Syndrome (AIDS) by inciting viral replication
in immunologically activated CD4 cells [5,6,7]. In South Africa
more than half of tuberculosis (TB) patients tested for HIV-1 are
seropositive[8] and very many of the 22.5 million HIV-1
seropositive people residing in Sub-Saharan Africa are co-infected
with M. tuberculosis (M.tb) [9].
Tuberculosis and HIV-1 control programmes in Africa are
complicated by the increasing emergence of drug resistant M.tb,
which can be associated with a very poor outcome and thus
adversely affect overall tuberculosis control programme perfor-
mance. In 2006, 44 HIV-1 seropositive patients died a median
of 16 days after obtaining a specimen that cultured extensively
drug resistant (XDR-) M.tb in a rural area of Kwa-Zulu Natal
[10]. Nosocomial exogenous re-infection was implicated as two-
thirds of patients were recently hospitalised before the diagnosis
of XDR-tuberculosis and genotyping of isolates showed that
85% of patients were infected with a genetically similar isolate,
belonging to the KZN family of strains. Focusing on patients
worsening or not stabilising on antitubercular treatment is
valuable in sentinel assessment of drug resistant M.tb transmis-
sion and mortality. Patients deteriorating on antitubercular
treatment constitute a clinical subgroup in which one would
predict higher rates of MDR- and XDR- M.tb. However, these
patients may also deteriorate due to other reasons. Reasons for
clinical deterioration[11] and death in patients on antitubercu-
lar treatment include co-morbid conditions [12,13,14,15],
exogenous re-infection or endogenous development of drug
resistant M.tb [10,16], tuberculosis associated-immune reconsti-
tution inflammatory syndrome (TB-IRIS)[17,18] and drug
toxicities from treatment for tuberculosis, HIV-1 and/or
concurrent opportunistic infections [19,20,21,22]. Other causes
are an incorrect diagnosis of tuberculosis, a paradoxical
tuberculosis reaction (if not receiving antiretroviral therapy),
poor adherence [23], incorrect antitubercular treatment,
malabsorption of antitubercular treatment [24], as well as
malabsorption of antibiotic drugs and subsequently altered
pharmacokinetics (particularly in HIV-1 infected individuals
with gastrointestinal problems). It is important to derive a rapid
diagnostic work-up to determine cause of clinical deterioration
as well as specific management to prevent further clinical
deterioration and death.
This study aimed to determine which of these reasons for
clinical deterioration on antitubercular treatment was most
significant at an exceptionally busy urban district hospital situated
in an area of high HIV-1 prevalence.
Methods
Setting
A prospective observational study conducted from 9 January to
8 April 2007 at GF Jooste Hospital (GFJH). GFJH is an urban
200-bed adult (.15 years age) district hospital in Cape Town,
South Africa that serves approximately 1.3 million people and
receives 8,000 referrals per month[25] from 30 primary care
clinics.
The national tuberculosis programme manages new tuberculo-
sis cases with 6 months treatment (isoniazid, rifampin, pyrazin-
amide, and ethambutol [HRZE] for 2 months followed by HR for
4 months [2HRZE/4HR]). The retreatment regimen adds
streptomycin (S) as follows 2HRZES/1HRZE/5HRE. New
tuberculosis cases do not routinely have tuberculosis drug
susceptibility testing (DST) performed. Retreatment cases and
patients not responding to antitubercular treatment may have
DST performed.
Over 10,000 people have initiated combination antiretroviral
treatment (cART) within the catchment area of GFJH (Meg Osler,
Provincial Government of the Western Cape- personal commu-
nication). First-line cART in South Africa is stavudine (d4T),
lamivudine (3TC) and either nevirapine or efavirenz (NVP, EFZ).
EFZ is preferred in patients receiving rifampin-based antituber-
cular treatment. Patients with a CD4 count less than 200cells/
mm3 and/or a history of a WHO stage 4 illness are eligible to
commence cART [26]. In patients diagnosed with tuberculosis,
cART is deferred if there is no history of a WHO Stage 4 illness
and the CD4 count is greater than 200 cells/mm3. If there is a
history of a WHO Stage 4 illness and/or the CD4 count is less
than 200 cells/mm3 cART is commenced 2 months after initiating
antitubercular treatment. If the CD4 count is less than 50 cells/
mm3 or a serious HIV-1 related illness exists, cART can be
commenced two weeks after initiating antitubercular treatment
[26].
Study procedures
Eligibility. Adult patients (.15 years) who received $14days
antitubercular treatment within GFJH’s catchment area and were
referred by a medical doctor or nurse to the Emergency
Department or Infectious Diseases Unit were assessed. Prior to
referral, patients were diagnosed with tuberculosis at any of the 12
tuberculosis clinics within the catchment population of GF Jooste
Hospital. If they deteriorated and were referred to GF Jooste
Hospital they underwent renewed/repeated diagnostic procedures
to either confirm tuberculosis disease (if previously
microbiologically unconfirmed) and to exclude drug resistant
M.tb. Patients were eligible if clinical worsening or failure to
stabilise on therapy was confirmed on clinical assessment by a
medical doctor at GFJH.
Tuberculosis diagnosis and referral. Microbiological
confirmation of tuberculosis disease was defined as a specimen
that cultured M.tb and/or was smear positive for acid-fast bacilli
and that was obtained from a patient with symptoms and signs of
tuberculosis [26]. An empiric diagnosis of tuberculosis was defined
as follows: antitubercular treatment was initiated when the
tuberculosis specimen was both smear negative for acid fast
bacilli and culture negative or pending for M.tb but the South
African National Tuberculosis Control Programme’s case
definitions for smear-negative and extra-pulmonary tuberculosis
were fulfilled [26]. Patients commenced antitubercular treatment
at their tuberculosis clinic and if they deteriorated or did not
improve on treatment they were referred to our hospital for
assessment.
Data collection. Clinical data regarding tuberculosis
diagnosis, antitubercular treatment, HIV-1 status and
antiretroviral therapy were recorded. Reasons for clinical
deterioration were determined by clinical assessment and
laboratory investigations performed by medical staff (doctors)
working in the Emergency Department and Infectious Diseases
Unit. All TB patients admitted to hospital were assessed by a
specialist physician and reviewed weekly during inpatient stay by
an Infectious Diseases physician. Investigations performed were
according to clinical presentation and included C-reactive protein,
full blood count (also called complete blood cell count), urea and
electrolytes, serological and blood culture investigations.
Specimens for tuberculosis microscopy, culture and sensitivity
included sputum, pleural fluid, lymph node aspirates, ascitic fluid
or cerebrospinal fluid (CSF). Chest radiography and computerised
tomographic scanning were performed as indicated. Investigations
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also included sputum direct immuno-fluorescent antigen tests
(DFAT) for Pneumocystis jiroveci pneumonia, CSF bacterial and
fungal cultures and stool microscopy for coccidian parasites and
culture for bacteria. All patients who develop drug-induced hepatitis
are initially managed as inpatients according to a standardised
protocol. The tuberculosis diagnosis is re-evaluated by reviewing
results of all tuberculosis specimens. After clinical stabilisation and
return to baseline of liver function tests, patients are carefully
monitored and antitubercular drugs are sequentially rechallenged in
cases of non-life threatening hepatitis and microbiologically proven
tuberculosis. In severe cases (coagulopathy or encephalopathy), re-
challenge of antitubercular treatment is not attempted. Instead,
patients are treated with an alternative antitubercular regimen that
does not involve rechallenge.
Tuberculosis diagnostics. The National Health Laboratory
Services performed tuberculosis diagnostics. Ziehl-Nielsen staining
was performed within 24 hours on all tuberculosis specimens,
while auramine staining was performed on broth culture isolates.
M.tb liquid culture, solid media susceptibility testing for isoniazid
and rifampin, and quality assurance were performed as described
elsewhere [27]. According to provincial protocol ethambutol
(7.5 mcg/mL), ethionamide (20 mcg/ml), amikacin (30 mcg/mL),
kanamycin (6 mcg/mL) and ofloxacin (2 mcg/mL) susceptibility
testing was only performed in patients with rifampin resistance.
Susceptibility testing to pyrazinamide, streptomycin and the
remaining three second line drugs—terizidone, capreomycin,
para-aminosalicylic acid— was not performed.
Definitions. Positive cultures for M.tb were categorised on
the basis of drug susceptibility as: (i) susceptible to both isoniazid
and rifampin; (ii) mono-resistant to rifampin; (iii) resistant to at
least isoniazid and rifampin (MDR- M.tb); (iv) resistant to
isoniazid, rifampin and either resistance to an injectable agent
(amikacin or kanamycin) or ofloxacin (pre-XDR M.tb); and
(v)resistant to isoniazid, rifampin, ofloxacin, and an injectable
agent or ofloxacin (XDR M.tb) ‘Rifampin resistance’ was defined
as any resistance to rifampin and included rifampin mono-
resistant-, MDR- , XDR- and pre-XDR- M.tb [28].
Extended-spectrum beta lactamase (ESBL) producing bacteria
were defined as bacteria having clavulanate-inhibited transferable
enzymes able to hydrolyse third and fourth generation cephalo-
sporins while methicillin resistant Staphylococcus aureus (MRSA) had
an oxacillin minimum inhibitory concentration (MIC) $4 mg/l.
TB-IRIS was defined according to a clinical case definition [29].
Adherence to antitubercular treatment was assessed by patient
report, tuberculosis clinic cards (upon which daily doses taken are
recorded) and/or collateral information from the health care
worker at the tuberculosis clinic. No specific criteria were utilised
but if no subsequent cause for deterioration was found and the
patient had ,80% adherence, the patient was assessed as having
poor adherence. An additional illness to tuberculosis was defined
as a second illness in patients where the initial tuberculosis
diagnosis was confirmed by smear, culture and/or initial clinical
response to antitubercular treatment where smear-negative and/
or extrapulmonary tuberculosis was observed. It excluded poor
adherence to antitubercular treatment, rifampin resistant M.tb,
TB-IRIS or a paradoxical tuberculosis reaction. The use of
concomitant cART distinguishes IRIS from a paradoxical TB
reaction; IRIS occurs in patients receiving cART while paradox-
ical TB reaction occurs in the absence of cART. An alternate
illness to tuberculosis was diagnosed when a clinical illness initially
diagnosed as tuberculosis was not confirmed by smear or culture,
there was no clinical response to antitubercular treatment and
evidence of an alternate illness to explain the clinical presentation
and course was found.
Outcomes. The primary outcome of the study was reason for
clinical deterioration despite antitubercular treatment, with a
specific focus on the proportion of rifampin resistant M.tb. The
secondary outcome was outcome of admission.
Analysis. Data analysis was conducted using STATA-10
(Stata Corporation, College Station, Texas). Descriptive statistics
were employed for basic characterization of variables. Wilcoxon
rank-sum tests to compare medians, and Fisher’s exact test of
probability to compare proportions were used, as appropriate, to
identify associations.
The Research Ethics Committee of the University of Cape
Town approved the study (REF: 239/2007).
Results
Characterization of cohort
Three hundred and fifty-two patients met study inclusion criteria
during the 3-month period. At initial tuberculosis diagnosis, 163
(46%) had pulmonary tuberculosis, 67 (19%) had extra-pulmonary
tuberculosis and 122 (35%) had combined pulmonary and
extrapulmonary tuberculosis. The median duration from initiation
of antitubercular treatment to clinical presentation was 92.5 days
(interquartile range, IQR 43–149). Eighty-four percent of TB
patients (n = 296) required hospital admission for a median duration
of 9.5 days (IQR 4–18). Admissions for patients deteriorating on
antitubercular treatment accounted for 17% medical admissions
(296/1,755) during the three-month study period.
Eighty-three percent of TB patients (n = 291) were HIV-1
seropositive and 9% (n = 33) were HIV-1 seronegative (Figure 1).
In 8% (n = 28), HIV-1 testing was not performed prior to referral
or during investigation at GFJH; reasons included: not offered
voluntary counselling and testing (VCT), VCT declined or too sick
to obtain informed consent. Baseline features of TB patients
stratified by HIV-1 status are shown in Table 1. HIV-1
seropositive TB patients were more frequently female, and less
likely to have a past history of tuberculosis or microbiological
confirmation (p#0.01). The median CD4 count among HIV-1
seropositive TB patients was 89 cells/mm3 (n = 270). Of 255
patients who met the South African Department of Health criteria
to receive cART [26], 122 (48%) were receiving this treatment.
Final diagnoses
An additional illness to tuberculosis was detected in 72% of TB
patients (n = 232) with known HIV-1 seropositive and HIV-1
seronegative status combined (n = 324) (Figure 1). Rifampin-
resistant M.tb (n = 41), TB-IRIS (n = 51) and other drug resistant
bacterial infections (n = 12) were diagnosed. Twenty-four TB
patients had poor adherence to antitubercular treatment and
fifteen patients had an alternate illness to tuberculosis.
Additional illness to tuberculosis. Additional illnesses to
tuberculosis differed according to HIV-1 status (Figure 1). In the
HIV-1 seropositive group (Table 2), new AIDS defining illnesses
(n = 80), bacterial infection (n = 53), gastroenteritis (n = 37) and
drug toxicity to cART, antitubercular, antibiotic or antineoplastic
medications (n = 35) were most frequent. In the HIV-1
seronegative group, complications of tuberculosis, or its therapy
(n = 7), and bacterial infection (n = 6) were most common.
Antitubercular drug resistance. Rifampin resistance M.tb
was found in 41 TB patients. Eight had rifampin mono-resistant
M.tb, 24 had MDR- M.tb, four had pre-XDR- M.tb and five had
XDR- M.tb. Extended sensitivity testing was performed on only 15
(37%) of the 41 rifampin resistant tuberculosis cases; one third (5/
15) of these patients had XDR- M.tb, while a further 27% (4/15)
had pre-XDR- M.tb.
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Figure 1. * Many patients had .1 cause for clinical deterioration, particularly additional illnesses. HIV-1 = human immunodeficiency
virus, M.tb = Mycobacterium tuberculosis, TB-IRIS = tuberculosis associated-immune reconstitution inflammatory syndrome, Paradoxical tuberculosis
reaction = initial clinical improvement with subsequent recurrence of tuberculosis clinical features but no evidence of drug resistant tuberculosis/or
any other illness and patient not receiving antiretroviral therapy, MRSA = methicillin resistant Staphylococcus Aureus, ESBL = extended spectrum beta
lactamase producing organism.
doi:10.1371/journal.pone.0004520.g001
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Figure 2 depicts TB culture results at initial TB diagnosis (left
figure) and at subsequent deterioration (right figure). At initial
tuberculosis diagnosis specimens were sent for tuberculosis culture
in 237/352 (67%) patients, with 131 TB patients having a positive
culture (Figure 2). Of 131 patients that cultured M.tb from
specimens at initial tuberculosis diagnosis, 46 (35%) did not have
drug susceptibility testing performed. Of the 85 TB patients who
did have tuberculosis drug sensitivity analysis at diagnosis, 12
(14%) cultured rifampin resistant M.tb and 73 patients (86%)
cultured rifampin sensitive M.tb.
At clinical deterioration specimens were sent for tuberculosis
culture in 234/352 (66%) patients, with 69 patients culturing M.tb.
Of these 69 patients, 4 (6%) did not have drug susceptibility testing
performed. Of 65 patients who did have antitubercular drug
sensitivity testing at clinical deterioration, 35 patients (54%)
cultured rifampin resistant M.tb and 30 patients (46%) cultured
rifampin sensitive M.tb.
Thus, at clinical deterioration, 29 new cases of rifampin resistant
tuberculosis were diagnosed. These 29 cases had the following
tuberculosis results at initial diagnosis: 6 M.tb sensitive to rifampin
and isoniazid, 4 M.tb no sensitivities requested, and 3 no
mycobacteria cultured. Sixteen of these 29 new cases of rifampin
resistant tuberculosis had no tuberculosis culture sent at initial
tuberculosis diagnosis.
Of 73 patients who had rifampin sensitive M.tb at initial
tuberculosis diagnosis, eight (11%) cultured rifampin resistant M.tb
at clinical deterioration. Of these eight, 2 patients cultured
rifampin-mono-resistant M.tb, 5 MDR- M.tb and 1 XDR- M.tb, 12
to 419 days following the start of antitubercular treatment. Thirty
seven percent of patients with rifampin resistant M.tb (15/41) are
known to have died within six months of initial assessment at
GFJH. The median duration from assessment to death was 28
days (IQR 11–72).
Forty-one patients who at initial TB diagnosis were culture
negative (n = 11) or no culture was sent (n = 30), subsequently
cultured M.tb at deterioration. In 11% (39/352) of cases, no
tuberculosis cultures were sent at initial tuberculosis diagnosis and
at clinical deterioration.
Extended spectrum beta lactamase producing organisms/
methicillin resistant Staphylococcus aureus. At clinical
deterioration, 214/352 (61%) TB patients had specimens sent for
bacterial culture (128 of these TB patients had blood cultures
performed). Of 214 TB patients that had $1 specimens sent for
bacterial culture, 35 (16%) cultured clinically significant organisms.
Cultured organisms and sites from which these specimens were
obtained are detailed in table 2.
Of 53 HIV-1 seropositive TB patients treated empirically for
bacterial infections (Figure 1), 32 had confirmatory cultures.
Twelve of these TB patients cultured either extended spectrum
beta lactamase (ESBL) producing organisms or methicillin
resistant Staph. aureus (MRSA) (Table 3). The median CD4 count
of these 12 TB patients was 57 cells/mm3 (IQR 21–80). Of nine
TB patients culturing ESBL organisms, five had intermediate or
high level resistance to amikacin while seven had high level
resistance to ciprofloxacin. All were sensitive to imipenem,
meropenem or piperacillin-tazobactam. Four TB patients had a
septic illness due to MRSA, all were sensitive to vancomycin. One
TB patient cultured both ESBL and MRSA organisms. Antibiotics
Table 1. Characteristics of patients deteriorating on
antitubercular treatment (N = 324) by HIV-1 status.
HIV-1 +ve HIV-1 2ve P-value
(n = 291) (n = 33)
Demographics
Male – N (%) 138 (47.4) 24 (72.7) 0.006
Median age – years (range) 34 (16–86) 37 (19–68) NS1
Basis of tuberculosis diagnosis
Smear +ve – N (%) 106 (36.4) 22 (66.7) 0.001
Smear 2ve/Culture +ve – N (%) 28 (9.6) 1 (3.0) NS
Empiric diagnosis – N (%)2 157 (54.0) 10 (30.3) 0.01
Previous tuberculosis
2n (%) 101 (34.7) 19 (57.6) 0.01
Admitted
2n (%) 238 (81.8) 31 (94.0) NS
Median duration – days (IQR3) 10 (4–18) 11 (5–22) NS
Outcome
Died as inpatient – N (%) 43 (14.8) 5 (15.2) NS
Illness contributory to death
Bacterial illness 12 1
Enteric illness 8 -
Pneumocystis jiroveci pneumonia 6 -
Venous thromboembolism 5 2
Drug side effects 3 -
Rifampin resistant-tuberculosis4 3 -
Kaposi sarcoma 2 -
Cryptococcal meningitis 2 -
Neurological TB-IRIS 2 -
Chronic renal failure - 1
Acute coronary syndrome - 1
1NS: not significant, p-value significant at p#0.05.
2i.e. No microbiological proof at commencement of tuberculosis treatment.
3Interquartile range.
4Rifampin resistant-tuberculosis = Mycobacterium tuberculosis, with resistance to
at least rifampin, cultured from a patient with clinical deterioration of
symptoms attributable to progressive tuberculosis disease.
doi:10.1371/journal.pone.0004520.t001
Table 2. Organisms cultured and sites from which they were
obtained*.
Organisms cultured n Site of cultured organisms n
Escheriae. coli 17 Blood 13
Klebsiella spp 5 Urine 10
Staphylococcus aureus 8 Soft tissue abscess 9
Proteus 3 Sputum 3
Acinetobacter 3 Ascitic fluid 2






Salmonella type C 1
*44 organisms were cultured from 38 sites from 35 patients: 3 patients cultured
MRSA from $2 sites, 5 patients cultured 2 clinically significant bacteria from a
single site.
doi:10.1371/journal.pone.0004520.t002
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administered to these 12 TB patients are shown in Table 3. Of
these 13 drug-resistant isolates, nine (69%) were drug resistant
bacteria cultured $48 hours after admission at GFJH (range 2–
21days) while four (31%) were cultured on the day of admission.
Six of the twelve (50%) TB patients were admitted to a hospital in
the month preceding this GFJH admission for a median duration
of 10 days (IQR 8–26). Nine TB patients (75%) with these
infections died with the median time from obtaining the specimen
to death being 10.5 days (IQR 6.3–14.5).
TB-IRIS. Fifty one (18%) of the 291 HIV-1 seropositive TB
patients were diagnosed with TB-IRIS. Their median CD4 count
nadir was 65 cells/mm3 (IQR 33–113). The median interval
between initiation of tuberculosis therapy and initiation of cART
was 69 days (IQR 35–94), and the median interval between cART
initiation and onset of TB-IRIS symptoms was 14 days (IQR 7–
24).
Alternate illness to tuberculosis. An alternate illness to
tuberculosis was found in 9% of patients (16/181) who started
empiric antitubercular treatment. In the HIV-1 infected group
(n = 12) alternate illnesses were predominantly new AIDS defining
illnesses including Kaposi’s sarcoma (n = 2), Pneumocystis jiroveci
pneumonia (n = 2) and non-Hodgkin’s lymphoma (n = 2).
Inpatient mortality
Inpatient mortality did not differ significantly according to HIV-
1 status (p = 0.566, Table 1). Inpatient HIV-1 seropositive deaths
(N = 43) were mainly due to bacterial infections (n = 12), new
AIDS defining illnesses (n = 10), enteric illnesses (n = 8), and
pulmonary embolism (n = 5).
An estimated 3500 patients start antitubercular treatment every
three months at public sector primary care tuberculosis clinics
within our catchment area (Judy Caldwell, Western Cape
Tuberculosis Control Programme- personal communication).
Private sector antitubercular treatment is not provided in our
catchment area. During the 3-month study period 352 patients
(10%, 95% confidence interval: 9–11%) deteriorated despite
antitubercular treatment and required referral to our facility.
Discussion
We undertook this study to investigate which reasons for clinical
deterioration on antitubercular treatment were most significant in
a resource-limited setting with a high prevalence of tuberculosis
HIV-1 co-infection in Cape Town, South Africa. Focusing on this
particular patient group may improve their outcomes and
contribute to a rational use of limited resources especially as in
our setting they account for 10% of patients started on
antitubercular treatment.
We found that drug resistant M.tb and drug resistant bacterial
infections were important reasons for clinical deterioration and
death. Additional illnesses to tuberculosis accounted for most
referrals, especially bacterial infections and new AIDS-defining
illneses. Our findings are best explained in the context of rigorous
admission criteria due to bed pressures at the 200-bed hospital;
only 7.5% of adult patients referred to the emergency department
are admitted to medical wards. Admission is prioritised for life-
threatening illnesses requiring intravenous fluids or intravenous
antibiotics (such as antibacterial or antifungal agents), drug
resistant M.tb requiring daily inpatient intramuscular amikacin
or kanamycin injections (while awaiting a bed at the nearby MDR-
tuberculosis hospital) or patients requiring monitored supervision
of antitubercular treatment because of severe disease. It is
inevitable that a larger contingent of patients with clinical
deterioration not meeting such strict admission criteria is not
referred to hospital for assessment. A prospective study is needed
to determine whether such a group exists, and if so whether the
causes for clinical deterioration differ.
Nearly one-sixth of our patients cultured either drug resistant
M.tb or other drug resistant bacterial infections. This has two
important implications. Firstly we have identified a clinical
subgroup of patients, namely patients deteriorating on antituber-
cular treatment, in whom the incidence of rifampin resistant
tuberculosis (8.2%, 95% confidence interval: 5–11%) is high
compared to the 2.5% of all tuberculosis cases reported to have
MDR-tuberculosis in South Africa [30]. Secondly, tuberculosis
Figure 2. TB = Tuberculosis, RS-TB = rifampin sensitive M. tuberculosis, RR-TB = rifampin resistant M. tuberculosis. 6 of 12 patients who
had rifampin resistant M. tuberculosis at initial tuberculosis diagnosis, re-cultured rifampin resistant M. tuberculosis at clinical deterioration. i.e. 29 new
cases of rifampin resistant M. tuberculosis were diagnosed at clinical deterioration, 8 of 73 patients who had rifampin sensitive M. tuberculosis at initial
tuberculosis diagnosis cultured rifampin resistant M. tuberculosis at clinical deterioration.
doi:10.1371/journal.pone.0004520.g002
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HIV-1 co-infected patients in a hospital setting appear prone to
acquire drug resistant bacteria such as ESBL and MRSA
organisms. Studies need to be conducted at other health facilities
to determine whether similar causes for clinical deterioration exist.
Nosocomial acquisition of XDR- M.tb among HIV-1 infected
patients with a very poor outcome has recently been described in
South Africa [10]; the contribution to death by co-morbid HIV-1
associated illnesses, however, was not discussed in that report. Our
study suggests co-morbidities may play a role in the death of such
patients.
The evolution from isoniazid and rifampin sensitive M.tb to
rifampin mono-resistant-, MDR-, preXDR- M.tb and XDR- M.tb
in eight patients may be due to initial mixed M.tb strain infection
[31], exogenous re-infection with rifampin resistant M.tb [16] or
the rapid development of M.tb drug resistance mutations despite a
multidrug-regimen i.e. amplified drug resistance. Nosocomial re-
infection of HIV-1 seropositive patients with MDR- and XDR-
M.tb has been documented in both resource rich and resource
constrained settings [10,16]. The possibility that drug resistance
evolved rapidly in drug susceptible cases receiving optimal
treatment appears less likely based on clinical history and collateral
information regarding adherence obtained from tuberculosis
clinics and relatives. The decline in proportion of patients
culturing M.tb may reflect either efficacious antitubercular
treatment, inability of the patient to expectorate sputa for culture,
or difficulty obtaining a non-pulmonary specimen for culture.
Nosocomial acquisition of drug resistant bacteria is also
suggested by the temporal association between i) the timing of
specimens that cultured ESBL and MRSA organisms and ii) the
duration of current and previous hospital admissions. The
unavailability of appropriate antimicrobial agents likely contrib-
uted to the high mortality rate in these 12 HIV-1 seropositive TB
patients. At the time of the study, the standard regimen for
suspected nosocomial sepsis was amikacin and ceftriaxone in the
absence of renal impairment, and ciprofloxacin and ceftriaxone if
present. Vancomycin was available to treat MRSA. Because of our
study findings, ertapenem is now available.
The incidence of additional illnesses such as new AIDS defining
illnesses, bacterial infections and gastroenteritis is indicative of the
profound immune suppression in the HIV-1 infected group.
Multiple opportunistic infections occur simultaneously in AIDS
patients. A necropsy study of HIV-1 infected patients from Brazil
reported more than one post-mortem diagnosis in 52% of the
patients, and 48% had at least one AIDS-related disease not
suspected clinically [32]. These researchers recommended aggres-
sive investigation for infections and cancers in sick patients with
AIDS, particularly in those not responding to initial antimicrobial
therapy [32]. Bacterial infections and enteric illnesses were found
in 26% and 18% of HIV-1 infected patients, respectively, in our
study. Current provincial government protocols recommend
starting co-trimoxazole prophylaxis in all HIV-1 positive patients
one month after initiating antitubercular treatment in order to
differentiate between side effects from antitubercular treatment
and co-trimoxazole [26,33]. This would likely reduce bacterial
infections. Adherence to this recommendation was not assessed
and needs to be determined in future studies. Although only 48%
of patients eligible for cART were receiving cART at assessment
for deterioration, it is likely that some patients subsequently
initiated cART.
TB-IRIS was a final diagnosis in 18% (51/291) of HIV-1
seropositive patients. This probably reflects the high incidence of
disseminated tuberculosis and the relatively late initiation of cART
in profoundly immune suppressed HIV-1 patients in our setting.
TB-IRIS is more likely to occur in patients with a low baseline
CD4 count, a short duration between initiation of antitubercular
treatment and cART and disseminated tuberculosis [34,35,36].
Fifteen cases of venous thrombo-embolic disease (12 deep vein
thrombosis and 3 pulmonary embolus) were observed among this
cohort. HIV-1 and rifampin are postulated risk factors for venous
thrombo-embolic disease [37,38].
Both HIV-1 uninfected and infected patients had prolonged
admissions (9.5 days) compared to the typical duration of
admission at GFJH (4 days) [25]. Longer inpatient admissions
increase the risk of acquisition of nosocomial drug resistant
pathogens, particularly in immune-compromised patients.
Our study’s limitations relate fundamentally to its design within
routine care in an exceptionally busy setting. Studies based in
hospitals suffer referral bias and so the extent of the problem of
clinical deterioration during antitubercular treatment cannot be
precisely determined although is clearly very significant and likely
to impact adversely on overall national tuberculosis programme
success. The initial tuberculosis diagnosis was often defined by
clinical algorithm rather than bacterial culture and, even at clinical
deterioration, not all patients were sampled. Of all 352 TB patients
assessed at deterioration, 182 (52%) did not culture M.tb at both
tuberculosis diagnosis and at deterioration. Final diagnosis relied
on available diagnostic modalities, better than in many parts of
Africa but not state-of-the-art. Resistance to second line
antitubercular agents was not always assayed: thus our estimates
of pre-XDR and XDR- M.tb may be falsely low. 8% of patients
were not tested for HIV-1 infection. Genotyping of drug resistance
M.tb and other bacterial strains would have allowed us to better
assess the likelihood of nosocomial transmission. All these factors
have been considered in a clinic-based second study of this
problem that is currently in progress.
As a result of these findings, basic infection control measures
have been strengthened; extraction fans have been installed at
high congestion areas and natural ventilation is encouraged to
reduce M.tb transmission. N95 respirator masks are readily
available to patients, relatives and health care workers to reduce
aerosol transmission and infection of tuberculosis. Simple
architectural modifications in the hospital are currently underway
to further improve ventilation and reduce M.tb transmission risk.
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M A J O R A R T I C L E
Neurologic Manifestations of Paradoxical
Tuberculosis-Associated Immune Reconstitution
Inflammatory Syndrome: A Case Series
Dominique J. Pepper,1,2,3 Suzaan Marais,1,2 Gary Maartens,1,4 Kevin Rebe,1,3 Chelsea Morroni,2,5
Molebogeng X. Rangaka,2,3,6 Tolu Oni,2,7 Robert J. Wilkinson,1,2,3,7,8 and Graeme Meintjes1,2,3
1Infectious Diseases Unit, GF Jooste Hospital, and 2Institute of Infectious Diseases and Molecular Medicine, 3Department of Medicine, 4Division
of Clinical Pharmacology, Department of Medicine, and 5Women’s Health Research Unit, School of Public Health and Family Medicine, University
of Cape Town, Cape Town, South Africa; and 6Infectious Diseases Epidemiology Unit, London School of Hygiene and Tropical Medicine, 7Division
of Medicine, Wright Fleming Institute, Imperial College London, and 8National Institute for Medical Research, London, England
Background. Paradoxical neurologic tuberculosis-associated immune reconstitution inflammatory syndrome
(TB-IRIS) is a potentially life-threatening condition that occurs within 3 months after starting combination
antiretroviral therapy (ART). The reports in the published literature are anecdotal, and the prevalence and outcomes
of neurologic TB-IRIS are unknown.
Methods. We prospectively assessed patients with suspected TB-IRIS from June 2005 through October 2007
at our hospital in Cape Town, South Africa. We defined paradoxical TB-IRIS and paradoxical neurologic TB-IRIS
with use of consensus clinical case definitions. We collected data on tuberculosis diagnosis, ART, details of TB-
IRIS diagnosis, other opportunistic infections, corticosteroid use, and outcome.
Results. We reviewed 279 patients with suspected TB-IRIS, 54 (19%) of whom had suspected neurologic TB-
IRIS, and 225 (81%) of whom had suspected non-neurologic TB-IRIS. Paradoxical TB-IRIS was diagnosed in 190
patients; 23 (12%) of these 190 patients had neurologic TB-IRIS (95% confidence interval, 7%–17%). Eight had
meningitis, 7 had tuberculoma, 5 had both tuberculoma and meningitis, and 3 had radiculomyelopathy. Twenty
(87%) of the 23 patients with neurologic TB-IRIS required hospital admission (median duration, 12 days; inter-
quartile range, 6–24 days), and 21 (91%) received corticosteroids (median duration, 58 days; interquartile range,
29–86 days). Outcomes 6 months after the initial assessment for neurologic deterioration were as follows: 16 (70%)
of the patients were alive (10 of these patients had documented full physical and mental recovery), 3 (13%) were
dead, and 4 (17%) were lost to follow-up.
Conclusions. Paradoxical neurologic TB-IRIS accounts for 12% of paradoxical TB-IRIS cases. Neurologic TB-
IRIS causes considerable short-term morbidity but has reasonable long-term outcomes. Further research is needed
to devise optimal diagnostic and management strategies for patients with tuberculosis who experience neurologic
deterioration after starting ART.
Paradoxical and unmasking tuberculosis-associated
immune reconstitution inflammatory syndromes (TB-
IRISs) [1] are emerging complications of combination
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antiretroviral treatment (ART) in countries with high
rates of tuberculosis, especially in Africa [2]. The tem-
poral sequence of events distinguishes paradoxical TB-
IRIS from unmasking TB-IRIS; antitubercular treat-
ment precedes ART in paradoxical TB-IRIS, whereas
ART precedes tuberculosis diagnosis in unmasking TB-
IRIS [1]. Currently, no confirmatory diagnostic test for
paradoxical TB-IRIS exists. Differential diagnoses in-
clude failure of antitubercular treatment because of an-
timicrobial resistance or suboptimal antitubercular
drug concentrations, drug reactions, and alternative op-
portunistic conditions [3, 4]. Published case definitions
require the exclusion of these differential diagnoses, if
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6]. Severe and life-threatening manifestations of paradoxical
TB-IRIS include respiratory failure [7, 8] and neurologic in-
volvement [9–13]. Several case reports, but no case series, of
paradoxical neurologic TB-IRIS have been published [9–13].
In paradoxical neurologic TB-IRIS, inflammation in the cen-
tral nervous system (CNS) may result in death or permanent
neurologic disability. Adjunctive corticosteroid therapy is often
used to treat neurologic TB-IRIS, despite a lack of evidence of
benefit. Determining the cause of neurologic deterioration in
patients with tuberculosis who are receiving ART is important;
inappropriate adjunctive corticosteroid therapy for patients
with immunosuppression who actually have suboptimally
treated tuberculosis or other untreated opportunistic infec-
tions may be fatal. However, if treatment with corticosteroids
is effective, then failure to administer them may have severe
consequences. Unfortunately, access to expensive tests, such as
neuroimaging and drug susceptibility testing, is poor in re-
source-limited settings, where most of the burden of disease
exists.
In this study, we evaluated patients with suspected TB-IRIS
who were referred to our hospital to determine causes for neu-
rologic deterioration. We used a published consensus clinical
case definition of paradoxical TB-IRIS for resource-limited set-
tings [1] to identify paradoxical neurologic TB-IRIS. Here, we
describe the clinical presentation, management, and outcomes
of paradoxical neurologic TB-IRIS and discuss challenges of
diagnosis and management in resource-limited settings.
PATIENTS AND METHODS
Study site and setting. We conducted a prospective study at
GF Jooste Hospital (Cape Town, South Africa) from 1 June
2005 through 31 October 2007. GF Jooste Hospital is a sec-
ondary-level, 200-bed, public-sector hospital that serves indi-
gent adult patients (!15 years of age) who are referred from
primary health care clinics in periurban communities of Cape
Town. GF Jooste Hospital receives !8000 referrals per month
[14] from 30 primary care clinics with a catchment population
of 1.3 million people.
In 2006, the reported tuberculosis case notification rate in
the Western Cape was 1031 cases per 100,000 population [15],
and the antenatal human immunodeficiency virus type 1 (HIV-
1) seroprevalence was 15% (95% confidence interval [CI],
12%–19%) [16]. According to national protocol, patients with
a new diagnosis of tuberculosis receive 6 months of treatment
(isoniazid, rifampin, pyrazinamide, and ethambutol for 2
months, then isoniazid and rifampin for 4 months) [17]. The
retreatment regimen adds streptomycin, as follows: 2 months
of isoniazid, rifampin, pyrazinamide, ethambutol, and strep-
tomycin, 1 month of isoniazid, rifampin, pyrazinamide, and
ethambutol, and 5 months of isoniazid, rifampin, and etham-
butiol. New patients with neurologic tuberculosis receive pro-
longed treatment of 9 months (2 months of isoniazid, rifampin,
pyrazinamide, and ethambutol, and 7 months of isoniazid and
rifampin) [17]. New patients with tuberculosis do not routinely
undergo drug susceptibility testing; patients receiving retreat-
ment and patients who do not respond to antitubercular treat-
ment may undergo drug susceptibility testing.
First-line ART in South Africa is stavudine, lamivudine, and
either nevirapine or efavirenz. Efavirenz is preferred for patients
who are receiving rifampin-based tuberculosis treatment. Pa-
tients with a CD4+ cell count !200 cells/mL and/or a history
of a World Health Organization stage 4 illness are eligible to
commence ART [18]. ART is commenced 2 months after ini-
tiation of antitubercular treatment. If the CD4+ cell count is
!50 cells/mL or a serious HIV-1–related illness is present, ART
may be commenced 2 weeks after starting antitubercular treat-
ment [18]. To date, 112,000 people have initiated ART at pri-
mary care clinics within the catchment area.
Definitions. Patients with suspected TB-IRIS were defined
as patients with HIV-1 infection who received antitubercular
treatment, then commenced ART, and subsequently experi-
enced deterioration within 3 months, with symptoms or signs
compatible with tuberculosis. Patients with suspected neurol-
ogic TB-IRIS were defined as having !1 new or recurrent
neurologic symptom and/or sign, including headache, focal
neurologic deficit, nuchal rigidity, confusion, seizures, cerebel-
lar signs, cognitive impairment, and/or psychiatric manifes-
tations. We adapted the consensus clinical case definition of
paradoxical TB-IRIS for resource-limited settings [1]. We
expanded the major neurologic criterion of this case definition
(i.e., new or worsening CNS tuberculosis, including meningitis
or focal neurologic deficit [e.g., caused by tuberculoma]) to
include the following 3 neurologic disease categories: (1) new
or worsening tuberculous meningitis; (2) new or worsening
intracerebral space-occupying lesion (probable tuberculoma);
and (3) new or worsening radiculomyelopathy. The consensus
clinical case definition requires exclusion of alternative expla-
nations for clinical deterioration, if possible. In a number of
cases, we were unable to definitively exclude alternative expla-
nations for clinical deterioration, but our clinical assessment
was likely paradoxical neurologic TB-IRIS. We therefore in-
cluded patients (1) who died despite treatment interventions,
(2) who, in addition to TB-IRIS treatment, received therapeutic
trimethoprim-sulfamethoxazole (320 mg/1600 mg twice daily)
to treat possible cerebral toxoplasmosis (the principal differ-
ential diagnosis in cases of tuberculoma IRIS), and/or (3) in
whom antitubercular treatment was intensified from 2 drugs
(isoniazid and rifampin) to 4 drugs (isoniazid, rifampin, pyr-
azinamide, and ethambutol) or from 4 drugs (isoniazid, rif-
ampin, pyrazinamide, and ethambutol) to 7 drugs (isoniazid,
rifampin, pyrazinamide, and ethambutol plus amikacin, oflox-
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possibility of drug-resistant tuberculosis). We regard all cases
of paradoxical neurologic TB-IRIS as probable, because a con-
firmatory test for TB-IRIS is not yet available.
We defined microbiologically confirmed tuberculosis as My-
cobacterium tuberculosis cultured or acid-fast bacilli seen in a
sputum, nodal aspirate, or CNS specimen. The CNS specimens
included cerebrospinal fluid and brain or paraspinal biopsy
specimens. We defined microbiologically unconfirmed tuber-
culosis according to World Health Organization case definitions
for smear-negative and extrapulmonary tuberculosis [19]. We
defined multidrug-resistant (MDR) tuberculosis as M. tuber-
culosis with resistance to isoniazid and rifampin. We defined
disseminated tuberculosis as tuberculosis disease at !2 non-
contiguous sites or a miliary pattern visible on chest radiograph.
We defined HIV-1 encephalopathy as chronic cognitive im-
pairment (with or without cerebral atrophy findings on com-
puted tomography), with exclusion of opportunistic infections
as the cause for neurologic deterioration. Delirium was con-
sidered if patients presented with a systemic illness and acute
cognitive deterioration. We diagnosed delirium when we ob-
served a return to baseline cognitive function on resolution of
systemic illness. We defined initial clinical improvement as
symptom improvement (e.g., improvement of headache) or
improvement assessed by neurologic examination (e.g., focal
weakness or Glasgow Coma Scale score improvement from
admission). Initial clinical improvement did not necessitate
complete resolution of symptoms and/or signs. We defined
residual deficit as persistence of any neurologic symptom or
sign. We defined complete physical and mental recovery as a
return to baseline functioning, as assessed by the physician who
discharged the patient from the hospital. Lastly, we defined a
patient as being lost to follow-up if we were unable to trace a
patient 6 months after initial assessment for neurologic de-
terioration. We used hospital medical notes, as well as the
National Health Laboratories Service and the Provincial Gov-
ernment of the Western Cape’s computer databases, to trace
patients.
Assessment of patients with suspected TB-IRIS and data
collection. We assessed patients with suspected TB-IRIS from
June 2005 through October 2007, during recruitment to a ran-
domized controlled trial of prednisone versus placebo for mild
and moderate paradoxical TB-IRIS. Before the trial, clinical case
definitions for TB-IRIS were prepared, circulated, and discussed
with participating primary care physicians. Patients with sus-
pected TB-IRIS who were referred to GF Jooste Hospital were
prospectively assessed (regardless of severity of illness, eventual
diagnosis, or inpatient or outpatient management) to exclude
differential diagnoses. For example, we excluded bacterial and
cryptococcal meningitis in patients with features that were
suggestive of meningitis. We also sent specimens, such as spu-
tum, cerebrospinal fluid, and nodal aspirates, for mycobacterial
culture and drug susceptibility testing, to exclude drug-resistant
M. tuberculosis. Patients with severe paradoxical TB-IRIS man-
ifestations, such as respiratory failure, altered level of con-
sciousness, or new focal neurologic signs, were excluded from
the randomized controlled trial and usually received
prednisone.
Data collected regarding patients with suspected neurologic
TB-IRIS included tuberculosis diagnosis, antiretroviral treat-
ment, CD4+ cell count before and after receipt of antiretroviral
treatment, details of neurologic deterioration, eventual diag-
nosis, clinical management, and outcome at 6 months after
presentation. The Research Ethics Committee of the University
of Cape Town approved this study (REC 337/2004).
RESULTS
During the 29-month study period, we assessed 279 patients
with suspected TB-IRIS (figure 1). Two hundred twenty-five
(81%) of 279 patients with suspected TB-IRIS had suspected
non-neurologic TB-IRIS, whereas 54 (19%) had suspected neu-
rologic TB-IRIS, because they had !1 neurologic symptom
and/or sign. TB-IRIS was diagnosed more often among patients
with suspected non-neurologic TB-IRIS than it was among
those with suspected neurologic TB-IRIS (166 [74%] of 225
vs. 23 [43%] of 54; , by x2 test). Among the 54 patientsP ! .001
with suspected neurologic TB-IRIS, we diagnosed paradoxical
neurologic TB-IRIS in 23 patients and other illnesses in 31
patients. Therefore, of 190 patients with a diagnosis of para-
doxical TB-IRIS, 23 (12%; 95% confidence interval, 7%–17%)
had neurologic TB-IRIS: 8 had meningitis, 7 had tuberculoma,
5 had both tuberculoma and meningitis, and 3 had radiculo-
myelopathy. Among the 31 patients with illnesses other than
paradoxical neurologic TB-IRIS, the most frequent diagnoses
were HIV-1 encephalopathy with delirium (7 patients), cryp-
tococcal meningitis (5 patients), and MDR tuberculosis (4
patients).
Table 1 gives the baseline characteristics and neurologic
symptoms and signs for patients with a diagnosis of paradoxical
neurologic TB-IRIS. The median CD4+ cell count was 61 cells/
mL (interquartile range [IQR], 29–97 cells/mL) before ART and
293 cells/mL (IQR, 128–482 cells/mL) a median of 183 days
(IQR, 161–223 days) after ART initiation. Median duration
from antitubercular treatment to initiation of ART was 65 days
(IQR, 41–87 days), and median duration from ART initiation
to new or recurrent neurologic symptoms was 14 days (IQR,
5–29 days). The most frequent neurologic symptoms and signs
were headache (16 patients; 70%), nuchal rigidity (9 patients;
39%), and seizure(s) (7 patients; 30%). Median duration from
onset of neurologic symptoms to initial hospital assessment
was 6 days (IQR, 3–14 days).
Table 2 summarizes details of the 23 patients with neurologic
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Figure 1. Diagnoses for 279 patients with suspected tuberculosis (TB)–associated immune reconstitution inflammatory syndrome (TB-IRIS) (1 June
2005–31 October 2007). Other* indicates headache cause undetermined (3 patients), motor axonopathy cause undetermined (2), cerebrovascular accident
(1), nosocomial pneumonia and hypoxic ischemic brain insult (1), cauda equine lesion with undetermined cause (1), or subtherapeutic antitubercular
drug level (1). CMV, cytomegalovirus; MDR-TB, multidrug-resistant TB resistant to rifampin and isoniazid; NTM, nontuberculous mycobacteria.
ceived a diagnosis of meningitis revealed the following values:
median lymphocytes count, 30 cells/mL (IQR, 14–65 cells/mL);
median polymorph count, 0 polymorphs/mL (IQR, 0–5 poly-
morphs/mL); median protein level, 1.6 g/L (IQR, 1.0–2.3 g/L);
and median glucose level, 2.1 mmol/L (IQR, 1.7–2.5 mmol/L).
For 21 of 23 patients, we performed computed tomography or
magnetic resonance imaging of the brain or spinal cord. Space-
occupying lesions were found in 13 of 21 patients who un-
derwent brain or spinal cord imaging. Immunoglobulin G se-
rologic analysis for Toxoplasma species was performed for 11
of these 13 patients, 7 of whom had positive results; however,
all 7 had radiologic features of tuberculosis outside of the ner-
vous system. We treated 7 patients with therapeutic trimeth-
oprim-sulfamethoxazole (320 mg/1600 mg twice daily) to cover
possible cerebral toxoplasmosis; 4 of these 7 patients had IgG
test results positive for Toxoplasma species.
Six patients (patients 7, 8, 10, 11, 18, and 21) had evidence
of neurologic tuberculosis before ART. The remaining patients
did not have clinical features of neurologic tuberculosis before
ART. At neurologic deterioration, we sent 17 patients’ CNS
specimens for mycobacterial culture; 16 had negative results,
and 1 patient had a culture that grew M. tuberculosis (patient
20).
Twenty (87%) of 23 patients required hospital admission
(median duration, 12 days; IQR, 6–24 days), 21 (91%) received
corticosteroids (median duration of therapy, 58 days; IQR, 29–
86 days), and 7 (30%) received intensified antitubercular treat-
ment. Initial clinical improvement occurred in 19 (83%) of the
23 patients; 18 of 19 patients with initial improvement received
corticosteroids. Median duration from corticosteroid treatment
to initial clinical improvement was 10 days (IQR, 4–22 days).
Three (13%) of 23 patients died within 6 months after initial
assessment for neurologic deterioration. Four (17%) of 23 pa-
tients were lost to follow-up 6 months after the initial assess-
ment for neurologic deterioration. In these 4 patients, duration
from initial assessment to loss to follow-up (presumed dead)
ranged from 121 to 278 days. Known survival was thus 70%
at 6 months after neurologic TB-IRIS diagnosis. We docu-
mented full physical and mental recovery in 10 (63%) of 16
patients who were alive and in care at 6 months. Six (37%) of
16 patients had residual neurologic deficit at 6 months. Below,
we describe case reports of tuberculoma IRIS, tuberculous men-
ingitis IRIS, and TB-IRIS spondylitis with radiculopathy which
occurred in patients 12, 14, and 23, respectively, from tables 1
and 2.
Patient 12: paradoxical brain tuberculoma and meningitis
IRIS. A 36-year-old woman with HIV infection received a
diagnosis of disseminated tuberculosis. Acid-fast bacilli were
seen in her sputum sample, a chest radiograph showed a miliary
pattern, and abdominal ultrasound visualized splenic hypo-
densities, ascites, and a pericardial effusion. She commenced
antitubercular treatment with isoniazid, rifampin, pyrazina-
mide, and ethambutol. She gained weight, her cough and sweat-










Table 1. Baseline characteristics, tuberculosis (TB) and human immunodeficiency virus type 1 (HIV-1) data, and details of neurologic symptoms for 23 patients seropositive for HIV-1






























1 M 43 No Nodal AFB visualized (node and
sputum)
7 14 89 178 260 Headache, cognitive im-
pairment, and left arm
weakness
2 F 34 Yes Pleural No microbiological
confirmation
8 9 25 … … Confusion and fever
3 M 44 No Disseminated Mycobacterium tuberculo-
sis cultured (node)
4 19 134 224 502 Headache and focal sei-
zures of right arm
4 M 35 Yes Pleural M. tuberculosis cultured
(sputum)
12 11 139 151 423 Seizures and left
hemiparesis
5 F 24 No Disseminated M. tuberculosis cultured
(node)
4 3 12 23 6 Generalized tonic clonic
seizures and postictal
confusion
6 F 39 No Pulmonary No microbiological
confirmation
11 28 79 306 326 Sudden-onset right arm
and leg weakness with
sensory loss
7 F 28 Yes Disseminated M. tuberculosis cultured
(sputum)
19 2 33 … … Seizures and confusion
8 F 23 Yes Disseminated M. tuberculosis cultured
(CSF)
9 49 254 214 1043 Headache and generalized
tonic clonic seizures
9 F 37 No Disseminated No microbiological
confirmation
5 33 17 … … Headache, left arm and
leg seizures, and
confusion
10 F 43 No Meningitis, SOL AFB visualized (CSF) 35 21 3 … … Headache, neck stiffness,
confusion, and fever
11 F 30 No Meningitis No microbiological
confirmation















13 F 30 Yes Abdominal nodes No microbiological
confirmation
5 5 19 157 104 Headache, confusion,
neck stiffness, photo-
phobia, and vomiting
14 M 34 No Disseminated No microbiological
confirmation
2 1 77 173 207 Headache, fever, and
vomiting
15 F 33 No Disseminated No microbiological
confirmation
10 1 61 359 539 Headache, nausea, vomit-
ing, and night sweats
16 F 28 No Disseminated M. tuberculosis cultured
(sputum)
13 8 37 110 118 Headache, fever, and neck
stiffness
17 M 37 Yes Disseminated AFB visualized (sputum) 7 1 8 221 111 Neck stiffness, confusion,
and generalized tonic
clonic seizures
18 M 30 No Meningitis No microbiological
confirmation
12 30 158 … … Headache, fever, vomiting,
and neck stiffness
19 M 27 Yes Disseminated AFB visualized (sputum) 2 38 48 … … Headache, neck stiffness,
and fever
20 M 31 No Pulmonary AFB visualized (sputum) 7 14 52 301 159 Headache and neck
stiffness
21 F 41 No Meningitis No microbiological
confirmation
10 30 80 … … Headache and worsening
lower limb weakness
22 F 26 Yes Disseminated M. tuberculosis cultured
(sputum)
6 7 137 … … Headache and lower limb
weakness and inconti-
nence of urine and
feces
23 F 31 No Disseminated M. tuberculosis cultured
(sputum)
34 61 99 173 703 Right leg weakness and
lower back and right hip
pain
All patients, median value (IQR) … … … … … 9 (6–13) 14 (5–29) 61 (29–97) 183 (161–223) 293 (128–482) …
NOTE. AFB, acid-fast bacilli; ART, antiretroviral therapy; CSF, cerebrospinal fluid; IQR, interquartile range; SOL, space-occupying lesion; TB, tuberculosis. All patients received stavudine (30 mg twice daily), lamivudine
(150 mg twice daily), and efavirenz (600 mg nightly) antiretroviral treatment except patients 16, 17, and 21, who received zidovudine (300 mg twice daily), lamivudine (150 mg twice daily), and efavirenz (600 mg nightly),
and patient 10, who received stavudine (30 mg twice daily), lamivudine (150 mg twice daily), and nevirapine (200 mg twice daily). Thirty-five percent of patients were male, and 65% did not have previous TB. The median










Paradoxical Neurologic TB-IRIS • CID 2009:48 (1 June) • 000
Table 2. Neurologic disease category, investigations, management, and outcome for 23 patients who are seropositive for human



















1 SOL … … … … CT brain: 1 SOL AFB visualized (node)
2 SOL 0 0 1.6 3.1 CT brain: 1 SOL Culture negative (CSF)
3 SOL 0 0 0.3 3 CT brain: multiple SOLs No culture (CSF)
4 SOL … … … … CT brain: 1 SOL No specimen obtained
5 SOL 0 0 0.4 3.1 CT brain: 4 SOLs Culture negative (CSF)
6 SOL … … … … CT brain: 1 SOL Culture negative (sputum)
7 SOL 3 0 0.9 2.1 MRI brain: 1 SOL Culture negative (CSF)
8 SOL and meningitis 8 3 0.8 NP CT brain: 3 SOLs No culture (CSF)
9 SOL and meningitis 29 0 1.3 4.1 CT brain: 3 SOLs Culture negative (CSF)
10 SOL and meningitis 2 0 2.3 2 CT brain: 3 SOLs No culture (CSF)
11 SOL and meningitis 72 0 1.8 2 CT brain: 1 SOL Culture negative (CSF)
12 SOL and meningitis 16 0 2.3 0.7 CT brain: 1 SOL Culture negative (CSF)
13 Meningitis 45 0 1.1 1.5 CT brain: atrophy Culture negative (CSF)
14 Meningitis 35 8 1.4 2.6 None Culture negative (CSF)
15 Meningitis 28 74 0.7 1.6 CT brain: basal ganglia infarct Culture negative (CSF)
16 Meningitis 253 31 5.1 2 CT brain: multiple SOLs Culture negative (CSF)
17 Meningitis 13 6 0.7 2.3 CT brain: no SOL Culture negative (CSF)
18 Meningitis 144 0 0.9 2.7 CT brain: no SOL Culture negative (CSF)
19 Meningitis 5 2 1.6 0.4 CT brain: meningeal
enhancement, 1 infarct
Culture negative (CSF)
20 Meningitis 30 0 2.3 2.2 CT brain: no SOL Mycobacterium tuberculosis cultured
(CSF)
21 Radiculomyelitis … … 23 2.9 None Culture negative (CSF)
22 Radiculomyelitis 86 0 72 2.3 MRI spine: radiculomyelitis Culture negative (CSF)
23 Spondylitis with radiculopathy … … … … MRI spine: spondylitis Culture negative (aspirate)
NOTE. ART, combination antiretroviral therapy; CSF, cerebrospinal fluid; CT, computed tomography; Glc, glucose; HR, isoniazid and rifampin; HRZE, isoniazid,
rifampin, pyrazinamide, and ethambutol; HRZES, isoniazid, rifampin, pyrazinamide, ethambutol, and streptomycin; MRI, magnetic resonance imaging; NA, not
ascertained; NP, not performed; SOL, space-occupying lesion; TMP-SMX, trimethoprim-sulfamethoxazole.
nadir was 50 cells/mL, and 19 weeks after starting antitubercular
treatment, she initiated ART (stavudine 30 mg twice daily, la-
mivudine 150 mg twice daily, efavirenz 600 mg nightly). She
received trimethoprim-sulfamethoxazole chemoprophylaxis
(160 mg/800 mg twice daily). Sixteen days after initiation of
ART, she developed headache, neck stiffness, and vomiting.
Computed tomography of her brain showed a 10-mm partly
solid, partly cystic, inhomogenously enhancing lesion in the
left temporo-parietal area (figure 2), with surrounding edema.
Lumbar puncture showed an aseptic lymphocytic meningitis
(table 2). Bacterial and fungal cultures had negative results, and
the results of serological tests for syphilis performed on cere-
brospinal fluid samples were negative. Although serological test
results were positive for toxoplasmosis, the patient did not
receive therapeutic trimethoprim-sulfamethoxazole (320 mg/
1600 mg twice daily). We intensified antitubercular treatment
from isoniazid and rifampin to isoniazid, rifampin, pyrazin-
amide, and ethambutol, and we prescribed prednisone (60 mg
daily; 1.5 mg/kg/day) for 4 weeks, followed by a 4-week taper.
The patient’s headache and neck stiffness resolved. No subse-
quent deterioration occurred.
Patient 14: paradoxical TB-IRIS meningitis. A 33-year-
old man with HIV infection received a diagnosis of miliary
tuberculosis on the basis of chest radiograph findings. We were
unable to obtain microbiological confirmation of tuberculosis,
because sputum induction was unsuccessful. The patient had
no history of tuberculosis and started treatment with isoniazid,
rifampin, pyrazinamide, and ethambutol. He experienced im-
provement while receiving antitubercular treatment; cough,
shortness of breath, and generalized weakness resolved. Sixteen
days after starting antitubercular treatment, he initiated ART
(stavudine, lamivudine, and efavirenz), because his CD4+ cell
count nadir was 41 cells/mL. One day after initiation of ART,
the patient developed headache, fever, and vomiting. On phys-
ical examination, he was febrile and tachycardic (heart rate,
128 beats per min) but had no nuchal rigidity. We performed
a lumbar puncture, which revealed an asceptic lymphocytic
meningitis (table 2). The patient continued to receive antitu-
bercular treatment with isoniazid and rifampin and received
prednisone (40 mg twice daily) for 16 days. His headache, fe-









































HRZE No Yes/10c No Yes Positive No Positive (blood) Alived
HRZE Yes Yes/5 Yes Yes Negative Yes NP Died
HR Yes Yes/49c Yes Yes Negative Yes Negative (blood) Alive
HRE No Yes/13c No Yes Negative Yes Negative (blood) Alive
HRZE No Yes/17c No Yes Positive Yes NP Alived
HR No Noc No NA Positive Yes Negative (blood) Alived
HR Yes Yes/4c No Yes Positive Yes Negative (blood) Lost
HRZE No Yes/11c No Yes Positive No Negative (blood) Alived
HRZE No Yes/4c No NA Negative No Negative (CSF) Alive
HR Yes Yes/1 Yes Yes Positive Yes Negative (CSF) Died
HR Yes Yes/1c No NA NP No NP Alived
HR Yes Yes/8c No Yes Positive No Negative (CSF) Alive
HRZES No Yes/1c No Yes NP No Negative (blood) Alive
HRZE No Yes/2c No Yes NP No Negative (blood) Alived
HR No Yes/19c No Yes NP No Negative (blood) Alived
HRZE No Yes/10c No Yes NP No Negative (blood) Alive
HRZE No Yes/1c No Yes NP No Negative (blood) Alived
HR No Yes/1c No NA NP No Negative (blood) Lostd
HRZES No Yes/6c No Yes NP No Negative (CSF) Died
HR Yes Yes/11c No Yes NP No Negative (CSF) Alived
HRZE No No No NA NP No Negative (blood) Lost
HRZE No Yes/8 No NA NP No NP Lost
HR No Yes/22c No NA NP No NP Alive
a Normal CSF values were as follows: lymphocyte count, !5 cells/mL; polymorphonuclear cell count, !1 cell/mL; protein level, 0.15–0.45 g/L; and glucose level,
2.2–3.9 mmol/L.
b Outcome 6 months after neurologic deterioration; Lost indicates lost to follow-up 6 months after neurologic deterioration.
c Initial clinical improvement.
d Full physical and mental recovery.
Patient 23: paradoxical TB-IRIS spondylitis complicated by
radiculopathy. A 31-year-old woman with HIV infection re-
ceived a diagnosis of disseminated tuberculosis; she had con-
stitutional symptoms, abdominal ultrasound visualized ascites
and adenopathy, and we cultured M. tuberculosis that was sus-
ceptible to isoniazid and rifampin from her sputum samples.
The patient had no history of tuberculosis and commenced
treatment with isoniazid, rifampin, pyrazinamide, and etham-
butol. She stopped coughing and gained weight, and her malaise
and night sweats resolved. Her CD4+ cell count nadir was 99
cells/mL, and 24 weeks after starting antitubercular treatment,
she initiated ART with stavudine, lamivudine, and efavirenz.
Ten days after initiation of ART, the patient’s symptoms of
night sweats and anorexia recurred, and a chest radiograph
revealed a new miliary infiltrate. Sixty-one days after ART ini-
tiation, the patient developed back pain radiating down her
right leg. On physical examination, we found weakness of hip
flexion and knee extension and loss of the right knee reflex but
no sensory deficit. The patient’s clinical features were in keeping
with a right L3/4 radiculopathy. Magentic resonance imaging
of her spine confirmed tuberculous spondylitis with an epidural
component impinging the right aspect of the thecal sac (figure
2). We diagnosed a neurological manifestation of paradoxical
TB-IRIS, and the patient initiated treatment with prednisone
(60 mg daily; 1.5 mg/kg/day). Despite prednisone, her pain
persisted. We performed a computed tomography–guided par-
aspinal fine-needle aspiration; on microscopic examination, the
aspirate showed 1+ neutrophils, and on culture, it was negative
for pyogenic bacteria, mycobacteria, and fungi. The patient
received a total of 152 days of corticosteroid therapy, which
was tapered on cessation. The patient’s back pain improved
with opiate and nonsteroidal anti-inflammatory drugs, but she
had residual weakness and sensory loss affecting the lateral
aspect of her right thigh. By 173 days after initiation of ART,
the patient’s CD4+ cell count had increased to 700 cells/mL,
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DISCUSSION
Our study is, to our knowledge, the first case series of neu-
rologic TB-IRIS. We found that neurologic TB-IRIS accounts
for 110% of paradoxical TB-IRIS cases in a hospital setting.
We found a mortality rate of 13% (3 deaths among 23 patients)
for neurologic TB-IRIS, but the mortality rate may have been
30% (7 deaths among 23 patients) if all 4 patients who were
lost to follow-up died. Published data suggest that, in devel-
oping countries, many patients in antiretroviral programs who
are lost to follow-up actually die [20]. In a Vietnamese report
that described 44 patients with HIV-1 infection who received
dexamethasone for tuberculous meningitis, 27 (61%) of 44
patients died [21]. Reasons for differences in mortality rates
include nonavailability of ART in the Vietnamese study and
the fact that the Vietnamese study assessed outcome at 9
months, not 6 months. In addition, in our study, by analyzing
data for patients who were referred with TB-IRIS, we may have
selected for a group of patients with neurologic tuberculosis
who had a more favorable prognosis. Patients with more-severe
and more-extensive neurologic tuberculosis may have died be-
fore receiving ART. Also, patients who developed neurologic
TB-IRIS may have died before referral to our hospital. The
published literature reports only 1 death due to neurologic TB-
IRIS [9]; however, this is almost certainly because of a paucity
of published case reports [9–13].
In our study, initial improvement of symptoms and/or signs
occurred in 19 of 23 patients; 18 of these 19 patients with initial
improvement received corticosteroids. Full physical and mental
improvement occurred in 10 of 16 patients who were alive and
in care at 6 months. A substantial number of patients (6 of 16
patients) had residual neurologic disability at 6 months that
was likely to be permanent. A recent meta-analysis of published
literature does not support or refute the use of corticosteroids
to reduce death and neurologic deficit among patients with
HIV-1 infection who have tuberculous meningitis [22]. Cor-
ticosteroids are proposed as a treatment for TB-IRIS, although
available evidence is anecdotal [23, 24]. To date, no clinical
trials show evidence to support the use of corticosteroids in
treating TB-IRIS. We are unable to conclude from our obser-
vational study whether corticosteroids reduce mortality or dis-
ability in neurologic TB-IRIS.
To diagnose TB-IRIS, differential diagnoses need to be ex-
cluded or resolution should occur without treatment for other
opportunistic infections [1]. This is difficult in cases involving
space-occupying lesions because of limited access to brain bi-
opsy. Differential diagnoses for TB-IRIS include cryptococ-
coma, progressive multifocal leukoencephalopathy IRIS [25],
bacterial abscess, lymphoma, neurocysticerci, and syphilitic
gumma. We were unable to definitively exclude all other dif-
ferential diagnoses by means of brain biopsy; however, 10 of
12 patients with space-occupying lesions did not experience
deterioration despite receiving no treatment for these other
aforementioned illnesses.
The major differential diagnosis for tuberculoma IRIS, how-
ever, is cerebral toxoplasmosis. A subgroup of patients (7 of
12 patients) received simultaneous treatment for toxoplasmosis
and tuberculosis in our study. In certain parts of South Africa,
Toxoplasma gondii is isolated more commonly than M. tuber-
culosis from biopsy specimens and aspirates of intracranial mass
lesions [26], whereas in other parts of South Africa, M. tuber-
culosis is isolated more commonly [27]. We anticipate a higher
proportion of tuberculosis cases in South Africa, because the
tuberculosis case notification rate in Cape Town is one of the
highest in the world [15]. In addition, key features that suggest
tuberculosis, rather than other infectious causes, include (1)
concurrent presence of pulmonary tuberculosis or other non-
neurologic tuberculosis and (2) basal meningeal enhancement
[27]. All of the patients in our study whose tuberculosis di-
agnosis was microbiologically unconfirmed had radiologic fea-
tures of non-neurologic tuberculosis. In addition, of 7 patients
who were treated for possible cerebral toxoplasmosis, 3 had
serologic test results that were negative for toxoplasmosis, and
all 7 had radiologic evidence of non-neurologic tuberculosis.
Although we had strong clinical suspicion of paradoxical neu-
rologic TB-IRIS in these 7 patients, we opted to also treat for
possible cerebral toxoplasmosis, because the clinical condition
of these patients was severe, and a confirmatory diagnostic test
for TB-IRIS is not yet available. Trimethoprim-sulfamethoxa-
zole, used in our setting, and pyrimethamine-sulfadiazine, used
elsewhere, have no significant difference with respect to clinical
efficacy during short-term therapy for toxoplasmic encephalitis
[28].
Patients without apparent neurologic tuberculosis before
ART may present with neurologic TB-IRIS after ART initiation.
This occurred in 17 of 23 patients in our case series. Presumably,
this is attributable to subclinical seeding of M. tuberculosis into
neurologic tissue that provokes an inflammatory response at
the time of IRIS. Although mycobacterial culture results are
usually negative at TB-IRIS diagnosis, M. tuberculosis may be
cultured, particularly if IRIS occurs early during antitubercular
treatment [1]. This occurred in 1 patient.
Incident MDR tuberculosis may occur in !10% of HIV-1–
infected patients with tuberculous meningitis [28]. Patients
with MDR tuberculous meningitis have significantly poorer
outcomes [29]. Previously, we diagnosed rifampin-resistant tu-
berculosis in 110% of patients with suspected TB-IRIS [2]. In
this study, we diagnosed MDR tuberculosis in !10% of patients
with suspected neurologic TB-IRIS. We empirically intensified
antitubercular treatment in 7 patients with paradoxical neu-
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Figure 2. A, Paradoxical brain tuberculoma and meningitis immune
reconstitution inflammatory syndrome (IRIS) in patient 12. Computed to-
mography of the patient’s brain showed a 10-mm partly solid, partly
cystic, inhomogenously enhancing lesion in the left temporo-parietal re-
gion (white arrow). B, Paradoxical tuberculosis (TB)–associated IRIS spon-
dylitis complicated by radiculopathy in patient 23. Magentic resonance
imaging of the patient’s spine confirmed a right paravertebral collection
(white arrow) with tuberculous spondylitis (black arrow). C, Computed
tomography of patient 23 revealed the epidural component of the spon-
dylitis lesion (dashed arrow) impinging the right aspect of the thecal sac.
susceptibility results; however, none of these patients cultured
MDR tuberculosis. We are unable to ascertain the extent that
intensified antitubercular treatment improved clinical outcome.
It is possible that the 7 patients who received a diagnosis of
HIV-1 encephalopathy and delirium (figure 1) may have ex-
perienced cognitive deterioration as a result of cerebral inflam-
mation (cerebritis) due to TB-IRIS. However, in these patients,
we did not diagnose neurologic TB-IRIS, because either (1) the
patient did not have a space-occupying lesion and thus did not
fulfill our case definition, or (2) the imaging modality that we
used (computed tomography rather than magnetic resonance
imaging in most cases) was not sensitive enough to detect all
space-occupying lesions [30, 31]. This may be a limitation of
our case definition and warrants further investigation.
We report a median duration of 14 days from ART initiation
to the onset of TB-IRIS symptoms in both this study and our
previous study of paradoxical TB-IRIS [2]. Other studies report
a median duration from ART initiation to the onset of TB-
IRIS symptoms of 12 days (IQR, 5–17 days) [32], 34 days (IQR,
8–97 days) [9], and 47 days (IQR, 36–81 days) [33]. Variability
in baseline CD4+ cell counts and duration of antitubercular
treatment before ART initiation may account for the discrep-
ancy among studies, because these are risk factors for TB-IRIS
[34, 35]. Median duration of hospitalization in patients with
TB-IRIS is usually !1 week [9], which is similar to our findings.
In HIV-1–infected patients with tuberculous meningitis, me-
dian symptom duration before assessment varies from 11 to
18 days [36–38]. Our shorter median symptom duration of 6
days before assessment for neurologic TB-IRIS may indicate
increased inflammation from IRIS. Differing referral patterns
between our setting and other settings may also account for
shorter symptom duration.
In a hospital setting, patients with suspected non-neurologic
TB-IRIS are more likely than patients with suspected neurologic
TB-IRIS to receive an eventual diagnosis of TB-IRIS. We at-
tribute this finding to screening of patients by physicians at
primary care clinics. It is likely that patients with suspected
non-neurologic TB-IRIS with alternative illnesses to TB-IRIS
were not assessed at our hospital, because they improved with
appropriate treatment prescribed by primary care physicians.
Intuitively, patients with suspected TB-IRIS with neurologic
deterioration require rapid referral to the hospital for inpatient
admission and investigation, thus increasing the likelihood of
diagnosis of other illnesses.
Although paradoxical neurologic TB-IRIS is a potentially life-
threatening manifestation of paradoxical TB-IRIS, there is most
likely a spectrum of disease severity in neurologic TB-IRIS.
Milder forms of neurologic TB-IRIS with spontaneous recovery
and extremely severe neurologic TB-IRIS with rapid progres-
sion to death before referral may not have been included in
our case series. We did not microbiologically confirm tuber-
culosis in 9 (39%) of 23 patients; however, tuberculosis is dif-
ficult to confirm microbiologically in neurological disease. M.
tuberculosis was cultured from only 31% of patients with tu-
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who died with a diagnosis of paradoxical neurologic TB-IRIS
did not have cultures positive for M. tuberculosis; thus, drug
susceptibility testing to exclude MDR tuberculosis could not
be performed. We obtained cerebrospinal fluid for analysis from
18 of 23 patients but could have improved diagnostic accuracy
by performing autopsies and brain biopsies. Brain biopsies
carry the risk of postoperative hemorrhage [39] and are difficult
to access in our setting. Standardized tools were not used to
assess neurocognitive function or neurologic outcomes. Rather,
we relied on the bedside clinical assessment of the attending
physician at hospital admission and discharge, as well as records
from clinic follow-up. Lastly, this study was conducted at a
referral hospital that served a large population with a high
incidence of HIV-1–associated tuberculosis. Our findings may
not be generalizable to primary care settings or settings where
HIV-1–associated tuberculosis is less common.
In conclusion, in a hospital setting, neurologic TB-IRIS is a
not-infrequent manifestation of TB-IRIS and causes consid-
erable short-term morbidity but is associated with reasonable
long-term outcomes. Future prospective studies may better (1)
determine the incidence of neurologic TB-IRIS among patients
with initial neurologic and non-neurologic tuberculosis disease;
(2) determine optimal management strategies to reduce death,
neurologic deficits, and disabilities; and (3) describe the path-
ophysiologic findings of neurologic TB-IRIS.
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Clinical deterioration during antituberculosis
treatment in Africa: Incidence, causes and
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Abstract
Background: HIV-1 and Mycobacterium tuberculosis cause substantial morbidity and mortality. Despite the
availability of antiretroviral and antituberculosis treatment in Africa, clinical deterioration during antituberculosis
treatment remains a frequent reason for hospital admission. We therefore determined the incidence, causes and
risk factors for clinical deterioration.
Methods: Prospective cohort study of 292 adults who initiated antituberculosis treatment during a 3-month
period. We evaluated those with clinical deterioration over the following 24 weeks of treatment.
Results: Seventy-one percent (209/292) of patients were HIV-1 infected (median CD4+: 129 cells/μL [IQR:62-277]).
At tuberculosis diagnosis, 23% (34/145) of HIV-1 infected patients qualifying for antiretroviral treatment (ART) were
receiving ART; 6 months later, 75% (109/145) had received ART. Within 24 weeks of initiating antituberculosis
treatment, 40% (117/292) of patients experienced clinical deterioration due to co-morbid illness (n = 70),
tuberculosis related illness (n = 47), non AIDS-defining HIV-1 related infection (n = 25) and AIDS-defining illness
(n = 21). Using HIV-1 uninfected patients as the referent group, HIV-1 infected patients had an increasing risk of
clinical deterioration as CD4+ counts decreased [CD4+>350 cells/μL: RR = 1.4, 95% CI = 0.7-2.9; CD4+:200-350 cells/
μL: RR = 2.0, 95% CI = 1.1-3.6; CD4+<200 cells/μL: RR = 3.0, 95% CI = 1.9-4.7]. During follow-up, 26% (30/117) of
patients with clinical deterioration required hospital admission and 15% (17/117) died. Fifteen deaths were in HIV-1
infected patients with a CD4+<200 cells/μL.
Conclusions: In multivariate analysis, HIV-1 infection and a low CD4+ count at tuberculosis diagnosis were
significant risk factors for clinical deterioration and death. The initiation of ART at a CD4+ count of <350 cells/μL
will likely reduce the high burden of clinical deterioration.
Background
Adherence to antituberculosis treatment in advanced
human immunodeficiency virus type 1 (HIV-1) infection
results in rapid sterilisation of sputum, radiographic
improvement and a low risk of relapse [1]. The benefits
of antiretroviral treatment (ART) in reducing HIV-1
replication and restoring pathogen-specific immunity are
well described [2,3]. Despite the availability of antituber-
culosis and antiretroviral treatment in Africa, clinical
deterioration during antituberculosis treatment in HIV-1
infected patients remains an important reason for hospi-
tal admission and death [4,5].
Profoundly immune-suppressed HIV-1 infected
patients may encounter a complicated clinical course
after starting antituberculosis treatment. While initiation
of ART during antituberculosis treatment reduces mor-
tality [6], the optimal interval from antituberculosis
treatment to initiation of ART is not known. Early
initiation of ART restores pathogen-specific immunity,
but also significantly increases the risk of the tuberculo-
sis-associated immune reconstitution inflammatory syn-
drome (TB-IRIS) [7]. Conversely, a delay in initiation of* Correspondence: dominiquepepper@gmail.com
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ART may allow additional AIDS-defining illnesses to
manifest. Other reasons for clinical deterioration during
antituberculosis treatment include antimicrobial resis-
tance, suboptimal antituberculosis drug concentrations,
drug reactions, and other opportunistic illnesses [8,9].
The greatest burden of HIV-1 infection and tuberculo-
sis occurs in resource-limited settings, such as South
Africa, where health systems are overwhelmed and rapid
diagnostic tools are not readily available. In 2006,
337,400 of 482,000 tuberculosis patients in South Africa
were HIV-1 co-infected and 105,000 tuberculosis deaths
were reported [10]. The fatal consequences of HIV-1/
Mycobacterium tuberculosis co-infection are well
described [11,12]. However, the incidence of clinical
deterioration during antituberculosis treatment amongst
HIV-1 infected patients (compared to HIV-1 uninfected
patients) is unknown. Determining the causes and risk
factors for clinical deterioration during antituberculosis
treatment may inform initiatives to reduce the burden
on both tuberculosis and ART programmes.
In this study, we assessed patients at initiation of anti-
tuberculosis treatment and followed them for 24 weeks,
in order to determine the incidence, causes and risk fac-
tors for clinical deterioration. We also discuss initiatives
to reduce the high burden of clinical deterioration in
resource-limited settings.
Methods
We conducted a prospective cohort study at Khayelitsha
Site B tuberculosis clinic (Cape Town, South Africa)
from 1 June 2008 through 15 February 2009. We
assessed adult (≥ 18 years age) patients diagnosed with
tuberculosis at Khayelitsha Site B tuberculosis clinic
from 1 June 2008 through 31 August 2008 (3-month
assessment period). Informed consent was obtained
from all enrolled patients. HIV-1 voluntary counselling
and testing is offered to all patients diagnosed with
tuberculosis at Site B Khayelitsha. Patients were fol-
lowed for 24 weeks from initiation of antituberculosis
treatment. Our study was nested within a tuberculosis
drug susceptibility testing (DST) survey in which first-
line DST (for isoniazid and rifampin) was routinely per-
formed, regardless of HIV-1 status or previous tubercu-
losis. The Research Ethics Committee of the University
of Cape Town approved this study (REC 178/2008).
Study site and setting
Khayelitsha Site B tuberculosis clinic is a primary-level
outpatient health care facility, which serves ~100,000
people within its high-density, low-income catchment
area. Approximately 1,200 adult cases of tuberculosis
are diagnosed per annum at Site B tuberculosis clinic.
In 2006, the antenatal HIV-1 seroprevalence in this
community was 33% (95%: 29.1 - 36.9%) [13]. According
to national protocol, patients with a new diagnosis of
tuberculosis receive 6 months of daily antituberculosis
treatment (isoniazid, rifampin, pyrazinamide, and etham-
butol for 2 months, followed by isoniazid and rifampin
for 4 months) [14]. The retreatment regimen is: isonia-
zid, rifampin, pyrazinamide, ethambutol, and streptomy-
cin for 2 months, followed by isoniazid, rifampin,
pyrazinamide, and ethambutol for 1 month, and then
isoniazid, rifampin, and ethambutol for 5 months. First-
line ART in South Africa is stavudine, lamivudine, and
either nevirapine or efavirenz. Efavirenz is preferred for
patients who are receiving rifampin-based antituberculo-
sis treatment. Patients with a CD4+ cell count <200
cells/μL and/or a history of a World Health Organiza-
tion (WHO) stage 4 illness, other than extra-pulmonary
tuberculosis, are eligible to commence ART [15]; ART
is typically commenced 2 months after initiation of anti-
tuberculosis treatment. If the CD4+ cell count is <50
cells/μL or a serious HIV-1-related illness is present,
ART may be commenced 2 weeks after starting antitu-
berculosis treatment [15]. To date, >5,000 people have
initiated ART at Khayelitsha Site B HIV clinic.
Definitions
“Tuberculosis patients” refers to patients diagnosed with
tuberculosis and initiated on antituberculosis treatment.
We defined microbiologically-confirmed tuberculosis as
Mycobacterium tuberculosis cultured or acid-fast bacilli
visualised in a biological specimen. Biological specimens
included sputum, pleural fluid, urine, nodal aspirates,
pericardial aspirates and cerebrospinal fluid. We defined
microbiologically-unconfirmed tuberculosis according to
the WHO case definitions for smear-negative and extra-
pulmonary tuberculosis [16]. Biological specimens were
obtained at tuberculosis diagnosis, at 8 and 20 weeks’
follow-up and at clinical deterioration. First-line DST
using the GenoType MTBDRplus assay [17] was per-
formed on biological specimens that were smear-positive
for acid-fast bacilli and/or culture positive for Mycobac-
terium tuberculosis. We defined multidrug-resistant
(MDR) tuberculosis as M. tuberculosis resistant to iso-
niazid and rifampin.
We defined clinical deterioration as symptomatic wor-
sening or failure to stabilise within 24 weeks following
initiation of antituberculosis treatment. We subdivided
the causes of clinical deterioration into HIV-1 related
illnesses and HIV-1 unrelated illnesses. HIV-1 related
causes included AIDS defining illnesses (according to
WHO stage 4 criteria [18]), and non AIDS-defining ill-
nesses i.e. Non-AIDS defining HIV-1 related infections.
HIV-1 unrelated illnesses included tuberculosis related
illnesses, and illnesses unrelated to tuberculosis i.e. co-
morbid illnesses. Tuberculosis-related illnesses included
MDR-TB, deterioration due to poor adherence,
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paradoxical tuberculosis-associated immune reconstitution
inflammatory syndrome (TB-IRIS) and paradoxical reac-
tions. A co-morbid illness was an acute illness that
occurred after tuberculosis diagnosis and was considered
not to be directly attributable to HIV-1 or tuberculosis. A
co-morbid illness also included an acute deterioration of a
pre-existing condition. For example, we regarded diabetic
ketoacidosis in a diabetic patient as a co-morbid illness.
We defined paradoxical TB-IRIS according to the con-
sensus clinical case definition for resource-limited set-
tings [7]. We defined paradoxical reactions using an
adaptation of this consensus clinical case definition of
paradoxical TB-IRIS [7]. Three criteria were required
for a diagnosis of paradoxical reaction:
1. Diagnosis of tuberculosis (microbiologic confirma-
tion or according to WHO criteria [16]) with initial
response to antituberculosis treatment,
2. The recurrence/new onset of tuberculosis disease
manifestations within 24 weeks of antituberculosis
treatment, and
3. Exclusion of alternative explanations for clinical
deterioration (such as antituberculosis drug resis-
tance, poor adherence, drug toxicity or reaction, or
an additional infection).
Paradoxical reactions were diagnosed in both HIV-1
infected and uninfected patients. HIV-1 infected patients
receiving ART at clinical deterioration were diagnosed
with paradoxical TB-IRIS rather than a paradoxical reac-
tion according to our definitions.
We defined a patient as being lost to follow-up if we
were unable to trace a patient 24 weeks after initiation
of antituberculosis treatment. We used clinic and hospi-
tal medical notes, as well as the National Health Labora-
tories Service database to trace specimens and the
Provincial Government of the Western Cape’s electronic
tuberculosis register to trace patients.
Assessment of patients with clinical deterioration
The study was discussed with physicians and nurses at
the tuberculosis clinic prior to commencement of the
study. Adult patients with clinical deterioration within
24 weeks of initiation of antituberculosis treatment were
prospectively evaluated (regardless of severity of illness,
eventual diagnosis, or inpatient or outpatient manage-
ment) to determine the reason for clinical deterioration.
Stable patients were assessed at Khayelitsha Site B
tuberculosis clinic; patients requiring hospital admission
or invasive outpatient procedures were assessed at GF
Jooste Hospital (the clinic’s referral hospital). At clinical
deterioration, we routinely obtained biological speci-
mens to investigate drug-resistant M. tuberculosis. Spe-
cimens were also cultured for bacterial organisms.
Data collection and analysis
Data collected included demographic information,
tuberculosis specimen results, HIV-1 status, antiretro-
viral treatment, CD4+ cell count at tuberculosis diagno-
sis, diagnosis at clinical deterioration and outcome 24
weeks after initiation of antituberculosis treatment. Sta-
tistical analyses were performed using Stata 10.0 (Texas,
USA). Wilcoxon rank-sum and Kruskall-Wallis tests
were used for group comparisons, and Fisher’s exact
tests for proportion comparisons. Variables with the
outcome of interest were entered into Cox proportional
hazards models to assess the independent effects of cov-
ariates. We censored patients at clinical deterioration
when performing Cox-proportional hazards model ana-
lysis and relative risk calculations. Significant variables
were removed from the model to assess whether these
effects remained. The assumptions of the Cox model
were verified; non-informative censoring was performed
and the tests for the proportional hazards assumption
were not significant. We censored patients at loss to fol-
low-up when determining the incidence rate of clinical
deterioration (illnesses diagnosed per 100 months of fol-
low-up). Individual patients could contribute more than
one event in the calculation of the incidence rate.
Results
During the 3-month assessment period (figure 1), 305
adults (≥ 18 years age) initiated antituberculosis treat-
ment, 7 of whom had untraceable clinical records and 6
of whom declined HIV-1 testing. We restricted our data
analysis to the 292 (96%) patients whose HIV-1 status
and clinic records were available. In 209 HIV-1 infected
and 83 HIV-1 uninfected patients, loss to follow-up (46
[22%] of 209 vs. 29 [35%] of 83, p-value = 0.026) and
mortality (16 [8%] of 209 vs. 1 [1%] of 83, p-value =
0.048) differed significantly at 24 weeks.
At initial tuberculosis diagnosis (table 1), HIV-1
infected patients were more likely than HIV-1 unin-
fected patients to be female, be of younger age, have
extra-pulmonary tuberculosis and be diagnosed with
tuberculosis at the referral hospital. HIV-1 uninfected
patients were more likely than HIV-1 infected patients
to have microbiologic confirmation of tuberculosis at
initial tuberculosis diagnosis and during the 24 weeks of
follow-up.
Prior to tuberculosis diagnosis, 34 (23%) of 145 HIV-1
infected patients who qualified for ART under national
guidelines were receiving ART. Six months later, 109
(75%) of 145 patients had received ART.
Causes of Clinical Deterioration and Hospital Admission
During the 24 weeks of follow-up, 117 (40%, 95% CI:
35-46%) of 292 tuberculosis patients experienced clinical
deterioration, of whom 101 were HIV-1 infected and 16
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were HIV-1 uninfected. Causes of clinical deterioration
(table 2) included: co-morbid illnesses (70 patients),
tuberculosis-related illnesses (47 patients), non AIDS-
defining HIV-1 related infections (25 patients) and
AIDS-defining illnesses (21 patients). Peripheral neuro-
pathy, enteric illness and deep venous thrombosis were
frequent co-morbid illnesses. TB-IRIS and paradoxical
reactions were frequent tuberculosis-related illnesses.
Oesophageal candida, Pneumocystis jirovecii pneumonia
and cryptococcal meningitis were frequent AIDS-defin-
ing illnesses. Of 117 patients who experienced dete-
rioration, 30 (26%) required hospital admission [27
(27%) of 101 HIV infected and 3 (19%) of 16 HIV-1
uninfected patients (p-value = 0.756)]. Causes of inpati-
ent hospital admission were paradoxical reaction or
TB-IRIS (9 patients), new AIDS-defining illness
(8 patients), deep venous thrombosis (6 patients),
MDR-TB (2 patients), cardiomyopathy (1 patient),
pneumothorax (1 patient), symptomatic deterioration
due to poor adherence with antituberculosis treatment
(1 patient), hyperglycaemic emergency (1 patient) and
seizure disorder (1 patient).
Risk Factors for Clinical Deterioration
In the 292 tuberculosis patients, 4 factors were signifi-
cantly associated with clinical deterioration in univariate
analysis: HIV-1 infection, diagnosis of tuberculosis at
the referral hospital, evidence of extra-pulmonary tuber-
culosis, and absence of a DST result at tuberculosis
diagnosis. Only HIV-1 infection (figure 2a) remained
significant in multivariate analysis (adjusted hazard ratio
[aHR]= 2.0, 95% CI = 1.1-3.6).
In subsequent analysis (figures not shown), we
assessed whether the probability of clinical deterioration
from non-HIV-1 related causes was associated with
HIV-1 infection. In univariate analysis, we found a sig-
nificant association between HIV-1 infection and non-
HIV-1 related causes for deterioration (RR = 1.3, 95%
305 Adults (> 18 years) started TB chemotherapy from 1 June through 31 August 2008 
7 records untraceable  
6 declined HIV testing 
292 HIV-1 status known1 
209 HIV-1 infected2 83 HIV-1 uninfected 
1 died 
29 lost to follow-up 
16 died 
46 lost to follow-up 
147 completed 24 
weeks of follow-up 
53 completed 24 
weeks of follow-up 
Figure 1 Flow-diagram of 305 adult patients who started antituberculosis treatment from 1 June - 31 August 2008. 1Subsequent data
analysis for 292 patients with known HIV-1 status 2CD4 counts not performed in 3 of 209 HIV-1 infected patients
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CI: 1.07 - 1.50). However, in the Cox proportional
hazards model, using the same variables as figure 2a,
this significant association was not confirmed (HR = 1.5,
95% CI: 0.81-2.64). This analysis suggests that HIV-1
infection is a significant variable for clinical deteriora-
tion because of HIV-1 related illnesses (either AIDS- or
non AIDS-defining illnesses).
In the 209 HIV-1 infected tuberculosis patients, 3 fac-
tors were significantly associated with clinical deteriora-
tion in univariate analysis: a lower CD4+ count,
diagnosis of tuberculosis at the referral hospital, and
antiretroviral treatment received during antituberculosis
treatment. Only a lower CD4+ stratum at tuberculosis
diagnosis (figure 2b) remained significant in multivariate
analysis (aHR = 1.5, 95% CI = 1.1-2.2).
In subsequent analysis (figures not shown), we
assessed whether the probability of clinical deterioration
from non-HIV-1 related causes was associated with
decreasing CD4+ counts. We did not find a significant
association between decreasing CD4+ count strata and
non-HIV-1 related causes in both the univariate analysis
(P = 0.189) and the Cox proportional hazards model
(HR = 1.3, 95%CI: 0.88 - 1.97). This analysis suggests
that decreasing CD4+ counts are a significant risk factor
for clinical deterioration because of their association
with HIV-1 related illnesses (either AIDS- or non AIDS-
defining illnesses).
Relative Risk and Incidence Rate of Clinical Deterioration
HIV-1 infection and a low CD4+ count were the only
significant risk factors for clinical deterioration in multi-
variate analysis. We therefore determined the relative
risk and incidence rate of clinical deterioration accord-
ing to HIV-1 status and CD4+ stratum. HIV-1 infected
patients were more likely than HIV-1 uninfected
patients to experience clinical deterioration (RR = 2.6,
95%CI: 1.6-4.0). Using HIV-1 uninfected patients as the
referent group, the relative risk (RR) of clinical dete-
rioration increased as the CD4+ counts in HIV-1
infected patients decreased (CD4+ >350 cells/μL: RR =
1.4, 95% CI = 0.7-2.9; CD4+200-350 cells/μL: RR = 2.0,
95% CI = 1.1-3.6; CD4+ <200 cells/μL: RR = 3.0, 95%
CI = 1.9-4.7). The incidence rate (IR) of clinical dete-
rioration (illnesses diagnosed per 100 months of follow-
up) also increased as the CD4+ counts decreased. Inci-
dence rates differed significantly between HIV-1 unin-
fected patients (IR = 5.1, 95% CI = 3.1-7.5) and HIV-1
infected patients with a CD4+ count of 200-350 cells/μL
(IR = 12.3, 95% CI = 8.2-17.0). Similarly, incidence rates
differed significantly between HIV-1 infected patients
with a CD4+ count of 200-350 cells/μL and HIV-1
infected patients with a CD4+ count < 200 cells/μL (IR =
20.7, 95% CI 17.8-23.9).
Figure 3 is a Lowess plot showing the proportion of
patients who experienced clinical deterioration during
Table 1 Baseline characteristics and microbiologic confirmation of tuberculosis in 209 HIV-1 infected and 83 HIV-1






Female, n (%) 112 (54) 25 (30) <0.001
Age in years, median (IQR) 35 (30-41) 38 (29-49) 0.035
CD4 count at TB diagnosis, n (%):
>350 cells/mm3 36 (17) -
200 - 350 cells/mm3 37 (18) -
< 200 cells/mm3 133 (64) -
Not performed 3 (1) -
Previous TB, n (%) 71 (34) 19 (23) 0.070
TB diagnosed at referral hospital, n (%): 79 (38) 13 (16) <0.001
Microbiologic confirmation at TB diagnosis1, n (%) 123 (59) 68 (82) <0.001
Drug susceptibilities known at TB diagnosis1, n (%) 67 (32) 49 (59) <0.001
Culture sent at TB diagnosis, n (%) 169 (81) 68 (82) 1.000
Extra-pulmonary TB, n (%): 82 (39) 14 (17) <0.001
Weight at TB diagnosis in kg, median (IQR) 54 (49-62) 54 (49-64) 0.644
Microbiologic confirmation at TB diagnosis and during 24 weeks of follow-up2, n (%) 153 (73) 70 (84) 0.048
Drug susceptibilities known at TB diagnosis and during 24 weeks of follow-up2, n (%) 117 (56) 57 (69) 0.296
Culture sent at TB diagnosis and/or during 24 weeks of follow-up, n (%) 190 (91) 76 (92) 1.000
Key:
1within 14 days of TB diagnosis. No TB specimens sent in 12 HIV-1 infected patients and 3 HIV-1 uninfected patients at TB diagnosis.
2no TB specimens sent in 2 HIV-1 infected patients.
TB = tuberculosis, IQR = inter-quartile range, OR = odds-ratio, 95% CI = 95% confidence interval.
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the 24 weeks of antituberculosis treatment. The initial
peak at 6 weeks in HIV-1 uninfected patients corre-
sponds with tuberculosis-related illnesses (mostly para-
doxical reactions) and the baseline fluctuations
represent co-morbid illnesses. The curve for HIV-1
infected patients with a CD4+ count > 350 cells/μL is
similar to that of HIV-1 uninfected patients, despite an
earlier peak for paradoxical reactions. The proportion of
HIV-1 infected patients with a CD4+ count of 200-350
cells/μL who experienced clinical deterioration substan-
tially increased after 10 weeks of follow-up. Further-
more, a substantially higher proportion of HIV-1
infected patients with a CD4+ count <200 cells/μL
experienced clinical deterioration compared to other
CD4+ strata.
Mortality
Fifteen of 17 deaths occurred in HIV-1 infected patients
with a CD4+ count < 200 cells/μL. The median interval
from antituberculosis treatment to death was 98 days
(IQR = 59 -128). Eight of 17 deaths occurred between
10 and 20 weeks of follow-up. Diagnoses at time of
death included: AIDS-defining illnesses (5), poor adher-
ence with antituberculosis treatment (4), paradoxical
neurologic TB-IRIS (3), enteric illness (2), MDR-TB (1),
pulmonary embolus (1) and tension pneumothorax (1).
Loss to follow-up
Within 24 weeks of commencing antituberculosis treat-
ment, 75 patients were lost to follow-up. The median
interval from antituberculosis treatment to loss to
Table 2 Illnesses (n = 199) in 101 HIV-1 infected and 16 HIV-1 uninfected patients who experienced clinical
deterioration during 24 weeks of antituberculosis treatment
HIV-1 infected HIV-1 uninfected
number of illnesses = n, (total number of patients = pnts) 180 (101) 19 (16)
1. Tuberculosis related illnesses, n (pnts) 49 (43) 5 (5)
TB-IRIS 22 -
Paradoxical reaction 17 4
MDR-TB1 4 1
Deterioration due to poor adherence 5 -
Low rifampin concentration in comparison to the recommended range 1 -
2. AIDS-defining illnesses, n (pnts) 29 (21) -
Oesophageal candida 11 -
Pneumocystis jiroveci pneumonia2 5 -
Cryptococcal meningitis 4 -
Cytomegalovirus retinitis 3 -
Other3 6 -
3. Non-AIDS defining HIV-1 related infections, n (pnts) 27 (25) -
Superficial herpes infection4 9 -
Bacterial infection5 9 -
Fungal (oral/vaginal/superficial) infection 9 -
4. Co-morbid illnesses, n (pnts) 76 (59)6 14 (11)7
Key:
TB = tuberculosis; TB-IRIS = TB-associated immune reconstitution inflammatory syndrome
1MDR-TB: Mycobacterium tuberculosis resistant to rifampin and isoniazid
2All 5 patients diagnosed with Pneumocystis jirovecii pneumonia received trimethoprim sulfamethoxazole chemoprophylaxis (160/800 mg daily).
3Other = HIV-1 associated nephropathy (2), HIV-1 associated encephalopathy (2), Disseminated Kaposi’s sarcoma (2)
45 patients diagnosed with herpes simplex, 4 patients diagnosed with herpes zoster (all < 1 month duration)
5Urinary tract infection (3) - E. coli, Klebsiella sp., enterococcus; Pelvic inflammatory disease (3); H. influenza pneumonia (1); otitis media (1); carbuncle (1)
676 illnesses diagnosed in 59 patients:
CD4 > 350 cells/mm3 = 7 illnesses diagnosed in 7 patients: deep venous thrombosis (2); sacroiliitis (1); acute asthmatic attack (1); cardiomyopathy (1); severe
epistaxis (1); supra-condylar fracture (1),
CD4200 - 350 cells/mm3 = 12 illnesses diagnosed in 7 patients: enteric illness with no pathogen isolated (4); hyperglycaemic emergency (2); seizures, cause not
determined (2); acute asthmatic attack (1); efavirenz side-effect (1); deep venous thrombosis (1); haemorrhoids/fistula-in-ano (1),
CD4 < 200 cells/mm3 = 56 illnesses in 44 patients: peripheral neuropathy (12); enteric illness with no pathogen isolated (8); deep venous thrombosis (7);
dermatitis (4); cerebrovascular accident (3); scabies (3); minor traumatic injury (3); pneumothorax (2); pancreatitis (1); cardiomyopathy (1); miscarriage (1);
cryptococcal IRIS (immune reconstitution inflammatory syndrome) adenitis (1); drug induced hepatitis (1); cause not determined but patient subsequently
improved (9).
714 illnesses diagnosed in 11 patients: Drug side effect (3) - hydrochlorothiazide (1), pyrazinamide (1), kanamycin (1); hyperglycaemic emergency (2); post-TB
bronchiectasis (1); peripheral neuropathy (1); pulmonary silicosis (1); miscarriage (1); cause not determined but patient subsequently improved (5)
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follow-up was 82 days (IQR = 48 -125). The CD4+
counts of 46 HIV-1 infected patients who were lost to
follow-up (median 150 cells/μL, IQR = 67-347) did not
differ significantly (P = 0.362) from the CD4+ counts of
147 HIV-1 infected patients who were not lost to fol-
low-up was (median 144 cells/μL, IQR = 66-272).
Discussion
Khayelitsha Site B TB clinic illustrates the successful
integration of public HIV-TB health-care services in
South Africa. These services include voluntary counsel-
ling and testing of HIV status in >95% of TB patients,
drug susceptibility testing on almost all bacteriologic
specimens, trimethoprim-sulfamethoxazole chemopro-
phylaxis in >85% of HIV-1 infected patients, and aggres-
sive ART initiation in HIV-1 infected patients according
to national guidelines. Despite these measures, clinical
deterioration remains an important clinical entity. Dur-
ing the 24 weeks of follow up, 40% of patients experi-
enced clinical deterioration. In multivariate analyses,
significant risk factors for clinical deterioration were
HIV-1 infection and a low CD4+ count at tuberculosis
diagnosis. Currently, HIV-infected patients present to
health care services when they are already profoundly
immune-suppressed. This results in a high burden of
tuberculosis, which is accompanied by multiple compli-
cations during antituberculosis treatment.
A distinct pattern of clinical deterioration emerged dur-
ing the 24 weeks of follow-up (Figure 3). After 10 weeks of
follow-up, we observed a rise in the proportion of patients
with a CD4+ count of 200-350 cells/μL who experienced
clinical deterioration. Few of these patients had initiated
ART (according to national protocol [15]). Further studies
are needed to determine whether ART initiated soon after
tuberculosis diagnosis in this subgroup could reduce the
incidence of clinical deterioration. A triple wave of illnesses
occurred in profoundly immune-suppressed HIV-1
infected patients (CD4+ count < 200 cells/μL). The first
wave (0-4 weeks) comprised co-morbid illnesses and
AIDS-defining illnesses (data not presented). This high-
lights the profound immune-suppression at tuberculosis
diagnosis and the rapid occurrence of AIDS-defining ill-
nesses soon thereafter. The second wave represented co-
morbid illnesses, tuberculosis-related illnesses and non
AIDS-defining HIV-1 related infections, while the third
wave included tuberculosis-related and co-morbid ill-
nesses. This demonstrates that immune restoration during
antituberculosis treatment and ART is not without compli-
cations [7]. The substantial occurrence of co-morbid ill-
nesses throughout the 24 weeks of follow-up was
Figure 2 a: Hazard ratios (95% CI) of risk factors for clinical deterioration during 24 weeks of antituberculosis (TB) treatment in
292 patients (Cox proportional hazards model) and Figure 2b>: Hazard ratios (95% CI) of risk factors for clinical deterioration during
24 weeks of TB treatment in 206 HIV-1 infected patients* (Cox proportional hazards model). *CD4 count not performed in 3 of 209
HIV-1 infected patients (1) Microbiologic confirmation with drug susceptibilities known at TB diagnosis (2) CD4 strata used: Stratum 1 = CD4+
> 350 cells/ μL, stratum 2 = CD4+ from 200 – 350 cells/ μL, stratum 3 = CD4+ < 200 cells/ μL; (3) TMP-SMX chemoprophylaxis = Trimethoprim
sulfamethoxazole 160/800mg daily (4) Antiretroviral treatment regimens as follows: D4T/3TC/EFV (89), D4T/3TC/NVP (3), AZT/3TC/EFV (13),
AZT/3TC/NVP (2), TDF/3TC EFV (2); D4T= stavudine 30mg twice daily, 3TC = lamivudine 150mg twice daily, EFV = efavirenz 600mg nocte,
AZT = zidovudine 300mg twice daily, NVP = nevirapine 200mg twice daily, TDF = tenofovir 300mg daily TB = tuberculosis, DST = drug
susceptibility testing, ART = antiretroviral treatment, P = p-value (significant if < 0.05), 95% CI = 95% confidence interval
Pepper et al. BMC Infectious Diseases 2010, 10:83
http://www.biomedcentral.com/1471-2334/10/83










unexpected. Hepatic, renal and cardiovascular related mor-
bidity and mortality are well described in HIV-infected
patients [19]. Similarly, co-morbid illnesses causing
death in HIV-1 uninfected tuberculosis patients have
also been reported [20]. However, the magnitude of
co-morbid illnesses in HIV-1 infected patients receiving
antituberculosis treatment has not previously been
reported. The plethora of illnesses and the 15 deaths
(related to AIDS-defining illnesses, poor adherence, and
neurologic TB-IRIS) suggest that the management of
tuberculosis in profoundly immune-suppressed HIV-1
infected patients is complicated.
Figure 3 Lowess plot showing the proportion of patients who experienced clinical deterioration during 24 weeks of antituberculosis
treatment.
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Preventing the transmission of HIV-1 and preserving
pathogen-specific immunity in those already infected
with HIV-1 (by initiating ART at higher CD4+ counts)
will likely reduce the incidence of tuberculosis. The
potential benefits include fewer deaths and less difficulty
in managing complex drug interactions related to rifam-
pin. However, the massive scale-up of ART to treat
patients at higher CD4+ counts would require consider-
able financial and medical resources. In South Africa,
less than 50% of patients who quality for ART under
current South African guidelines receive ART[15]. Due
to the observational nature of our study, we were unable
to compare the incidence of clinical deterioration after
ART initiation in two groups of tuberculosis patients:
those with a CD4+ count of 200-350 cells/μL and those
with a CD4+ count < 200 cells/μL. Only patients in the
latter group were eligible for ART according to South
African guidelines [15].
Fewer deaths than anticipated occurred during the
first 8 weeks [5]; many deaths (8 of 17) occurred from
weeks 10 to 20 of follow-up. It is possible that patients
with severe tuberculosis may have died in the referral
hospital, precluding enrolment in our study. Patients
requiring hospital admission for fatal AIDS-defining ill-
nesses at tuberculosis diagnosis would similarly have not
been enrolled. Ninety-two (32%) of 292 patients were
diagnosed with tuberculosis at hospital, suggesting that
tuberculosis disease at tuberculosis diagnosis was severe.
Bacterial pneumonia is an important cause of hospita-
lisation and death in HIV-1 infected patients with [21],
or without [22] a diagnosis of tuberculosis. In our
clinic-based cohort, only one patient with pneumonia
cultured a bacterial organism (Haemophilus influenzae).
We attribute this finding to the combined antibacterial
properties of rifampin and trimethoprim-sulfamethoxa-
zole (TMP-SMX) [23]. Most HIV-1 infected patients
(86%) in our study received TMP-SMX chemoprophy-
laxis (160/800 mg daily).
We diagnosed symptomatic drug-induced hepatitis in
one patient. Drug-induced hepatitis, defined as a 5-fold
rise in liver enzymes (AST or ALT), is reported in 2-
28% of patients receiving antituberculosis treatment [24]
and 6% of HIV-1 infected patients receiving both antitu-
berculosis and antiretroviral treatment [25]. In our
study, liver function tests were not performed in asymp-
tomatic patients receiving antituberculosis treatment or
efavirenz-based ART, according to routine practice.
Liver function tests were performed when patients
experienced clinical deterioration.
During the course of our study, DST was performed at
tuberculosis diagnosis, at 8 and 20 weeks of follow-up
and at clinical deterioration. This differs from routine
practice in South Africa where only certain patients
(such as those receiving retreatment for tuberculosis
and those who do not respond to antituberculosis treat-
ment) [14] receive DST due to resource constraints. The
ability to perform DST in all patients in our study,
regardless of previous tuberculosis, likely expedited diag-
nosis and appropriate management of MDR-TB, espe-
cially where the differential diagnoses included MDR-TB
and TB-IRIS.
Our study has some limitations. Our definition of clin-
ical deterioration (symptomatic worsening or failure to
stabilise within 24 weeks after initiation of antitubercu-
losis treatment) did not include episodes of clinical dete-
rioration that occurred after 24 weeks of follow-up.
Twenty-four weeks of follow-up is a short period of
observation. It is possible that the causes for deteriora-
tion could differ after 24 weeks of follow-up. The rela-
tively low number of patients diagnosed with MDR-TB
during follow-up (n = 5) may underestimate the inci-
dence of MDR-TB presenting after 24 weeks. It is note-
worthy that 6 patients were diagnosed with MDR-TB
during the 24 weeks of follow-up without fulfilling our
definition of clinical deterioration. We have previously
described the phenomenon of initial clinical improve-
ment with rifampin-resistant M. tuberculosis despite
receiving standard antituberculosis treatment [26]. At
diagnosis of MDR-TB in these 6 patients, we appropri-
ately intensified their antituberculosis treatment and no
subsequent clinical deterioration occurred. We also
excluded isolated radiological worsening from our case
definition of clinical deterioration. Thus, our finding of
clinical deterioration in 40% of patients may be an
underestimate. Also, in 14 episodes the cause of dete-
rioration could not be identified. Our study did not
evaluate the proportion of patients whose HIV-1 status
was known prior to tuberculosis diagnosis. In addition,
we included patients initially assessed at the tuberculosis
clinic, who subsequently presented to the hospital, and
then deteriorated and died during their first hospital
admission. Patients who presented to the hospital with
fatal tuberculosis may not have been included in the
study. A substantial proportion of patients were lost to
follow-up (75 of 292 patients); reasons for this require
further work. Loss to follow-up did not relate to the
degree of immunosuppression of patients: In HIV-1
infected patients, the CD4+ counts of patients who were
lost to follow-up were similar to the CD4+ counts of
patients who were not lost to follow-up. Finally, this
study was conducted at a tuberculosis clinic and a refer-
ral hospital that serve a large population with a high
incidence of HIV-1-associated tuberculosis; thus, our
findings may not be generalisable to other settings.
Conclusions
The two pandemics of HIV-1 and tuberculosis are inex-
tricably intertwined in Africa. Reducing the extraordinary
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burden of tuberculosis and clinical deterioration during
antituberculosis treatment is a priority for resource-lim-
ited settings. Future prospective studies are required to
determine (1) the optimal interval from antituberculosis
treatment to ART initiation in profoundly immune-sup-
pressed HIV-1 infected patients, and (2) whether ART
initiation during antituberculosis treatment at higher
CD4+ counts reduces the burden of clinical
deterioration.
Disclaimer
The contents of this article are the responsibility of the
authors and do not necessarily reflect the views of the
US Agency for International Development or the US
government.
Acknowledgements
We thank the patients and dedicated staff who participated in the study. We
especially thank Ms Monica Magwayi, the study counsellor, for care provided
to patients during the study.
Financial support. The Perinatal HIV Research Unit, the US Agency for
International Development, and the President’s Emergency Plan for AIDS
Relief (to D.J.P. and S.M.); and Wellcome Trust (fellowships to R.J.W. and G.
Meintjes, WT 081667, 084323 and 088316). The data analysis was supported
by a Fogarty International Center South Africa TB/AIDS Training Award
(NIH/FIC 1U2RTW007373-01A1, 1U2RTW007370).
Author details
1Infectious Diseases Unit, GF Jooste Hospital, Cape Town, South Africa.
2Institute of Infectious Diseases and Molecular Medicine, University of Cape
Town, South Africa. 3Department of Medicine, University of Cape Town,
South Africa. 4Division of Medicine, Imperial College of London, London, UK.
5MRC National Institute for Medical Research, Mill Hill, London, NW7 1AA, UK.
6Groote Schuur Hospital, Cape Town, South Africa. 7Division of Clinical
Pharmacology, Department of Medicine, University of Cape Town, South
Africa. 8Khayelitsha Site B Tuberculosis Clinic, City Health, Cape Town, South
Africa. 9Macfarlane Burnet Institute for Medical Research and Public Health,
Australia. 10MedecinsSans Frontieres, Cape Town, South Africa.
Authors’ contributions
DJP, RJW and G. Meintjes were responsible for study conception. DJP, SM,
RJW, G. Maartens, HM, VDA, HC, CM, and G. Meintjes were responsible for
study design. DJP, SM, SS, JP, G. Meintjes were responsible for data
acquisition, DJP, SM, RJW, FB, G. Maartens, HM, VDA, HC, CM, SS, JP, G.
Meintjes were responsible for data interpretation. DJP compiled the first
draft. SM, RJW, FB, G. Maartens, HM, VDA, HC, CM, SS, JP, and G. Meintjes
critically revised the manuscript for important intellectual content. All
authors read and approved the final manuscript.
Competing interests
The authors declare that they have no competing interests.
Received: 13 November 2009 Accepted: 30 March 2010
Published: 30 March 2010
References
1. Small PM, Schecter GF, Goodman PC, Sande MA, Chaisson RE, Hopewell PC:
Treatment of tuberculosis in patients with advanced human
immunodeficiency virus infection. N Engl J Med 1991, 324(5):289-94.
2. Plana M, Martínez C, García F, Maleno MJ, Barceló JJ, García A, Lejeune M,
Vidal C, Cruceta A, Miró JM, Pumarola T, Gallart T, Gatell JM: Immunologic
reconstitution after 1 year of highly active antiretroviral therapy, with or
without protease inhibitors. J Acquir Immune Defic Syndr 2002,
29(5):429-34.
3. May MT, Sterne JA, Costagliola D, Sabin CA, Phillips AN, Justice AC, Dabis F,
Gill J, Lundgren J, Hogg RS, de Wolf F, Fätkenheuer G, Staszewski S,
d’Arminio Monforte A, Egger M, Antiretroviral Therapy (ART) Cohort
Collaboration: HIV treatment response and prognosis in Europe and
North America in the first decade of highly active antiretroviral therapy:
a collaborative analysis. Lancet 2006, 368(9534):451-8.
4. Pepper DJ, Rebe K, Morroni C, Wilkinson RJ, Meintjes G: Clinical
deterioration during antituberculosis treatment at a district hospital in
South Africa: the importance of drug resistance and AIDS defining
illnesses. PLoS One 2009, 4(2):e4520.
5. Zachariah R, Fitzgerald M, Massaquoi M, Acabu A, Chilomo D,
Salaniponi FM, Harries AD: Does antiretroviral treatment reduce case
fatality among HIV-positive patients with tuberculosis in Malawi? Int J
Tuberc Lung Dis 2007, 11(8):848-53.
6. Karim SA, Naidoo K, Grobler A, Padayatchi N, Nair G, Bamber S, Pienaar J,
Friedland G, El-Sadr W, Karim QA: Initiating ART during TB Treatment
Significantly Increases Survival: Results of a Randomized Controlled
Clinical Trial in TB/HIV-co-infected Patients in South Africa. CROI 2009
Abstract #36a Session 8 Oral Abstracts Prevention and Treatment of Serious
OIs and Malignancies [http://www.retroconference.org/2009/Abstracts/34255.
htm].
7. Meintjes G, Lawn SD, Scano F, Maartens G, French MA, Worodria W,
Elliott JH, Murdoch D, Wilkinson RJ, Seyler C, John L, Loeff van der MS,
Reiss P, Lynen L, Janoff EN, Gilks C, Colebunders R, International Network
for the Study of HIV-associated IRIS: Tuberculosis-associated immune
reconstitution inflammatory syndrome: case definitions for use in
resource-limited settings. Lancet Infect Dis 2008, 8(8):516-23.
8. Pepper DJ, Meintjes GA, McIlleron H, Wilkinson RJ: Combined therapy for
tuberculosis and HIV-1: the challenge for drug discovery. Drug Discov
Today 2007, 12:980-9.
9. McIlleron H, Wash P, Burger A, Norman J, Folb PI, Smith P: Determinants of
rifampin, isoniazid, pyrazinamide, and ethambutol pharmacokinetics in a
cohort of tuberculosis patients. Antimicrob Agents Chemother 2006,
50:1170-7.
10. Karim SS, Churchyard GJ, Karim QA, Lawn SD: HIV infection and
tuberculosis in South Africa: an urgent need to escalate the public
health response. Lancet 2009, 374(9693):921-33.
11. Connolly C, Davies GR, Wilkinson D: Impact of the human
immunodeficiency virus epidemic on mortality among adults with
tuberculosis in rural South Africa, 1991-1995. Int J Tuberc Lung Dis 1998,
2(11):919-25.
12. Zwang J, Garenne M, Kahn K, Collinson M, Tollman SM: Trends in mortality
from pulmonary tuberculosis and HIV/AIDS co-infection in rural South
Africa (Agincourt). Trans R Soc Trop Med Hyg 2007, 101(9):893-8.
13. Results of the 2006 HIV-1 Antenatal Provincial and Area Surveys. Cape
Town: Western Cape Provincial Department of Health 2007.
14. South African National Tuberculosis Control Programme Practical
guidelines. [http://www.doh.gov.za/aids/docs/tuberculosis.html], [Accessed
7 September 2009]..
15. South African Department of Health HIV-1 and AIDS and STI strategic
plan for South Africa 2007-2011. [http://www.info.gov.za/otherdocs/2007/
aidsplan2007/index.html], [Accessed 7 September 2009]..
16. World Health Organization: Improving the diagnosis and treatment of
smear-negative pulmonary and extrapulmonary tuberculosis among
adults and adolescents recommendations for HIV-1-prevalent and
resource-constrained settings. [http://www.who.int/tb/publications/2006/
tbhiv_recommendations.pdf], [Accessed 7 September 2009]..
17. Hain Lifescience: GenoType MTBDRplus, version 1.0. [http://www.hain-
lifescience.de/en/products/microbiology/mycobacteria/genotype-mtbdrplus.
html], [Accessed 24 September 2009]..
18. WHO: HIV Clinical Staging. [http://www.who.int/hiv/pub/guidelines/
clinicalstaging.pdf], [Accessed 24 September 2009]..
19. El Sadr , et al: CD4+ Count-Guided Interruption of Antiretroviral
Treatment: The Strategies for Management of Antiretroviral Therapy
(SMART) Study Group. N Engl J Med 2006, 355:2283-96.
20. Sterling TR, Zhao Z, Khan A, Chaisson RE, Schluger N, Mangura B, Weiner M,
Vernon A: Mortality in a large tuberculosis treatment trial: modifiable
and non-modifiable risk factors. Int J Tuberc Lung Dis 2006, 10(5):542-549.
21. Corbett EL, Churchyard GJ, Charalambos S, Sam B, Maloi B, Clayton T,
Grant AD, Murray J, Hayes RJ, De Cock KM: Morbidity and Mortality in
Pepper et al. BMC Infectious Diseases 2010, 10:83
http://www.biomedcentral.com/1471-2334/10/83










South African Gold Miners: Impact of Untreated Disease Due to Human
Immunodeficency Virus. Clinical Infectious Diseases 2002, 34:1251-8.
22. Martinson NA, Karstaedt A, Venter F, Omar T, King P, Mbengo T, Marais E,
McIntyre J, Chaisson RE, Hale M: Causes of death in hospitalized adults
with a premortem diagnosis of tuberculosis: an autopsy study. AIDS
2007, 21:2043-2050.
23. Dirienzo AG, Horst Van der C, Finkelstein DM, FRAME P, Bozzette SA,
Tashima KT: Efficacy of Trimethoprim-Sulfamethoxazole for the
Prevention of Bacterial Infections in a Randomized Prophylaxis Trial of
Patients with Advanced HIV Infection. AIDS Research and Human
retroviruses 2002, 18(2):89-94.
24. Tostmann A, Boeree MJ, Aarnoutse RE, de Lange WCM, Ven van der AJAM,
Dekhuijzen R: Antituberculosis drug-induced hepatotoxicity: Concise up-
to-date review. Journal of Gastroenterology and Hepatology 2008,
23:192-202.
25. Dean GL, Edwards SG, Ives NJ, Matthews G, Fox EF, Navaratne L, Fisher M,
Taylor GP, Miller R, Taylor CB, de Ruiter A, Pozniak AL: Treatment of
tuberculosis in HIV-infected persons in the era of highly active
antiretroviral therapy. AIDS 2002, 16:75-83.
26. Meintjes G, Rangaka MX, Maartens G, Rebe K, Morroni C, Pepper DJ,
Wilkinson KA, Wilkinson RJ: Novel relationship between tuberculosis
immune reconstitution inflammatory syndrome and antituberculosis
drug resistance. Clin Infect Dis 2009, 48(5):667-76.
Pre-publication history
The pre-publication history for this paper can be accessed here:
http://www.biomedcentral.com/1471-2334/10/83/prepub
doi:10.1186/1471-2334-10-83
Cite this article as: Pepper et al.: Clinical deterioration during
antituberculosis treatment in Africa: Incidence, causes and risk factors.
BMC Infectious Diseases 2010 10:83.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Pepper et al. BMC Infectious Diseases 2010, 10:83
http://www.biomedcentral.com/1471-2334/10/83
































































{AU: Please provide the next two author names, 



















INT J TUBERC LUNG DIS 14(2):188–196
© 2010 The Union
Neuroradiological features of the tuberculosis-associated 
immune reconstitution infl ammatory syndrome 
S. Marais,*† P. Scholtz,‡ D. J. Pepper,*†§ G. Meintjes,*†§ R. J. Wilkinson,*†§¶# S. Candy‡
* Department of Medicine, GF Jooste Hospital, Manenberg, † Clinical Infectious Diseases Research Initiative, Institute of 
Infectious Diseases and Molecular Medicine, ‡ Department of Radiology and § Department of Medicine, University of 
Cape Town, Cape Town, South Africa; ¶ Division of Medicine, Wright Fleming Institute, Imperial College, London, 
# National Institute for Medical Research, London, UK
Correspondence to: Suzaan Marais, GF Jooste Hospital, Infectious Diseases, 20 Westbrook Court, Haldane Road, 
Rondebosch, Cape Town 7700, South Africa. Tel: (+27) 079 501 3242. Fax: (+27) 021 692 0289. e-mail: suzaanmarais@
gmail.com
Article submitted 19 June 2009. Final version accepted 13 September 2009.
S E T T I N G :  Paradoxical tuberculosis-associated immune 
reconstitution infl ammatory syndrome (TB-IRIS) is an 
important complication in human immunodefi ciency 
virus type I (HIV-1) infected tuberculosis (TB) patients 
who start combination antiretroviral treatment (ART). 
Neurological manifestations occur in more than 10% of 
TB-IRIS cases. Apart from a few case reports, the radio-
logical features of neurological TB-IRIS have not been 
described.
O B J E C T I V E :  To describe the neuroradiological fi ndings 
of patients with paradoxical neurological TB-IRIS. 
D E S I G N :  Computed tomography (CT; n = 13) and 
magnetic resonance imaging (n = 3) fi ndings of 16 pa-
tients were reviewed. 
R E S U LT S :  IRIS manifestations included meningitis (n = 
4), intracranial space occupying lesions (SOLs, presumed 
tuberculomas; n = 5), meningitis and SOLs (n = 5), 
r adiculomyelitis (n = 1) and spondylitis (n = 1). In pa-
tients with tuberculoma IRIS, we observed a high preva-
lence of 1) low density lesions on non-contrast-enhanced 
CT (all lesions), 2) multiple lesions (in 5/10 patients) 
and 3) perilesional oedema (17/22 lesions). In patients 
with meningitis, meningeal enhancement (n = 2) and 
hydrocephalus (n = 1) were infrequently observed.
C O N C L U S I O N :  This is the fi rst substantial series to de-
scribe the radiological features of paradoxical neurologi-
cal TB-IRIS. Compared to published radiological fi ndings 
of tuberculomas in HIV-1-infected patients (not receiv-
ing ART), an increased infl ammatory response is sug-
gested in tuberculoma IRIS. However, this was not ob-
served in patients with TB meningitis IRIS.
K E Y  W O R D S :  immune reconstitution infl ammatory 
syndrome (IRIS); neuroradiology; HIV; tuberculoma
DISEASE due to Mycobacterium tuberculosis is the 
main cause of morbidity and death in human im-
muno defi ciency virus type 1 (HIV-1) infected persons 
worldwide. The disease is disproportionately preva-
lent in resource-limited countries.1 The increased avail-
ability of combination antiretroviral treatment (ART) 
in these countries has played a signifi cant role in re-
ducing morbidity and mortality associated with HIV-1/ 
M. tuberculosis co-infection.2 Despite the benefi t of 
ART in improving clinical outcome, patients may de-
teriorate clinically and/or radiologically after com-
mencing ART due to the immune reconstitution in-
fl ammatory syndrome (IRIS).3,4 IRIS is associated with 
a wide spectrum of infectious and non-infectious dis-
eases, and mycobacteria are frequently implicated.3 
Tuberculosis–associated IRIS (TB-IRIS) may present 
in one of two recognised ways: fi rst as paradoxical 
worsening of symptoms after commencement of ART, 
and second, as an ‘unmasking’ syndrome.4 Unmasking 
TB-IRIS occurs when HIV-1-infected patients who 
have unrecognised tuberculosis (TB) start ART and 
subsequently develop clinical manifestations of TB 
that may have a prominent infl ammatory component. 
Lymph node enlargement and pulmonary involve-
ment are common manifestations of TB-IRIS; clinical 
and radiological features are well described.3–6 Neu-
rological TB-IRIS, although accounting for over 10% 
of paradoxical TB-IRIS cases in a hospital setting,7 is 
less well documented; only one clinical case series7 
and a handful of radiological case reports exist.5,6,8–14 
Here we describe the radiological features of para-
doxical neurological TB-IRIS. 
STUDY POPULATION AND METHODS
We have previously reported our patient cohort in a 
prospective clinical case series of paradoxical neuro-
logical TB-IRIS.7 We identifi ed 23 cases of neurologi-
cal TB-IRIS from a cohort of 279 adult paradoxical 
TB-IRIS suspects at GF Jooste Hospital, a district 
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public hospital in Cape Town, South Africa. Of these 
23 patients, 16 patients’ neuroradiological fi ndings 
are reported in this paper. Data published included 
demographic characteristics, TB investigations, clini-
cal examination and laboratory fi ndings as well as 
management and outcome.7 Microbiologically con-
fi rmed tuberculosis was diagnosed when acid-fast ba-
cilli (AFB) were visualised or M. tuberculosis was 
cultured from a clinical specimen. Microbiologically 
non-confi rmed tuberculosis was diagnosed according 
to World Health Organization (WHO) guidelines for 
HIV-1-infected patients with smear-negative or extra-
pulmonary TB.15 TB meningitis (TBM) was diagnosed 
when clinical and laboratory fi ndings were consistent 
with the diagnosis. Paradoxical neurological TB-IRIS 
was defi ned according to a modifi ed published consen-
sus clinical case defi nition (Table 1).4,7 All cases were 
regarded as probable, because a confi rmatory labo-
ratory test for TB-IRIS is not available. In all pa-
tients, ART consisted of two nucleoside- and one non-
nucleoside reverse transcriptase inhibitor.
Computed tomography (CT) of the head was per-
formed at GF Jooste Hospital or at Groote Schuur 
Hospital (GSH), a tertiary referral hospital in Cape 
Town. Scanners utilised at these facilities were Philips 
Brilliance Air 6 Multi slice scanner (Philips, Amster-
dam, The Netherlands) and Siemens Somatom Bal-
ance Single slice spiral scanner (Siemens, Berlin, Ger-
many), respectively. In each case, 5-mm contiguous 
axial scans were obtained from skull base to vertex 
before and/or after intravenous administration of 
50 ml iodinated contrast medium, Ultravist-300® 
(Bayer Schering Pharma, Berlin, Germany). Magnetic 
resonance imaging (MRI) was performed on a Siemens 
Magnetom Symphony 1.5 Tesla scanner using stan-
dard multiplanar T1 and T2 spin-echo sequences with-
out and with gadolinium administration (Magnevist®, 
Bayer Schering). CT and MRI images were retrospec-
tively evaluated by an experienced neuroradiologist 
and a neuroradiologist in training. Both were blinded 
to clinical information. 
CT brain scans were evaluated for the presence 
or absence of 1) brain atrophy, 2) hydrocephalus, 
3) meningeal enhancement, 4) infarction/white matter 
oedema and 5) parenchymal space occupying lesions 
(SOLs). When SOLs were visualised, their location, 
size, number and enhancement pattern were recorded. 
Where available, follow-up imaging studies were re-
viewed and compared with scans at presentation. 
Although neuro-imaging was obtained in 21 of the 
23 patients at the time of neurological TB-IRIS, only 
16 patients’ scans were available later for blinded re-
view. These 16 patients comprise the study population. 
The Research Ethics Committee of the University 
of Cape Town approved the study (REC494/2008).
RESULTS
The neurological presentations of paradoxical TB-
IRIS included meningitis (n = 4), intracranial SOLs: 
presumed tuberculomas (n = 5), both meningitis and 
SOLs (n = 5) and spinal TB (n = 2). The clinical pre-
sentation and laboratory data are summarised in 
Table 2. Of the 16 patients, 10 were female. Age 
ranged from 23 to 44 years (median 30). The median 
CD4+ T-lymphocyte count before starting ART was 
70 cells/μl (interquartile range [IQR] 19–135), and 
the median rise in CD4+ T-lymphocyte count within 
the fi rst year of starting ART was 284 cells/μl (IQR 
103–368). The onset of neurological TB-IRIS symp-
toms occurred 15 days (median IQR 5–31) after ART 
initiation. The median duration from initiation of 
anti-tuberculosis treatment to ART was 56 days (IQR 
35–105). 
Good adherence to both anti-tuberculosis treat-
ment and ART was documented in all but one patient. 
This patient initially defaulted from anti-tuberculosis 
treatment, but was subsequently adherent to in-patient 
treatment for 3 months before starting ART. Micro-
biological confi rmation of TB was obtained in 12 of 
the 16 patients. In three patients, lumbar puncture 
was contraindicated because of intracerebral or intra-
spinal mass effect. Alternative diagnoses were ex-
cluded, as previously published.7 In all patients who 
presented with meningitis (n = 9), cryptococcal and 
bacterial meningitis were excluded. In patients with 
meningitis and/or SOLs (n = 14), syphilis serological 
tests were negative in 11, positive in one, and not 
performed in two patients. Case 9, with a positive 
syphilis serological test, and Case 8, in whom the 
Table 1 Case defi nition for paradoxical neurological TB-IRIS
The case defi nition includes three components:
Antecedent requirements 
Both of the two following requirements must be met:
• Diagnosis of TB: the TB diagnosis was made before starting 
combination ART and this should fulfi l World Health 
Organization criteria for diagnosis of smear-positive PTB, 
smear-negative PTB or extra-pulmonary TB. 
• Initial response to TB treatment: the patient’s condition should 
have stabilised or improved on appropriate anti-tuberculosis 
treatment prior to ART initiation, e.g., cessation of night 
sweats, fevers, cough, weight loss. (Note: this does not apply 
to patients starting ART within 2 weeks of starting anti-
tuberculosis treatment, as insuffi cient time may have elapsed 
for a clinical response to be observed).
Clinical criteria
The onset of neurological TB-IRIS manifestations should be 
within 3 months of ART initiation, re-initiation, or regimen 
change due to treatment failure. These include: 
• New or worsening TB meningitis 
• New or worsening intracerebral space occupying lesion, likely 
tuberculoma
• New or worsening spinal TB 
Alternative explanations for clinical deterioration must be excluded, 
if possible:
• Failure of anti-tuberculosis treatment due to TB drug resistance
• Poor adherence to anti-tuberculosis treatment
• Another opportunistic infection or neoplasm 
• Drug toxicity or reaction
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test was not performed, had microbiological evidence 
of extra-central nervous system (CNS) TB at the time 
of neurological deterioration. Both patients in whom 
syphilis serological tests were not performed (Cases 3 
and 8) improved without concomitant treatment for 
neurosyphilis. 
Immunoglobulin G serological assays for Toxo-
plasma species was performed in 9 of 10 patients with 
SOLs. Although the test was positive in six patients, 
all six were receiving toxoplasmosis chemoprophy-
laxis prior to neurological deterioration. In addition, 
all six patients had radiological features of TB outside 
of the nervous system. The one patient who did not 
have Toxoplasma species serology performed (Case 3) 
was alive 6 months after initial assessment without 
receiving treatment with therapeutic trimethoprim-
sulfamethoxazole (320 mg/1600 mg twice daily) for 
possible toxoplasmosis. The median duration from 
neurological symptom onset to imaging was 18 days 
(IQR 9–43). Before imaging, nine patients received 
corticosteroid treatment for a median duration of 
5 days (IQR 4–15). 
Brain imaging fi ndings
CT scans of the head were performed in 13 patients 
and MRI was performed in one patient (see Tables 3 







Site of TB 









to CD4 count 
(days)
Neurological symptoms 
and signs at TB-IRIS event
1 Female 37 No Disseminated No microbiological 
confi rmation
 17  —  — Headache, left arm and leg 
seizures, confusion
2 Female 43 No Meningitis, 
SOL
AFB visualised (CSF)   3  —  — Headache, neck stiffness, 
confusion 
3 Female 30 No Meningitis No microbiological 
confi rmation
 95  423 187 Headache, neck stiffness, 
generalised tonic clonic 
seizures
4 Female 28 Yes Disseminated M. tuberculosis cultured 
(sputum)
 33  —  — Seizures, confusion
5 Female 36 No Disseminated AFB visualised (sputum)  50  —  — Headache, neck stiffness, 
vomiting, agitation 
6 Male 44 No Disseminated M. tuberculosis cultured 
(node)
134  502 224 Headache, focal seizures 
of right arm
7 Male 35 Yes Pleural M. tuberculosis cultured 
(sputum)
139  423 151 Seizures, left hemiparesis 
8 Female 24 No Disseminated M. tuberculosis cultured 
(node)
 12    6  23 Generalised tonic clonic 
seizures, post-ictal 
confusion
9 Male 43 No Nodal AFB visualised (node + 
sputum)
 89  260 178 Headache, cognitive 
impairment, left arm 
weakness
10 Female 23 Yes Disseminated M. tuberculosis cultured 
(CSF)
254 1043 214 Headache, generalised 
tonic clonic seizures




 19  104 157 Headache, confusion, neck 
stiffness, photophobia, 
vomiting
12 Male 27 Yes Disseminated AFB visualised (sputum)  48  —  — Headache, neck stiffness 
13 Male 37 Yes Disseminated AFB visualised (sputum)   8  111 221 Neck stiffness, confusion, 
generalised tonic clonic 
seizures
14 Male 30 No Meningitis No microbiological 
confi rmation
158  —  — Headache, vomiting, neck 
stiffness
15 Female 31 No Disseminated M. tuberculosis cultured 
(sputum)
 99  703 173 Right leg weakness, lower 
back pain radiating to 
the right hip 
16 Female 26 Yes Disseminated M. tuberculosis cultured 
(sputum)
137  —  — Headache, lower limb 
weakness, incontinence 
of urine + faeces
% Male: 38 Yes: 44
Median 30  70  423 178
IQR 28–37 19–135 111–502 157–214
* All patients received d4T/3TC/EFV ART except patient 13, who received AZT/3TC/EFV, and patient 2, who received d4T/3TC/NVP.
† © 2009 by the Infectious Diseases Society of America.7
TB = tuberculosis; HIV-1 = human immunodefi ciency virus type 1; TB-IRIS = TB immune reconstitution infl ammatory syndrome; ART = combination antiretro-
viral treatment; SOL = space occupying lesion; AFB = acid-fast bacilli; CSF = cerebrospinal fl uid; IQR = interquartile range; AZT = zidovudine 300 mg twice 
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and 4). In the majority (10/14) of the patients, signifi -
cant age-inappropriate generalised atrophy was noted. 
Ten patients had a total of 22 SOLs, fi ve solitary and 
fi ve multiple (see Figures 1 and 2 for illustrative cases). 
All lesions were supratentorial; 17 had perilesional 
oedema but only two had signifi cant mass effect. 
Three lesions were <6 mm, 8 between 6 and 10 mm, 
10 between 11 and 20 mm and only one lesion was 
>20 mm. The median size was 11 mm (IQR 10–15). 
Pre-contrast, all lesions had lower attenuation than 
surrounding brain. Contrast enhancement was pres-
ent in 20 lesions. Obstructive hydrocephalus was ob-
served in one patient who had visible basal meningeal 
enhancement as well as a subacute middle cerebral 
perforator infarct. Communicating hydrocephalus 
was observed in one (Patient 9). Small areas of focal 
leptomeningeal enhancement were present in an ad-
ditional two patients. Another patient had an infarct 
in the white matter of the centrum semiovale. 
Spinal imaging fi ndings
MRI of the spine was performed in two patients pre-
senting with myeloradiculopathic symptoms. In one 
(Patient 15), the features were consistent with tuber-
culous spondylitis, with an epidural collection caus-
ing thecal sac compression at L4. In the other (Patient 
16), we observed features of adhesive arachnoiditis 
with extensive leptomeningeal enhancement through-
out the spinal canal. This was associated with dif-
fuse cord oedema, presumably the result of meningo-
vascular compromise. In addition, basal meningeal 
enhancement of the brain was observed in this case 
(see Figure 3). 
DISCUSSION
We report the radiological fi ndings of 16 patients 
whose clinical presentation met diagnostic criteria 
for paradoxical neurological TB-IRIS. These fall into 
fi ve groups based on a combination of clinical, cerebro-
spinal fl uid (CSF) and radiological fi ndings: 1) SOLs 
without meningitis (n = 5), 2) meningitis without 
SOLs (n = 4), 3) meningitis and SOLs (n = 5), 4) ra-
diculomyelitis (n = 1) and 5) spondylitis (n = 1).
Parenchymal space occupying lesions 
The development of new or expanding intracranial 
tuberculomas as a manifestation of neurological TB-
IRIS has been described previously.5–9,14 Although pa-
renchymal tuberculomas are commonly reported in 
HIV-1-infected patients,16 some studies suggest that 
multiple tuberculomas occur less frequently than in 
non-HIV-1-infected patients. Brain imaging fi ndings 









11 29/female — NECT + CECT No No No Yes
12 27/male 6 CECT Yes, basal Yes Yes, MCA Yes
13 37/male — CECT No No No Yes
14 29/male 2 CECT No No No Yes
* Duration of corticosteroid treatment at time of imaging.
CT = computed tomography; NECT = non-contrast enhanced CT; CECT = contrast enhanced CT; MCA = middle cerebral artery.
Figure 1 Illustrative case of paradoxical tuberculoma IRIS (Pa-
tient 9). A 43-year-old HIV-1-infected male was diagnosed with 
AFB smear-positive lymph node TB. His CD4+ T-lymphocyte 
count was 89 cells/μl, and he was receiving trimethoprim-
s ulfamethoxazole (160/800 mg daily) as primary prophylaxis. 
He showed clinical improvement on anti-tuberculosis treatment 
and was started on combination ART (stavudine, lamivudine, 
efavirenz) 50 days after anti-tuberculosis treatment was initi-
ated. Fourteen days after starting ART, he developed headache, 
cognitive impairment and left upper limb weakness. One month 
later, he also developed an enlarged, fl uctuant left supraclavic-
ular lymph node. Fine-needle aspiration of lymph node revealed 
AFB, but TB culture was negative. Axial images of contrast en-
hanced computed tomography of the brain performed 56 days 
after neurological symptom onset showed generalised cerebral 
atrophy and communicating hydrocephalus. A 12 mm mixed 
hypodense and hyperdense lesion with surrounding oedema was 
present in the right thalamus. Lumbar puncture was deferred 
because of intracerebral mass effect. He was continued on ART, 
anti-tuberculosis treatment and prophylactic trimethoprim-
sulfamethoxazole. Prednisone, which he received for a total du-
ration of 69 days, was started at a dose of 1.5 mg/kg. His weak-
ness resolved, and he was alive after 180 days of starting ART. 
Six months after ART was commenced his CD4+ T-lymphocyte 
count was 260 cells/μl and his HIV viral load was undetectable. 
IRIS = immune reconstitution infl ammatory syndrome; HIV = 
human immunodefi ciency virus; AFB = acid-fast bacilli; TB = 
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Figure 2 Illustrative case of paradoxical tuberculoma IRIS (Patient 6). A 44-year-old HIV-1-infected male was diagnosed with pul-
monary and culture-positive lymph node TB. His CD4+ T-lymphocyte count was 134 cells/μl, and he was receiving trimethoprim-
sulfamethoxazole (160/800 mg daily) as primary prophylaxis. He improved on anti-tuberculosis treatment and was started on combi-
nation ART (stavudine, lamivudine, efavirenz) 27 days after commencing TB treatment. Two days after starting ART, he developed 
painful bilateral cervical lymphadenopathy. Lymph node aspirate cultured M. tuberculosis susceptible to rifampicin and isoniazid. 
Nineteen days after ART initiation the patient developed headache and focal seizures of his right arm. Neurological examination re-
vealed an expressive aphasia which had been present since a left carotid injury resulting in a left MCA infarct several years before. 
Lumbar puncture performed was normal, and Toxoplasma gondii serum serology negative. Axial CECT (A) brain images performed 
18 days after neurological symptom onset showed generalised cerebral atrophy, an old left MCA infarct, and multiple bilateral con-
trast enhancing lesions with surrounding oedema. The patient was diagnosed with neurological TB-IRIS and commenced on pred-
nisone 1.5 mg/kg/day. Initially ART was continued. Serial brain imaging was performed over the next 11 months. Follow-up CECT 
performed 3 months later (B) showed progression in size, loculation and surrounding oedema of lesions. The patient was subse-
quently treated with therapeutic trimethoprim-sulfamethoxazole (320/1600 mg twice daily) for possible T. gondii encephalitis, with 
no radiological response 2 and 4 weeks later. ART was stopped at this time point but restarted 3 months later. Three repeat scans 
performed over the next 6 months showed radiological reduction in lesion size and surrounding oedema. (C shows the last CECT 
performed, 11 months after the fi rst). The patient received prednisone for a total duration of 347 days. He was alive 180 days after 
starting ART, but subsequently died after defaulting from anti-tuberculosis treatment. His CD4+ T-lymphocyte count 7 months after 
starting ART was 502 cells/μl. IRIS = immune reconstitution infl ammatory syndrome; HIV = human immunodefi ciency virus; TB = 
tuberculosis; ART = antiretroviral treatment; MCA = middle cerebral artery; CECT = contrast-enhanced computed tomography.
for 100 patients with intracranial tuberculoma from a 
low HIV-1 prevalence population17 showed multiple 
lesions in 69% of patients. A cohort of predominantly 
HIV-1-infected patients not on ART showed multiple 
lesions in only 33% of cases.18 In our study, multiple 
lesions were present in 50% of patients. Of interest is 
our fi nding that all SOLs were of low density on non-
contrast-enhanced CT (NECT). A study in a low HIV 
prevalence population17 reported low density on 
NECT in only 3% of tuberculous lesions. In our co-
hort, 17/22 (77%) lesions had a variable degree of 
oedema, with signifi cant mass effect in two. In an 
ART-naïve HIV-1-infected TBM cohort, Thonell et 
al. found perilesional oedema in less than 50% of tu-
berculomas.18 The high prevalence of multiple lesions 
and surrounding oedema may refl ect increased CNS 
infl ammation in the context of neurological TB-IRIS. 
Radiological features consistent with increased in-
fl ammation have been observed in neurological IRIS 
associated with other pathogens, including Polyoma-
virus JC and Cryptococcus neoformans.19 TB abscess 
formation has been reported as a rare complication 
of CNS TB.20 TB abscesses are usually solitary, multi-
loculated, thin-walled enhancing lesions, often >3 cm 
in diameter.20 Although previously described as a 
neurological TB-IRIS manifestation,9,11 none of the 
parenchymal lesions documented in our patients met 
the radiological criteria for intracerebral TB abscess.
The imaging appearance of intracranial tuberculo-
mas is non-specifi c, toxoplasmosis being the most 
frequent differential diagnosis in HIV-1-infected per-
sons not on ART. In a brain biopsy study from South 
Africa conducted in HIV-1-infected patients,21 a soli-
tary parenchymal lesion was due to toxoplasmosis in 
39% of cases. Other confi rmed diagnoses in this study 
included brain abscess (16%), tuberculoma (11%), 
CNS cryptococcal infection (5%) and infarct (3%). 
For a quarter of patients, a specifi c histological diag-
nosis could not be obtained. No cases of primary CNS 
lymphoma, an additional differential diagnosis, were 
reported in this study. Dual infection of the CNS with 
M. tuberculosis and Toxoplasma gondii has also been 
reported.22,23 In the context of ART and trimethoprim-
sulfamethoxazole prophylaxis, the diagnosis of ‘un-
masking’ toxoplasmosis becomes less likely, but should 
still be considered.24 In the absence of invasive brain 
biopsy, the diagnosis of solitary or multiple parenchy-
mal lesions remains presumptive based on a combi-
nation of imaging fi ndings together with CSF fi nd-
ings, ancillary tests (toxoplasmosis serology, CD4+ 
T-lymphocyte count, evidence for TB or TB-IRIS else-
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Meningitis
TBM is the most frequent form of intracranial TB in 
HIV-1-infected25 and non-infected26 patients. Com-
mon neuroradiological fi ndings in TBM include basal 
meningeal enhancement, hydrocephalus and infarc-
tion.20,26 In HIV-1-infected patients with TBM, these 
fi ndings occur with the following frequencies: menin-
geal enhancement 23–33%,22,23,27 hydrocephalus 20–
42%,23,27,28 obstructive hydrocephalus 5.5% and in-
farcts 39%.22 
In TBM, the presence of meningeal enhancement 
(33% vs. 82%) and obstructive hydrocephalus (5.5% 
vs. 64%) have previously been reported to be less 
frequent in profoundly immune-suppressed HIV-1-
i nfected patients than in non-HIV-1-infected patients.22 
This was ascribed to the attenuated immune response 
confi rmed on histology. However, these fi ndings are 
by no means consistent.23,27 
MRI features of TBM-IRIS have previously been 
described in only three patients: meningeal enhance-
ment developed on imaging subsequent to com-
mencement of ART in one patient,12 intra- and extra-
axial lesions with peripheral contrast enhancement 
involving basal cisterns developed in another,13 and 
in the third, no meningeal enhancement was observed 
at the time of presentation.10
In our patient cohort, basal meningeal enhance-
ment, which refl ects infl ammation, and the consequent 
hydrocephalus, were not seen with greater frequency 
in TBM-IRIS patients (1 of 9 patients) compared 
to HIV-1-infected patients with TBM not receiving 
ART.22,23,27,28 One explanation for this could be that 
more than half of this subgroup was receiving corti-
costeroids at the time of initial scanning. However, 
the use of corticosteroids has not been found to infl u-
ence the degree of meningeal enhancement or reduce 
the development of hydrocephalus in non-HIV-1-
i nfected adults with TBM.29 
Radiculomyelitis
TB radiculomyelitis is a relatively rare manifestation 
of CNS TB which may develop during the treatment 
of TBM.30 The most consistent MRI fi nding is spinal 
cord hyperintensity on T2-weighted imaging.31 Locu-
lation and obliteration of the subarachnoid space with 
post gadolinium intradural, leptomeningeal or cauda 
equina enhancement are also frequently noted.30 Con-
current intracranial tuberculoma and TBM are com-
mon.31 Mycobacterial IRIS with spinal cord involve-
ment has been described in two cases: one patient 
developed an expansive extra-axial thoracic lesion 
concurrent with a TBM-IRIS episode,13 while another 
patient with spinal mycobacterial IRIS (without con-
fi rmation of M. tuberculosis) presented with an en-
hancing intradural extramedullary spinal lesion.32 
Patient 16, with radiculomyelitis as a manifesta-
tion of TB-IRIS, initially presented with TBM before 
starting ART. At IRIS presentation, she developed 
rapid onset paraplegia; her MRI revealed leptomen-
ingeal enhancement around the basal cisterns of the 
brain as well as marked enhancement of the spinal 
subarachnoid space. 
Spondylitis
Classically, TB spondylitis affects two contiguous ver-
tebral bodies (usually thoracolumbar),33,34 often with 
destruction of the intervertebral disc, and is associ-
ated with paravertebral abscess formation.33 Involve-
ment of a single vertebral body or posterior elements 
of the spine (especially when it is present without an-
terior element disease) occurs less frequently.34 Pa-
tient 15 (previously reported by Dhasmana et al.35) 
demonstrated osteitis of a single lumbar vertebra, no-
tably with involvement of the vertebral body, pedicles 
and posterior elements. Although there was no signif-
icant paraspinal abscess, there was an epidural col-
lection with resultant spinal stenosis.
Figure 3 Illustrative case of paradoxical TB radiculomyelitis IRIS 
(Patient 16). A 26-year-old HIV-1-infected female was diagnosed 
with culture-positive pulmonary TB (susceptible to rifampicin 
and isoniazid) and TB meningitis. Her CD4+ T-lymphocyte 
count was 137 cells/μl. She showed clinical improvement on 
anti-tuberculosis treatment, and combination ART (stavudine, 
lamivudine, efavirenz) was commenced 43 days after starting 
anti-tuberculosis treatment. The patients developed headache, 
paraparesis, T10 spinal sensory level and urinary and faecal in-
continence 7 days after starting ART. Lumbar puncture per-
formed showed protein 72 g/l, glucose 2.3 mmol/l, lymphocytes 
86/μl. TB, fungal and bacterial cultures were negative. T1, T2 
and T1 gadolinium enhanced sagittal magnetic resonance im-
ages performed (A, B, C) 20 days after symptom onset showed 
abnormal spinal cord signal from craniocervical junction to 
conus medullaris with cord expansion between C2–C6 verte-
bral bodies. Cerebrospinal fl uid revealed signal abnormalities 
on both T1 and T2 weighted images. The cauda equina ap-
peared thickened. Post gadolinium enhancement of arachnoid 
mater and epidural soft tissue surrounding the spinal cord as 
well as basal leptomeninges of the brain were present. Lung 
nodules were also evident. Diagnosis of paradoxical TB radicu-
lomyelitis IRIS was made, with anti-tuberculosis treatment and 
ART being continued. She also received 58 days of prednisone 
started at an initial dose of 1.5 mg/kg/day 5 days prior to scan. 
There was no documented clinical improvement, presumably 
due to irreversible cord damage, but the patient was alive 
3 months after starting ART and was then lost to follow-up. 
TB = tuberculosis; IRIS = immune reconstitution infl ammatory 
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Sequential radiological assessment of the develop-
ment and resolution of lesions was not possible, as 
most patients did not have imaging performed either 
before or after initial assessment for neurological 
deterioration. In our setting, neuroradiological imag-
ing, particularly MRI, is still relatively inaccessible 
compared to resource-rich settings. We did not use 
MRI in most of the patients with intracranial TB-IRIS. 
MRI may have detected more subtle cerebral lesions. 
CONCLUSIONS
Although the largest series to date, our relatively small 
cohort of cases with various forms of neurological 
TB-IRIS and the absence of an appropriate control 
group precludes identifi cation of a novel radiological 
marker of TB-IRIS. Our observations need to be con-
fi rmed in future prospective comparative studies. 
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R É S U M É
C O N T E X T E  :   Le syndrome infl ammatoire paradoxal de re-
constitution immunitaire chez les tuberculeux (TB-IRIS) 
constitue une complication importante chez les patients 
tuberculeux infectés par le virus de l’immunodéfi cience 
humaine (VIH) et placés sous traitement antirétroviral 
combiné (ART). Des manifestations neurologiques sur-
viennent dans plus de 10% des cas TB-IRIS. A l’exception 
de quelques cas signalés, les caractéristiques radiologiques 
de la TB-IRIS neurologique n’ont pas été décrites.
O B J E C T I F  :   Passer en revue les observations de 16 pa-
tients, dont 13 examinés par tomodensitométrie (CT) et 
trois par résonance magnétique. 
R É S U LTAT S  :   Les manifestations de l’IRIS ont comporté 
4 méningites, 5 lésions situées dans l’espace intracrânien 
(SOL), probablement des tuberculomes, 5 cas de ménin-
gite avec SOL, une radiculomyélite et une spondylite. 
Chez les patients IRIS avec tuberculomes, nous avons 
observé une prévalence élevée : 1) de lésions de faible 
densité dans les CT sans renforcement par produit de 
contraste (toutes les lésions) ; 2) des lésions multiples 
(chez 5 des 10 patients) et 3) de l’œdème périlésionnel 
dans 17 des 22 lésions. Chez les patients atteints de mé-
ningite, on n’a observé que peu fréquemment un épaissis-
sement méningé (n = 2) ou une hydrocéphalie (n = 1).
C O N C L U S I O N  :   Cette série est la première qui décrit de 
manière substantielle les caractéristiques radiologiques 
du TB-IRIS paradoxal avec atteinte méningée. Par com-
paraison avec les observations radiologiques publiées de 
tuberculome chez les patients infectés par le VIH mais 
non traités par ART, les tuberculomes IRIS s’accom-
pagnent probablement d’une accentuation de la réaction 
infl ammatoire. Celle-ci n’a toutefois pas été observée 
dans les méningites chez les patients IRIS.
M A R C O  D E  R E F E R E N C I A :   El síndrome infl amatorio de 
reconstitución inmunitaria asociado con la tuberculosis 
(TB-IRIS) representa una complicación grave en los pa-
cientes tuberculosos coinfectados por el virus de la in-
munodefi ciencia humana 1 (VIH-1), en quienes se inicia 
el tratamiento antirretrovírico (ART) combinado. En 
más del 10% de los casos se observan manifestaciones 
neurológicas. Aparte de algunos informes de casos, no 
se han descrito las características del estudio neurorra-
diográfi co de la TB-IRIS.
O B J E T I V O :   Describir los hallazgos en 16 pacientes: 
13 por tomografía computarizada y 3 por resonancia 
magnética. 
R E S U LTA D O S :   Las manifestaciones del fueron meningi-
tis (n = 4), lesiones intracranealas con efecto de masa 
(SOL; presunción de tuberculoma, n = 5), meningitis y 
lesiones con SOL (n = 5), radiculomielitis (n = 1) y es-
pondilitis (n = 1). En pacientes con IRIS y tuberculo-
mas, se observó una alta frecuencia de: 1) lesiones de 
baja densidad o sin realce con el contraste en el escáner 
(en todas las lesiones); 2) lesiones múltiples (en 5 de 
10 pacientes); y 3) edema perilesional (en 17 de 22 lesio-
nes). En los pacientes con meningitis, rara vez se observó 
realce meníngeo (n = 2) o hidrocefalia (n = 1).
C O N C L U S I Ó N :   Esta es la primera serie de casos impor-
tante donde se describen las características radiográfi cas 
de TB-IRIS. Comparados con los hallazgos publicados 
en pacientes infectados por el VIH-1 que no reciben 
ART, los tuberculomas IRIS indican una respuesta in-
fl amatoria acentuada. Sin embargo, ese aspecto no se 
encontró en los pacientes con meningitis y IRIS.
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Background: At the turn of the century, only 300 cases of warfarin induced skin necrosis 
(WISN) had been reported. WISN is a rare but potentially fatal complication of warfarin 
therapy. There are no published reports of WISN occurring in patients with HIV-1 infection 
or tuberculosis (TB). 
Methods: We retrospectively reviewed 6 cases of WISN presenting from April 2005 – July 
2008 at a referral hospital in Cape Town, South Africa. 
Results: Six cases of WISN occurred in 973 patients receiving warfarin therapy for venous 
thrombosis (0.61%, 95% CI: 0.25-1.37%). All 6 cases occurred in HIV-1 infected women 
(median age: 30 years, range 27-42) with microbiologically confirmed TB and venous 
thrombosis. All patients were profoundly immune suppressed (median CD4 at TB diagnosis: 
49 cells/mm3, interquartile range 23-170). Of the 3 patients receiving combination 
antiretroviral therapy, 2 had TB-IRIS. Median duration from initiation of antitubercular 
treatment to venous thrombosis was 37 days (range: 0-150). Median duration of parallel 
heparin and warfarin therapy was 2 days (range: 1-6). WISN manifested 6 days (range: 4-8) 
after initiation of warfarin therapy. The INR at WISN onset was supra-therapeutic, median: 
6.2 (range: 3.8-6.6). Site of WISN included breasts, buttocks, and thighs. Four of six WISN 
sites were secondarily infected with drug-resistant nosocomial bacteria (MRSA, 
Acinetobacter, ESBL E. coli and Klebsiella pn.) 17 to 37 days after WISN onset. In four 
patients, median duration from WISN onset to death was 43 days (range: 25-45). One of the 
two surviving patients underwent bilateral mastectomies and extensive skin grafting at a 
specialist centre.  
Conclusion: This is one of the largest case series of WISN. We report a novel clinical entity: 
WISN in HIV-1 infected patients with TB and venous thrombosis. The occurrence of 6 
WISN cases in a 40 month period may be attributed to i) hypercoagulability, secondary to 
HIV-1 and TB, ii) short concurrent heparin and warfarin therapy, and iii) the high loading 
dose of warfarin. Active prevention and appropriate management of WISN will likely 













Warfarin induced skin necrosis (WISN) is a rare complication of warfarin therapy, with an 
estimated prevalence of 0.01-0.1% in individuals receiving warfarin.1,2 WISN is associated 
with high morbidity, often necessitating aggressive surgical intervention, and may be fatal in 
the absence of early accurate diagnosis and treatment. Originally described in 1943, WISN 
was first associated with oral anticoagulants in 1954.3 As of 2000, only 300 case reports had 
been reported internationally.4 Most cases arise in patients receiving treatment for venous 
thromboembolism; 25% of WISN occurs in patients with cardiac indications for therapy (e.g. 
atrial fibrillation, valve replacement) or cerebral vascular insufficiency.2 To date, published 
reports do not associate WISN with HIV-1 infection or tuberculosis. Here, we describe six 
cases of WISN with poor outcome, occurring in HIV-1 infected patients receiving treatment 















We retrospectively reviewed 6 cases of WISN at GF Jooste Hospital, Cape Town, South 
Africa from April 2005 through July 2008. GF Jooste Hospital is a 200-bed adult (>15 years) 
public hospital, which receives referrals from primary care clinics, serving a catchment 
population of 1.3 million indigent people. We have previously described national guidelines 
for antitubercular treatment and antiretroviral therapy in South Africa.5,6 
 
Definitions 
We defined venous thrombosis as either visualisation of a non-compressible thrombus with 
doppler ultrasound (popliteal or femoral venous thrombosis) or a venous filling defect with 
radio-contrast during computer tomography [CT] (inferior vena cava or superior sagittal sinus 
thrombosis). A radiologist performed sonography and interpreted CT findings. Warfarin 
induced skin necrosis (WISN) was defined as a characteristic drug eruption on the skin, 
which occurred shortly after starting warfarin therapy for a venous thrombosis, and which 
progressed to skin and subcutaneous tissue loss. We defined microbiologically confirmed 
tuberculosis as Mycobacterium tuberculosis (M.tb) cultured or acid-fast bacilli (AFB) seen in 
sputum or a lymph node aspirate. We defined TB-IRIS using the consensus clinical case 
definition of paradoxical TB-IRIS for resource-limited settings.7 We defined extended-
spectrum beta lactamase (ESBL) producing bacteria as bacteria having clavulanate-inhibited 
transferable enzymes able to hydrolyse third and fourth generation cephalosporins as tested 
by disc diffusion (fishtail) method. We defined methicillin resistant Staphylococcus aureus 















We obtained clinical information from hospital notes, laboratory reports, and communication 
with attending physicians. The following data was reviewed: patient demographics, HIV-1 
status, CD4 counts (nadir and post ART where available), tuberculosis episode 
(microbiological confirmation, drug susceptibility testing), site of venous thrombosis, 
anticoagulation therapy, site of WISN, international normalised ratio (INR) at WISN onset, 
antibiotic treatment, and outcome (e.g. death, surgical intervention, etc). All patients admitted 
to GF Jooste Hospital from 2005 through 2008 were managed using a standardised venous 
thrombosis protocol. Following venous thrombosis diagnosis, low molecular weight heparin 
(Enoxiparin 1 mg / kg twice daily by deep subcutaneous injection) was prescribed for a 
maximum of five days. Warfarin was started 2 days after heparin initiation to minimize the 
risk of warfarin-induced skin necrosis. If the patient had been on TB treatment for 10 days or 
longer, the loading dose of warfarin was adjusted from 5mg to 10mg.  
















Nine-hundred seventy three patients were diagnosed with venous thromboses and received 
warfarin therapy at GF Jooste Hospital over the 40-month study period. WISN occurred in 
six HIV-1 infected women receiving treatment for microbiologically confirmed tuberculosis 
(Table 1). The prevalence of WISN in our study population was 0.61%, 95% CI: 0.25-1.37% 
(6/973). The median age was 33 years (range: 27-42). The median CD4 count at TB 
diagnosis was 49 cells/mm3 (interquartile range: 23-170). Three patients received ART 
(regimens specified in Table 1). Two patients (Cases 2 and 3) were diagnosed with TB-IRIS. 
The median interval from initiation of antitubercular therapy to venous thrombosis was 37 
days (range: 0-150). Venous thrombosis sites included popliteal and femoral veins, the 
inferior vena cava, and the superior sagittal sinus. Only Case 3 was an inpatient at the time of 
venous thrombosis (and received low molecular weight heparin prophylaxis); the remaining 
patients were admitted to hospital as a result of venous thrombosis. No patient had a personal 
or family history of previous venous thrombosis.  
 
Clinical features at WISN and outcomes  
The warfarin loading dose was 5mg or 10mg (Table 2). The median duration of parallel 
heparin and warfarin therapy was 2 days (range: 1-6). The median duration from initiation of 
warfarin therapy to WISN was 6 days (range: 4-8). The INR at WISN onset was supra-
therapeutic, median: 5.6 (range: 3.8-6.6). Activated partial thromboplastin times (aPTT) were 
not measured. Site of WISN included breasts, buttocks, and thighs (Figure 1). Skin biopsy 
was performed in one patient (Figure 1). After WISN diagnosis, warfarin was stopped and 












infected WISN sites produced the following drug-resistant nosocomial organisms: E.coli 
(ESBL), Klebsiella pneumoniae (ESBL), Staph. aureus (MRSA), A.baumannii, and 
S.marcescens. Antimicrobial sensitivities of each organism are listed in Table 2. 
Four patients died, and no autopsies were performed. All 4 patients were profoundly 
immune-suppressed at TB diagnosis. The median duration from WISN onset to death was 43 
days (range: 25-45). The two surviving patients’ CD4 counts at TB diagnosis exceeded 
200cells/mm3. Case 1 was referred to a specialist centre for aggressive surgical management 
(Figure 1 D-F). Case 6 recovered with appropriate wound care and prophylactic broad-























ART regimen TB-IRIS CD4 at TB 
diagnosis 
(cells/mm3) 




ART to venous 
thrombosis 
Duration:           




1 42, F Yes Pulmonary, drug 
sensitive M.tb 
* AZT/3TC/ EFV –  396 - 28 months 0 days** L popliteal vein 
2 36, F No Cervical node, 
smear positive 
4 weeks D4T/3TC/ EFV Yes 41 199 1 month 65 days R SFV,               
R popliteal vein 
3 30, F No Pulmonary, drug 
sensitive M.tb 
2 weeks D4T/3TC/ EFV Yes 10 91 1 month 50 days IVC, into L renal 
vein 
4 28, F Yes Pulmonary, drug 
sensitive M.tb 
– – – 56 – – 0 days** L popliteal and 
femoral veins 
5 27, F No Pulmonary,  
smear positive 
– – – 17 – – 152 days Superior sagittal 
sinus  
6 35, F No Pulmonary, drug 
sensitive M.tb 
–  –  – 208 –  – 24 days L common 
femoral vein 
Key:  
F = female, NP = not performed, ART = combination antiretroviral treatment, AZT = zidovudine 300mg twice daily, D4T= stavudine 30mg twice daily, 3TC = lamivudine 150mg twice daily, EFV = 
efavirenz 600mg nocte, smear positive = acid fast bacilli seen with Ziehl Neelsen stain, drug sensitive M.tb = Mycobacterium tuberculosis cultured sensitive to rifampin and isoniazid, TB treatment = 
antitubercular treatment, TB-IRIS = tuberculosis associated immune reconstitution inflammatory syndrome, L = left, R = right, PE = pulmonary embolus, SFV = superficial femoral vein, IVC = inferior 































Site of WISN Duration from 




from WISN site 
Antimicrobial sensitivities WISN to 
death 
1 5mg 2 days 6 days 6.6 ART, HRZES, 
TMP-SMX, 
ceftriaxone 
Breasts, L thigh 21 days S. aureus (MRSA) Clindamycin, erythromycin, vancomycin Alive 
A. baumannii Colistin 
2 10mg 3 days 4 days 6.2 ART, HRZE R buttock 26 days Klebs pn (ESBL), Amikacin, ertapenem, imipenem, 
meropenem 
44 days 
E.coli Amikacin, cefotaxime, ceftriaxone, 
cefuroxime, ciprofloxacin, co-amoxyclav, 
gentamicin 
3 10mg 1 day 4 days 4.9 ART, HRZE, 
ampicillin, 
amikacin 
Buttocks 17 days E. coli (ESBL), Amikacin, imipenem, meropenem, 
piperacillin-tazobactem 
25 days 
A. Baumannii Amikacin, colistin, tobramycin 
4 10mg 2 days 8 days 4.5 HRZE L breast 37 days S.marcescens, Imipenem, meropenem, piperacillin-
tazobactem 
42 days 
Klebs pn (ESBL) Amikacin, imipenem, meropenem 
5 - 6 days 6 days 6.4 HRZE L breast, L hip - Not requested 45 days 
6 5mg 3 days 8 days 3.8 HRZE, 
Metronidazole 
TMP-SMX 
L thigh - Not requested (wound not infected) Alive 
Key: WISN = warfarin induced skin necrosis; ART = combination antiretroviral treatment; HRZES = antitubercular treatment: H: isoniazid, R: rifampicin, Z: pyrazinamide, E: ethambutol, S: streptomycin; TMP-SMX: 
trimethoprim-sulfamethoxazole; INR = International Normalised Ratio; L = left, R = right; S. aureus = Staphylococcus aureus, MRSA = methicillin resistant Staphylococcus aureus, ESBL = extended spectrum beta-












Figure 1: Left thigh of Case 6 showing typical macroscopic features of warfarin induced skin 
necrosis: A painful, well-localised purplish lesion with a poorly-demarcated erythematous flush9 
developed 6 days after commencing warfarin therapy (A). Oedema formed in the dermis and 
subcutaneous tissues, which elevated and further demarcated the lesions from unaffected skin (B). 
Petechiae and hemorrhagic bullae were also observed; such bullae signified irreversible damage and 
ensuing full-thickness skin necrosis3,4,9 Sloughing of the eschar revealed deep defects that extended 
into the subcutaneous tissue (C). Warfarin induced skin necrosis occurring in a HIV-1 infected 
woman with tuberculosis and venous thrombosis (Case 1): A 42 year-old HIV-infected woman 
was admitted to hospital in June 2008. She was compliant with antiretroviral treatment (ART), and 
her CD4 count was 396 cells/mm3. Drug-sensitive Mycobacterium tuberculosis was cultured from her 
sputa. Ultrasound confirmed a left popliteal thrombosis. Six days after starting warfarin therapy, she 
developed skin lesions on her breasts and left thigh, consistent with warfarin induced skin necrosis 
(WISN) (D). Sixteen days after WISN onset, a punch biopsy of her left thigh was performed. 
Histology showed full thickness epidermal necrosis with numerous thrombosed vessels in the 
superficial dermis (E, arrowed), consistent with WISN. She received antibiotics for wound infection 
according to microbial sensitivities. 44 days after WISN onset, plastic surgeons performed a bilateral 
mastectomy and an extensive tissue excision from her left thigh. Split thickness skin grafts were used 
to cover the defects. Microscopy of tissue excised from her left thigh showed extensive necrosis of 
subcutaneous fat, numerous foreign body-type giant cells and focal suppuration (F, arrowed).  There 
were fresh thrombi in vessels, and some vessels showed recanalisation.  No organisms were seen on 
Brown and Brenn (modified Gram stain) or Ziehl Neelsen stains. 10 months after WISN, she has an 













This is one of the largest case series of warfarin induced skin necrosis (WISN). We report a 
novel clinical entity: WISN occurring in HIV-1 infected patients with tuberculosis and 
venous thrombosis.  
 
All 6 patients were chronically ill women of reproductive-age with venous thromboses. 
WISN typically occurs in obese, perimenopausal women who are receiving anticoagulant 
therapy for a deep vein thrombosis or pulmonary embolism.2 Women are affected more 
frequently than men (4:1)2 – the reason for this predilection is unclear. In women, the breast 
is most commonly affected, followed by the buttocks and thighs;8 our patients were similarly 
affected. It is postulated that local tissue factors contribute to the development of WISN at 
these sites; such factors include trauma and variation in local temperature and perfusion.9,10  
 
About 90% of affected patients develop symptoms between the third and sixth day of 
warfarin therapy,2 ,4,11 which is similar to our experience. The clinical presentation of WISN 
is characteristic (Figure 1 A-C); all our patients demonstrated these clinical features. 
Widespread disease may result in deep tissue necrosis, secondary infection, and multi-organ 
failure.2  
 
Mortality within 3 months of WISN onset is substantial (15%), even with appropriate 
treatment.2 Four of our 6 patients died within 45 days of WISN onset. All deaths were 
probably due to sepsis syndrome complicating wound infection. All wound cultures were 












rifampicin, trimethoprim-sulfamethoxazole and cephalosporin use in our patients may have 
favoured the selection of highly antibiotic resistant organisms. In South Africa, more than 
50% of Staph. aureus isolates from public hospitals are resistant to either rifampicin and/or 
trimethoprim sulfamethoxazole.12 Failure of effective infection control measures, lack of 
appropriate antimicrobial chemotherapy,6 delayed referral to a specialist centre for surgical 
debridement, and profound immune-suppression at TB diagnosis probably contributed to the 
4 deaths. Comparatively, the superior immune function at TB diagnosis of Cases 1 and 6 may 
account for their survival. Pulmonary emboli may have also complicated warfarin cessation 
and contributed to death. We were unable to determine the exact cause of death; relatives 
refused permission to perform autopsies. It is important to note that despite prompt referral to 
a specialist centre, Case 1 has considerable morbidity. This morbidity includes bilateral 
mastectomies, an impaired gait due to a contracture of her left thigh, and the associated 
psychosocial stigma.  
 
Histology of WISN classically shows full thickness epidermal necrosis with thrombosed 
vessels in the dermis. While the underlying pathophysiological mechanisms remain unclear, 
it is postulated that WISN results from an imbalance between intrinsic pro- and anticoagulant 
factors during the first few days of warfarin therapy.2,11 Warfarin is a vitamin K antagonist 
and reduces serum levels of vitamin K-dependant factors, which include factors II, VII, IX, 
X, protein C, and protein S. Serum levels of factor VII (procoagulant factor), and protein C 
and protein S (anticoagulant factors) decline more rapidly than serum levels of factors II, IX, 
and X (procoagulant factors) on warfarin therapy.2,11 This results in an initial 
hypercoagulable state, which, especially in the presence of additional risk factors such as 
protein C and/or S deficiency, may predispose to WISN.4 The INR is factor VII dependent, 












relative protein C deficiency.13 Screening for these conditions prior to warfarin 
commencement, however, is not recommended, as they lack the necessary sensitivity and 
specificity to accurately predict the risk of developing WISN.2,4 Due to the retrospective 
nature of our study, serum levels of protein C, protein S, and antithrombin III were not 
performed. The lack of genetic testing and coagulation work-up is a limitation of our study.  
 
The prevalence of WISN in our study population is 0.61% (6/973), which is six times higher 
than reported in HIV un-infected patients.1,2 The occurrence of 6 WISN cases in a 40-month 
period at one centre is unusual. This may be a result of the short duration of parallel heparin 
and warfarin therapy (median duration 2 days), observed in our patients. Parallel heparin and 
warfarin therapy is postulated to prevent the development of WISN, and should be continued 
until the vitamin K-dependent clotting factors have been consumed (72-96 hours).2,4,8,11 In our 
patients, premature cessation of heparin during the initial hypercoagulable period of warfarin 
therapy may have exacerbated an underlying hypercoagulable disorder (such as a protein C or 
S deficiency) and culminated in WISN. In our setting, we routinely prescribe a loading dose 
of 5 or 10mg warfarin in tuberculosis patients with venous thromboses as rifampin induces 
the rate of warfarin clearance by cytochrome p450 (CYP) 2C9.14 This dose of warfarin with a 
short window of parallel heparin and warfarin therapy may have contributed to the high 
prevalence of WISN (0.61%). 
 
HIV infection is a widely acknowledged risk factor for venous thromboembolism (VTE).15-17 
Some reports cite a tenfold increase in incidence of DVT in HIV/AIDS as compared to the 
general population.15 The following independent risk factors have been identified for VTE in 












immunocompromise, opportunistic infections, AIDS-related neoplasms, HIV-associated 
autoimmune disorders (eg. AIHA), hospitalisation in the past 3 months, and central venous 
catheter use in the past 3 months.16-18 Exposure to HAART has not been associated with 
VTE.16,17 HIV-positive patients are also more likely to demonstrate multiple acquired and 
persistent thrombophilic abnormalities; the frequency of these abnormalities increases with 
progression to AIDS, and the presence of such abnormalities may contribute to the high 
prevalence of venous and arterial thrombosis in patients with HIV infection.19 These 
abnormalities include antiphospholipid antibodies, lupus anticoagulant, anticardiolipin 
antibodies, increased von Willebrand factor, increased d-dimers, and deficiencies of protein 
C, protein S, antithrombin, and heparin cofactor II.20 The acquired protein S and protein C 
deficiencies seen in acutely ill patients may be reversible following treatment for OIs and/or 
ART.18  
 
M.tb infection may present clinically as DVT; 2 of our patients (Cases 1 and 4) were 
diagnosed with TB and DVT simultaneously. DVT usually occurs shortly after initiating 
antitubercular therapy (about 2 weeks).21 Rifampin-based regimens have a fivefold increased 
risk of DVT (relative risk = 5), thus DVT prevention is recommended in patients on 
rifampicin.21 DVT is associated with advanced HIV infection and PTB. The following 
thrombogenic factors probably contribute to this association: acquired protein C and protein S 
deficiencies, elevated plasma fibrinogen, impaired fibrinolysis, depressed ATIII, reactive 
thrombocytosis, increased platelet aggregation, and antiphospholipid antibodies.22 These 













It is not known whether IRIS predisposes to venous thrombosis. A single case is reported of 
IRIS manifesting as disseminated tuberculosis, myelopathy, encephalopathy, and deep vein 
thrombosis;23 with appropriate treatment, IRIS resolved and no adverse drug effects occurred. 
We report the first two cases of TB-IRIS and WISN occurring simultaneously. The 2 patients 
diagnosed with TB-IRIS were profoundly immune-suppressed, had a short duration from 
starting antitubercular treatment to initiation of ART, and presented with recurrence of 
tuberculosis symptoms soon after initiating ART.7 
 
Active prevention and appropriate management of venous thromboses will likely alleviate the 
dire morbidity and mortality associated with WISN. Prophylactic heparinisation of acutely ill 
hospital patients with HIV-1 infection and/or tuberculosis will reduce the incidence of venous 
thrombosis. In patients with venous thrombosis, parallel heparin therapy for at least the first 4 
days of warfarinisation2,4,8,11  may limit the occurrence of WISN. WISN should be considered 
in all newly-warfarinised patients with new skin lesions. Effective infection control measures 
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Abstract
The immune reconstitution inflammatory syndrome (IRIS) has emerged as an important early
complication of antiretroviral therapy (ART) in resource-limited settings, especially in patients with
tuberculosis. However, there are no consensus case definitions for IRIS or tuberculosis-associated
IRIS. Moreover, previously proposed case definitions are not readily applicable in settings where
laboratory resources are limited. As a result, existing studies on tuberculosis-associated IRIS have
used a variety of non-standardised general case definitions. To rectify this problem, around 100
researchers, including microbiologists, immunologists, clinicians, epidemiologists, clinical trialists,
and public-health specialists from 16 countries met in Kampala, Uganda, in November, 2006. At this
meeting, consensus case definitions for paradoxical tuberculosis-associated IRIS, ART-associated
tuberculosis, and unmasking tuberculosis-associated IRIS were derived, which can be used in high-
income and resource-limited settings. It is envisaged that these definitions could be used by clinicians
and researchers in a variety of settings to promote standardisation and comparability of data.
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The immune reconstitution inflammatory syndrome (IRIS; also known as immune
reconstitution disease, immune reconstitution syndrome, or immune restoration disease) is a
widely recognised phenomenon that can complicate antiretroviral therapy (ART).1,2 The
condition results from rapid restoration of pathogen-specific immune responses to
opportunistic infections, causing either the deterioration of a treated infection or the new
presentation of a previously subclinical infection. IRIS typically occurs during the initial
months of ART and is associated with a wide spectrum of pathogens, most commonly
mycobacteria, herpes-viruses, and deep fungal infections such as cryptococcal meningitis.1–3
In recent years, access to ART has increased rapidly in resource-limited settings, reaching over
2 million people by December, 2006, with an estimated 1 340 000 of these individuals living
in sub-Saharan Africa.4 Since the burden of HIV/tuberculosis co-infection is very high in many
low-income and middle-income countries,5 many of the patients who enter ART programmes
in these settings have a current diagnosis of tuberculosis, or later develop tuberculosis following
initiation of ART. For example, one South African study reported that 238 (25%) of 944
patients attending a community-based ART programme were receiving tuberculosis treatment
at ART initiation and in the first year of ART the incidence of tuberculosis was 13·4 cases per
100 person-years (95% CI 10·4–16·9).6 Up to one-third of patients with HIV/tuberculosis co-
infection who begin ART in such settings could be at risk of developing tuberculosis-associated
IRIS (also known as TB-IRIS),3 and this condition is emerging as an important clinical
challenge in resource-limited settings.7–10
Since there is no diagnostic test for IRIS, confirmation of the disease relies heavily upon case
definitions incorporating clinical and laboratory data. However, clinical management and
research on IRIS are hindered by the lack of consensus case definitions and definitions that are
specific to particular opportunistic infections. To address this shortcoming, an international
meeting of researchers working in this field was convened in Kampala, Uganda, in November,
2006, and the International Network for the Study of HIV-associated IRIS (INSHI) was formed.
The specific aim of the meeting was to develop consensus case definitions for tuberculosis-
associated IRIS that are appropriate for low-income settings where laboratory capacity is often
limited, and that can be used by researchers working in dierent settings to permit comparability
of results. We present these consensus case definitions in this paper.
Participants and consensus methods
The need for a public-health definition for tuberculosis-associated IRIS was first proposed at
the WHO consultation on tuberculosis and HIV research priorities in resource-limited settings
in February, 2005.11 The organisers of the meeting in Kampala contacted individuals involved
in research related to tuberculosis-associated IRIS, particularly those working in resource-
limited settings or collaborating with researchers in these settings. Contacting these individuals
was dependent on whether they had published or presented data about tuberculosis-associated
IRIS at international conferences, whether they were involved in ongoing research projects
about the disease, or whether they had clinical experience of the disease. 97 researchers from
16 countries on six continents attended the meeting. Among the delegates were microbiologists,
immunologists, clinicians, epidemiologists, clinical trialists, public-health specialists, and
representatives from WHO.
At the meeting a subgroup was assembled to develop the case definitions. Two participants
presented published IRIS case definitions (panel 1)2,7,12–14 as well as eight dierent
tuberculosis-associated IRIS case definitions currently being used by researchers in ongoing
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cohort and intervention studies. The common features among these case definitions were
highlighted, and their practical use in resource-limited settings was discussed. Tuberculosis-
associated IRIS case definitions were agreed and taken back to a plenary session for further
discussion and consensus building. Thereafter,
Panel 1
Existing case definitions for IRIS and tuberculosis-associated IRIS that have
been most widely used
General IRIS case definition 1 (French et al, 2004)2
Diagnosis requires two major criteria (A+B) or major criterion (A) plus two minor criteria
to be fulfilled:
Major criteria
(A) Atypical presentation of opportunistic infections or tumours in patients responding to
ART
• Localised disease
• Exaggerated inflammatory reaction
• Atypical inflammatory response in affected tissues
• Progressive organ dysfunction or enlargement of pre-existing lesions after definite
clinical improvement with pathogen-specific therapy before the initiation of ART
and exclusion of treatment toxicity and new alternative diagnoses
(B) Decrease in plasma HIV RNA concentration by more than 1 log10 copies per mL
Minor criteria
• Increase in blood CD4 T-cell count after starting ART
• Increase in an immune response specific to the relevant pathogen—eg, delayed-
type hypersensitivity skin test response to mycobacterial antigens
• Spontaneous resolution of disease without specific antimicrobial therapy or
tumour chemotherapy with continuation of ART
General IRIS case definition 2 (Shelburne et al, 2006)13
Criteria for IRIS diagnosis include:
• HIV-infected patient
• Receiving effective ART as evidenced by a decrease in HIV-1 RNA concentration
from baseline or an increase in CD4+ T cells from baseline (may lag behind HIV-1
RNA decrease)
• Clinical symptoms consistent with inflammatory process
• Clinical course not consistent with expected course of previously diagnosed
opportunistic infection, expected course of newly diagnosed opportunistic
infection, or drug toxicity
Case definition specific for tuberculosis-associated IRIS (Colebunders et al, 2006)7
For patients receiving treatment for tuberculosis and starting ART:
Suspected tuberculosis-associated IRIS case
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Cases must meet the following three criteria:
• An initial clinical response to tuberculosis treatment, based on a combination of
some of the following factors: cessation of fever, relief of pulmonary symptoms,
decrease in lymph node size, termination of signs of meningeal irritation
(depending on presenting symptoms)
• New persistent fevers without another identifiable cause and/or one or more of the
following: worsening or emergence of dyspnoea, stridor, an increase in lymph
node size, development of abscesses, development of abdominal pain with
ultrasound evidence of abdominal adenopathies, unexplained CNS symptoms
• Adequate adherence to ART and tuberculosis treatment
Confirmed tuberculosis-associated IRIS case
Cases must meet the following three criteria:
• Radiological examinations showing worsening or emergence of intrathoracic
lymphadenopathy, pulmonary infiltrates, pleural effusions, abdominal lymph
nodes, hepatosplenomegaly
• A good virological response and/or increase in CD4+ lymphocyte count, and/or
conversion of tuberculin skin test from negative to positive, and/or adequate
adherence to ART and tuberculosis treatment
• A clear exclusion of other conditions that could explain the clinical manifestations
of the patient, such as tuberculosis treatment failure or other concomitant
infections, tumours, or allergic reactions
ART=antiretroviral therapy. IRIS=immune reconstitution inflammatory syndrome.
a writing committee of 17 members was appointed to finalise the consensus case definitions.
Changes to existing case definitions
General case definitions for IRIS have previously been published (panel 1).2,12–14 These case
definitions include the following criteria: confirmed HIV diagnosis, temporal association with
initiation of ART, demonstration of response to ART (ie, plasma viral load reduction, blood
CD4 cell count increase, or another marker of immune recovery such as conversion of
tuberculin skin test from negative to positive for mycobacterial IRIS), clinical deterioration
with an inflammatory process, and exclusion of other causes that could explain deterioration
(such as antimicrobial drug resistance, drug hypersensitivity reaction, or another opportunistic
infection). However, since manifestations of IRIS are infection-specific, it has been recognised
that particular definitions applicable to individual diseases such as tuberculosis would be
useful.7 The case definitions presented in this manuscript focus specifically on the clinical
manifestations of tuberculosis-associated IRIS.
Case definitions should be readily applicable in resource-limited settings where the vast
majority of patients requiring ART live and yet where facilities for diagnosis and management
of the complications of ART are least well developed. In this respect, the requirement within
existing definitions for documentation of changes in CD4 cell count and plasma viral load is
not achievable in these settings. Viral load testing has limited availability and is very costly.
In the South African public sector a viral load test costs US$39, more than the cost of 1 month’s
supply of first-line ART. Even where CD4 and viral load testing are available (such as in South
Africa), use of these tests under programmatic conditions is usually permitted for monitoring
of ART at 6-monthly intervals only and not for individual patient diagnostic work-up.
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We believe that omission of these laboratory parameters would not substantially compromise
case definitions for tuberculosis-associated IRIS. First, within the initial months of ART—
when most cases of tuberculosis-associated IRIS arise—most ART-naive patients adhering to
treatment have substantial viral load reductions;15–17 thus, inclusion of viral load changes in
definitions is largely redundant in the context of a patient who adheres to therapy. Second,
tuberculosis-associated IRIS frequently develops shortly after initiation of ART and before
any measurable increase in peripheral blood CD4 cell count. In a series of 51 patients presenting
with non-tuberculous mycobacterial IRIS, six (12%) of 51 IRIS events occurred without a
substantial increase in CD4 cell count (four patients had a CD4 increase from baseline to time
of IRIS diagnosis of less than 25 cells per μL and in two patients the CD4 cell count had actually
fallen at the time of presentation).18 The number of CD4 T cells measured in peripheral blood
does not necessarily reflect function nor how many cells are actually present at the site of an
opportunistic infection. Moreover, it is very likely that CD4 T cells are not the only cellular
mediators of IRIS.19,20 For these reasons we, like others,12 propose that a rise in peripheral
blood CD4 cell count should not be a necessary marker for the diagnosis of tuberculosis-
associated IRIS.
A further important modification to existing definitions is the inclusion of a timeframe of the
first 3 months of ART. Such a timeframe is not present in the widely used case definitions to
date (panel 1). Onset of the clinical manifestations of tuberculosis-associated IRIS should occur
within this timeframe for a diagnosis of tuberculosis-associated IRIS to be made, since this
represents the period when rapid immune recovery usually occurs.3,21
Categories of tuberculosis-associated IRIS
Tuberculosis-associated IRIS can present as one of two main syndromes: (1) a paradoxical
reaction after the start of ART in patients receiving tuberculosis treatment (here termed
paradoxical tuberculosis-associated IRIS), or (2) a new presentation of tuberculosis that is
“unmasked” in the weeks following initiation of ART with an exaggerated inflammatory
clinical presentation or complicated by a paradoxical reaction (here termed unmasking
tuberculosis-associated IRIS).
Paradoxical tuberculosis-associated IRIS
In paradoxical tuberculosis-associated IRIS, patients have been diagnosed with active
tuberculosis before initiation of ART, and have typically been responding to antituberculosis
treatment. Following initiation of ART, IRIS presents as the development of recurrent, new,
or worsening symptoms or signs of tuberculosis, such as fever, return of cough, or lymph node
enlargement, or recurrent, new, or deteriorating radiological manifestations (figure 1). These
symptoms typically occur within the first few weeks and up to 3 months after ART is initiated,
restarted, or changed because of treatment failure.
Reports of the frequency of paradoxical tuberculosis-associated IRIS using a variety of existing
case definitions range from 8% to 43% (table).8–10,21–28 Paradoxical tuberculosis-associated
IRIS has been linked with large expansions of purified protein derivative-specific T cells in
peripheral blood and increased pro-inflammatory cytokine levels.29 Risk factors for the disease
are shown in table 1 and include more advanced HIV disease with lower CD4 cell count,
disseminated and extrapulmonary tuberculosis, a shorter delay between the start of tuberculosis
treatment and initiation of ART, and a more vigorous immunological and virological response
to ART. Most cases of paradoxical tuberculosis-associated IRIS are self-limiting. The median
duration of symptoms reported in the literature is 2 months,26,28 but this ranges from mild
cases where symptoms resolve after a few days to isolated prolonged cases that have still been
symptomatic after more than a year (figure 1).28 Mortality from tuberculosis-associated IRIS
has been reported infrequently in the literature,3,9,10,26 but morbidity and the need for hospital
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admission and therapeutic procedures can be substantial.26 Rates of morbidity and mortality
attributable to paradoxical tuberculosis-associated IRIS may be higher in resource-limited
settings where diagnostic and treatment options are restricted. Neurological tuberculosis-
associated IRIS in particular can be associated with poor outcome.
Tuberculosis paradoxical reactions, such as enlargement of lymph nodes or cerebral
tuberculomas, can also occur in HIV-uninfected individuals and HIV-infected individuals who
are receiving appropriate tuberculosis treatment but who are not receiving ART;30–32 however,
the frequency of paradoxical reactions is much lower in these groups compared with patients
receiving ART.22,23 In one study, paradoxical reactions following tuberculosis treatment
occurred in one (2%) of 55 HIV-seronegative patients, two (7%) of 28 HIV-infected patients
not on ART, and 12 (36%) of 33 HIV-infected patients on tuberculosis treatment and ART.
22 The timing of the paradoxical reaction in the latter group was more closely related to the
initiation of ART than it was to the initiation
Panel 2
Case definition for paradoxical tuberculosis-associated IRIS
There are three components to this case definition:
(A) Antecedent requirements
Both of the two following requirements must be met:
• Diagnosis of tuberculosis: the tuberculosis diagnosis was made before starting
ART and this should fulfil WHO criteria for diagnosis of smear-positive
pulmonary tuberculosis, smear-negative pulmonary tuberculosis, or
extrapulmonary tuberculosis44
• Initial response to tuberculosis treatment: the patient’s condition should have
stabilised or improved on appropriate tuberculosis treatment before ART initiation
—eg, cessation of night sweats, fevers, cough, weight loss. (Note: this does not
apply to patients starting ART within 2 weeks of starting tuberculosis treatment
since insufficient time may have elapsed for a clinical response to be reported)
(B) Clinical criteria
The onset of tuberculosis-associated IRIS manifestations should be within 3 months of ART
initiation, reinitiation, or regimen change because of treatment failure.
Of the following, at least one major criterion or two minor clinical criteria are required:
Major criteria
• New or enlarging lymph nodes, cold abscesses, or other focal tissue involvement
—eg, tuberculous arthritis
• New or worsening radiological features of tuberculosis (found by chest
radiography, abdominal ultrasonography, CT, or MRI)
• New or worsening CNS tuberculosis (meningitis or focal neurological deficit—
eg, caused by tuberculoma)
• New or worsening serositis (pleural effusion, ascites, or pericardial effusion)
Minor criteria
• New or worsening constitutional symptoms such as fever, night sweats, or weight
loss
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• New or worsening respiratory symptoms such as cough, dyspnoea, or stridor
• New or worsening abdominal pain accompanied by peritonitis, hepatomegaly,
splenomegaly, or abdominal adenopathy
(C) Alternative explanations for clinical deterioration must be excluded if possible*
• Failure of tuberculosis treatment because of tuberculosis drug resistance
• Poor adherence to tuberculosis treatment
• Another opportunistic infection or neoplasm (it is particularly important to exclude
an alternative diagnosis in patients with smear-negative pulmonary tuberculosis
and extrapulmonary tuberculosis where the initial tuberculosis diagnosis has not
been microbiologically confirmed)
• Drug toxicity or reaction
ART=antiretroviral therapy. IRIS=immune reconstitution inflammatory syndrome. *It
might be difficult or impossible in resource-poor settings to confirm tuberculosis drug
resistance and to exclude certain other infections or neoplasia. Cases where alternative
diagnoses cannot be fully excluded because of limited diagnostic capacity should be
regarded as “probable paradoxical tuberculosis-associated IRIS”. In these probable cases,
should resolution of clinical or radiological findings of the suspected IRIS episode occur
without a change in tuberculosis treatment or ART having been made, they could then be
reclassified as ”paradoxical tuberculosis-associated IRIS” cases.
of tuberculosis treatment. Thus, the greatly increased frequency of paradoxical reactions in
patients receiving ART suggests that ART-related immunological changes have an important
role in their aetiology. Additionally, our clinical experience is that paradoxical tuberculosis-
associated IRIS is more severe and more frequently a multisystemic condition in ART patients
than paradoxical reactions in patients not receiving ART.
ART-associated tuberculosis and unmasking tuberculosis-associated IRIS
Compared with paradoxical tuberculosis-associated IRIS, there is much less clarity
surrounding the second major category of tuberculosis-associated-IRIS. High rates of
tuberculosis have been diagnosed during ART, especially in the initial months of treatment in
ART programmes in resource-limited settings.6,33–36 The mechanisms underlying the
presentation of tuberculosis after the initiation of ART are likely to be heterogeneous.37 Since
ART-induced immune recovery is a time-dependent process and some patients initially fail to
show an increased circulating CD4 T-cell count,38,39 a proportion of cases might present as a
result of persisting immunodeficiency. Diagnoses of active tuberculosis before ART initiation
might be missed because of the inherent insensitivity of tuberculosis diagnostics in patients
with advanced immunodeficiency and only confirmed later during ART. Other patients might
have active subclinical disease at the time of ART initiation and presentation of symptomatic
disease might result from ART-induced restoration of an immune response against
Mycobacterium tuberculosis antigens that causes inflammation. Some patients with a missed
tuberculosis diagnosis or active subclinical tuberculosis at the time of ART initiation may later
present with exuberant inflammatory clinical features that are consistent with a diagnosis of
unmasking tuberculosis-associated IRIS (figure 2).
Paradoxical reactions in patients started on tuberculosis treatment while receiving ART have
also been described,26,40 and one study reported that paradoxical reactions are more frequent
in patients who are diagnosed with tuberculosis in the first 3 months of ART than in patients
who start ART after tuberculosis treatment (eight [62%] of 13 patients vs nine [30%] of 30
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patients, respectively, p=0·05).40 This finding suggests that ART-related immunological
changes have a role in the development of paradoxical reactions in patients who present with
tuberculosis while receiving ART and that these reactions are a form of tuberculosis-associated
IRIS.
Only a few cases of unmasking tuberculosis-associated IRIS have been described in the
literature to date.40–43 In the absence of a diagnostic test, it is currently difficult to dierentiate
the varied mechanisms underlying most cases of tuberculosis that present during early ART,
especially in resource-limited settings where rates of infection are high. We therefore propose
that, as elsewhere,37 the term ART-associated tuberculosis is used
Panel 3
Case definition for ART-associated tuberculosis and provisional case
definition for unmasking tuberculosis-associated IRIS
ART-associated tuberculosis
We propose that ART-associated tuberculosis (all cases of tuberculosis that are diagnosed
during ART) should be defined as follows:
• Patient is not receiving treatment for tuberculosis when ART is initiated
• Active tuberculosis is diagnosed after initiation of ART
• The diagnosis of tuberculosis should fulfil WHO criteria for smear-positive
pulmonary tuberculosis, smear-negative pulmonary tuberculosis, or
extrapulmonary tuberculosis44
Unmasking tuberculosis-associated IRIS (provisional)
We propose that the following could suggest a diagnosis of unmasking tuberculosis-
associated IRIS:
• Patient is not receiving treatment for tuberculosis when ART is initiated and then
presents with active tuberculosis within 3 months of starting ART
AND one of the following criteria must be met:
• Heightened intensity of clinical manifestations, particularly if there is evidence of
a marked inflammatory component to the presentation. Examples include
tuberculosis lymphadenitis or tuberculosis abscesses with prominent acute
inflammatory features, presentation with pulmonary tuberculosis that is
complicated by respiratory failure due to adult respiratory distress syndrome, and
those who present with a marked systemic inflammatory syndrome related to
tuberculosis. See example in figure 2
• Once established on tuberculosis treatment, a clinical course that is complicated
by a paradoxical reaction
ART=antiretroviral therapy. IRIS=immune reconstitution inflammatory syndrome.
Researchers in the field are encouraged not to regard all patients with ART-associated
tuberculosis as having tuberculosis-associated IRIS, but only those that fit this provisional
unmasking tuberculosis-associated-IRIS case definition. We suggest that the clinical
manifestations of all patients developing ART-associated tuberculosis should be well
characterised and reported in studies, which will assist with refinement of this case
definition in the future. Studies of the immunological processes underlying the presentation
of these cases are also likely to assist with refining this case definition.
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to refer to all patients who present with active tuberculosis while receiving ART (figure 3).
We also suggest a provisional case definition for unmasking tuberculosis-associated IRIS and
clinical scenarios where the diagnosis could be considered.
Further research into the clinical characteristics and immunological mechanisms underlying
cases of ART-associated tuberculosis will permit a more refined case definition for unmasking
tuberculosis-associated IRIS in the future. However, in view of the heterogeneity in the natural
history and clinical manifestations of tuberculosis it is unlikely that a clinical case definition
that robustly separates patients with unmasking tuberculosis-associated IRIS from others with
ART-associated tuberculosis will be derived.37
Case definitions
With the rationale described above, we have developed case definitions for “paradoxical
tuberculosis-associated IRIS” (panel 2), “ART-associated tuberculosis” (panel 3), and
“unmasking tuberculosis-associated-IRIS” (panel 3). The case definitions are presented
schematically in figure 3. These case definitions have been designed for use in resource-limited
settings and are consensus case definitions that need validation in clinical practice.
Search strategy and selection criteria
Data for this Personal View were obtained by searching Medline for articles published from
1990 to 2008. Search terms included “immune reconstitution”, “immune restoration”,
“immune recovery”, “IRIS”, “antiretroviral”, “tuberculosis”, and “paradoxical reaction”.
Only English language papers were reviewed. Additionally, unpublished data and
tuberculosis-associated IRIS case definitions presented by researchers at the INSHI meeting
were used.
Conclusions
The use of standardised case definitions in different populations will help to provide greater
insight into the incidence, clinical manifestations, risk factors, and impact of tuberculosis-
associated IRIS, ultimately leading to better prevention and management strategies for this
condition. Further clinical and immunological research on patients with ART-associated
tuberculosis is needed to better dierentiate the subset of cases that have unmasking tuberculosis-
associated IRIS and to further refine this case definition. It is hoped that open research networks
such as INSHI will provide opportunities for researchers to engage in collaborative research
into tuberculosis-associated IRIS using these case definitions.
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Figure 1. Illustrative case of paradoxical tuberculosis-associated IRIS
A 36-year-old HIV-infected man was diagnosed with culture-positive pulmonary tuberculosis
(sensitive to rifampicin and isoniazid) without evidence of extrapulmonary involvement. His
CD4 count was 39 cells per μL and HIV-1 viral load 1 300 000 copies per mL. He commenced
antiretroviral therapy (ART; stavudine, lamivudine, and efavirenz) 7 weeks after initiating
antituberculous therapy. 1 week later he presented with a recurrence of tuberculosis symptoms
and cervical node enlargement. Paradoxical tuberculosis-associated IRIS was diagnosed. Over
the next 18 months he presented with several tuberculosis-associated IRIS manifestations that
sequentially emerged, despite corticosteroid therapy, then resolved. Photographs show
development of massive cervical lymphadenitis (A), a chest wall cold abscess (B, arrows), and
a massive right psoas abscess shown here on CT scan (C, arrow) from which over 2 L of pus
was aspirated (D). Repeated mycobacterial cultures of aspirates from these collections have
been negative. After 6 months on ART his CD4 count was 181 cells per μL and viral load
undetectable. After 12 months his CD4 count was 448 cells per μL and viral load 35 copies
per mL. This was an unusually prolonged course for paradoxical tuberculosis-associated IRIS
given that the median duration of symptoms is reported to be 2 months (see text).
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Figure 2. Illustrative case of unmasking tuberculosis-associated IRIS
A 48-year-old HIV-infected man with a CD4 count of 10 cells per μL presented with low-grade
fevers, retrosternal chest pain, and a dry cough. Examination was non-contributory. He could
not produce sputum and his chest radiograph showed no features of active tuberculosis (A).
No other investigations for tuberculosis were available in this resource-limited setting
(Uganda). Antiretroviral therapy (ART) was started (zidovudine, lamivudine, and efavirenz).
10 days later he returned acutely unwell with a productive cough. His temperature was 38·7°
C and he was in respiratory distress. Chest radiograph now showed left mid-zone consolidation
(B) and his sputum was positive for acid-fast bacilli. The unusual rapidity and clinical severity
of his tuberculosis presentation was attributed to unmasking tuberculosis-associated IRIS. He
responded well to continued ART and tuberculosis treatment.
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Figure 3. Schematic representation showing the different forms of tuberculosis-associated IRIS
and ART-associated tuberculosis
ART=antiretroviral therapy.
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